

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
22 April 2004 (22.04.2004)

PCT

(10) International Publication Number
WO 2004/032614 A2

(51) International Patent Classification⁷: **A01K 67/027**

(21) International Application Number:
PCT/EP2003/010118

(22) International Filing Date:
11 September 2003 (11.09.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/410,776 13 September 2002 (13.09.2002) US
60/426,609 15 November 2002 (15.11.2002) US
60/444,920 4 February 2003 (04.02.2003) US

(71) Applicant (for all designated States except US): **INGENIUM PHARMACEUTICALS AG** [DE/DE];
Fraunhofer Strasse 13, 82152 Martinsried (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **KLOCKE, Rainer** [DE/DE]; Grosshaderner Strasse 5b, 82152 Martinsried (DE). **MARQUARDT, Andreas** [DE/DE]; Fraunhofer Strasse 13, 82152 Martinsried (DE). **PERAUS, Glsela** [DE/DE]; Fraunhofer Strasse 13, 82152 Martinsried (DE). **STUMM, Gabriele** [DE/DE]; Fraunhofer Strasse 13, 82152 Martinsried (DE). **WABNITZ, Philipp** [DE/DE]; Fraunhofer Strasse 13, 82152 Martinsried (DE).

(74) Agent: **DÖRRIES, FRANK-MOLNIA & POHLMAN**;
Triftstrasse 13, 80538 München (DE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,

GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— as to the identity of the inventor (Rule 4.17(i)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CYTOPLASMIC DYNEIN HEAVY CHAIN 1 GENES, EXPRESSION PRODUCTS, NON-HUMAN ANIMAL MODEL: USES IN HUMAN NEUROLOGICAL DISEASES

(57) Abstract: A non-human animal model is provided, particularly a mouse model for movement hyperactivity, excitotoxicity disorders (e.g. myoclonic cramping) and neurodegeneration, in which modified cytoplasmic dynein heavy chain1 is expressed. Modified human and mouse cytoplasmic dynein heavy chain1 proteins and nucleic acids are also provided, including the corresponding recombinant proteins. The invention further provides uses for the non-human animal model and the modified cytoplasmic dynein heavy chain1 proteins and nucleic acids, in particular for the diagnosis and treatment of medical conditions associated with over-expression of cytoplasmic dynein heavy chain1.



WO 2004/032614 A2

BEST AVAILABLE COPY

Cytoplasmic dynein heavy chain1 genes, expression products, non-human animal model: uses in human neurological diseases

FIELD OF THE INVENTION

5 The present invention *inter alia* relates to a non-human animal model for movement hyperactivity, hyperexcitability disorders (e.g. myoclonic cramping, epilepsy), excitotoxicity disorders, and neurodegeneration. This animal model bears a mutation in the cytoplasmic dynein heavy chain1 gene. The invention also relates to modified peptides and the corresponding nucleic acid sequences of the modified
10 mouse and human cytoplasmic cytoplasmic dynein heavy chain1. Furthermore, the invention relates to the use of these peptides and nucleic acids for manufacturing therapeutics suitable for the treatment of diseases, such as Alzheimer's disease, Huntington's disease, Parkinson's disease and amyotrophic lateral sclerosis (ALS), as well as other diseases associated with overexpression, over-activity, or undesirable
15 activity of cytoplasmic dynein heavy chain1.

BACKGROUND OF THE INVENTION

Eukaryotic cells are characterized by biochemical and physiological processes which under normal conditions are exquisitely balanced to achieve the preservation and propagation of the cells. When such cells are components of multicellular
20 organisms such as vertebrates, or more particularly organisms such as mammals, the regulation of the biochemical and physiological processes involves intricate signaling pathways. Frequently, such signaling pathways consist of extracellular signaling proteins, cellular receptors that bind the signaling proteins and signal transducing components located within the cells.

25

Signaling processes may elicit a variety of effects on cells and tissues, including by way of nonlimiting example induction of cell or tissue proliferation, suppression of growth or proliferation and induction or suppression of differentiation or maturation of a cell or tissue.

30

Many pathological conditions involve dysregulation of expression of important effector proteins. In certain classes of pathologies the dysregulation is manifested as a diminished or suppressed level of synthesis and secretion of protein effectors. In a clinical setting a subject may be suspected of suffering from a condition brought on by diminished or suppressed levels of a protein effector of interest. Therefore, there is a need to assay for the level of the protein effector of interest in a biological sample from such a subject and to compare the level with that characteristic of a nonpathological condition. There is a further need to provide the protein effector as a product of manufacture. Administration of the effector to a subject in need thereof is useful in treatment of the pathological condition. Accordingly, there is a need for a method of treatment of a pathological condition brought on by a diminished, suppressed, or in some cases elevated, level of the protein effector of interest.

Motor neuron degenerative diseases are severely debilitating and largely fatal in humans as well as other mammalian species. Several hypotheses have been proposed to explain the pathogenesis of the diseases, but none addressed the underlying cause for the specificity of disease in motor neurons, the late onset of the disease, and the cumulative progressive nature of the disease.

Degenerative disorders of motor neurons include a range of progressive diseases such as amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA), the most common genetic cause of death of children (Nicole, S. et al., J. Muscle Nerve 26, 4-13, 2002).

In ALS, commonly known as Lou Gehrig's Disease in the US, the motor neurons (nerve cells in the brain, brain stem, and spinal cord that control movement of the skeletal muscles) gradually degenerate, resulting in progressive weakness and functional loss of involved muscles. Diseases that cause selective progressive death of motor neurons are surprisingly common -- ALS is the third most frequent neurodegenerative cause of adult death, after Alzheimer disease and Parkinson disease, and is significantly more common than multiple sclerosis (Motor Neurone Disease Association Information Sheet Number 9, Motor Neurone Disease Association, 1998). Targeted at adults in their prime years of life, the average age of onset is the mid-fifties, although adults of all ages can be affected. Men get the disease

slightly more often than women. Worldwide, the incidences of ALS is 0.5 to 2.4 cases per 100,000, with a prevalence of 2.5 to 7 cases per 100,000 population (Cleveland, D.W. and Rothstein, J.D. Nat. Rev. Neurosci 2, 806-819, 2001). The prevalence of ALS in the United States will probably increase dramatically as the baby boomer generation ages. In ALS the majority of patients die within 2 – 5 years of clinical onset (Motor Neurone Disease Association Information Sheet Number 9, Motor Neurone Disease Association (1998). ALS and related motor neuron disorders are not contagious but in some cases known to be hereditarily transmitted. Up to 10% of ALS is familial (FALS) and causative mutations have been found in the SOD1 gene that account for up to 20% of these FALS cases (Julien, J.P., Cell 104, 581-591, 2001). SOD1 encodes the ubiquitously expressed enzyme superoxide dismutase 1 which takes on an unknown dominant gain of function in ALS that results in the selective death of motor neurons. Mutations have also been found in alsin, probably a GTPase regulatory protein, in rare juvenile recessive forms of motor neuron disease (Hadano, S. et al. Nat. Genet. 29, 166-173, 2001; Yang, Y. et al.. Nat. Genet. 29, 160-165, 2001). In a few sporadic ALS patients and one FALS case mutations have been identified in the NFH (neurofilament heavy chain) gene (Robberecht, W. J. Neurol 247, 2-6, 2000). Approximately, 90% of all ALS is without history and is referred to as sporadic ALS, although the clinical course and the neuropathological alterations are often indistinguishable from the proven cases of genetic disease. If a genetic cause would be responsible also for a subgroup of so called sporadic ALS, the mutation would likely be germline or very early embryonic, as mosaic type pathological alterations expected in later acquired mutations are not reported nor expectable in ALS.

25

Currently, diagnosing ALS is a combination of medical history and physical and neurological examinations performed by a clinical neurologist (Brooks, Benjamin R., El Escorial J Neurol Sci 124 (Suppl.), pages 96-107, 1994; Karitzky J, Ludolph AC. J Neurol Sci, Oct 15;191(1-2):35-41, 2001; Ludolph AC, and Knirsch U, J Neurol Sci, Jun;165 Suppl 1:S14-20, 1999). An electromyogram is a diagnostic test which is done to determine abnormal nerve and muscle activity. The clinical examination and tests also rule out other conditions that might mimic motor neuron disease. The certainty of the diagnosis is determined by the clinical evidence of upper and lower motor neuron signs, according to the criteria established by the World

30

Federation of Neurology. Therefore, a definitive diagnosis of ALS is performed when clearly detectable classical clinical signs such as muscular fibrillation of distal muscle groups or tongue, difficulty to swallow, and predominantly distal muscular atrophy with the typical histological picture of grouped angular shaped atrophic muscle fibres
5 indicative of muscle denervation are present which means that the disease course is already proceeded.

Some persons are diagnosed to have other clinical variant forms of motor neuron disease which may later evolve into classical ALS over time. These clinical
10 subtypes of motor neuron disease include: Progressive bulbar palsy (PBP) which affects the brain stem (referred to as bulbar involvement), causes weakness of the speech and swallowing muscles. Progressive muscular atrophy (PMA) which affects the lower motor neurons causes skeletal muscle wasting. Primary lateral sclerosis (PLS) which affects the upper motor neurons causes muscle spasticity and may be
15 slowly progressive over many years (Brooks, BR.: El Escorial J Neurol Sci 124 (Suppl.), 1994, pages 96-107).

The most common form of spinal muscular atrophy (SMA) affects up to 1 in 6,000 newborns and is the leading hereditary cause of infant mortality worldwide,
20 causing death before the age of 2 years. Defects in the widely expressed SMN1 (survival motor neuron 1) gene are responsible for most SMA (Hofmann, Y. and Wirth, B. Hum. Mol. Genet. 11, 2037-2049, 2002; Lefebvre, S. et al.. Cell 80, 155-165, 1995).

25 Another inherited motor neuron degeneration of early adulthood is the spinobulbar muscular atrophy (SBMA), which in some families is linked to a X-chromosomal trait and CAG triplet repeat expansion within the androgen receptor (Sparfeld AD et al., Arch. Neurol. 59:1921-1926, 2002). SBMA x-linked is also termed Kennedy disease. However, there are also SBMA like syndromes following
30 autosomal inheritance, the underlying mutations are not yet identified.

Current hypothesis to the pathogenesis of motor neuron degeneration address a variety of cellular insults that may intersect, leading individually or in concert to motor neuron degeneration, motor neuron death and finally ALS (Julien, J.P. Cell 104,

581-591, 2001). A faulty gene and excess glutamate may lead to damaging free radicals, which can harm the nerve cell's DNA (Munch, C et al., J Neurochem, Aug. 82(3):594-603, 2002; Ludolph AC, and Meyer T, Riepe MW J Neurol 2000 Mar;247 Suppl 1:I7-16; Meyer T et al. J Neurol Neurosurg Psychiatry, Dec;65(6):954, 1998; 5 Meyer T. et al., J Neurol Neurosurg Psychiatry, Oct;65(4):594-6, 1998). Glutamate also may lead to the production of detrimental calcium, which can churn out its own supply of DNA-harming free radicals. The free radicals also may injure neurofilaments, proteins that serve as the skeleton of the cell. In addition, the immune system (Hofmann, Y. and Wirth, B. Hum. Mol. Genet. 11, 2037-2049, 2002) may be 10 involved in harming neurons. Abnormalities can lead to an accumulation of the toxic calcium.

Glutamate-induced excitotoxicity is a potential contributor to ALS pathogenesis. Depolarization of the neuronal membrane after activation of neuronal 15 glutamate receptors activates voltage-dependent Ca^{2+} channels, allowing Ca^{2+} entry into the cell. Thus, excess activation of neuronal glutamate receptors can cause cell death via alterations in cytosolic free Ca^{2+} homeostasis. For spinal motor neurons, rapid recovery of synaptic glutamate is accomplished by the glutamate transporter EAAT2 present in astrocytes. Loss of EAAT2 transporter could lead to increased 20 extracellular concentrations of glutamate and excitotoxic degeneration of motor neurons (Julien, Review; Cell. 2001 Feb 23;104(4):581-91).

ALS researchers at the John Hopkins University have recently enabled mouse ALS models to make an excess of glutamate transport proteins in both brains and 25 spinal cords. Preliminary studies of these mice show huge increases in their survival time, which led to the development of an "EAAT2 replacement therapy" for ALS patients at the John Hopkins University (The Robert Packard Center for ALS Research at John Hopkins, www.alscenter.org, 2002).

30 The excitotoxicity hypothesis is supported by the observation that the majority of sporadic ALS cases (~ 65%) have a reduction in the astroglial glutamate transporter EAAT2 in motor cortex and spinal cord (Rothstein et al., Ann Neurol. 1995 Jul;38(1):73-84). Germline mutations in the EAAT2 gene are very rare. Only one sporadic ALS case was identified with an EAAT2 gene variant that affects N-linked

glycosylation and glutamate clearance capacity (Aoki et al., *Ann Neurol.* 1998 May;43(5):645-53; Trotti et al., *J Biol Chem.* 2001 Jan 5;276(1):576-82.).

One major support for the excitotoxicity hypothesis comes from the first drug
5 therapy for ALS which is Riluzole (Rilutek, (Rhone-Poulenc Rorer Pharmaceuticals
Inc., College-ville, PA) approved by the FDA in 1995), an antiglutamate compound.
Riluzole retards nerve cells' release of glutamate. Although the effects of Riluzole are
clearly modest, it has been the only drug that reliably shows clinical efficacy
compared to the dozens of drugs studied by clinicians around the world in thousands of
10 ALS patients (Nervous Breakdown, A detailed analysis of the neurology market, UBS
Warburg, June 2001). Riluzole was reported to extend survival of ALS diagnosed
patients for a few months. However, all therapeutic approaches tested so far are prone
to fail when applied in later stages of the disease (Al-Chalabi A, and Leigh PN. *Curr
Opin Neurol*, Aug;13(4):397-405, 2000; Munch C, and Ludolph AC. *Neurol*
15 *Neurochir Pol*, ;35(1 Suppl):41-50, 2001; Ludolph AC. *J Neurol*, Dec;247:13-18,
2000). Therefore, an early or even subclinical diagnostic marker might also have
implications for therapeutic effectiveness.

It has been postulated that defects in axonal transport may be an underlying
20 common pathway that leads to the degeneration of motor neurons in ALS patients and
in relevant spontaneous and transgenic mouse models such as wobbler, nmd or SOD1
(Yang, Y. et al., *Nat. Genet.* 29, 160-165, 2001; Cleveland DW. *Neuron*,
Nov;24(3):515-20, 1999; Jonsson PA et al. *Neurobiol Dis.*, Aug;10(3):327-33, 2002;
Winter SM et al. *J Neurol.*, Oct;247(10):783-6, 2000) For example, SOD mice with a
25 mutation in the SOD-1 gene display a motor neuron degenerative phenotype with a
decreased rate of slow axonal transport (Collard et al., *Nature* 375:61-64, 1995;
Zhang et al., *J. Cell Biol.* 139:1307-1315, 1997; Williamson and Cleveland, *Nat.
Neurosci.* 2:50-56, 1999.

30 Motor neurons of the brain and spinal cord are characterized by the length of
their axons, which can reach a meter in length in an adult human. The significant
length of these neuronal projections makes active axonal transport essential for normal
cellular function. The axonal transport is microtubule dependant and includes both, an
anterograde transport of organelles to the axonal synapse and the retrograde transport

of multivesicular bodies and trophic factors back to the neuron cell body. The retrograde transport is mediated by the dynein-dynactin complex.

The dynein-dynactin complex

5 Dyneins are cytoskeletal motor proteins. These can be defined as molecules that convert chemical energy, originating from nucleotide hydrolysis, into the mechanical force necessary for them to move along cytoskeletal polymers (*cf* Vallee and Howard (1990) *Annu. Rev. Biochem* 59: 909-932). Dyneins and kinesins constitute the superfamily of microtubule-dependent motor proteins, (Hirokawa
10 (1998) *Science* 279, 519-526). Although the superfamily of dyneins is probably less diverse than that of kinesins, the family, which contributes to the structure and function of flagellar and ciliary axonemes (axonemal dyneins), comprises more than a dozen dynein heavy chain isoforms (Milisav (1998) *Cell Motil Cytoskeleton* 39, 261-272). Only four dynein heavy chain isoforms, contributing to different forms of the
15 protein complex, called cytoplasmic dynein, are known in mammals.

The most abundant form of cytoplasmic dynein, whose identity is defined by the cytoplasmic dynein heavy chain1, is involved in a wide range of cellular functions. In mouse and human, the homologous proteins are referred to as cytoplasmic dynein
20 heavy chain1. These proteins correspond, respectively, to the translation product of the transcript of the mouse gene *Dnchc1* (Genbank Accession No. AY004877) and the translation product of the full-length cDNA of the human gene *DNCH1*. The full-length human cytoplasmic dynein heavy chain1 cDNA is disclosed herein (SEQ ID NO:17). Several lines of evidence (*e.g.* immunodepletion of cytoplasmic dynein
25 heavy chain1 in *in vitro* motility studies and antibody injection) revealed that it functions as a molecular motor in prometaphase chromosome movement, mitotic spindle pole organization, Golgi organization, spindle orientation, nuclear migration, microtubule organization and reorganization and intracellular trafficking, including retrograde axonal transport, of membraneous organelles, (*e.g.* lysosomes and
30 endosomes) (for review see Milisav (1998) *Cell Motil Cytoskeleton* 39, 261-272). Another isoform has been reported to be involved in intraflagellar protein transport (Pazour *et al.* (1999) *J Cell Biol* 144, 473-481). Cytoplasmic dynein was initially identified in nervous tissue (Paschal *et al.* (1987) *J Cell Biol* 105, 1273-1282) although it is expressed in several tissues (Mikami *et al.* (1993) *Neuron* 10, 787-796).

Harada *et al.* ((1998) J Cell Biol 141, 51-59) generated mice lacking cytoplasmic dynein heavy chain 1 by targeted disruption of the *cDHC* (= *Dnchc1*) gene. Whereas *cDHC*^{-/-} preimplantation embryos were microscopically indistinguishable from *cDHC*^{+/-} and *cDHC*^{+/+} littermates, by 8.5 days p.c., no *cDHC*^{-/-} embryo were found. This observation demonstrates that cytoplasmic dynein is essential for embryonic development. In conjunction with the functional data mentioned above, Harada *et al.* found that cells from *cDHC*^{-/-} blastocysts, in contrast to those from *cDHC*^{+/+} blastocysts, were incapable of dividing in culture. Additionally, the Golgi complex was highly vesiculated and distributed in these cells as were the endosomes and lysosomes.

The cytoplasmic dynein complex consists of at least four classes of subunits: heavy, intermediate, light intermediate and light dynein chains. The dynein intermediate chain, dynein light intermediate chain, and dynein light chain specify the intracellular location of the dynein complex and regulate its motor activity, whereas the dynein heavy chains contain the machinery which imparts the motor activity.

The architecture of the complex is dominated by two heavy chains of 530 kDa each, which form a stem by the interaction of a large portion (amino acids 300 – 1140) of their N-termini. This stem also binds the dynein chains of lower molecular weight, *e.g.* two 74 kDa intermediate chains (between amino acids 446 and 701 of the heavy chains) and four 53-59 kDa light intermediate chains (between amino acids 649 and 800 of the heavy chains) (Tynan *et al.* (2000) J Biol Chem. 275, 32769-32774). Several 8-22 kDa light chains bind to the complex via interaction with the intermediate or light intermediate chains (*cf* Makoka *et al.* (2002) Biochemistry 41, 4302-4311). The intermediate chains probably impart the tethering of the dynein complex to the cargos (review: Asai and Koonce (2001) Trends Cell Biol 11, 196-202). Intracellular transport processes mediated by cytoplasmic dynein additionally involve a variety of accessory proteins that are thought to target the cytoplasmic dynein complex to the intracellular cargos. Another large complex formed by several of these accessory proteins is named dynactin. Dynactin binds to dynein by the interaction of a subunit called p150Glued with the dynein intermediate chains (Vaughan and Vallee(1995) J Cell Biol 131, 1507-1516). This interaction implicates

dynactin as a receptor or adaptor that mediates the association of cytoplasmic dynein with cargo. Subsequent studies have demonstrated the essential nature of the dynein-dynactin interaction for most examples of dynein-mediated transport (Holleran et al., Int. Rev. Cytol. 182:69-109, 1998)

5

The binding of dynactin to dynein is essential for dynein-dependent intracellular movements (Gill *et al.* (1991) J Cell Biol 115, 1639-1650; Schroer and Sheetz (1991) J Cell Biol 115, 1309-1318) including those required for neuronal function. It has been shown that antibodies which specifically disrupt the binding of dynactin to dynein block vesicle motility along microtubules in extruded squid axoplasm (Waterman-Storer *et al.* (1997) Proc Natl Acad Sci USA 94, 12180-12185). Additionally, an overexpression of the dynamitin subunit of dynactin, which results in the dissociation of the dynactin complex, (Eckley *et al.* (1999) J Cell Biol 147, 307-320) causes an inhibition of dynein-mediated processes in the cell (Burkhardt *et al.* (1997) J Cell Biol 139, 469-484).

15

Dynein-mediated intracellular movements are directed along microtubules towards their proximal (-) ends. This process is accomplished by ATP hydrolysis, which is predominantly catalysed by the first of four (counted from the one nearest to the N-terminus) P-loop motifs of each of two C-terminal globular heads which are formed by approximately 3000 amino acids of each of the two dynein heavy chains. Both globular heads also contain a microtubule binding domain, which is thought to be located at the tip of a stalk (Asai and Koonce (2001) Trends Cell Biol 11, 196-202).

20

25

The dynein-dynactin complex and neurodegeneration

Recently, disruption of the dynein-dynactin complex in postnatal motor neurons of transgenic mice that overexpress dynamitin has been shown to result in reduction of microtubule based axonal transport and degeneration of the motor neurons and muscle atrophy over a time-course of many months (LaMonte *et al.* (2002) Neuron 34, 715-727) The pathology described therein is the result of a highly artificial transgenic approach for regional and time dependent disruption of the dynein-dynactin complex selectively in adult motor neurons. This situation is not comparable with any clinical situation with an underlying genetic cause, but would

30

only address motor neuron specific stress factors for the dynein-dynactin system. The model described by LaMonte et al. is thus quite different from the model described in the present invention.

5 No effective therapy exists for the neurodegenerative disorders described herein. The selective nature of the degeneration is unexplained, but may relate to the highly specialized form and function of the motor neuron. There are known gene mutations in some familial cases of ALS and in almost all SMA, but the underlying defect in the majority of familial and sporadic ALS and a small proportion of SMA
10 remains unknown. As mentioned before, in ALS the pathogenetic link between causal mutations in *SOD1* (superoxide dismutase) and the death of motor neurons is not clear, although a variety of mechanisms have been proposed, including pathways disrupting neurofilament secondary structure (Miller (2002) Cell Mol Life Sci 59, 323-330) that result in slowing of axonal transport. Only in 2 % of ALS cases a
15 preclinical genetic diagnosis by detection of *SOD1* mutations responsible for 20% of familial ALS is possible. No preclinical or subclinical diagnostic tool for the broad majority of ALS cases is available, therefore treatment can so far only start late in the course of the disease when already a large number of motor neurons have died. Therapy might not be suitable to stop the ongoing disease process. Therefore, new
20 diagnostic tools such as a genetic test for disease relevant genes are urgently needed.

 The present invention provides an animal model for correlating mutations or defects in the cytoplasmic dynein heavy chain1 gene with human disorders, including movement hyperactivity, hyperexcitability disorders (e.g. myoclonic cramping,
25 epilepsy), excitotoxicity disorders, and neurodegeneration, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, and specifically motor neuron degeneration, such as ALS (Amyotrophic Lateral Sclerosis), SMA (Spinal Muscular Atrophy), SBMA (Bulbo-Spinal Muscular Atrophy), PBP (progressive Bulbar Palsy), PMA (Progressive Muscular Atrophy), and PLS (Primary Lateral Sclerosis),
30 resulting in whole or in part from these mutations or defects in the cytoplasmic dynein heavy chain1 gene or the protein it encodes. The *Cral* (cramping 1) mutation in cytoplasmic dynein itself results in progressive motor neuron degeneration in heterozygous mice. Specifically, this invention provides an animal model that demonstrates the role of cytoplasmic dynein heavy chain1 in movement hyperactivity,

hyperexcitability disorders (e.g. myoclonic cramping, epilepsy), excitotoxicity disorders and neurodegeneration, specifically α -motor neuron degeneration, resulting from a mutation or defect in cytoplasmic dynein heavy chain1. The Cra1 animal model described herein demonstrates a germline missense mutation that causes subtle changes in the cytoplasmic dynein heavy chain 1, and is sufficient to specifically induce age dependent motor neuron degeneration without grossly affecting the housekeeping function of the dynein-dynactin complex in other cell types. The Cra1 mutation in cytoplasmic dynein heavy chain 1 allows normal development and normal function of the organism in early adulthood. The animal model provided herein meets the currently unfulfilled need for a validated model to study the causes and precise physiological effects of such diseases associated with aberrant cytoplasmic dynein heavy chain1 function. Similarly, this invention provides a means for identifying antagonists and inhibitors for cytoplasmic dynein heavy chain1 in such disorders.

The present invention also provides significant data useful in neurobiology and clinical research, as it describes in an animal model a new pathway involved in neurodegeneration, and also suggests a possible genetic cause for ALS/Lou Gehrig's disease.

Furthermore, the present invention provides diagnostic tests for latent or progressive diseases, or a propensity to develop a disease or passing on a contributing or causatory recessive genetic mutation to progeny, wherein the disease is selected from, but not limited to, the group of human disorders, including movement hyperactivity, hyperexcitability disorders (e.g. myoclonic cramping, epilepsy), excitotoxicity disorders, and neurodegeneration, in particular Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, spinal muscular atrophy, and fiber type grouping in Musculus tibialis anterior. More specifically the present invention provides diagnostic tests for latent or progressive diseases, or a propensity to develop a disease or passing on a contributing or causatory recessive genetic mutation to progeny, wherein the disease is selected from, but not limited to, the group of human motor neuron degeneration disorders, including ALS (Amyotrophic Lateral Sclerosis), SMA (Spinal Muscular Atrophy), SBMA (Bulbo-Spinal Muscular Atrophy), PBP (progressive Bulbar Palsy), PMA (Progressive Muscular Atrophy), and PLS (Primary Lateral Sclerosis).

SUMMARY OF THE INVENTION

This invention provides *inter alia* a non-human animal useful as a model of dynein heavy chain disorders in humans, particularly cytoplasmic dynein heavy chain1 disorders.

In one embodiment, the invention provides an animal model which carries a mutated cytoplasmic dynein heavy chain1 gene encoding a cytoplasmic dynein heavy chain1 protein with a modified amino acid sequence compared to the wild type sequence. The invention also provides cell lines derived from the animal model of the present invention.

The present invention also relates to the use of the animal model of the invention for the study of disorders associated with deficiencies or malfunctions in cytoplasmic dynein heavy chain1. In one embodiment, the invention provides methods of diagnosis for deficiencies or malfunction in cytoplasmic dynein heavy chain1 or the gene encoding it. In another embodiment, the invention provides a method for screening of preventive or therapeutic agents of disorders and symptoms associated with movement hyperactivity, hyperexcitability disorders (*e.g.* myoclonic cramping, epilepsy), excitotoxicity disorders and neurodegenerative diseases; overactivity or undesirable activity of endogenous cytoplasmic dynein heavy chain1; overexpression, over-production or under-production of endogenous cytoplasmic dynein heavy chain1; an excessive or undesirable condition shown to be modulated by endogenous cytoplasmic dynein heavy chain1.

25

Furthermore, the present invention provides mutated cytoplasmic dynein heavy chain1 nucleic acids and amino acids having modified sequences compared to the wild type sequence, as well as vectors and cell lines for expressing the muteins recombinantly. These mutated nucleic acids and amino acids may also be used in the diagnostic and therapeutic methods contemplated herein. In a specific embodiment, the cytoplasmic dynein heavy chain1 mutein has an amino acid substitution at a position that corresponds to a conserved amino acid of mouse or human cytoplasmic

30

dynein heavy chain 1 as described in an individualized manner in connection with the preferred muteins of the invention below. In a specific embodiment, the cytoplasmic dynein heavy chain1 mutein has an amino acid substitution, e.g., at position 1055 resulting from a point mutation at nucleotide +3169 of the coding sequence, corresponding to position 3328 of SEQ ID NO:1 (Genbank Acc. No. AY004877; murine Dnchc1 mRNA). Also provided are recombinantly generated cytoplasmic dynein heavy chain1 muteins of the invention (both the murine and human orthologs), as well as antibodies binding to these muteins, and chimeric protein derivatives of these cytoplasmic dynein heavy chain1 muteins.

10

Uses of these muteins as modulators (e.g. agonists or antagonists) of endogenous cytoplasmic dynein heavy chain1 activity are also contemplated. Consequently, pharmaceutical compositions comprising the cytoplasmic dynein heavy chain1 muteins of this invention with or without a pharmaceutically acceptable carrier are also contemplated. Specifically, the invention includes the use of the cytoplasmic dynein heavy chain1 muteins of the present invention, the polynucleotides encoding them, and vectors bearing said polynucleotides, for the prevention, treatment or amelioration of a medical condition in a mammalian subject, particularly a human subject. In particular, the invention provides the use of these muteins for the manufacture of a medicament for prevention, treatment or amelioration of any medical conditions characterized by movement hyperactivity, hyperexcitability disorders (e.g. myoclonic cramping, epilepsy), excitotoxicity disorders and neurodegeneration.

15

20

The invention also includes a method of gene delivery and expression in a target cell of a mammal, comprising the step of introducing a viral vector into the target cell, wherein the viral vector is derived from a virus that has a low replicative efficiency in the target cell and has at least one insertion site containing a wild type or mutant cytoplasmic dynein heavy chain1 nucleic acid, wherein the nucleic acid is operably linked to a promoter capable of expression in the host. In a preferred embodiment, the viral vector is a non-lytic viral vector.

25

30

The invention also provides a method of gene delivery and expression in a target cell of a mammal comprising the steps of: (a) providing an isolated nucleic acid

fragment of wild type or mutant cytoplasmic dynein heavy chain1 of the invention; (b) selecting a viral vector derived from a virus that has a low replicative efficiency in the target cell, wherein the vector has at least one insertion site for insertion of said isolated nucleic acid fragment operably linked to a promoter capable of expression in the target cells; (c) inserting the isolated nucleic acid fragment into the insertion site, and (d) introducing the vector into said target cell wherein said gene is expressed at detectable levels. In a preferred embodiment, the virus is selected from the group consisting of retrovirus, adenovirus, and pox virus. In another embodiment, the virus is a strain that has been genetically modified or selected to be non-virulent in a host. In another embodiment, the pox virus is vaccinia. In one embodiment, the virus is selected from the group consisting of retrovirus, adenovirus, iridoviruses, coronaviruses, togaviruses, caliciviruses and picornaviruses.

In the context of the present invention it has been recognized that all members (or subunits) of the dynein-dynactin complex should be considered as suitable targets for screening for a predisposition in hereditary and sporadic forms of motor neuron degenerative diseases like ALS (Amyotrophic Lateral Sclerosis), SMA (Spinal Muscular Atrophy), SBMA (Bulbo-Spinal Muscular Atrophy), PBP (progressive Bulbar Palpsy), PMA (Progressive Muscular Atrophy), and PLS (Primary Lateral Sclerosis). It is also contemplated that not only diseases such as ALS but also other neurodegenerative disorders will be connected to mutations or alterations within the dynein-dynactin complex. This applies, e.g., to disorders which are connected to axonal transport dysfunction such as Huntington's disease (dynein-dynactin binds Huntington associated binding protein 1 (Hap1)), Parkinson's disease (demonstration of inclusion body formation similar to ALS indicated intracellular transport errors) or Alzheimer's disease (disturbance of glutamate homeostasis similar to ALS could be a result of altered retrograde axonal transport kinetics). Thus, such neurodegenerative diseases are likewise disease targets contemplated e.g. in connection with the methods of screening for a predisposition for a neurodegenerative disease according to the present invention.

Accordingly, the present invention provides in a further embodiment a method of identifying a protein or nucleic acid marker indicative of an increased risk of a mammalian subject, particularly a human subject, or a mouse, a rat, a rabbit, a cow or

a hamster, preferably a mouse or a rat, of developing a neurodegenerative disease, said method comprising the step of analyzing a test sample derived from said subject for the presence of a difference compared to a similar test sample if derived from a subject of the same species unaffected by or known not to be at risk of developing said disease, wherein said difference is indicative of the presence of a mutation in an allele of a gene coding for a protein, which is a subunit of the dynactin/dynein complex.

In a further aspect, the present invention provides a method of identifying a protein or nucleic acid marker indicative of an association of a neurodegenerative disease in a mammalian subject, particularly a human subject, or a mouse, a rat, a rabbit, a cow or a hamster, preferably a mouse or a rat, with a mutation in an allele of a gene coding for a protein, which is a subunit of the dynactin/dynein complex.

In yet a further aspect of the present invention, a method is provided for identifying a predisposition of a mammalian subject, particularly a human subject, or a mouse, a rat, a rabbit, a cow or a hamster, preferably a mouse or a rat, for developing a neurodegenerative disease, said method comprising the step of determining whether a test sample derived from said subject indicates the presence of a mutation in an allele of a gene coding for a protein, which is a subunit of the dynactin/dynein complex, indicative of an increased risk of said subject of developing said neurodegenerative disease.

Also provided is a method for determining whether a neurodegenerative disease in a mammalian subject, particularly a human subject, or a mouse, a rat, a rabbit, a cow or a hamster, preferably a mouse or a rat, is associated with a mutation in an allele of a gene coding for a protein, which is a subunit of the dynactin/dynein complex, said method comprising the step of determining whether a test sample derived from said subject indicates the presence of a mutation in an allele of a gene coding for said protein.

In yet another aspect of the present invention, oligonucleotides suitable for identifying the above-mentioned mutations, kits containing such oligonucleotides, and

solid supports, such as DNA chips, to which said oligonucleotides are bound, are provided.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In addition, the examples are illustrative only and are not intended to be limiting.

Features and advantages of the invention in addition to those explained above will be apparent from the following detailed description and claims.

15

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 presents a heterozygous *Cra1* animal (right) compared to a wildtype mouse (left) demonstrating cramping of the hindlimbs and forelimbs of the mutant animal.

Figure 2 is a chart diagram, indicating movement as ambulatory activity expressed as beam breaks (average counts per hour) detected by a Cage Rack Photobeam Activity Cage System (San Diego Instruments, Inc., San Diego, CA, USA) of heterozygous *Cra1* (*Cra1*+) animals and wildtype individuals during four 6-hour periods of an artificial 24 hour diurnal cycle, in which darkness lasted from 6pm to 6am, and the period from 6 am to 6 pm was light.

25

Figure 3 is a listing of the latency to fall values (seconds) of heterozygous *Cra1* mice (*Cra1*+) and control individuals (+/+) in a semi-quantitative hanging wire assay. Muscle endurance of adult heterozygous *Cra1* individuals (*Cra1*+) was measured in comparison to wildtype individuals by measuring the mouse's latency to fall from an inverted wire grid, as described in Example 3.

30

Figure 4 depicts photomicrographs of hematoxylin and eosin (H&E) stained histological sections of a *Cra1/+* and a wildtype mouse hippocampus. Neurons characterized by reversible excitatory neuronal damage can be identified by the dark staining ("dark neurons"; indicated by arrows). (See Example 5)

5

Figure 5 depicts photomicrographs of cross sections of the lumbar area of spinal cords from a wild type (left panel) and a homozygous *Cra1/Cra1* individual (right panel). The top row photomicrographs depicts a drastic reduction of the number of neurons in the anterior horn area of the *Cra1/Cra1* individual (right), as compared to the wildtype (left). In the middle row, TUNEL stains of anterior horn are shown (see arrow), demonstrating significantly enhanced levels of apoptosis in the anterior horns of the *Cra1/Cra1* individuals (right). In the upper row of photomicrographs a reduction is seen in the number of spinal ganglia neurons of *Cra1/Cra1* individuals (right).

10
15

Figure 5.2 shows that progressive impairment of muscle function and motor coordination is associated with decreasing numbers of α -motor neurons and altered composition of muscle fibre types. Motor neuron degeneration in 16 month old *Cra1/+* heterozygotes (b, d, f) mice in comparison to wildtype (+/+) littermates (a, c, e) (a-d: immunohistochemistry using NeuN primary antibody; e, f: H&E histochemical staining). Loss of spinal α -motor neurons in 16 months old *Cra1/+* (h) mice is accompanied by altered composition of muscle fibre types, with a predominance of large type 1 fibres in Periodic acid-Schiff (PAS) staining, compared to +/+ littermates (g).

20
25

Figure 6 represents a list of selected genes expressed in fetal brain of individual *Cra1/Cra1* mice, shown to be transcriptionally deregulated by comparison of transcript levels to those detected in wildtype individuals. The direction of deregulation (up or down) and the biological significance of those genes is indicated.

30

Figure 7 schematically depicts an exon structure comparison of the human cytoplasmic dynein heavy chain1 (HsDNCH1) and the mouse cytoplasmic dynein heavy chain1 (MmDnchc1) genes. Exonic sequences were aligned with sequencer software (version 4.0.5, GeneCodes Corp., Ann Arbor Mi, USA). Assembly of the

human exons and the mouse exons, respectively, results in a full-length cDNA of human DNCH1 and a full-length cDNA of mouse Dnchc1 (representing the protein coding sequence within the mRNA, defined under GenBank Accession No. AY004877) as indicated by the arrows at the top of the figure. Equivalent exons are paired, with the human exon positioned above the corresponding mouse exon.

Figure 8 is a comparative listing of all exons of the mouse (MmDnchc1) and human (Hs DNCH1) dynein heavy chain1 genes. The size of each exon is indicated by its length in basepairs (bp). The human gene consists of 78 exons, and the mouse gene consists of 77 exons. The difference in exon number between these two species is caused by an additional RNA splice event in human, separating exon 67 (61 bp) and exon 68 (124 bp); mouse exon 67 having 185 bp.

Figure 9 depicts the amino acid sequence alignment between the human (Hs DNCH1) and the mouse (Mm Dnchc1) cytoplasmic dynein heavy chain1 proteins. Black boxes indicate amino acid identity, and grey boxes indicate conserved amino acid substitutions. The degree of identity is 97%.

Figure 10 depicts the amino acid sequence alignment between the human (Hs DNCH1), the mouse (Mm Dnchc1), and the rat cytoplasmic dynein heavy chain1 proteins, indicating highly conserved amino acid residues between species. Black boxes indicate amino acid identity, and grey boxes indicate conserved amino acid substitutions. The degree of identity is 96%.

Figure 11 depicts the amino acid sequence alignment between the human and the mouse cytoplasmic dynein intermediate chain 1 proteins. Black boxes indicate amino acid identity, and grey boxes indicate conserved amino acid substitutions. The degree of identity is 88%.

Figure 12 depicts the amino acid sequence alignment between the human, the mouse, and the rat cytoplasmic dynein intermediate chain 1 proteins, indicating highly conserved amino acid residues between species. Black boxes indicate amino acid identity, and grey boxes indicate conserved amino acid substitutions. The degree of identity is 87%.

Figure 13 depicts the amino acid sequence alignment between the human and the mouse cytoplasmic dynein intermediate chain 2 proteins. Black boxes indicate amino acid identity, and grey boxes indicate conserved amino acid substitutions. The degree of identity is 94%.

Figure 14 depicts the amino acid sequence alignment between the human, the mouse, and the rat cytoplasmic dynein intermediate chain 2 proteins, indicating highly conserved amino acid residues between species. Black boxes indicate amino acid identity, and grey boxes indicate conserved amino acid substitutions. The degree of identity is 93.5%.

Figure 15 depicts the amino acid sequence alignment between the human and the mouse DCTN1 proteins. Black boxes indicate amino acid identity, and grey boxes indicate conserved amino acid substitutions. The degree of identity is 97%.

Figure 16 depicts the amino acid sequence alignment between the human, the mouse, and the rat DCTN 1 proteins, indicating highly conserved amino acid residues between species. Black boxes indicate amino acid identity, and grey boxes indicate conserved amino acid substitutions. The degree of identity is 95%.

DETAILED DESCRIPTION OF THE INVENTION

This invention provides a non-human animal useful as a model of dynein heavy chain disorders in humans, particularly cytoplasmic dynein heavy chain1 disorders. The *Cral* mutation, disclosed herein, was generated in offspring of male C3HeB/FeJ mice (*Cral*, Institute of Mammalian Genetics at the GSF – National Research Center for Environment and Health) mutagenized with *N*-ethyl-*N*-nitrosourea (ENU). The mutation was detected by *Cral* mice displaying an unusual twisting of the body and clenching of the hindlimbs when suspended by the tail. Subsequent breeding and phenotype analysis showed *Cral* as an autosomal dominant trait that gives rise to progressive loss of muscle tone and locomotor ability in heterozygous mice, although life-span appears normal. Furthermore, *Cral*

heterozygotes were impaired in motor coordination tests and in muscle function tests. Homozygous *Cral* mice die shortly after birth, and exhibit increased neuronal apoptosis. It is predicted that these homozygous mice also have neuronal inclusion bodies that are positive for both neurofilaments and SOD1 protein. This result
5 implicates modulation of dynein gene function in mechanisms of human motor neuron degeneration, and cell death in general. It also shows an unexpected link between the dynein complex and SOD1 function that may shed further light on why SOD1 mutations cause motor neuron degeneration and ALS.

10 Dyneins are implicated in a number of different diseases and disorders. Abnormalities in axonal transport are described in the human disease ALS (Sasaki and Iwata (1996) *Neurology* 47, 535-540). Such abnormalities are also observed in several mouse models with motor neuron degeneration, *e.g.* the wobbler mouse (Mitsumoto *et al.* (1986) *Ann Neurol* 19, 36-43) and transgenic mice overexpressing the heavy chain
15 of neurofilament protein (Collard *et al.* (1995) *Nature* 375, 61-64), SOD-1 (Zhang *et al.* (1997) *J Cell Biol* 139, 1307-1315) and dynamitin (LaMonte *et al.* (2002) *Neuron* 34, 715-727). Studies in *Drosophila* have shown that mutations in the cytoplasmic dynein heavy chain (cDhc64c) lead to a disruption of axonal organelle transport in both directions and as a consequence to axonal swelling and posterior paralysis
20 (Martin *et al.* (1999) *Mol Biol Cell* 10, 3717-3728).

In contrast to the dynactin-overexpressing transgenic mouse described by LaMonte *et al.* ((2002) *Neuron* 34, 715-727) which is characterized by an indirect mechanism of inhibition of dynein function in only the neurons, the mouse mutant of
25 the present invention is suitable to investigate the role of cytoplasmic dynein heavy chain1 not only in transport processes in neurons but in all cell types expressing cytoplasmic dynein heavy chain1. Additionally, the mouse mutant of the present invention enables the analysis of cytoplasmic dynein malfunction during development whereas the transgenic mouse described by LaMonte *et al.* ((2002) *Neuron* 34, 715-
30 727) does not express the transgene before birth and, therefore, it is characterized by a late onset of symptoms. It has been shown that dynein can associate with its cargo also through interactions with proteins other than dynactin (for review: Karcher *et al.* (2002) *Trends in Cell Biology* 12, 21-27). Since the mutation found in the cytoplasmic dynein heavy chain 1 gene of the mouse mutant of the present invention

is located outside the binding site for the dynein intermediate chains which impart the binding of dynactin, the mouse mutant of the present invention will prove useful for studying dynactin-independent dynein functions.

5 Apart from diseases characterized by motorneuron degeneration other types of neurodegenerative diseases and age-related neurodegenerative processes may be related to disturbances of axonal transport. One example is the atrophy of basal forebrain cholinergic neurons in the rat which have been shown to be accompanied by an impairment of uptake or retrograde transport of tracer molecules (De Lacalle et al,
10 (1996) Neuroscience 75, 19-27). It is predicted that dynein function may play a role in the development of such neurodegenerative diseases and age-related neurodegenerative processes, and embodiments of the invention include correlative diagnostic methods, therapeutic medicaments and treatments, as described in greater detail below.

15

Another example is Huntington's disease. HAP1, a neuronal cytoplasmic protein, is associated with huntingtin, the protein which carries a polyglutamine repeat that is expanded in Huntington's disease (>36 units). It has been shown that the affinity of HAP1 for huntingtin is increased if the latter bears an expanded
20 polyglutamine repeat (cf Li et al. (2002) J Biol Chem, in press). HAP1 has been found on synaptic vesicles (Gutekunst et al. (1998) J Neurosci 18, 7674-7686) and it binds to P150 (Li et al. (1998) J Biol Chem 273, 19220-19227), the largest subunit of the dynactin complex, which in turn, is required for cytoplasmic dynein mediated intracellular movement including retrograde axonal transport. Functional results
25 obtained by Block-Galarza ((1997) Neuroreport 8, 2247-2251) are in agreement with this potential link between huntingtin and dynein-mediated axonal transport processes. Additionally, Li et al. ((2002) J Biol Chem, in press) provided evidence that HAP1 is involved in the regulation of vesicular trafficking from early endosomes to the late endocytotic compartment as does dynein (Apodaca (2001) Traffic 2, 149-159).
30 Recent work by Kamal et al. (2000, Neuron 28, 449-459) suggests that the amyloid precursor protein (APP), which plays a major role in the development of Alzheimer's disease might function as a membrane bound cargo receptor for kinesin which is responsible for the anterograde transport of vesicles in neurons. Gunawardena and Goldstein ((2001) Neuron 32, 389-401) again found that the axonal transport

phenotypes of certain Appl (the Drosophila homolog of APP) mutants are suppressed by a reduction of dynein expression. This result for the first time suggests a functional link between dynein and APP.

5 The mouse mutant of the present invention provides a means to analyze whether three proteins (huntingtin, HAP1 and APP) involved in the pathogenesis of the neurodegenerative diseases, Huntington's disease and Alzheimer's dementia are linked by the same intracellular transport pathways. This connection will help reveal the pathogenetic mechanisms of both diseases.

10

Lissencephaly syndromes are a family of diseases which involve incomplete development of the human brain (Dobyns et al. (1993) JAMA 270, 2838-2842) characterized by extensive disorganization of cortical neurons. This defect is thought to be due to a failure of the capability of neuronal cell body migration during the early stage of brain development. As a consequence of this, the convolutions characteristic of the normal brain surface are reduced in extent and number leading to a smooth appearance of wide portions of the brain.

15

Syndromes involving lissencephaly include Norman-Roberts Syndrome, Fukuyama Syndrome, Walker-Warberg Syndrome and Miller-Dieker Syndrome. Some cases of isolated lissencephaly have been shown to arise from mutations in the LIS-1 gene (e.g. Lo Nigro et al. (1997) Hum Mol Genet 6, 157-164).

20

Recent work has implicated the human LIS-1 gene in the regulation of function of cytoplasmic dyneins (for review see Vallee et al. (2000) Biochim Biophys Acta 1496, 89-98). Neurons in genetic mosaics of Drosophila which contain a mutated cytoplasmic dynein heavy chain (Dhc64C) display phenotypes similar to Lis 1 mutants (Liu et al. (2000) Nat Cell Biol 2, 776-783). We predict that deregulation of cytoplasmic dynein might be of causative relevance for the development of lissencephalic symptoms.

25

30

Homozygous null mice for the Lis1 gene die early in embryogenesis whereas mice bearing mutations which cause different degrees of reduction of the function of Lis1 exhibit corresponding degrees of brain disorganization as well as cerebellar

defects (Hirotsume et al. (1998) Nature Genetics 19, 333-339). The mouse mutant of the present invention provides a mean to comparatively analyze the overlap and the differences of cytoplasmic dynein and Lis 1 function in a mammalian model organism.

5

The homozygous knockout of the gene encoding cytoplasmic dynein heavy chain1 in the mouse results in embryonic lethality before 8.5 days post coitus. Heterozygous individuals have no obvious phenotype (Harada et al. (1998) J Cell Biol 141, 51-59). The transgenic dynamin-overexpressing mouse described by LaMonte et al. ((2002) Neuron 34, 715-727) is characterized by a motoneuron specific inhibition of the functions of cytoplasmic dynein, which is mediated by the accessory protein complex dynactin. Due to the developmental regulation of the transgene by the Thy2 promotor of the transgene construct, inhibition is restricted to postnatal stages.

15

There is no animal model available which reflects the consequences of malfunction of cytoplasmic dynein heavy chain1 in vivo in all types of cells and during embryonic and fetal development. The mutation leading to cytoplasmic dynein heavy chain1 dysfunction in the mouse model of the present invention is located within a region of cytoplasmic dynein heavy chain1 dimerization (Tynan et al. (2000) J Biol Chem 275, 32769-32774) which does not overlap with intermediate chain binding. Intermediate chain binding is required for dynactin binding although Vaughan and Vallee ((1995) J Cell Biol 131, 1507-1516) and Tynan et al. ((2000) J Biol Chem 275, 32769-32774) have provided evidence for the existence of non-dynactin based cargo binding mechanisms.

25

The characterization of such an animal model (*i.e.* one that reflects the consequences of malfunction of cytoplasmic dynein heavy chain1 *in vivo* in all types of cells and during embryonic and fetal development) would provide a model for determining the consequences of cytoplasmic dynein malfunction in humans. This in turn would help to evaluate the role of dynein malfunction in various disease processes such as those described above.

30

The present invention provides a non-human animal model which expresses a modified cytoplasmic dynein heavy chain1 protein compared to the amino acid sequence of the wild type protein. The expressed cytoplasmic dynein heavy chain1 may have similarity in sequence and secondary structure to a vertebrate cytoplasmic dynein heavy chain1. In a preferred embodiment, the vertebrate is preferably from a genus selected from the group consisting of *Homo sapiens*, *Mus musculus* (e.g. mice), *Rattus* (e.g. rats), *Oryctolagus* (e.g. rabbits) and *Mesocricetus* (e.g. hamsters).

Animals carrying a mutated cytoplasmic dynein heavy chain1 allele expressing the modified cytoplasmic dynein heavy chain1, exhibit a variety of phenotypical features including: myoclonic cramps (which are especially pronounced in the hindlimbs), movement hyperactivity, reduced muscle endurance, excitatory neuronal damage ("dark neurons") in the hippocampus (gyrus dentatus, CA4, CA3) as well as in the upper layer of the cortex and in the Purkinje cell layer of the cerebellum. These animals also exhibit decreasing numbers of α -motor neurons and altered composition of musculus vastus fibre types.

Compared with heterozygous animals, homozygous individuals exhibit an elevated incidence of perinatal lethality (100% in homozygous animals, *versus* approximately 20% amongst heterozygous animals), accelerated neurondegeneration in the anterior horns of the spinal cord, and accelerated neurodegeneration in the dorsal root ganglia. Neurodegeneration in heterozygous animals is apparent at a much later stage, *i.e.* late adulthood.

The observed neurological phenotype of myoclonic cramping and epilepsy in combination with the morphological correlate of reversible excitatory neuronal cell stress within the hippocampal layers CA4 and CA3 are indications for a hyperexcitability status in Cra1 animals. This in turn is consistent with an ambulatory locomotor hyperactivity of Cra1 animals. Hyperexcitation, if occurring repeatedly or continuously over longer periods of time, could result in excitotoxicity by mechanisms such as enhanced generation of reactive oxygen species (ROS) (see Haberny *et al.* (2002) Toxicol Sci, 68, 9-17; Bondy and LeBel, (1993) Free Radic Biol Med 14, 633-642; Tapia *et al.* (1993) Neurochem Int 34, 23-31; Niebroj-Dobosz *et al.* (2002) Acta Neurol Scand 106, 39-43; Shaw and Bains (2002) Cell Mol Biol

(Noisy-le-grand) 48, 127-136). ROS are suggested to be involved in the development of several neurodegenerative disorders, *e.g.* ALS, Parkinson's disease and Alzheimer's disease as well as aging. Therefore there is a possible link between the hyperexcitation status in Cral animals and the development of neurodegeneration at a later age.

The term "modified" according to the present invention refers to an alteration compared to the wild type. The term "phenotype" according to the invention refers to a collection of morphological, physiological, behavioral and biochemical traits possessed by a cell or organism that results from the interaction of the genotype and the environment. As mentioned above, the animal model of the present invention displays readily observable abnormalities. In a preferred embodiment the animal of the invention shows at least 2, preferably at least 4, more preferably 6 and most preferably all of the above listed phenotypical features.

Nucleic Acids

The present invention provides nucleic acid sequences encoding wild type and mutated murine and human cytoplasmic dynein heavy chain1 proteins, *i.e.*, muteins as described in an individualized manner in connection with the preferred muteins of the invention below. Specifically, this invention provides mutated nucleic acid sequences for wild type murine cytoplasmic dynein heavy chain1 mRNA (GenBank Accession Number AY004877.1, SEQ ID NO:1). For example, a mutated version of SEQ ID NO:1, containing a point mutation at position 3328 (which is position +3164 of the polypeptide coding sequence) is shown in SEQ ID NO:3. In addition, this invention provides a mutated coding nucleic acid sequence for human cytoplasmic dynein heavy chain1 containing the open reading frame for the human ortholog nucleic acid sequence, with a point mutation at the corresponding position (position +3170) in the sequence, as shown in SEQ ID NO:5. In addition, this invention provides the wild type coding nucleic acid sequence for human cytoplasmic dynein heavy chain1, as shown in SEQ ID NO:17.

Table 1. GenBank Accession Number AY004877.1 (SEQ ID NO:1)

gi|9717244|gb|AY004877.1| Mus musculus cytoplasmic dynein heavy chain1 mRNA, complete cds

GCCGCGTCGACAGCCGGCTCCGCTGTCCGCAGTCGGCCGCGGGTT
AGCGGGCAGAGCGTCTCCTGTGCGCGGTTCCCCTCGCTTACTGCT
CTCTCGTGCCGGAGGCCGCTCCTCTCGGCTCTCGCTCTCTCTTT
5 TCTATCTCTCTCCCTTCCGCGGATCCGCCATGTCGGAGCCGGGCG
GCGGCGAGGACGGCTCGGCAGGCCCTGGAGGTGTCGGCGGTGCAGA
ATGTGGCGGACGTGGCGGTGCTGCAGAAAGCACCTGCGTAAGCTGG
TGCCGCTGCTGCTGGAGGACGGCGGCGACGCGCCGGCTGCGCTGG
AGGCGGCGCTGGAGGAGAAGAGCGCCCTGGAGCAGATGCGCAAGT
10 TCCTGTCAGACCCGCAGGTCCACACGGTCCTGGTGGAGCGCTCCA
CCCTCAAAGAGGACGTGGTGATGAAGGAGAAGAGGAGAAAGAAT
TCATTTCTATAACATCAACATAGACATTATTACGGGGTAAAGT
CCAACAGCTTGGCGTTTCATCAAGCGAGCTCCTGTGATTGATGCAG
ACAAGCCAGTGTGCTCCAGCTCCGAGTCCTCACTCTGAGTGAAG
15 ACTCGCCGTATGAGACACTGCACTCTTTCATCAGCAATGCAGTGG
CTCCTTTCTTTAAGTCCTACATCAGAGAGTCTGGCAAAGCAGACA
GGGATGGTGATAAGATGGCTCCTTCAGTTGAAAAAAGATTGCAG
AGCTTGAAATGGGACTCCTCCACCTGCAGCAGAACATTGAGATCC
CAGAGATCAGCTTGCCAAATTCATCCCATCATCACGAACGTTGCGA
20 AGCAGTGCTATGAGCGCGGAGAAAAGCCCAAAGTTACAGATTTTG
GTGATAAGGTTGAAGACCCAACTTTCCTTAACCAATTACAGTCTG
GAGTTAATCGGTGGATCCGAGAAATTCAAAGGTGACCAAGCTTG
ACCGGGATCCAGCATCAGGAACCTGCCTTGCAAGAAATCAGCTTTT
GGCTAAACTTGGAACGTGCGTTGTACCGCATCCAAGAGAAGCGGG
25 AGAGCCCCGAGGTGCTCCTGACTCTGGACATCCTGAAGCATGGCA
AACGTTTCCATGCCACTGTCAGTTTTTGACACTGACACAGGTCTGA
AGCAGGCGTTGGAACGGTGAATGACTACAACCCTCTGATGAAAG
ACTTCCCTCTGAATGACTTGCTGTCTGCCACGGAGCTGGACAAGA
TAAGGCAGGCCCTTGTTGCAATTTTTCACACATCTGAGAAAGATCC
30 GCAACACGAAGTACCCGATTTCAGCGGGCCCTGCGTCTCGTGGAGG
CCATCTCCAGAGACCTGAGTTCTCAGCTGCTCAAGGTCTTGGGCA
CTCGGAAGTTGATGCATGTAGCCTATGAAGAGTTTGAAAAGGTCA
TGGTGGCTTGCTTCGAAGTCTTCCAGACGTGGGACGACGAGTACG
AGAAGCTCCAGGTGCTGCTGCGAGACATCGTCAAGAGGAAGCGGG
35 AGGAGAACCTGAAGATGGTGTGGCGCATCAACCCCGCTCACAGGA
AGCTTCAGGCCCGCCTCGACCAGATGAGGAAGTTCCGCCGCCAGC
ACGAGCAGCTGAGGGCTGTCATTGTCAGGGTCCTGAGGCCACAGG
TCACAGCAGTCGCACAACAGAACCAAGGAGAAGCACCTGAACCCC
AAGACATGAAAGTGGCCGAGGTGCTCTTTGATGCTGCCGACGCCA
40 ACACCATTGAGGAGGTGAACCTGGCCTACGAGAATGTCAAGGAAG
TCGATGGTCTGGATGTTTCCAAAGAAGGGACGGAGGCCTGGGAGG
CCGCGATGAAGAGATACGATGAGAGGATCGACCGTGTGGAGACCC
GCATCACCGCCCGCCTCCGAGATCAGCTCGGCACGGCCAAGAATG
CCAATGAGATGTTTCAGGATTTTCTCCAGGTTCAATGCACTGTTCTG
45 TCCGCCCACACATCCGAGGGGCCATTCTGTAATACCAGACCCAGC
TGATCCAACGTGTGAAAGATGACATCGAATCTCTGCACGACAAGT
TCAAGGTCCAGTACCCGCAAAGCCAAGCTTGTAATAATGAGTCATG
TCCGTGACCTGCCCCCGTGTGAGGGTCTATCATCTGGGCTAAAC
AGATCGACAGACAGCTCACTGCCTACATGAAGCGAGTGGAGGATG
50 TCCTGGGCAAAGGCTGGGAGAACCACGTGGAAGGGCAGAAGCTGA
AGCAGGATGGAGACAGCTTCCGAATGAAGCTCAACACCCAGGAGA
TCTTCGATGACTGGGCGAGGAAGGTTTCAGCAGCGCAACCTTGGTG
TCTCCGGGCGCATCTTACCATTGAGAGCGCTCGCGTGCGGGGCC
GCACTGGGAATGTCTCAAGCTAAAGGTGAACTTCTTCCAGAGA
55 TCATAACACTCTCCAAAGAAGTCCGGAACCTCAAGTGGCTTGGCT
TCCGAGTGCCACTTGCAATTGTGAACAAGGCTCACCAAGCCAACC

AGCTCTACCCATTTGCCATCTCGCTGATTGAAAGCGTCCGGACTT
ACGAGCGCACCTGTGAGAAGGTGGAGGAGCGCAATACCATTTCCC
TGCTAGTGGCCGGCCTAAAGAAGGAGGTGCAGGCCTTAATCGCAG
AAGGCATCGCGTTGGTGTGGGAGTCCTACAAGCTCGACCCCTACG
5 TGCAGCGCCTGGCAGAGACGGTTTTCAACTTCCAGGAGAAGGTGG
ACGACCTACTGATTATTGAGGAAAAGATAGACCTGGAGGTCCGCT
CCTTGGAAACCTGCATGTATGACCACAAGACATTCTCAGAGATCT
TGAACAGAGTGCAGAAAGCAGTGGACGACCTAAACCTGCACTCCT
ATTCCAATCTGCCCATCTGGGTCAACAAGCTGGACATGGAGATTG
10 AAAGGATACTGGGCGTCCGCCTGCAAGCTGGCCTTCGAGCTTGA
CCCAGGTTCTTCTTGGACAAGCTGAGGATAAAGCAGAAAGTCGACA
TGGATACAGATGCTCCACAAGTCAGTCACAAGCCTGGTGGAGAGC
CCAAGATCAAAAACGTGGTTCACGAGCTGAGGATAACAAATCAGG
TCATCTATCTGAACCCACCCATTGAGGAGTGCAGGTACAAGCTGT
15 ACCAGGAGATGTTGCGGTGGAAGATGGTTGTGCTGTCCCTGCCCA
GGATCCAGAGCCAGAGGTACCAGGTGGGAGTGCATTACGAGTTGA
CGGAGGAAGAGAAGTTCTATCGGAATGCACTGACAAGGATGCCCG
ACGGCCCTGTGCGCCTGGAAGAGTCTACTCTGCGGTGATGGGCA
TAGTGACTGAAGTTGAGCAGTATGTTAAGGTTTGGCTTCAGTACC
20 AGTGTGTTGTGGGATATGCAGGCAGAAAACATTTACAACAGGCTAG
GGGAAGATCTCAACAAGTGGCAAGCTCTCCTGGTCCAGATAAGGA
AAGCCAGAGGAACCTTTGACAATGCGGAAACCAAGAAAGAGTTTG
GTCCGGTGGTGATAGATTACGGCAAGGTCCAGTCCAAGGTGAACT
TGAAGTATGACTCCTGGCATAAAGGAGGTTCTCAGCAAGTTTGGGC
25 AGATGCTGGGCTCAAACATGACAGAATTCCACTCCCAGATCTCAA
AGTCTCGCCAAGAGCTGGAGCAGCACTCCGTTGACACAGCCAGTA
CCTCTGACGCGGTGACCTTCATCACCTATGTGCAGTCTCTGAAAC
GGAAGATCAAACAGTTTGAGAAGCAAGTTGAACTCTACCGCAATG
GTCAGCGTCTGCTGGAAAAACAAAGGTTCCAGTTCCCGCCTTCTT
30 GGCTTTACATTGACAACATCGAGGGTGAGTGGGGGGCCTTCAATG
ACATCATGCGGCGGAAGGACTCTGCCATTCAGCAACAGGTGGCAA
ACCTGCAAATGAAGATCGTACAGGAGGACAGAGCTGTGGAAAGCC
GGACCACGGATCTGTTGACAGACTGGGAGAAGACCAAACCTGTCA
CAGGCAATCTGCGTCCTGAGGAGGCTCTTCAGGCCCTCACCATAT
35 ATGAAGGGAAGTTGCGCCGGCTGAAGGACGACAGAGAGAAATGTG
CAAAGGCTAAGGAAGCGTTGGAACCTCACAGACACAGGCCTCCTCA
GTGGCAGTGAAGAGCGTGTACAGGTGGCCTTGGAGGAGTTACAAG
ACCTCAAAGGTGTGTGGTCAGAGCTTTCTAAGGTCTGGGAACAAA
TTGATCAAATGAAGGAGCAGCCGTGGGTCTCCGTTTCAGCCTCGGA
40 AGCTTCGACAAAACCTAGACGGCCTCTTGAACCAGCTGAAGAACT
TCCCTGCGAGGCTTCGGCAGTATGCTTCCTATGAGTTTGTTCAGA
GGCTGCTGAAAGGCTACATGAAGATAAACATGTTGGTAATTGAAC
TGAAATCAGAAGCACTCAAAGACCGGCACTGGAAACAGCTGATGA
AGAGGCTTCATGTAACTGGGTGGTTTCTGAGCTGACGCTGGGCC
45 AGATCTGGGACGTGGACCTTCAGAAGAACGAAGCTGTGCTCAAGG
ATGTGCTGCTGGTGGCACAAAGGCGAGATGGCCTTGGGAAGAATTTT
TGAAGCAGATACGAGAAGTGTGGAACACATACGAACCTAGACTTGG
TCAACTATCAGAACAAATGCCGCCTCATCCGAGGCTGGGATGACC
TCTTCAACAAGGTCAAGGAGCATATCAACAGCGTCTCTGCCATGA
50 AACTCTCTCCCTATTACAAGGTTTTTTGAAGAAGATGCCCTGAGCT
GGGAGGACAAGCTGAACCGAATCATGAGTCTCTTTGACGTGTGGA
TTGACGTGCAGAGGCGCTGGGTCTACTTGGAAGGCATCTTCACAG
GCAGTGCGGACATCAAACATCTGCTGCCTGTGGAAACCCAGCGCT
TCCAGAGTATCAGCACGGAGTTTTTTGGCTCTGATGAAAAAAGTCT
55 CCAAGTCTCCACTTGTGATGGATGTTCTGAACATACAGGGAGTCC
AGAGGTCTCTGGAAAGGTTGGCAGACCTGCTGGGGAAGATCCAGA

AAGCATTGGGGGAGTACCTGGAACGGGAGCGCTCGTCTTTCCCCA
GGTTCTACTTTGTGGGTGATGAGGATTTGCTTGAGATCATTGGGA
ATAGCAAGAACGTGGCTAAGTTGCAGAAGCACTTCAAGAAAATGT
TCGCCGGCGTTTCCAGCATCATCTTAAATGAGGATAACTCTGTGG
5 TCCTCGGCATCTCATCCCGAGAAGGGGAGGAGGTTATGTTTAAAA
CTCCAGTGTCCATCACTGAACACCCCCAAAATCAATGAGTGGCTCA
CTCTGGTGGAAAAGGAGATGAGAGTCACCTTGGCTAAACTTCTGG
CAGAGTCTGTTACAGAAGTGGAGATTTTTTGGAAAAGCAACTTCTA
TTGACCCAAATACCTACATTACTTGGATTGATAAATACCAGGCCC
10 AGCTAGTGGTATTGTGTCAGCCCAGATAGCCTGGTCCGAGAACGTGG
AGAATGCGCTGAGCAACGTTGGGGGAGGTGGTGTATGTGGGGCCCT
TGCAGTCTGTGCTGAGCAATGTGGAGGTCACACTCAACGTCTTAG
CGGACTCTGTCTCATGGAGCAGCCTCCTCTCCGGAGACGGAAGC
TGGAGCACTTGATCACAGAGCTGGTTCACCAAAGAGACGTTACCA
15 GGTCCTTGATCAAAAGCAAGATCGACAACGCCAAATCTTTCGAAT
GGCTCAGCCAGATGCGATTTTACTTTGACCCTAAGCAAACGGACG
TGTTACAGCAGCTGTCCATTGAGATGGCCAATGCCAAGTTTAACT
ACGGCTTTGAGTACCTGGGTGTTCAAGACAAGCTGGTTCAGACGC
CCCTCACTGACCGTTGCTATTTGACAATGACACAAGCTTTGGAGG
20 CCAGGCTTGGGGGCTCCCCATTTGGACCTGCTGGAACCGGAAAGA
CGGAGTCCGTCAAAGCCCTCGGCCATCAGCTGGGGCGGTTTCGTCT
TAGTTTTCAACTGTGACGAAACCTTTGATTTCCAGGCGATGGGAC
GTATCTTTGTGGGGCTTTGCCAAGTGGGCGCGTGGGGCTGCTTTG
ATGAGTTTAACCGCCTGGAGGAGCGGATGCTCTCAGCTGTATCCC
25 AGCAGGTGCAGTGCATACAAGAGGCACTGCGGGAGCATTCCAACC
CCAACCTACGACAAGACCTCAGCCCCCATTACTTGTGAGCTGCTGA
ACAAACAAGTCAAGGTTAGCCCAGACATGGCTATCTTCATCACCA
TGAACCCAGGCTATGCAGGTGCGTCAAACCTCCCCGACAACCTCA
AGAAGCTCTTCCGGAGCTTGGCGATGACCAAGCCTGACCGGCAGC
30 TGATCGCCCAGGTGATGCTGTACTCGCAGGGCTTCCGGACTGCTG
AGGTCTTTGCCAACAAGATCGTCCCGTTCTTCAAACGTGTGTGATG
AGCAACTGTCTTCTCAAAGCCATTATGACTTTGGGCTTTCGGGCTT
TGAAGAGTGTGCTTGTAAGTGCAGGCAATGTGAAGAGGGAGAGGA
TCCAGAAGATAAAGAGGGAGAAAGAAGAACGGGGGGAAGCAGTTG
35 ATGAAGGAGAGATCGCTGAGAACCTACCTGAGCAGGAGATTCTGA
TCCAGAGTGTCTGCGAGACAATGGTGCCCAAGCTGGTGGCAGAAG
ATATCCCGCTGCTCTTCAGCCTCCTGTCTGACGTGTTCCTGGAG
TCCAGTACCACCGTGGGGAGATGACAGCCCTTCGAGAAGAGCTGA
AGAAAGTGTGTCAGGAGATGTACTTGACATATGGCGACGGAGAAG
40 AAGTTGGCGGGATGTGGGTTGAAAAGGTTCTCCAGCTCTATCAGA
TCACGCAGATTAACCACGGCCTGATGATGGTTGGGCCTTCAGGAA
GTGGGAAGAGCATGGCCTGGCGAGTGCTGCTGAAGGCTCTAGAGA
GGCTTGAGGGTGTGGAGGGCGTGGCCACATAATTGACCCCAAGG
CCATCAGCAAAGACCACCTCTACGGAACCTTGGATCCCAACACCA
45 GGGAGTGGACAGACGGACTCTTCACACACGTGCTGAGAAAGATCA
TAGACAATGTGAGAGGTGAGCTGCAGAAACGCCAGTGGATTGTCT
TTGATGGCGATGTGGACCCCGAGTGGGTGGAGAACCTGAACTCCG
TGCTGGATGACAACAAGCTCCTGACGCTGCCTAATGGAGAGCGCC
TTAGCCTGCCTCCCAATGTGCGGATAATGTTTGAAGTGCAGGACT
50 TGAATAACGCGACGCTGGCCACGGTGTCTCGCTGTGGCATGGTGT
GGTTCAGTGAGGACGTCTTGAGCACAGACATGATCTTAAATAACT
TCCTGGCCAGGCTGCGCAGCATTCCCCTGGATGAAGGGAGGACG
AGGCACAGCGTAGGCGAAAAGGCAAAGAAGACGAGGGCGAAGAGG
CGGCTTCTCCAATGCTACAGATTCAAAGAGATGCAGCAACGATCA
55 TGCAGCCGTACTTCACGTCCAACGGCCTGGTCACCAAGGCGCTGG
AGCACGCCTTCAAGCTGGAGCACATCATGGACCTGACGCGCCTGC

GCTGCCTGGGCTCGCTCTTCTCCATGCTGCACCAGGCCTGCCGCA
ACGTGGCGCAGTACAATGCCAACCATCCTGATTTCCCCATGCAGA
TTGAGCAGCTGGAGCGCTACATTCAGCGCTATCTGGTTTACGCCA
TCCTCTGGTCCTTATCTGGAGACAGCCGGCTGAAGATGAGAGCAG
5 AGCTGGGCGAGTACATCCGGAGGATCACCCTGTGCCGCTGCCCA
CTGCGCCCAACGTCCCCATCATTGACTATGAGGTGTCCATCAGTG
GAGAGTGGTTCGCCGTGGCAGGCCAAGGTGCCTCAGATTGAAGTGG
AGACACACAAGGTGGCAGCCCCAGATGTCGTCGTGCCAACCTTAG
ATACAGTCCGCCATGAAGCTCTCCTGTACACTTGGCTGGCTGAAC
10 ACAAACCCCTGGTCTTATGTGGCCCTCCTGGGTCTGGCAAGACCA
TGACACTCTTCAGTGCTCTCCGGGCCTTGCTTGACATGGAGGTTG
TGGGCCTAACTTCTCAAGTGCCACTACACCAGAGCTGTTGCTGA
AGACGTTTGACCACTACTGCGAATACAGGCGCACACCTAACGGTG
TTGTCTTGGCTCCTGTTTCAAGTGGCTGGTCTTGTCTCT
15 GTGATGAAATCAACTTGCCCGATATGGATAAATACGGCACACAGA
GAGTCATCTCCTTCATCAGACAGATGGTGGAGCATGGAGCCTTCT
ATCGTACCTCAGACCAAACGTGGGTAAAGCTAGAGAGAATCCAGT
TTGTTGGGGCTTGCAATCCACCCACTGACCCTGGGAGAAAGCCCC
TCTCACACAGGTTCTTGCGCCACGTGCCTGTTGTATATGTGATT
20 ACCCAGGACCAGCCTCCCTGACGCAAATCTATGGCACCTTCAACC
GCGCCATGCTGAGGCTCATTCCCTCTCTCCGTACCTATGCAGAAC
CCCTCACTGCCGCCATGGTGGAGTTCTATACCATGTCACAGGAGC
GGTTTACTCAGGACACACAGCCACACTATATCTACTCGCCCCGTG
AGATGACTCGGTGGGTAAGAGGAATCTTTGAAGCACTGAGACCCC
25 TGGAGACATTGCCTGTTGAAGGTCTCATTTCGTATTTGGGCACATG
AAGCCCTCCGTCTCTTCCAAGACAGGCTTGTGGAGGATGAGGAGC
GGCGCTGGACTGACGAAAACATTGACATGGTTGCCTTGAAGCACT
TCCCTAACATAGACAAAGAGAAAGCCATGAGCCGGCCTATCCTGT
ACAGCAACTGGCTGTCAAAGGATTATATCCCAGTTGACCAAGAAG
30 AGCTAAGGGATTATGTCAAGGCTAGGCTGAAGGTCTTCTATGAAG
AAGAACTTGATGTTCCCTTGGTCTTGTTCATGAAGTTCTGGACC
ATGTGCTGAGGATAGACAGAATATTCCGACAACCTCAAGGCCATC
TGCTTCTGATTGGTGTAGTGGAGCTGGAAAAACCACCTGTCTC
GCTTTGTGCGCTGGATGAATGGCTTGAGTGTATACCAGATTAAGG
35 TCCACAGGAAGTACACTGGGGAAGACTTCGATGAAGATCTTAGGA
CAGTGCTGAGACGGTCTGGCTGTAAAAATGAAAAGATAGCATTCA
TAATGGATGAGTCCAACGTCTTAGATTCCGGATTCTTGAACGAA
TGAATACCCTTCTGGCTAATGGCGAGGTTCTTGGGCTCTTTGAAG
GGGATGAGTACGCCACGCTGATGACACAGTGCAAAGAGGGGGCCC
40 AGAAGGAGGGGCTCATGCTGGACTCCCACGAGGAGCTCTACAAGT
GGTTCAACCAGCCAGGTGATCCGCAACCTGCACGTGGTCTTCACCA
TGAACCCGTCCTCAGAGGGGCTCAAGGACAGGGCGGCCACCTCAC
CAGCCCTTTTCAACAGGTGTGTGCTGAACTGGTTTGGTGACTGGT
CCACTGAAGCACTGTATCAAGTCGGCAAAGAATTCACCAGTAAGA
45 TGGACCTGGAGAAGCCGAACATATAGTGCCTGACTACATGCCAG
TTGTGTATGATAAACTGCCGCAGCCCCAACACACCGGGAAGCCA
TTGTGAACAGCTGTGTGTTTGTCCATCAGACTCTTCACCAGGCTA
ATGCGCGCCTGGCGAAGCGAGGTGGCAGAACGATGGCCATCACAC
CTCGGCACTACCTGGACTTCATCAACCACTACGCCAACCTCTTCC
50 ATGAGAAGCGCAGCGAGTTGGAGGAGCAGCAGATGCACCTGAATG
TTGGGCTCCGAAAAATCAAAGAGACCGTGGACCAGGTGGAAGAAC
TGCGCCGTGACCTGAGGATCAAGAGCCAAGAGCTGGAGGTCAAGA
ACGCAGCGGCAATGACAAGCTGAAGAAAATGGTGAAAGACCAGC
AAGAGGCTGAGAAGAAGAAGGTGATGAGCCAAGAAATCCAGGAGC
55 AGCTACACAAACAGCAGGAAGTGATCGCAGACAAGCAGATGAGTG
TCAAGGAGGACCTGGATAAAGTGGAGCCTGCTGTCATCGAGGCCC

AGAACGCTGTGAAGTCCATCAAGAAGCAGCACCTGGTGGAGGTGA
GGTCCATGGCCAACCCTCCTGCAGCTGTGAAGCTGGCTCTGGAGT
CCATCTGCCTGCTGCTTGGTGAGAGCACCACGGACTGGAAGCAGA
TCCGCTCCATCATCATGAGAGAGAACTTCATCCCCACCATCGTCA
5 ACTTCTCGGCTGAGGAGATCAGTGATGCCATACGAGAGAAGATGA
AGAAAACTACATGTCCAACCCCAGTTACAACATATGAGATCGTCA
ACCGGGCTTCCCTGGCTTGTGGTCCTATGGTGAAGTGGGCGATTG
CACAGCTCAATTATGCAGACATGTTAAAGCGAGTGGAGCCCCTGA
GGAATGAGCTGCAGAAGCTGGAAGATGACGCCAAGGACAACCAGC
10 AGAAAGCCAATGAGGTGGAGCAGATGATCAGGGACCTGGAAGCCA
GCATTGCCCCTACAAGGAGGAGTACGCTGTCCTCATCTCTGAGG
CCCAGGCCATCAAGGCAGACCTGGCAGCTGTGGAAGCAAAGGTAA
ACCGGAGCACTGCACTTCTAAAGAGTTTATCTGCCGAAAGGGAAC
GTTGGGAAAAGACGAGTGAACTTTCAAAAACCAGATGTCTACCA
15 TTGCTGGGGACTGCCTCCTGTGCGCGGCCTTCATTGCTTACGCTG
GCTACTTTGACCAGCAAATGCGCCAGAACTTGTTACCACTGGT
CTCATCACTTACAGCAAGCCAACATCCAGTTCGCGACAGACATTG
CAAGGACGGAGTACCTCTCCAATGCTGACGAACGCCTCCGCTGGC
AGGCCAGCTCTCTGCCTGCCGACGACCTGTGCACAGAGAATGCCA
20 TCATGCTAAAACGATTCAATAGGTACCCGCTGATCATCGACCCCT
CCGGACAGGCCACAGAATTCATCATGAATGAATATAAGGACCGGA
AGATCACAAGGACCAGCTTCTTAGATGATGCCTTCCGGAAGAATT
TGGAGAGTGCTCTGAGATTTGGCAATCCCCTTCTTGTCAGGATG
TGGAAAGCTACGATCCAGTTTTGAATCCAGTACTGAACCGTGAAG
25 TTCGGCGAACAGGAGGGAGGGTGCTGATTACCCTCGGTGACCAAG
ACATAGACCTGTCACCATCCTTTGTCATCTTTCTGTCTACCCGAG
ACCCAATGTGGAGTTCCCACCAGACCTCTGCTCCCGGGTGACCT
TTGTGAACTTCACCGTCACCCGCAGCAGTTTACAGAGCCAGTGTG
TCAATGAAGTGCTTAAAGCAGAAAGGCCAGACGTGGACGAGAAGC
30 GCTCCGACCTCCTGAAACTGCAAGGGGAGTTCCAATCCGTTTAC
GGCAGCTTGAAAAGTCTCTGCTCCAAGCTCTGAATGAGGTAAAAG
GCCGCATTCTGGTTGACGACACCATCATTACAACCCTGGAGAATC
TGAAGCGGGAAGCTGCCGAGGTTACCAGAAAGGTGGAGGAGACAG
ATATTGTCATGCAGGAGGTGGAGACCGTGTCCCAGCAGTACCTGC
35 CGCTGTCCACTGCCTGCAGCAGCATCTACTTCACTATGGAGTCCT
TGAAGCAGGTTCACTTCCTGTACCAGTACTCTCTGCAGTTCTTCC
TGGACATCTACCACAACGTGCTGTATGAGAACCCCAACCTGAAGG
GTGCCACCGATCACACACAGCGCCTCTCCGTCATAACCAAGGACC
TCTTCCAGGTGGCCTTTAACCGAGTGGCTCGAGGCATGCTGCACC
40 AGGACCACATCACCTTCGCCATGCTGCTAGCGAGGATCAAGCTGA
AAGGCACCGTGGGGGAGCCACCTATGATGCAGAGTTCCAGCACT
TCCTCAGAGGGAAGGAGATTGTGCTGAGTGCTGGCTCCACCCCA
AAATCCAGGGCCTGACCGTAGAGCAGGCAGAAGCTGTCTGAGGT
TGAGCTGTCTGCCTGCATTTAAAGATCTGATTGCCAAGGTGCAGG
45 CAGATGAGCAGTTTGGCATTGCTGGCTGGATAGCAGTTCACCAGAGC
AGACCGTGCCATACCTCTGGAGCGAGGAAACGCCTACAACCTCCA
TTGGGCAGGCCATCCACCGCCTGCTCCTGATTCAAGCCTTCCGAC
CCGACCGCCTGTTGGCCATGGCCACATGTTTGTTCACAAACCC
TCGGAGAGTCCCTTCATGTCCATCATGGAGCAGCCTCTCGACCTCA
50 CCCACATTGTGGGCACAGAGGTGAAGCCAAACACACCTGTCTGA
TGTGCTCTGTGCCTGGGTATGATGCCAGCGGACATGTTGAGGACC
TCGCACAGAGCAGAACACGCAGATCACGTCTATTGCCATCGGCT
CAGCAGAAGGCTTTAACCAAGCAGATAAGGCCATCAACACCGCCG
TGAAGTCAGGCAGGTGGGTGATGTTGAAGAACGTGCACCTGGCCC
55 CGGGCTGGCTGATGCAGCTGGAGAAGAAGCTGCACTCCCTGCAGC
CCCACGCCTGCTTCCGACTTTTCTCACCATGGAGATCAACCCCA

AGGTGCCCCGTGAACCTGCTCCGTGCTGGTCCGATCTTTGTGTTTG
 AGCCACCACCCGGAGTGAAAGCCAACATGCTGAGGACATTTAGCA
 GCATCCCTGTCTCTAGGATATGCAAGTCTCCAAATGAGCGCGCCC
 GCTTGTATTTCTGCTGGCTTGGTTCCATGCCATCATCCAAGAGC
 5 GCCTGCGCTATGCTCCACTGGGGTGGTCAAAGAAGTACGAATTTG
 GAGAATCTGACCTTCGATCAGCTTGTGACACGGTGGACACGTGGC
 TGGACGACACAGCCAAGGGCCGGCAGAACATCTCACCGGATAAGA
 TCCCATGGTCTGCCCTGAAGACCCTGATGGCGCAGTCCATCTATG
 GTGGGCGGGTGGACAATGAGTTCGACCAGCGTCTGCTCAACACCT
 10 TCCTGGAGCGGCTGTTCAACCACCCGCAGCTTCGACAGTGAATTCA
 AGCTGGCGTGCAAGGTTGACGGGCACAAGGACATCCAGATGCCTG
 ATGGTATCAGGCGAGAGGAGTTTGTGCAGTGGGTGGAGCTGCTGC
 CTGACGCCCAGACACCCTCATGGCTGGGCCTCCCCAACAAATGCTG
 AAAGGGTCCTGCTTACCACCCAAGGCGTGGACATGATCAGCAAGA
 15 TGCTGAAGATGCAGATGCTGGAGGACGAGGATGACCTGGCCTACG
 CAGAGACGGAGAAGAAGGCAAGGACGGACTCCACCTCCGATGGCC
 GTCCAGCCTGGATGAGGACACTGCACACCACGGCGTCCAACCTGGC
 TGCACCTCATCCACAGACACTGAGCCCCCTGAAGCGCACCGTGG
 AGAACATCAAGGATCCTTTGTTTAGGTTCTTTGAGAGAGAAGTAA
 20 AGATGGGGGCCAAGTTACTCCAAGATGTGCGCCAAGACCTTGCTG
 ACGTCGTTCAAGTGTGCGAGGGGAAAAAGAAGCAGACAAACTACC
 TGCGCACGCTCATCAATGAGCTGGTGAAAGGGATCTTGCTCGGA
 GCTGGTCCCATTACACAGTGCTGCAGGCATGACGGTGATCCAGT
 GGGTGTGAGATTTAGCGAGAGGATCAAACAGCTGCAGAACATCT
 25 CACAAGCAGCTGCATCTGGTGGTGCCAAGGAACTGAAGAACATCC
 ACGTGTGCCTGGGTGGCCTGTTGTACCTGAGGCCTACATCACTG
 CCACCAGACAGTATGTGGCACAAGCTAACAGCTGGTCCCTGGAGG
 AACTCTGCCTGGAAGTCAATGTCACCGCCTCACAGAGTGCCACCC
 TTGATGCCTGCAGCTTTGGAGTCACAGGTCTGAAGCTCCAAGGGG
 30 CCACGTGCAGCAACAACAAGCTATCACTCTCCAATGCCATCTCCA
 CAGTCTCCCCCTCACACAGCTGCGCTGGGTGAAACAAACAAGCG
 CCGAGAAGAAGGCCAGCGTGGTGACCTTACCTGTCTACCTGAAC
 TCACCCGGGCAGACCTCATCTTACCGTGGACTTTGAAATTGCTA
 CAAAGGAAGATCCTCGCAGCTTCTATGAGCGTGGAGTTGCCGTTT
 35 TGTGCACTGAGTAAAGCTAGACTTTTCTCCAGTCCTCTTTCTGGA
 ATAGGAAACTCCCAATATTTAACCTTCATTTCATCCTTAACGGTGT
 GGAAGGGTTGATGGACTGGAAAGCAAGTGGTTGGTTTCGCGTTGGC
 GGGTGACAGGTGCTGCGGTTGGAGACGGTGGGATGGGAGAAGAGA
 AGAGTGCGCTGTCCGAGGGCTGACCGAATGGCTGGGTTTAGTAAA
 40 TAAACACTAAGCATGACGGGCAAAAAAAAAAAAAAAAAAAAAA

Table 2. Mutated murine cytoplasmic dynein heavy chain1, mRNA (SEQ ID NO:3)

GCCGCGTCGACAGCCGGCTCCGCTGTCCGAGTCGGCCGCGGGTTAGCGGGC
 45 AGAGCGTCTCCTGTCGCCGGTTCCCTCGCTTACTGCTCTCTCGTGCCGGAG
 GCCGCTCCTCTCGGCTCTCGTCTCTCTCTTTCTATCTCTCTCCCTTCCGCG
 GATCCGCCATGTCGGAGCCGGGCGGCGGAGGACGGCTCGGCAGGCCTGGA
 GGTGTGCGCGGTGCAGAATGTGGCGGACGTGGCGGTGCTGCAGAAGCACCTG
 CGTAAGCTGGTGCCGCTGCTGCTGGAGGACGGCGGCGACGCGCCGGCTGCGC
 50 TGGAGGCGGCGCTGGAGGAGAAGAGCGCCCTGGAGCAGATGCGCAAGTTCTT
 GTCAGACCCGCGAGGTCCACACGGTCTGGTGGAGCGCTCCACCCTCAAAGAG
 GACGTTGGTGATGAAGGAGAAGAGGAGAAAGAATTCATTTCTATAACATCA
 ACATAGACATTTCATTACGGGGTAAAGTCCAACAGCTTGGCGTTCATCAAGCG
 AGCTCCTGTGATTGATGCAGACAAGCCAGTGTGCTCCAGCTCCGAGTCCTC

ACTCTGAGTGAAGACTCGCCGTATGAGACACTGCACTCTTTCATCAGCAATG
CAGTGGCTCCTTTCTTTAAGTCTACATCAGAGAGTCTGGCAAAGCAGACAG
GGATGGTGATAAGATGGCTCCTTCAGTTGAAAAAAGATTGCAGAGCTTGAA
ATGGGACTCCTCCACCTGCAGCAGAACATTGAGATCCCAGAGATCAGCTTGC
5 CAATTCATCCCATCATCACGAACGTTGCGAAGCAGTGCTATGAGCGCGGAGA
AAAGCCCAAAGTTACAGATTTTGGTGATAAGGTTGAAGACCCAACTTTCTT
AACCAATTACAGTCTGGAGTTAATCGGTGGATCCGAGAAATTCAAAAGGTGA
CCAAGCTTGACCGGGATCCAGCATCAGGAAGTGCCTTGACAGGAAATCAGCTT
10 TTGGCTAAACTTGGAACGTGCGTTGTACCGCATCCAAGAGAAGCGGGAGAGC
CCCGAGGTGCTCCTGACTCTGGACATCCTGAAGCATGGCAAACGTTTCCATG
CCACTGTCAGTTTTGACACTGACACAGGTCTGAAGCAGGCGTTGGAAACGGT
GAATGACTACAACCTCTGATGAAAGACTTCCCTCTGAATGACTTGCTGTCT
GCCACGGAGCTGGACAAGATAAGGCAGGCCCTTGTTGCAATTTTCACACATC
15 TGAGAAAGATCCGCAACACGAAGTACCCGATTCAGCGGGCCCTGCGTCTCGT
GGAGGCCATCTCCAGAGACCTGAGTTCTCAGCTGCTCAAGGTCTTGGGCACT
CGGAAGTTGATGCATGTAGCCTATGAAGAGTTTGAAAAGGTCATGGTGGCTT
GCTTCGAAGTCTTCCAGACGTGGGACGACGAGTACGAGAAGCTCCAGGTGCT
GCTGCGAGACATCGTCAAGAGGAAGCGGGAGGAGAACCTGAAGATGGTGTGG
CGCATCAACCCCGCTCACAGGAAGCTTCAGGCCCGCCTCGACCAGATGAGGA
20 AGTTCGCGCCGCCAGCACGAGCAGCTGAGGGCTGTCAATTGTGAGGGTCTGAG
GCCACAGGTCACAGCAGTCGCACAACAGAACCAAGGAGAAGCACCTGAACCC
CAAGACATGAAAGTGGCCGAGGTGCTCTTTGATGCTGCCGACGCCAACACCA
TTGAGGAGGTGAACCTGGCCTACGAGAATGTCAAGGAAGTCGATGGTCTGGA
TGTTTCCAAAGAAGGGACGGAGGCCTGGGAGGCCGCGATGAAGAGATACGAT
25 GAGAGGATCGACCGTGTGGAGACCCGCATCACCGCCCGCCTCCGAGATCAGC
TCGGCACGGCCAAGAATGCCAATGAGATGTTTCAAGGATTTTCTCCAGGTTCAA
TGCACTGTTTCGTCCGCCCACACATCCGAGGGGCCATTCGTGAATACCAGACC
CAGCTGATCCAACGTGTGAAAGATGACATCGAATCTCTGCACGACAAGTTCA
AGGTCCAGTACCCGCAAAGCCAAGCTTGTAATAAGTATGATGTCCTGACCT
30 GCGCCCCGTGTGAGGGTCTATCATCTGGGCTAAACAGATCGACAGACAGCTC
ACTGCCTACATGAAGCGAGTGGAGGATGTCCTGGGCAAAGGCTGGGAGAACC
ACGTGGAAGGGCAGAAGCTGAAGCAGGATGGAGACAGCTTCCGAATGAAGCT
CAACACCCAGGAGATCTTCGATGACTGGGCGAGGAAGGTTGAGCAGCGCAAC
CTTGGTGTCTCCGGGCGCATCTTCACCATTGAGAGCGCTCGCGTGGGGGCC
35 GCACTGGGAATGTCTCAAGCTAAAGGTGAACTTCCTTCCAGAGATCATAAC
ACTCTCCAAAGAAGTCCGGAACCTCAAGTGGCTTGGCTTCCGAGTGCCACTT
GCAATTGTGAACAAGGCTCACCAAGCCAACCAGCTCTACCCATTTGCCATCT
CGCTGATTGAAAGCGTCCGGACTTACGAGCGCACCTGTGAGAAGGTGGAGGA
GCGCAATACCATTTCCCTGCTAGTGGCCGGCCTAAAGAAGGAGGTGCAGGCC
40 TTAATCGCAGAAGGCATCGCGTTGGTGTGGGAGTCTTACAAGCTCGACCCCT
ACGTGCAGCGCTGGCAGAGACGGTTTTTCAACTTCCAGGAGAAGGTGGACGA
CCTACTGATTATTGAGGAAAAGATAGACCTGGAGGTCCGCTCCTTGGAACCC
TGCACTGATGACCACAAGACATTCTCAGAGATCTTGAACAGAGTGCAGAAAG
45 CAGTGGACGACCTAAACCTGCACTCCTATTCCAATCTGCCCATCTGGGTCAA
CAAGCTGGACATGGAGATTGAAAGGATACTGGGCGTCCGCCTGCAAGCTGGC
CTTCGAGCTTGGACCCAGGTTCTTCTTGACAAGCTGAGGATAAAGCAGAAG
TCGACATGGATACAGATGCTCCACAAGTCAGTCACAAGCCTGGTGGAGAGCC
CAAGATCAAAAACGTGGTTCACGAGCTGAGGATAACAAATCAGGTCATCTAT
CTGAACCCACCCATTGAGGAGTGCAGGTACAAGCTGTACCAGGAGATGTTTCG
50 CGTGGGAAGATGGTTGTGCTGTCCCTGCCAGGATCCAGAGCCAGAGTACCA
GGTGGGAGTGCATTACGAGTTGACGGAGGAAGAGAAGTTCTATCGGAATGCA
CTGACAAGGATGCCCGACGGCCCTGTGCGCCCTGGAAGAGTCTACTCTGCGG
TCATGGGCATAGTGACTGAAGTTGAGCAGTATGTTAAGGTTTGGCTTCAGTGG
55 CAGTGTTTGTGGGATATGCAGGCAGAAAACATTTACAACAGGCTAGGGGAA
GATCTCAACAAGTGGCAAGCTCTCCTGGTCCAGATAAGGAAAGCCAGAGGAA
CCTTTGACAATGCGGAAACCAAGAAAGAGTTTGGTCCGGTGGTGATAGATTA

CGGCAAGGTCCAGTCCAAGGTGAACTTGAAGTATGACTCCTGGCATAAGGAG
GTTCTCAGCAAGTTTGGGCAGATGCTGGGCTCAAACATGACAGAATTCCTACT
CCCAGATCTCAAAGTCTCGCCAAGAGCTGGAGCAGCACTCCGTTGACACAGC
CAGTACCTCTGACGCGGTGACCTTCATCACCTATGTGCAGTCTCTGAAACGG
5 AAGATCAAACAGTTTGAGAAGCAAGTTGAACTCTACCGCAATGGTCAGCGTC
TGCTGGAAAAACAAAGGTTCCAGTTCCTCGCCTTCTTGGCTTTACATTGACAA
CATCGAGGGTGAGTGGGGGGCCTTCAATGACATCATGCGGCGGAAGGACTCT
GCCATTCAGCAACAGGTGGCAAACCTGCAAATGAAGATCGTACAGGAGGACA
GAGCTGTGGAAAGCCGGACCACGGATCTGTTGACAGACTGGGAGAAGACCAA
10 ACCTGTACAGGCAATCTGCGTCTGAGGAGGCTCTTCAGGCCCTCACCATA
TATGAAGGGAAGTTTCGGCCGGCTGAAGGACGACAGAGAGAAATGTGCAAAGG
CTAAGGAAGCGTTGGAACCTCACAGACACAGGCCCTCCTCAGTGGCAGTGAAGA
GCGTGTACAGGTGGCCTTGGAGGAGTTACAAGACCTCAAAGGTGTGTGGTCA
GAGCTTCTAAGGTCTGGGAACAAATTGATCAAATGAAGGAGCAGCCGTGGG
15 TCTCCGTTACAGCTCGGAAGCTTCGACAAAACCTAGACGGCCTCTTGAACCA
GCTGAAGAACTTCCCTGCGAGGCTTCGGCAGTATGCTTCTATGAGTTTGT
CAGAGGCTGCTGAAAGGCTACATGAAGATAAACATGTTGGTAATTGAACCTGA
AATCAGAAGCACTCAAAGACCGGCACTGGAAACAGCTGATGAAGAGGCTTCA
TGTTAACTGGGTGGTTTCTGAGCTGACGCTGGGCCAGATCTGGGACGTGGAC
20 CTTCAGAAGAACGAAGCTGTCTGATCAAGGATGTGCTGCTGGTGGCACAAGGCG
AGATGGCCTTGAAGAATTTTGAAGCAGATACGAGAAGTGTGGAACACATA
CGAAGTAGACTTGGTCAACTATCAGAACAATGCCGCTCATCCGAGGCTGG
GATGACCTCTTCAACAAGGTCAAGGAGCATATCAACAGCGTCTCTGCCATGA
AACTCTCTCCCTATTACAAGGTTTTTGAAGAAGATGCCCTGAGCTGGGAGGA
25 CAAGCTGAACCGAATCATGGCTCTCTTTGACGTGTGGATTGACGTGCAGAGG
CGCTGGGTCTACTTGAAGGCATCTTCACAGGCAGTGGGACATCAAACATC
TGCTGCCTGTGGAAACCCAGCGCTTCCAGAGTATCAGCACGGAGTTTTTGGC
TCTGATGAAAAAAGTCTCCAAGTCTCCACTTGTGATGGATGTTCTGAACATA
CAGGGAGTCCAGAGGTCTCTGGAAAGGTGGCAGACCTGCTGGGGAAGATCC
30 AGAAAGCATTGGGGGAGTACCTGGAACGGGAGCGCTCGTCTTCCCCAGGTT
CTACTTTGTGGGTGATGAGGATTTGCTTGAGATCATTGGGAATAGCAAGAAC
GTGGCTAAGTTGCAGAAGCACTTCAAGAAAATGTTCCGCCGGCGTTTTCCAGCA
TCATCTTAAATGAGGATAACTCTGTGGTCTCGGCATCTCATCCCGAGAAGG
GGAGGAGGTTATGTTTAAACTCCAGTGTCCATCACTGAACACCCCAAAATC
35 AATGAGTGGCTCACTCTGGTGGAAAAGGAGATGAGAGTCACCTTGGCTAAAC
TTCTGGCAGAGTCTGTTACAGAAGTGGAGATTTTGGAAAAGCAACTTCTAT
TGACCCAAATACCTACATTACTTGGATTGATAAATACCAGGCCAGCTAGTG
GTATTGTCAGCCAGATAGCCTGGTCCGAGAACGTGGAGAATGCGCTGAGCA
ACGTTGGGGGAGGTGGTGTATGTGGGGCCCTTGCACTCTGTGCTGAGCAATGT
40 GGAGGTCACACTCAACGTCTTAGCGGACTCTGTCCTCATGGAGCAGCTCCT
CTCCGGAGACGGAAGCTGGAGCACTTGATCACAGAGCTGGTTACCAAAGAG
ACGTTACCAGGTCCCTTGATCAAAGCAAGATCGACAACGCCAAATCTTTCGA
ATGGCTCAGCCAGATGCGATTTTACTTTGACCCTAAGCAAACGGACGTGTTA
CAGCAGCTGTCCATTCAGATGGCCAATGCCAAGTTTAACTACGGCTTTGAGT
45 ACCTGGGTGTTCAAGACAAGCTGGTTCAGACGCCCCCTCACTGACCGTTGCTA
TTTGACAATGACACAAGCTTTGGAGGCCAGGCTTGGGGGCTCCCCATTTGGA
CCTGCTGGAACCGGAAAGACGGAGTCCGTCAAAGCCCTCGGCCATCAGCTGG
GGCGGTTCTGCTTAGTTTTCAACTGTGACGAAACCTTTGATTTCCAGGCGAT
GGGACGTATCTTTGTGGGGCTTTGCCAAGTGGGCGCGTGGGGCTGCTTTGAT
50 GAGTTTAAACCGCTTGGAGGAGCGGATGCTCTCAGCTGTATCCCAGCAGGTGC
AGTGCATACAAGAGGCACTGCGGGAGCATCCAACCCCACTACGACAAGAC
CTCAGCCCCCATTACTTGTGAGCTGCTGAACAAACAAGTCAAGGTTAGCCCA
GATCATGGCTATCTTCATCACCATGAACCCAGGCTATGCAGGTGCTCAAACC
TCCCCGACAACCTCAAGAAGCTCTTCCGGAGCTTGGCGATGACCAAGCCTGA
55 CCGGCAGCTGATCGCCAGGTATGCTGTACTCGCAGGGCTTCCGGACTGCT
GAGGTCCTTGCCAACAAGATCGTCCCGTTCTTCAAACCTGTGTGATGAGCAAC

5 TGTCTTCTCAAAGCCATTATGACTTTGGGCTTCGGGCTTTGAAGAGTGTGCT
TGTAAGTGCAGGCAATGTGAAGAGGGAGAGGATCCAGAAGATAAAGAGGGAG
AAAGAAGAACGGGGGGAAGCAGTTGATGAAGGAGAGATCGCTGAGAACCTAC
CTGAGCAGGAGATTCTGATCCAGAGTGTCTGCGAGACAATGGTGCCCAAGCT
GGTGGCAGAAGATATCCCGCTGCTCTTCAGCCTCCTGTCTGACGTGTTCCCT
GGAGTCCAGTACCACCGTGGGGAGATGACAGCCCTTCGAGAAGAGCTGAAGA
AAGTGTGTGTCAGGAGATGTACTTGACATATGGCGACGGAGAAGAAGTTGGCGG
GATGTGGGTTGAAAAGGTTCTCCAGCTCTATCAGATCACGCAGATTAACCAC
10 GGCCTGATGATGGTTGGGCCTTCAGGAAGTGGGAAGAGCATGGCCTGGCGAG
TGCTGCTGAAGGCTCTAGAGAGGCTTGAGGGTGTGGAGGGCGTGGCCACAT
AATTGACCCCAAGGCCATCAGCAAAGACCACCTCTACGGAACCTTGGATCCC
AACACCAGGGAGTGGACAGACGGACTCTTCACACACGTGCTGAGAAAGATCA
TAGACAATGTGAGAGGTGAGCTGCAGAAACGCCAGTGGATTGTCTTTGATGG
CGATGTGGACCCCGAGTGGGTGGAGAACCTGAACTCCGTGCTGGATGACAAC
15 AAGCTCCTGACGCTGCCTAATGGAGAGCGCCTTAGCCTGCCTCCCAATGTGC
GGATAATGTTTGAAGTGCAGGACTTGAAATACGCGACGCTGGCCACGGTGTCTC
TCGCTGTGGCATGGTGTGGTTTCACTGAGGACGTCTGAGCACAGACATGATC
TTAAATAACTTCCCTGGCCAGGCTGCGCAGCATTCCCCTGGATGAAGGGGAGG
ACGAGTACAGCGTAGGCGAAAAGGCAAAGAAGACGAGGGCGAAGAGGCGGC
20 TTCTCCAATGCTACAGATTCAAAGAGATGCAGCAACGATCATGCAGCCGTAC
TTCACGTCCAACGGCCTGGTCAACCAAGGCGCTGGAGCACGCCTTCAAGCTGG
AGCACATCATGGACCTGACGCGCCTGCGCTGCCTGGGCTCGCTCTTCTCCAT
GCTGCACCAGGCTGCCGCAACGTGGCGCAGTACAATGCCAACCATCCTGAT
TTCCCCATGCAGATTGAGCAGCTGGAGCGCTACATTCAGCGCTATCTGGTTT
25 ACGCCATCCTCTGGTCTTATCTGGAGACAGCCGGCTGAAGATGAGAGCAGA
GCTGGGCGAGTACATCCGGAGGATCACCCTGTGCCGCTGCCACTGCGCCC
AACGTCCCCATCATTGACTATGAGGTGTCCATCAGTGGAGAGTGGTCGCCGT
GGCAGGCCAAGGTGCCTCAGATTGAAGTGGAGACACACAAGGTGGCAGCCCC
AGATGTGCTGCTGCCAACCTTAGATACAGTCCGCCATGAAGCTCTCCTGTAC
30 ACTTGGCTGGCTGAACACAAACCCCTGGTCTTATGTGGCCCTCCTGGGTCTG
GCAAGACCATGACACTCTTCAGTGCTCTCCGGGCCTTGCCTGACATGGAGGT
TGTGGGCCTAACTTCTCAAGTGCCACTACACCAGAGCTGTTGCTGAAGACG
TTTGACCACTACTGCGAATACAGGCGCACACCTAACGGTGTGCTTGGCTC
CTGTTTCACTTGGAAAGTGGCTGGTCTTGTCTGTGATGAAATCAACTTGCC
35 CGATATGGATAAATACGGCACACAGAGAGTCATCTCCTTCATCAGACAGATG
GTGGAGCATGGAGCCTTCTATCGTACCTCAGACCAAACGTGGGTAAAGCTAG
AGAGAATCCAGTTTGTGGGGCTTGCAATCCACCCACTGACCTGGGAGAAA
GCCCTCTCACACAGGTTCTTGCGCCACGTGCCTGTTGTATATGTGGATTAC
CCAGGACCAGCCTCCCTGACGCAAATCTATGGCACCTTCAACCGCGCCATGC
40 TGAGGCTCATTCCCTCTCTCCGTACCTATGCAGAACCCTCACTGCCGCCAT
GGTGGAGTTCTATACCATGTACAGGAGCGGTTTACTCAGGACACACAGCCA
CACTATATCTACTCGCCCCGTGAGATGACTCGGTGGGTAAAGAGGAATCTTTG
AAGCACTGAGACCCCTGGAGACATTGCCTGTTGAAGGTCTCATTCTGATTTG
GGCACATGAAGCCCTCCGTCTCTTCCAAGACAGGCTTGTGGAGGATGAGGAG
45 CGGCGCTGGACTGACGAAAACATTGACATGGTTGCCTTGAAGCACTTCCCTA
ACATAGACAAAGAGAAAGCCATGAGCCGGCCTATCCTGTACAGCAACTGGCT
GTCAAAGGATTATATCCAGTTGACCAAGAAGAGCTAAGGGATTATGTCAAG
GCTAGGCTGAAGGTCTTCTATGAAGAAGAACTTGATGTTCCCTTGGTCTTGT
TCAATGAAGTTCTGGACCATGTGCTGAGGATAGACAGAATATTCCGACAACC
50 TCAAGGCCATCTGCTTCTGATTTGGTGTAGTGGAGCTGGAAAAACCACCTG
TCTCGCTTTGTGCGCTGGATGAATGGCTTGAGTGTATACCAGATTAAGGTCC
ACAGGAAGTACACTGGGGAAGACTTCGATGAAGATCTTAGGACAGTGTGAG
ACGGTCTGGCTGTAAAAATGAAAAGATAGCATTTCATAATGGATGAGTCCAAC
GTCTTAGATTCCGGATTCTTGGAAACGAATGAATACCCTTCTGGCTAATGGCG
55 AGGTTTCTGGGCTCTTTGAAGGGGATGAGTACGCCACGCTGATGACACAGTG
CAAAGAGGGGGGCCAGAAGGAGGGGCTCATGCTGGACTCCCACGAGGAGCTC

TACAAGTGGTTCACCAGCCAGGTGATCCGCAACCTGCACGTGGTCTTCACCA
TGAACCCGTCCTCAGAGGGGCTCAAGGACAGGGCGGCCACCTCACCAGCCCT
TTTCAACAGGTGTGTGCTGAACTGGTTTGGTGACTGGTCCACTGAAGCACTG
TATCAAGTCGGCAAAGAATTCACCAGTAAGATGGACCTGGAGAAGCCGAAC
5 ATATAGTGCCTGACTACATGCCAGTTGTGTATGATAAACTGCCGCAGCCCC
AACACACCGGGAAGCCATTGTGAACAGCTGTGTGTTTGTCCATCAGACTCTT
CACCAGGCTAATGCGCGCCTGGCGAAGCGAGGTGGCAGAACGATGGCCATCA
CACCTCGGCACTACCTGGACTTCATCAACCACTACGCCAACCTCTTCCATGA
GAAGCGCAGCGAGTTGGAGGAGCAGCAGATGCACCTGAATGTTGGGCTCCGA
10 AAAATCAAAGAGACCGTGGACCAGGTGGAAGAACTGCGCCGTGACCTGAGGA
TCAAGAGCCAAGAGCTGGAGGTCAAGAACGCAGCGGCCAATGACAAGCTGAA
GAAAATGGTGAAAGACCAGCAAGAGGCTGAGAAGAAGAAGGTCATGAGCCAA
GAAATCCAGGAGCAGCTACACAAACAGCAGGAAGTGATCGCAGACAAGCAGA
TGAGTGTCAAGGAGGACCTGGATAAAGTGGAGCCTGCTGTCTCGAGGCCCA
15 GAACGCTGTGAAGTCCATCAAGAAGCAGCACCTGGTGGAGGTGAGGTCCATG
GCCAACCCCTCCTGCAGCTGTGAAGCTGGCTCTGGAGTCCATCTGCCTGCTGC
TTGGTGAGAGCACCACGGACTGGAAGCAGATCCGCTCCATCATCATGAGAGA
GAACTTCATCCCCACCATCGTCACTTCTCGGCTGAGGAGATCAGTGATGCC
ATACGAGAGAAGATGAAGAAAACTACATGTCCAACCCAGTTACAACATATG
20 AGATCGTCAACCGGGCTTCCCTGGCTTGTGGTCCCTATGGTGAAGTGGGCGAT
TGCACAGCTCAATTATGCAGACATGTTAAAGCGAGTGGAGCCCCTGAGGAAT
GAGCTGCAGAAGCTGGAAGATGACGCCAAGGACAACCAGCAGAAAGCCAATG
AGGTGGAGCAGATGATCAGGGACCTGGAAGCCAGCATTGCCCGCTACAAGGA
GGAGTACGCTGTCTCATCTCTGAGGCCCAGGCCATCAAGGCAGACCTGGCA
25 GCTGTGGAAGCAAAGGTAAACCGGAGCACTGCACTTCTAAAGAGTTTATCTG
CCGAAAGGGAACGTTGGGAAAAGACGAGTGAACCTTCAAAAACAGATGTC
TACCATTGCTGGGACTGCCTCCTGTCGGCGGCCTTCATTGCTTACGCTGGC
TACTTTGACCAGCAAATGCGCCAGAACTTGTTACCACCTGGTCTCATCACT
TACAGCAAGCCAACATCCAGTTCCGCACAGACATTGCAAGGACGGAGTACCT
30 CTCCAATGCTGACGAACGCCTCCGCTGGCAGGCCAGCTCTCTGCCTGCCGAC
GACCTGTGCACAGAGAATGCCATCATGCTAAAACGATTCAATAGGTACCCGC
TGATCATCGACCCCTCCGGACAGGCCACAGAATTCATCATGAATGAATATAA
GGACCGGAAGATCACAAGGACCAGCTTCTTAGATGATGCCTTCCGGAAGAAT
TTGGAGAGTGCTCTGAGATTTGGCAATCCCCTTCTTGTCCAGGATGTGGAAA
35 GCTACGATCCAGTTTGAATCCAGTACTGAACCGTGAAGTTCGGCGAACAGG
AGGGAGGGTGCTGATTACCCTCGGTGACCAAGACATAGACCTGTCAACCATCC
TTTGTCTCTTTCTGTCTACCCGAGACCCAACGTGTGGAGTTCCCACCAGACC
TCTGCTCCCGGGTGACCTTTGTGAACCTTACCCGTACCCGCAGCAGTTTACA
GAGCCAGTGTCTCAATGAAGTGCTTAAAGCAGAAAGGCCAGACGTGGACGAG
40 AAGCGCTCCGACCTCCTGAAACTGCAAGGGGAGTTCCAACCTCCGTTTACGGC
AGCTTGAAAAGTCTCTGCTCCAAGCTCTGAATGAGGTAAAAGGCCGATTCT
GGTTGACGACACCATCATTACAACCCTGGAGAATCTGAAGCGGGAAGCTGCC
GAGGTTACCAGAAAGGTGGAGGAGACAGATATTGTCTATGCAGGAGGTGGAGA
CCGTGTCCCAGCAGTACCTGCCGCTGTCCACTGCCTGCAGCAGCATCTACTT
45 CACTATGGAGTCCTTGAAGCAGGTTCACTTCCCTGTACCAGTACTCTCTGCAG
TTCTTCCCTGGACATCTACCACAACGTGCTGTATGAGAACCCCAACCTGAAGG
GTGCCACCGATCACACACAGCGCCTCTCCGTGATAACCAAGGACCTCTTCCA
GGTGGCCTTTAACCGAGTGGCTCGAGGCATGCTGCACCAGGACCACATCACC
TTCGCCATGCTGCTAGCGAGGATCAAGCTGAAAGGCACCGTGGGGGAGCCCCA
50 CCTATGATGCAGAGTTCCAGCACTTCCCTCAGAGGGAAGGAGATTGTGCTGAG
TGCTGGCTCCACCCCCAAAATCCAGGGCCTGACCGTAGAGCAGGAGAGCT
GTCGTGAGGTTGAGCTGTCTGCCTGCATTAAAGATCTGATTGCCAAGGTGC
AGGCAGATGAGCAGTTTGGCATTGGCTGGATAGCAGTTACCAGAGCAGAC
CGTGCCATACCTCTGGAGCGAGGAAACGCCTACAACCTCCCATTGGGCAGGCC
55 ATCCACCGCCTGCTCCTGATTCAAGCCTTCCGACCCGACCGCCTGTTGGCCA
TGGCCACATGTTTGTTCACAAACCTCGGAGAGTCCTTCATGTCCATCAT

GGAGCAGCCTCTCGACCTCACCCACATTGTGGGCACAGAGGTGAAGCCAAAC
 ACACCTGTCTGATGTGCTCTGTGCTGGGTATGATGCCAGCGGACATGTTG
 AGGACCTCGCAGCAGAGCAGAACACGCAGATCACGTCTATTGCCATCGGCTC
 AGCAGAAGGCTTTAACCAAGCAGATAAGGCCATCAACACCGCCGTGAAGTCA
 5 GGCAGGTGGGTGATGTTGAAGAACGTGCACCTGGCCCCGGGCTGGCTGATGC
 AGCTGGAGAAGAAGCTGCACTCCCTGCAGCCCCACGCCTGCTCCGACTTTT
 CCTCACCATGGAGATCAACCCCAAGGTGCCCGTGAACCTGCTCCGTGCTGGT
 CGGATCTTTGTGTTTGAGCCACCACCCGGAGTGAAAGCCAACATGCTGAGGA
 CATTTAGCAGCATCCCTGTCTCTAGGATATGCAAGTCTCCAAATGAGCGCGC
 10 CCGCTTGATTTTCTGCTGGCTTGGTTCATGCCATCATCCAAGAGCGCCTG
 CGCTATGCTCCACTGGGGTGGTCAAAGAAGTACGAATTTGGAGAATCTGACC
 TTCGATCAGCTTGTGACACGGTGGACACGTGGCTGGACGACACAGCCAAGGG
 CCGGCAGAACATCTCACCGGATAAGATCCCATGGTCTGCCCTGAAGACCCTG
 ATGGCGCAGTCCATCTATGGTGGGCGGGTGGACAATGAGTTCGACCAGCGTC
 15 TGCTCAACACCTTCTGGAGCGGCTGTTACCAACCCGCAGCTTCGACAGTGA
 ATTCAAGCTGGCGTGCAAGGTTGACGGGCACAAGGACATCCAGATGCCTGAT
 GGTATCAGGCGAGAGGAGTTTGTGCAGTGGGTGGAGCTGCTGCCTGACCCC
 AGACACCCTCATGGCTGGGCCTCCCCAACAATGCTGAAAGGGTCTGCTTAC
 CACCCAAGGCGTGGACATGATCAGCAAGATGCTGAAGATGCAGATGCTGGAG
 20 GACAGGATGACCTGGCCTACGCAGAGACGGAGAAGAAGGCAAGGACGGACT
 CCACCTCCGATGGCCGTCCAGCCTGGATGAGGACACTGCACACCACGGCGTC
 CAACTGGCTGCACCTCATCCACAGACACTGAGCCCCCTGAAGCGCACCGTG
 GAGAACATCAAGGATCCTTTGTTTAGGTTCTTTGAGAGAGAAGTAAAGATGG
 GGGCCAAGTTACTCCAAGATGTGCGCCAAGACCTTGCTGACGTGCTTCAAGT
 25 GTGCGAGGGGAAAAAGAAGCAGACAACTACCTGCGCACGCTCATCAATGAG
 CTGGTGAAAGGGATCTTGCCCTCGGAGCTGGTCCCATTACACAGTGCCTGCAG
 GCATGACGGTGATCCAGTGGGTGTCAGATTTAGCGAGAGGATCAAACAGCT
 GCAGAACATCTCACAAGCAGCTGCATCTGGTGGTGCCAAGGAACTGAAGAAC
 ATCCACGTGTGCCTGGGTGGCCTGTTTGTACCTGAGGCCTACATCACTGCCA
 30 CCAGACAGTATGTGGCACAAGCTAACAGCTGGTCCCTGGAGGAACTCTGCCT
 GGAAGTCAATGTACCGCCTCACAGAGTGCCACCCTTGATGCCTGCAGCTTT
 GGAGTCACAGGTCTGAAGCTCCAAGGGGCCACGTGCAGCAACAACAAGCTAT
 CACTCTCCAATGCCATCTCCACAGTCTCCCCCTCACACAGCTGCGCTGGGT
 GAAACAAACAAGCGCCGAGAAGAAGGCCAGCGTGGTGACCTTACCTGTCTAC
 35 CTGAACTTCACCCGGGCAGACCTCATCTTACCGTGGACTTTGAAATTGCTA
 CAAAGGAAGATCCTCGCAGCTTCTATGAGCGTGGAGTTGCCGTTCTGTGCAC
 TGAGTAAAGCTAGACTTTTCTCCAGTCTCTTTCTGGAATAGGAACTCCCA
 ATATTTAACCTTCATTATCTTAAACGGTGTGGAAGGGTTGATGGACTGGAA
 AGCAAGTGGTTGGTTTCGCGTTGGCGGGTGACAGGTGCTGCGGTTGGAGACGG
 40 TGGGATGGGAGAAGAGAAGAGTGCCTGTCCGAGGGCTGACCGAATGGCTGG
 GTTTAGTAAATAAAACACTAAGCATGACGGGCACAAAAA

Table 3. Mutated human cytoplasmic dynein heavy chain 1, cDNA (SEQ ID

45 NO:5)

ATGTCGGAGCCCCGGGGGCGGCGGCGGCGAGGACGGCTCGGCCGGA
 TTGGAAGTGTGCGCCGTGCAGAATGTGGCGGACGTGTGCGTGCTG
 CAGAAGCACCTGCGCAAGCTGGTGCCGCTGCTGCTGGAGGACGGC
 GCGGAGGCGCCGGCCGCGCTGGAGGCGGCGCTGGAGGAGAAGAGC
 50 GCCCTGGAGCAGATGCGCAAGTTCCCTTTCGACCCGCAGGTCCAC
 ACGGTGCTGGTGGAGCGCTCCACGCTCAAAGAGGACGTGCGTGAT
 GAAGGAGAAGAAGAAAAAGAATTCAATTCCTATAACATCAACATA
 GACATTCATTATGGGGTTAAATCCAATAGCTTGGCATTCAATTA

CGTACTCCCGTGATTGATGCAGATAAACCCGTGTCTTCTCAGCTC
CGGGTCCTTACACTCAGTGAAGACTCGCCCTACGAACTTTGTCAT
TCTTTCATTAGCAATGCAGTGGCTCCTTTTTTTAAGTCCTACATT
AGAGAGTCTGGCAAGGCAGACAGGGATGGTGATAAAATGGCTCCT
5 TCAGTTGAAAAGAAGATTGCAGAACTCGAAATGGGACTCCTTCAC
TTGCAGCAAAATATTGAAATTCCGGAGATCAGCCTGCCGATTTCAT
CCAATGATCACAAATGTTGCAAAACAGTGTTATGAGCGTGGAGAA
AAGCCAAAAGTTACAGACTTTGGTGATAAGGTTGAAGACCCACA
TTTCTTAATCAGTTACAATCTGGAGTTAACCGCTGGATCCGAGAA
10 ATTCAAAAAGTGACCAACTGGATCGAGATCCTGCATCAGGAACT
GCCTTACAGGAAATTAGTTTTTGGCTAACTTGGAACTGCGTTA
TACCGCATCCAGGAGAAACGGGAGAGCCCGGAAGTTCTCCTGACT
CTGGATATCTTGAAACATGGCAAGCGCTTCCATGCCACCGTCAGT
TTTGACACTGACACAGGTCTAAACAGGCTTTGGAACTGTGAAT
15 GACTACAATCCTCTGATGAAAGATTTCCCTCTGAATGATTGTCTG
TCTGCCACGGAGCTGGACAAAATAAGACAGGCGCTTGTTGCCATT
TTCACACATTTGAGAAAGATCCGAAACACAAAATATCCTATTTCAG
AGGGCACTGCGTTTGGTGGAGGCAATTTCAAGAGACTTGAGTTCT
CAATTACTCAAAGTATTGGGCACTAGGAAATTGATGCATGTTGCT
20 TATGAAGAATTTGAAAAAGTTATGGTAGCATGCTTTGAAGTTTTT
CAGACTTGGGATGATGAGTATGAGAAACTTCAGGTATTGTTGAGA
GACATCGTCAAAAGAAAAAGGGAAGAAAAATCTGAAGATGGTGTGG
CGTATCAACCCTGCCACAGGAAGCTGCAGGCCCGCCTTGACCAG
ATGAGAAAATTTAGACGCCAGCATGAACAGCTAAGAGCTGTTATC
25 GTCAGGGTCCTGAGGCCACAGGTCACGGCAGTTGCACAACAGAAT
CAAGGAGAGGTCCCTGAACCCCAAGATATGAAAGTGGCTGAGGTT
CTCTTTGATGCTGCAGATGCAAATGCCATTGAGGAAGTAAACCTT
GCTTATGAGAACGTCAAGGAAGTGGATGGACTGGATGTTTCCAAA
GAGGGCACGGAAGCCTGGGAGGCTGCTATGAAGAGGTACGATGAG
30 AGGATCGACAGAGTGGAGACCCGGATCACCGCTCGCCTTCGGGAT
CAGCTTGGCACAGCCAAGAATGCCAACGAGATGTTTAGGATTTTC
TCCAGGTTTAATGCACTGTTTGTGTCAGGCCTCACATCCGTGGGGCC
ATTCGCGAATACCAGACCCAGCTGATCCAGCGCGTGAAAGATGAC
ATTGAGTCTCTTCACGACAAGTTCAAGGTCCAGTACCCACAGAGT
35 CAGGCTTGTAAAGATGAGTCACGTTTCGTGACTTGCCCCCTGTGTCA
GGGTCTATCATCTGGGCTAAACAGATCGACAGGCAGCTGACGGCC
TACATGAAGCGGGTGGAAGATGTCCTTGGCAAGGGCTGGGAGAAT
CACGTGGAGGGGCAGAAGCTGAAGCAGGATGGAGACAGCTTCCGC
ATGAAGCTCAACACGCAGGAGATCTTTGATGACTGGGCAAGGAAG
40 GTGCAGCAGCGCAACCTCGGTGTCTCGGGGCGCATTTCACCATC
GAAAGTACTCGGGTTTCGGGGCCGAACTGGAAATGTGCTTAAGCTG
AAAGTTAACTTTCTTCCTGAGATTATCACACTATCCAAAGAAGTC
CGGAACCTCAAATGGCTTGGTTTCCGCGTCCCACTGGCGATTGTG
AACAAAGCCCATCAAGCAAACAGCTTTACCCGTTTGCCATCTCA
45 CTGATCGAGAGCGTTCGTACCTATGAACGGACCTGCGAGAAGGTG
GAGGAGCGGAACACCATTTCCCTTTTGGTGGCTGGCTTGAAAAAG
GAAGTGCAGGCCCTGATCGCAGAAGGCATTGCGTTGGTGTGGGAG
TCCTACAACTTGACCCATATGTACAGCGCTTAGCAGAGACTGTC
TTCAACTTCCAAGAAAAGGTGGATGATCTGCTGATCATTGAAGAA
50 AAAATAGACCTAGAAGTCCGTTTCTTGGAACTTGTATGTATGAC
CATAAGACATTCTCGGAAATCTTGAACAGAGTCCAGAAAGCAGTG
GATGACTTAAATCTGCACTCCTATTCCAATTTGCCATCTGGGTC
AACAGCTTGACATGGAGATTGAAAGAATATTGGGCGTCCGTCTG
CAAGCTGGCCTGAGAGCTTGGACGCAGGTTCTTCTTGGACAAGCT
55 GAAGATAAAGCAGAAGTTGACATGGACACAGATGCTCCACAAGTT
AGTCACAAGCCTGGTGGAGAGCCAAAGATCAAAAATGTCGTTTCAT

GAGCTAAGAATAACCAATCAGGTAATCTACTTGAATCCACCAATT
GAAGAGTGCAGATACAAGCTGTATCAGGAAATGTTTGCCTGGAAG
ATGGTTGTACTGTCTCTCCCCAGGATCCAGAGTCAGAGGTACCG
GTGGGTGTACATTACGAATTGACTGAGGAAGAGAAATTCTATCGG
5 AATGCTTTTAACACGGATGCCTGATGGCCCTGTTGCCCTGGAAGAG
TCGTATTCTGCTGTCATGGGCATTGTATCTGAAGTTGAACAGTAT
GTCAAGGTTTGGCTTCAGTGTTCAGTGTATGTTTATGGGATATGCAAGCT
GAAAACATCTATAACAGACTTGGAGAAGATCTCAACAAATGGCAG
GCTCTCCTGGTCCAAATAAGGAAGGCCAGAGGAACCTTTGACAAT
10 GCAGAAACCAAGAAAGAGTTTGGACCAGTAGTTATAGATTATGGC
AAGGTACAATCTAAGGTGAACTTGAAATATGACTCTTGGCATAAG
GAGGTTCTTAGCAAATTTGGGCAGATGCTAGGATCAAACATGACG
GAATTCCATTCCCAGATCTCAAAGTCCCGCCAAGAGTTGGAGCAG
CACTCAGTAGACACGGCCAGCACCTCCGATGCAGTGACCTTCATC
15 ACCTATGTGCAGTCTTTGAAACGGAAGATCAAGCAGTTTGAGAAG
CAAGTTGAGCTCTACCGCAATGGCCAGCGCTTACTGGAAAAGCAA
AGGTTCCAGTTCCCACCTTCCTGGCTTTATATTGACAACATCGAG
GGAGAGTGGGGAGCCTTCAATGACATCATGCGGCGAAAGGACTCT
GCCATTGAGCAGCAGGTGGCAAACCTGCAAATGAAGATTGTCCAG
20 GAGGATCGGGCCGTGAAAGCCGACCCAGCAGCTGCTGACTGAC
TGGGAGAAGACCAAGCCTGTCACGGGCAACCTTCGCCCAGAAGAG
GCACTTCAGGCTCTCACCATATATGAGGGGAAGTTTGGTAGGCTG
AAGGACGACAGAGAGAAGTGTGCAAAGGCCAAGGAGGCGCTGGAA
TTGACAGATACTGGGCTTCTCAGTGGCAGTGAAGAGCGCGTGCAG
25 GTGGCCTTAGAAGAATTACAGGACCTCAAAGGCGTTTGGTCAGAA
CTTTCTAAGGTTTGGGAGCAAATCGATCAGATGAAGGAGCAACCC
TGGGTTTTCAGTACAGCCTCGAAAGCTTCGACAAAATTTGGATGCC
CTCCTGAACCAGCTGAAAAGCTTCCCTGCCCGGTTGCGACAGTAT
GCGTCCTATGAGTTTGTTCAGAGGCTTCTGAAAGGTTACATGAAG
30 ATAAATATGCTGGTGAATTGAACTGAAATCCGAAGCACTTAAAGAC
CGCCATTGGAAACAGCTCATGAAAAGGCTTCACGTTAATTGGGTT
GTTTCTGAGCTAACCCTTGGCCAAATCTGGGATGTTGACTTGCAG
AAAAATGAAGCGATTGTCAAGGATGTACTGCTTGTGGCACAAGGG
GAGATGGCTTTGGAAGAATTTTGAAGCAGATAAGAGAAGTGTGG
35 AATACTTATGAACTAGACTTGGTTAATTATCAGAACAAAGTGCCGC
TTGATCCGTGGCTGGGATGACCTCTTCAACAAGGTCAAAGAACAC
ATCAACAGCGTCTCGGCCATGAAGCTCTCTCCGTATTACAAGGTT
TTTGAAGAGGATGCTCTCAGCTGGGAAGATAAGCTGAACAGGATC
ATGGCTCTCTTTGATGTGTGGATTGATGTGCAGAGGCGGTGGGTC
40 TACCTGGAAGGTATCTTCACAGGCAGTGCAGATATCAAGCACCTG
CTGCCAGTGGAAACCCAGCGGTTTCAGAGCATCAGCACTGAGTTT
TTGGCTCTAATGAAAAAAGTGTCCAAGTCTCCCTTGTTATGGAT
GTTCTGAACATCCAGGGAGTACAGAGGTCTCTGGAAAGATTGGCA
GACCTGCTAGGAAAGATCCAGAAAGCATTGGGAGAATATCTGGAA
45 AGAGAGCGGTCATCTTTCCCAGGTTCTATTTTGTGGGTGATGAA
GATTTGCTTGAAATCATTGGAAACAGCAAGAATGTCGCTAAATTA
CAGAAACACTTCAAGAAGATGTTTGTGGAGTTTCGAGCATCATC
CTGAACGAGGATAACTCTGTTGTTTTGGGTATTTTCATCTCGGGAA
GGAGAGGAGGTTATGTTTAAACTCCTGTGTCAATTACTGAACAT
50 CCCAAAATCAATGAGTGGCTCACATTGGTAGAAAAGGAGATGAGA
GTCACCCCTGGCCAAACTGCTTGTCTGAGTCTGTTACGGAAGTTGAG
ATTTTTGGTAAAGCAACTTCAATTGACCCAAATACCTACATCACT
TGGATTGATAAATACCAGGCCAGCTTGTGGTTTTTGTGAGCCAG
ATAGCCTGGTCTGAGAACGTGGAGACCGCACTGAGCAGCATGGGC
55 GGAGGTGGAGATGCCGCGCCCTTGCACTCTGTGCTGAGCAATGTG
GAGGTCACCCTCAATGTGTTAGCAGACTCTGTCCTCATGGAGCAG

CCCCACTCCGAAGGCGGAAGCTAGAACACTTGATTACAGAGTTG
GTTACACCAGAGAGATGTTACAAGGTCCTTGATCAAAGCAAGATT
GACAACGCCAAATCTTTTGAATGGCTCAGCCAGATGCGATTTTAC
TTTGACCCTAAGCAAACCTGATGTGTTACAGCAGTTGTCAATTCAA
5 ATGGCAAATGCCAAATTTAACTATGGCTTTGAGTACCTGGGTGTT
CAGGACAAACTGGTCCAGACCCCCCTCACTGACCGCTGCTATTTG
ACAATGACACAAGCCTTGAGAGGCCAGGCTGGGGGGTTCCCCATTT
GGACCTGCTGGAACCTGGGAAAACAGAGTCTGTCAAAGCTCTTGGC
CATCAGCTTTGGACGGTTTGTTTTAGTTTTCAACTGTGATGAAACC
10 TTTGATTTCCAGGCAATGGGCCGGATCTTTGTGGGCCTTTGCCAG
GTGGGTGCCTGGGGCTGCTTTGACGAGTTCAACCGCCTGGAGGAG
CGGATGCTCTCGGCTGTGTCCAGCAGGTGCAGTGCATACAGGAA
GCACTGCGTGAACATTTCAAACCCCAACTACGACAAGACCTCTGCC
CCCATTAATTGTGAGCTGCTGAACAAACAAGTCAAGGTGAGCCCG
15 GACATGGCCATCTTCATCACCATGAACCCTGGCTACGCGGGCCGG
TCTAACCTTCCTGACAACTTGAAGAAGCTGTTCCGGAGCTTGCC
ATGACCAAGCCCGACCGGCAGTTAATCGCCAGGTCATGCTGTAC
TCACAGGGTTTCCGCACTGCTGAAGTGCTTGCCAACAAAATCGTC
CCGTTTTTTTAACTATGCGATGAGCAGCTCTCTTCCCAAAGCCAT
20 TATGACTTCGGTCTTCGGGCTTTGAAGAGTGTGCTGGTGAGTGCA
GGCAATGTGAAGAGAGAGAGAATCCAGAAGATAAAGAGGGAGAAA
GAGGAACGAGGGGAAGCAGTTGATGAAGGAGAAATTGCTGAAAT
CTCCCTGAACAAGAGATTCTGATACAGAGCGTCTGTGAGACGATG
GTGCCAAAGCTGGTGGCAGAGGACATCCCGCTGCTCTTCAGCCTC
25 CTGTGCGACGTGTTCCCTGGAGTCCAGTATCACAGGGGTGAGATG
ACTGCCCTTCGAGAGGAGCTGAAGAAAGTGTGTCAGGAGATGTAT
TTGACATATGGAGATGGAGAAGAAGTTGGTGGAATGTGGGTGAA
AAGGTTCTCCAGCTCTATCAGATCACCCAGATCAATCATGGCCTG
ATGATGGTGGGGCCCTCGGGAAGTGGGAAGAGCATGGCCTGGCGT
30 GTCCTGCTGAAGGCATTGGAGAGACTCGAGGGTGTGGAAGGTGTG
GCCCATATCATCGACCCCAAGGCCATCAGCAAAGACCACCTCTAC
GGAACCCTGGACCCCAACACCAGGGAATGGACAGATGGGCTCTTC
ACACACGTGCTGAGAAAGATCATCGACAGCGTGAGAGGCGAGCTG
CAGAAGCGCCAGTGGATCGTCTTCGATGGCGATGTGGATCCAGAG
35 TGGGTTGAGAACTTGAACCTCAGTGCTGGATGACAATAAGCTCCTA
ACTTTGCCCAATGGAGAGCGCCTCAGTCTTCCACCCAATGTGAGA
ATAATGTTTGAGGTACAGGACTTGAAATACGCGACCTTGGCCACA
GTGTCGCGCTGCGGCATGGTCTGGTTTCAGTGAGGATGTGCTGAGC
ACCGACATGATCTTCAACAACCTTCCTGGCCAGGCTGCGCAGCATC
40 CCGCTGGATGAAGGGGGAGGATGAGGCACAGCGGCGGCGTAAGGGC
AAAGAGGATGAGGGGGAGGAGGCCGCTTCCCCCATGCTGCAGATC
CAAAGAGATGCAGCTACGATCATGCAACCGTACTTCACGTCCAAC
GGCCTGGTCACCAAGGCGCTAGAGCACGCCTTCCAGCTGGAGCAC
ATCATGGACCTAACACGCCTGCGCTGCCTGGGCTCGCTCTTCTCC
45 ATGCTGCACCAGGCCTGCCGCAACGTGGCGCAGTATAACGCCAAC
CATCCCGACTTCCCCATGCAGATCGAGCAGCTGGAGCGCTACATT
CAGCGATATCTGGTTTTATGCCATACTCTGGTCCCTGTCTGGAGAC
AGCCGGCTAAAAATGAGAGCAGAGCTGGGTGAATACATCAGAAGA
ATCACGACCGTGCCCTCTGCCCACTGCGCCCAACATACCCATTATC
50 GATTATGAGGTGTCCATCAGCGGAGAATGGTCTCCGTGGCAGGCC
AAGGTGCCTCAGATTGAAGTGAGAGACGCACAAGGTGGCAGCCCT
GATGTCGTGTCGCAACGCTGGACACAGTCCGCCACGAAGCCCTC
TTGTACACTTGGCTGGCCGAACACAAGCCCTGGTCTTGTGTGGC
CCTCCTGGGTCTGGCAAGACCATGACACTCTTCAGCGCCCTCCGG
55 GCCTTGCTGACATGGAGGTGGTGGGTCTCAACTTCTCCAGTGCT
ACTACTCCAGAGCTGCTTCTGAAGACTTTTGATCACTACTGCGAG

TACAGGCGCACACCTAATGGGGTGGTTTTGGCTCCTGTTCAACTT
GGAAAGTGGCTGGTGTGTTCTGTGATGAAATCAACTTGCCAGAT
ATGGATAAATATGGGACCCAGAGGGTCATATCCTTCATCAGACAG
ATGGTGGAGCACGGAGGCTTTTACCGTACCTCAGATCAAACATGG
5 GTGAAGCTGGAGAGAATCCAGTTTGTGTTGGGGCTTGTAATCCCCC
ACAGACCCTGGAAGAAAGCCCCCTCTCACACAGGTTCTGCGCCAC
GTGCCTGTCGTGTATGTGGATTACCCGGGCCCCGCTCCCTCACA
CAGATCTACGGCACCTTCAACCGCGCCATGCTGAGGCTCATTCCA
TCCCTGCGGACGTATGCAGAGCCGCTCACTGCTGCCATGGTGGAG
10 TTCTACACCATGTCTCAGGAGAGATTACCCAGGATACACAACCT
CACTATATCTATTACCCCGTGAAATGACTAGGTGGGTGAGAGGC
ATCTTTGAAGCGCTGAGACCTCTGGAGACCCTGCCTGTTGAAGGC
CTCATTCCGGATTTGGGACATGAAGCTCTGCGTCTCTTCCAAGAT
AGACTCGTAGAGGATGAGGAGAGGCGTTGGACTGATGAGAACATC
15 GACACGGTTGCTCTGAAGCACTTCCCTAACATCGACAGAGAGAAG
GCAATGAGCCGACCCATCTTGTACAGCAACTGGCTGTCAAAGGAT
TACATCCCAGTAGACCAAGAAGAGTTAAGAGATTATGTCAAAGCT
AGGCTGAAGGTCTTTTATGAAGAAGAACTTGATGTTCCGCTGGTG
CTGTTTAATGAAGTCTTAGACCACGTGCTGAGGATTGACAGAATA
20 TTCCGTCAACCTCAAGGCCACTTGCTTCTGATTGGTGTAGTGA
GCAGGAAAACTACCCTGTCTCGTTTCGTCGCCTGGATGAACGGT
TTGAGTGTGTACCAGATTAAAGTCCATAGGAAGTACACAGGGGAA
GACTTTGATGAAGATCTACGGACAGTGTTGAGACGTTCTGGCTGT
AAAAATGAAAAGATAGCATTTATAATGGATGAATCTAATGTGTTA
25 GATTCTGGATTCTTGAGCGAATGAATACCCTTCTGGCCAATGGA
GAGGTGCCTGGTCTCTTTGAAGGAGACGAGTATGCCACCTTGATG
ACGCAGTGCAAAGAGGGGGCACAGAAGGAAGGCCTGATGCTGGAC
TCGCACGAGGAGCTCTACAAGTGGTTCACTAGCCAGGTTATCCGC
AACCTCCACGTGCTGTTTACCATGAACCCGTCCTCGGAGGGACTC
30 AAGGACCGGGCAGCTACATCACCAGCACTTTTCAACAGGTGTGTG
TTGAATTGGTTTGGGAGACTGGTCCACCGAAGCACTGTATCAGGTT
GGCAAAGAATTACAAAGTAAGATGGATCTGGAGAAGCCAAATTAC
ATCGTGCCTGATTACATGCCAGTTGTGTATGATAAGCTGCCGCAG
CCACCATCCCATCGGGAAGCCATTGTGAACAGCTGTGTGTTTGT
35 CATCAGACTCTTACCAGGCGAATGCTCGGCTAGCAAAGCGAGGC
GGCAGAACGATGGCCATCACCCCTCGCCACTACCTGGACTTCATC
AATCACTATGCCAACCTGTTCCACGAGAAGCGGAGCGAGCTGGAG
GAGCAGCAGATGCACTTGAACGTGGGGCTCAGGAAGATCAAAGAG
ACAGTCGACCAGGTAGAAGAACTGCGTCGTGACTTGAGGATAAAG
40 AGCCAAGAGCTGGAGGTGAAGAATGCAGCAGCCAATGACAAGCTG
AAAAAGATGGTGAAAGACCAGCAGGAGGCTGAAAAGAAGAAGGTT
ATGAGCCAAGAAATCCAGGAACAGCTGCATAAGCAGCAGGAGGTA
ATTGCAGACAAACAGATGAGTGTCAAAGAAGATCTTGATAAGGTG
GAACCTGCCGTCATTGAGGCCCAGAATGCTGTGAAGTCGATCAAG
45 AAGCAGCACCTGGTGGAGGTGAGGTCCATGGCCAACCCTCCTGCT
GCTGTGAAGCTGGCGCTGGAGTCCATCTGCCTGCTGCTGGGGGAA
AGCACACAGACTGGAAGCAGATCCGCTCCATCATCATGCGGGAG
AACTTCATCCCCACCATCGTCAACTTCTCTGCAGAGGAGATCAGT
GACGCCATAAGGGAGAAGATGAAGAAAAATTACATGTCCAATCCA
50 AGTTACAATTATGAAATTGTGAATCGGGCTTCCCTGGCTTGGCGC
CCTATGGTGAAATGGGCAATTGCACAGCTTAAGTATGCAGACATG
TTAAAGAGAGTGGAGCCCCACGCAATGAGCTGCAGAAGCTGGAA
GATGACGCCAAGGACAACCAGCAGAAGGCCAACGAGGTGGAGCAG
ATGATCCGAGACCTGGAAGCCAGCATCGCCCGCTACAAGGAGGAA
55 TACGCCGTCCTGATCTCAGAGGCCCAGGCCATCAAGGCAGACCTG
GCAGCTGTCGAGGCCAAAAGTAAACCGGAGCACTGCTCTTCTGAAG

AGCTTGTCTGCTGAACGTGAACGATGGGAAAAACAAGTGAAACT
TTCAAAAACCAGATGTCCACCATTGCTGGGGACTGTCTCTTGCTCA
GCTGCGTTTCATTGCCTACGCGGGTTACTTTGACCAGCAGATGCGT
CAGAACTTGTTCACTACCTGGTCCCATCACCTACAGCAAGCCAAC
5 ATCCAGTTCCGTACAGATATTGCCAGGACGGAATACCTTTCCAAT
GCTGATGAGCGTCTTCGCTGGCAGGCCAGCTCCTTGCTGCTGAT
GACCTTTGCACAGAAAATGCCATCATGCTGAAACGATTCAATAGG
TATCCGCTGATCATTGACCCCTCTGGACAGGCCACAGAATTCATT
10 ATGAATGAATATAAGGATCGTAAGATCACACGGACCAGCTTCCTG
GATGACGCCTTCAGAAAGAACTTAGAGAGTGCAGTGAAGATTCGGT
AACCCCTTCTGGTCCAGGATGTGGAAAGCTACGATCCAGTTTTG
AACCCGGTGCTGAACCGTGAAGTGCGGGCAACAGGGGGGAGAGTG
CTGATCACTCTCGGGGACCAGGACATAGACCTGTGCGCCATCGTTT
15 GTCATCTTCTGTCCACCCGGGATCCAACTGTGAGTTCCCACCA
GATCTCTGTTCCCGGGTTACTTTTGTAAGTTTACAGTTACCCGT
AGCAGTTTACAAAGCCAGTGTCTAAATGAAGTACTTAAAGCAGAA
AGACCTGATGTGGACGAGAAACGATCTGATCTTCTTAAACTTCAA
GGGGAATTTAGCTCCGTTTGCGTCAGCTGGAAAAATCTCTACTA
CAAGCTCTGAACGAGGTGAAAGGGCGCATTTTGGATGACGACACG
20 ATCATAACCACTCTGGAGAACCTGAAGAGAGAGGCTGCAGAGGTC
ACCAGGAAAGTTGAGGAGACGGACATTGTGATGACGAGGTGGAG
ACCGTGTCTCCAGCAGTACCTCCCGCTCTCCACCGCCTGCAGCAGC
ATCTACTTCAACATGGAGTCCCTCAAGCAGATACTTCTTGATAC
CAGTACTCCCTCCAGTTTTTCTGGACATTTATCACAAACGTCCTA
25 TACGAGAACCCGAACCTGAAGGGTGTACCGACCACACACAGCGC
CTGTCCATTATAACAAAGGACCTCTTCCAGGTGGCGTTTAACCGA
GTGGCTCGAGGCATGCTGCATCAGGACCACATTACCTTTGCCATG
CTGCTGGCAAGAATCAAACCTGAAGGGCACCGTGGGGGAGCCCACC
TACGATGCAGAATTCCAGCACTTCTTGAGAGGAAATGAGATTGTC
30 CTGAGTGCTGGCTCCACCCCGAGGATCCAGGGCCTGACTGTGGAG
CAGGCGGAGGCGGTGGTGAGGCTGAGCTGCCTTCCCGCGTTTAAG
GACTTGATTGCAAAGGTTTCAAGCAGACGAGCAATTTGGCATCTGG
CTGGACAGCAGCTCCCCGGAGCAGACTGTGCCCTACCTCTGGAGT
GAAGAAACACCTGCAACACCCATTGGCCAGGCCATCCACCGCCTG
35 CTCCTGATCCAGGCTTTCCGGCCCGATCGCCTGTTGGCCATGGCC
CACATGTTTGTTCACAAACCTTGGGGAGTCTTTCATGTCCATC
ATGGAGCAGCCGCTCGACCTGACCCACATTGTGGGCACAGAGGTG
AAGCCCAACACTCCTGTCTTAATGTGCTCTGTGCCTGGTTATGAT
GCCAGTGGACATGTGAGGACCTTGCAGCCGAGCAGAACACGCAG
40 ATCACTTCAATTGCAATCGGCTCTGCAGAAGGCTTTAACCAAGCA
GATAAGGCAATAAACACCGCTGTAAAGTCGGGCAGGTGGGTGATG
CTGAAGAATGTGCATCTGGCCCCAGGGTGGCTGATGCAGCTGGAG
AAGAAGTTGCATTCCCTGCAGCCGCATGCCTGCTTCCGACTCTTC
CTCACCATGGAGATCAACCCCAAGGTGCCTGTGAATCTGCTCCGT
45 GCGGGCCGCATCTTTGTGTTTCAGGCCACCGCCAGGGGTGAAGGCC
AACATGCTGAGGACGTTTCAAGCAGATTCCCGTCTCACGGATATGC
AAGTCTCCCAACGAGCGTGCCCGCTTGTACTTCTGCTGGCCTGG
TTTCATGCGATCATCCAAGAACGCTTACGATACGCACCACTGGGG
TGGTCAAAGAAGTATGAATTTGGAGAGTCTGACCTGCGGTGAGCT
50 TGCATACGGTGGACACGTGGCTGGATGACACGGCCAAGGGCAGG
CAGAACATCTCACCGGATAAGATCCCGTGGTCTGCACTAAAGACC
TTAATGGCCCCAGTCCATTTATGGCGGGCGCGTGGACAACGAGTTT
GACGAGCTCTGCTCAACACCTTCCCTGGAGCGCCTGTTTCAACACC
AGGAGTTTTCGACAGTGAAGTTTAAAGCTGGCATGCAAGGTGACGGA
55 CATAAAGACATTCAAATGCCAGATGGCATCAGGCGAGAGGAGTTT
GTGCAGTGGGTGGAGTTGCTCCCCGACACCCAGACGCCCTCCTGG

CTGGGCCTGCCCAACAACGCCGAGAGAGTCCTCCTTACCACACAG
GGTGTGGACATGATCAGTAAAATGCTGAAGATGCAGATGTTGGAG
GATGAGGACGACCTGGCCTACGCAGAGACTGAGAAGAAGACGAGG
ACAGACTCCACGTCCGACGGGCGCCCTGCCTGGATGCGGACACTG
5 CACACCACCGCGTCCAACCTGGCTGCACCTCATCCCCAGACGCTG
AGCCACCTCAAGCGCACCGTGGAGAATATCAAGGATCCTTTGTTC
AGGTTCTTTGAGAGAGAAGTGAAGATGGGCGCAAAGCTGCTTCAG
GACGTTTCGCCAGGACCTTGCAGATGTCGTCCAGGTGTGCGAAGGA
AAGAAGAAGCAGACCAACTACTTGCGCACGCTGATCAACGAGCTA
10 GTGAAAGGGATCTTGCCTCGGAGCTGGTCCCCTACACGGTGCCT
GCCGGCATGACCGTCATCCAGTGGGTGTCCGACTTCAGCGAGAGG
ATCAAACAGCTGCAGAACATCTCACTGGCAGCTGCATCTGGTGGC
GCCAAGGAGCTAAAGAACATCCACGTGTGCCTGGGTGGCCTGTTC
GTGCCTGAGGCGTACATCACTGCCACCAGGCAGTATGTGGCCCAG
15 GCCAACAGCTGGTCCCTGGAGGAGCTCTGCCTGGAAGTCAACGTC
ACCACCTCACAGGGCGCCACCCTTGACGCTTGCAGCTTCGGAGTC
ACGGGTTTGAAACTTCAAGGGGCCACGTGCAACAACAACAAGCTG
TCACTGTCCAATGCCATCTCAACCGCCCTTCCCCTGACGCAGCTG
CGCTGGGTCAAGCAGACAAACACCGAGAAGAAGGCCAGTGTGGTA
20 ACCTTACCTGTCTACCTGAACCTCACCCGTGCAGACCTCATCTTC
ACCGTGGACTTCGAAATTGCTACAAAGGAGGATCCTCGCAGCTTC
TACGAGCGGGGTGTGCGAGTCTTGTGCACAGAGTAA

25 **Table 4.** Wild type human cytoplasmic dynein heavy chain 1, cDNA (SEQ ID
NO:17)

ATGTCGGAGCCCGGGGGCGGGCGGCGGCGAGGACGGCTCGGCCGGA
TTGGAAGTGTCGGCCGTGCAGAATGTGGCGGACGTGTCGGTGCTG
30 CAGAAGCACCTGCGCAAGCTGGTGCCGCTGCTGCTGGAGGACGGC
GGCGAGGCGCCGGCCGCGCTGGAGGCGGCGCTGGAGGAGAAGAGC
GCCCTGGAGCAGATGCGCAAGTTCTTTTCGGACCCGCAGGTCCAC
ACGGTGCTGGTGGAGCGCTCCACGCTCAAAGAGGACGTCGGTGAT
GAAGGAGAAGAAGAAAAAGAATTCAATTTCTATAACATCAACATA
GACATTCATTATGGGGTTAAATCCAATAGCTTGGCATTCAATAAA
35 CGTACTCCCGTGATTGATGCAGATAAACCCGTGTCTTCTCAGCTC
CGGGTCCTTACACTCAGTGAAGACTCGCCCTACGAAACTTTGCAT
TCTTTCAATAGCAATGCAGTGGCTCCTTTTTTTTAAGTCCTACAT
AGAGAGTCTGGCAAGGCAGACAGGGATGGTGATAAAATGGCTCCT
TCAGTTGAAAAGAAGATTGCAGAACTCGAAATGGGACTCCTTCAC
40 TTGCAGCAAAATATTGAAATTCGGGAGATCAGCCTGCCGATTTCAT
CCAATGATCACAAATGTTGCAAAACAGTGTTATGAGCGTGGAGAA
AAGCCAAAAGTTACAGACTTTGGTGATAAGGTTGAAGACCCAAACA
TTTCTTAATCAGTTACAATCTGGAGTTAACCGCTGGATCCGAGAA
ATTCAAAAAGTGACCAAACTGGATCGAGATCCTGCATCAGGAACT
45 GCCTTACAGGAAATTAGTTTTTTGGCTAAACTTGGAACGTGCGTTA
TACCGCATCCAGGAGAAACGGGAGAGCCCGGAAGTTCTCCTGACT
CTGGATATCTTGAAACATGGCAAGCGCTTCCATGCCACCGTCAGT
TTTGACACTGACACAGGTCTAAAACAGGCTTTGGAAACTGTGAAT
GACTACAATCCTCTGATGAAAGATTTCCCTCTGAATGATTTGCTG
50 TCTGCCACGGAGCTGGACAAAATAAGACAGGCGCTTGTTGCCATT
TTCACACATTTGAGAAAGATCCGAAACACAAAATATCCTATTTCAG
AGGGCACTGCGTTTTGGTGGAGGCAATTTCAAGAGACTTGAGTTCT
CAATTACTCAAAGTATTGGGCCTAGGAAATTGATGCATGTTGCT

TATGAAGAATTTGAAAAAGTTATGGTAGCATGCTTTGAAGTTTTT
CAGACTTGGGATGATGAGTATGAGAACTTCAGGTATTGTTGAGA
GACATCGTCAAAAGAAAAAGGGAAGAAAATCTGAAGATGGTGTGG
CGTATCAACCCTGCCACAGGAAGCTGCAGGCCCGCCTTGACCAG
5 ATGAGAAAATTTAGACGCCAGCATGAACAGCTAAGAGCTGTTATC
GTCAGGGTCTTGAGGCCACAGGTCACGGCAGTTGCACAACAGAAT
CAAGGAGAGGTCCCTGAACCCCAAGATATGAAAGTGGCTGAGGTT
CTCTTTGATGCTGCAGATGCAAATGCCATTGAGGAAGTAAACCTT
GCTTATGAGAACGTCAAGGAAGTGGATGGACTGGATGTTTCCAAA
10 GAGGGCACGGAAGCCTGGGAGGCTGCTATGAAGAGGTACGATGAG
AGGATCGACAGAGTGGAGACCCGGATCACCGCTCGCCTTCGGGAT
CAGCTTGGCACAGCCAAGAATGCCAACGAGATGTTTAGGATTTTC
TCCAGGTTTAAATGCACTGTTTGTGAGGCCCTCACATCCGTGGGGCC
ATTGCGGAATACCAGACCCAGCTGATCCAGCGCGTGAAAGATGAC
15 ATTGAGTCTCTTCACGACAAGTTCAAGGTCCAGTACCCACAGAGT
CAGGCTTGTAAGATGAGTCACGTTCTGACTTGCCCCCTGTGTCA
GGGTCTATCATCTGGGCTAAACAGATCGACAGGCAGCTGACGGCC
TACATGAAGCGGGTGGAAGATGTCCTTGGCAAGGGCTGGGAGAAT
CACGTGGAGGGGCAGAACGTGAAGCAGGATGGAGACAGCTTCCGC
20 ATGAAGCTCAACACGCAGGAGATCTTTGATGACTGGGCAAGGAAG
GTGACGACGCGCAACCTCGGTGTCTCGGGGCGCATTTTACCATC
GAAAGTACTCGGGTTCGGGGCCGAAGTGGAAATGTGCTTAAGCTG
AAAGTTAACTTTCTTCTGAGATTATCACACTATCCAAAGAAGTC
CGGAACCTCAAATGGCTTGGTTTCCGCGTCCCACTGGCGATTGTG
25 AACAAAGCCCATCAAGCAAACCAGCTTTACCCGTTTGCCATCTCA
CTGATCGAGAGCGTTTCGTACCTATGAACGGACCTGCGAGAAGGTG
GAGGAGCGGAACACCATTTCCCTTTTGGTGGCTGGCTTGAAAAAG
GAAGTGCAGGCCCTGATCGCAGAAGGCATTGCGTTGGTGTGGGAG
TCCTACAACTTGACCCATATGTACAGCGCTTAGCAGAGACTGTC
30 TTCAACTTCCAAGAAAAGGTGGATGATCTGCTGATCATTGAAGAA
AAAATAGACCTAGAAGTCCGTTCTTGGAACTTGTATGTATGAC
CATAAGACATTCTCGGAAATCTTGAACAGAGTCCAGAAAGCAGTG
GATGACTTAAATCTGCACTCCTATTCCAATTTGCCCATCTGGGTC
AACAAGCTTGACATGGAGATTGAAAGAATATTGGGCGTCCGTCTG
35 CAAGCTGGCCTGAGAGCTTGGACGCAGGTTCTTCTTGGACAAGCT
GAAGATAAAGCAGAAGTTGACATGGACACAGATGCTCCACAAGTT
AGTCACAAGCCTGGTGGAGAGCCAAAGATCAAAAATGTCGTTTCAT
GAGCTAAGAATAACCAATCAGGTAATCTACTTGAATCCACCAATT
GAAGAGTGCAGATACAAGCTGTATCAGGAAATGTTTGCCTGGAAG
40 ATGGTTGTACTGTCTCTCCCCAGGATCCAGAGTCAGAGGTACCAG
GTGGGTGTACATTACGAATTGACTGAGGAAGAGAAATCTATCGG
AATGCTTTAACACGGATGCCTGATGGCCCTGTTGCCCTGGAAGAG
TCGTATTCTGCTGTCTATGGGCATTGTATCTGAAGTTGAACAGTAT
GTCAAGGTTTGGCTTCAGTATCAGTGTTTATGGGATATGCAAGCT
45 GAAAACATCTATAACAGACTTGGAGAAGATCTCAACAAATGGCAG
GCTCTCCTGGTCCAAATAAGGAAGGCCAGAGGAACCTTTGACAA
GCAGAAACCAAGAAAGAGTTTGGACCAGTAGTTATAGATTATGAGC
AAGGTACAATCTAAGGTGAACTTGAATATGACTCTTGGCATAGG
GAGGTTCTTAGCAAATTTGGGCAGATGCTAGGATCAAACATGACG
50 GAATTCCATTCCCAGATCTCAAAGTCCCGCCAAGAGTTGGAGCAG
CACTCAGTAGACACGCGCCAGCCTCCGATGCAGTGACCTTCATC
ACCTATGTGCAGTCTTTGAAACGGAAGATCAAGCAGTTTGAGAAG
CAAGTTGAGCTCTACCGCAATGGCCAGCGCTTACTGGAAAAGCAA
AGGTTCCAGTTCCACCTTCTGGCTTTTATATTGACAACATCGAG
55 GGAGAGTGGGGAGCCTTCAATGACATCATGCGGCGAAAGGACTCT
GCCATTGAGCAGCAGGTGGCAAACCTGCAAATGAAGATTGTCCAG

GAGGATCGGGCCGTGGAAAGCCGCACACCGACCTGCTGACTGAC
TGGGAGAAGACCAAGCCTGTCACGGGCAACCTTCGCCCAGAAGAG
GCACTTCAGGCTCTCACCATATATGAGGGGAAGTTTGGTAGGCTG
AAGGACGACAGAGAGAAGTGTGCAAAGGCCAAGGAGGCGCTGGAA
5 TTGACAGATACTGGGCTTCTCAGTGGCAGTGAAGAGCGCGTGCAG
GTGGCCTTAGAAGAATTACAGGACCTCAAAGGCGTTTGGTCAGAA
CTTTCTAAGGTTTGGGAGCAAATCGATCAGATGAAGGAGCAACCC
TGGGTTTTCAGTACAGCCTCGAAAGCTTCGACAAAATTTGGATGCC
CTCCTGAACCAGCTGAAAAGCTTCCCTGCCCCGGTTGCGACAGTAT
10 GCGTCCTATGAGTTTGTTCAGAGGCTTCTGAAAGGTTACATGAAG
ATAAATATGCTGGTGATTGAACTGAAATCCGAAGCACTTAAAGAC
CGCCATTGGAAACAGCTCATGAAAAGGCTTCACGTTAATTGGGTT
GTTTCTGAGCTAACCCTTGGCCAAATCTGGGATGTTGACTTGCAG
AAAATGAAGCGATTGTCAAGGATGTACTGCTTGTGGCACAAGGG
15 GAGATGGCTTTGGGAAGAATTTTGAAGCAGATAAGAGAAGTGTGG
AATACTTATGAACTAGACTTGGTTAATTATCAGAACAAAGTGCCGC
TTGATCCGTGGCTGGGATGACCTCTTCAACAAGGTCAAAGAACAC
ATCAACAGCGTCTCGGCCATGAAGCTCTCTCCGTATTACAAGGTT
TTTGAAGAGGATGCTCTCAGCTGGGAAGATAAGCTGAACAGGATC
20 ATGGCTCTCTTTGATGTGTGGATTGATGTGCAGAGGCGGTGGGTC
TACCTGGAAGGTATCTTCACAGGCAGTGCAGATATCAAGCAGCTG
CTGCCAGTGGAAACCCAGCGGTTTCAGAGCATCAGCACTGAGTTT
TTGGCTCTAATGAAAAAAGTGTCCAAGTCTCCCCTTGTTATGGAT
GTTCTGAACATCCAGGGAGTACAGAGGTCTCTGGAAAGATTGGCA
25 GACCTGCTAGGAAAGATCCAGAAAGCATTGGGAGAATATCTGGAA
AGAGAGCGGTCATCTTCCCCAGGTTCTATTTTGTGGGTGATGAA
GATTTGCTTGAATCATTGGAAACAGCAAGAATGTCGCTAAATTA
CAGAAACACTTCAAGAAGATGTTTGCTGGAGTTTCGAGCATCATC
CTGAACGAGGATAACTCTGTTGTTTTGGGTATTTTATCTCGGGAA
30 GGAGAGGAGGTTATGTTTAAACTCCTGTGTCAATTACTGAACAT
CCCAAAATCAATGAGTGGCTCACATTGGTAGAAAAGGAGATGAGA
GTCACCCTGGCCAAACTGCTTGCTGAGTCTGTTACGGAAGTTGAG
ATTTTTGGTAAAGCAACTTCAATTGACCCAAATACCTACATCACT
TGGATTGATAAATACCAGGCCAGCTTGTGGTTTTTGTGAGCCAG
35 ATAGCCTGGTCTGAGAACGTGGAGACCGCACTGAGCAGCATGGGC
GGAGGTGGAGATGCCGCGCCCTTGCACTCTGTGCTGAGCAATGTG
GAGGTACCCCTCAATGTGTTAGCAGACTCTGTCTCATGGAGCAG
CCCCCACTCCGAAGGCGGAAGCTAGAACACTTGATTACAGAGTTG
GTTACACAGAGAGATGTTACAAGGTCCTTGATCAAAGCAAGATT
40 GACAACGCCAAATCTTTTGAATGGCTCAGCCAGATGCGATTTTAC
TTTGACCCTAAGCAAACCTGATGTGTTACAGCAGTTGTCAATTCAA
ATGGCAAATGCCAAATTTAACTATGGCTTTGAGTACCTGGGTGTT
CAGGACAAACTGGTCCAGACCCCCCTCACTGACCGCTGCTATTTG
ACAATGACACAAGCCTTGGAGGCCAGGCTGGGGGGTTCCCCATTT
45 GGACCTGCTGGAACCTGGGAAAACAGAGTCTGTCAAAGCTCTTGGC
CATCAGCTTGGACGGTTTGTTTTAGTTTTCAACTGTGATGAAACC
TTTGATTTCCAGGCAATGGGCGGATCTTTGTGGGCCCTTGGCCAG
GTGGGTGCCTGGGGCTGCTTTGACGAGTTCAACCGCCTGGAGGAG
CGGATGCTCTCGGCTGTGTCCCAGCAGGTGCAGTGCATACAGGAA
50 GCACTGCGTGAACATTCCAACCCCAACTACGACAAGACCTTGCC
CCCATTACTTGTGAGCTGCTGAACAAACAAGTCAAGGTGAGCCCG
GACATGGCCATCTTCATCACCATGAACCCTGGCTACGCGGGCCGG
TCTAACCTTCCTGACAACCTGAAGAAGCTGTTCCGGAGCTTGGCC
ATGACCAAGCCCCGACCGGAGTTAATCGCCCAGGTCATGCTGTAC
55 TCACAGGGTTTCCGCACTGCTGAAGTGCTTGCCAACAAAATCGTC
CCGTTTTTTAACTATGCGATGAGCAGCTCTCTTCCCAAAGCCAT

TATGACTTCGGTCTTCGGGCTTTGAAGAGTGTGCTGGTGAGTGCA
GGCAATGTGAAGAGAGAGAGAATCCAGAAGATAAAGAGGGAGAAA
GAGGAACGAGGGGAAGCAGTTGATGAAGGAGAAATTGCTGAAAAT
CTCCCTGAACAAGAGATTCTGATACAGAGCGTCTGTGAGACGATG
5 GTGCCAAAGCTGGTGGCAGAGGACATCCCGCTGCTCTTCAGCCTC
CTGTGCGGACGTGTTCCCTGGAGTCCAGTATCACAGGGGTGAGATG
ACTGCCCTTCGAGAGGAGCTGAAGAAAGTGTGTCAGGAGATGTAT
TTGACATATGGAGATGGAGAAGAAGTTGGTGGAAATGTGGGTGAA
AAGGTTCTCCAGCTCTATCAGATCACCCAGATCAATCATGGCCTG
10 ATGATGGTGGGGCCCTCGGGAAGTGGGAAGAGCATGGCCTGGCGT
GTCCTGCTGAAGGCATTGGAGAGACTCGAGGGTGTGGAAGGTGTG
GCCCATATCATCGACCCCAAGGCCATCAGCAAAGACCACCTCTAC
GGAACCCTGGACCCCAACACCAGGGAATGGACAGATGGGCTCTTC
ACACACGTGCTGAGAAAGATCATCGACAGCGTGAGAGGCGAGCTG
15 CAGAAGCGCCAGTGGATCGTCTTCGATGGCGATGTGGATCCAGAG
TGGGTTGAGAACTTGAACCTCAGTGTGGATGACAATAAGCTCCTA
ACTTTGCCCAATGGAGAGCGCCTCAGTCTTCCACCCAATGTGAGA
ATAATGTTTGAGGTACAGGACTTGAAATACGCGACCTTGGCCACA
GTGTCGCGCTGCGGCATGGTCTGGTTCAGTGAGGATGTGCTGAGC
20 ACCGACATGATCTTCAACAACTTCTGGCCAGGCTGCGCAGCATC
CCGCTGGATGAAGGGGAGGATGAGGCACAGCGGCGGCGTAAGGGC
AAAGAGGATGAGGGGGAGGAGGCCGCTTCCCCCATGCTGCAGATC
CAAAGAGATGCAGCTACGATCATGCAACCGTACTTCACGTCCAAC
GGCCTGGTCACCAAGGCGCTAGAGCACGCCCTTCCAGCTGGAGCAC
25 ATCATGGACCTAACACGCCCTGCGCTGCCTGGGCTCGCTCTTCTCC
ATGCTGCACCAGGCCTGCCGCAACGTGGCGCAGTATAACGCCAAC
CATCCCGACTTCCCCATGCAGATCGAGCAGCTGGAGCGCTACATT
CAGCGATATCTGGTTTATGCCATACTCTGGTCCCTGTCTGGAGAC
AGCCGGCTAAAAATGAGAGCAGAGCTGGGTGAATACATCAGAAGA
30 ATCACGACCGTGCTCTGCCACTGCGCCCAACATAACCCATTATC
GATTATGAGGTGTCCATCAGCGGAGAATGGTCTCCGTGGCAGGCC
AAGGTGCCTCAGATTGAAGTGGAGACGCACAAGGTGGCAGCCCCT
GATGTCGTGCTGCCAACGCTGGACACAGTCCGCCACGAAGCCCTC
TTGTACACTTGGCTGGCCGAACACAAGCCCCCTGGTCTTGTGTGGC
35 CCTCCTGGGTCTGGCAAGACCATGACACTCTTCAGCGCCCTCCGG
GCCTTGCCTGACATGGAGGTGGTGGGTCTCAACTTCTCCAGTGCT
ACTACTCCAGAGCTGCTTCTGAAGACTTTTGATCACTACTGCGAG
TACAGGGCGCACACCTAATGGGGTGGTTTTTGGCTCCTGTTCAACTT
GGAAAGTGGCTGGTGTGTTCTGTGATGAAATCAACTTGCCAGAT
40 ATGGATAAATATGGGACCCAGAGGGTCATATCCTTCATCAGACAG
ATGGTGGAGCACGGAGGCTTTTACCGTACCTCAGATCAAACATGG
GTGAAGCTGGAGAGAATCCAGTTTGTGGGGCTTGTAATCCCCC
ACAGACCCTGGAAGAAAGCCCTCTCACACAGGTTCTGCGCCAC
GTGCCTGTCGTGTATGTGGATTACCCGGGCCCCGCCTCCCTCACA
45 CAGATCTACGGCACCTTCAACCGCGCCATGCTGAGGCTCATTCCA
TCCCTGCGGACGTATGCAGAGCCGCTCACTGCTGCCATGGTGGAG
TTCTACACCATGTCTCAGGAGAGATTACCCAGGATACACAACCT
CACTATATCTATTACCCCCGTGAAATGACTAGGTGGGTGAGAGGC
ATCTTTGAAGCGCTGAGACCTCTGGAGACCCTGCCTGTTGAAGGC
50 CTCATTCCGATTGGGACATGAAGCTCTGCGTCTCTTCCAAGAT
AGACTCGTAGAGGATGAGGAGAGGCGTTGGACTGATGAGAACATC
GACACGGTTGCTCTGAAGCACTTCCCTAACATCGACAGAGAGAAG
GCAATGAGCCGACCCATCTTGTACAGCAACTGGCTGTCAAAGGAT
TACATCCAGTAGACCAAGAAGAGTTAAGAGATTATGTCAAAGCT
55 AGGCTGAAGGTCTTTTATGAAGAAGAAGTGGATGTTCCGCTGGTG
CTGTTTAAATGAAGTCCTAGACCACGTGCTGAGGATTGACAGAATA

TTCCGTCAACCTCAAGGCCACTTGCTTCTGATTGGTGTTAGTGGA
GCAGGAAAACTACCCTGTCTCGTTTCGTCGCCTGGATGAACGGT
TTGAGTGTGTACCAGATTAAGGTCCATAGGAAGTACACAGGGGAA
GACTTTGATGAAGATCTACGGACAGTGTTGAGACGTTCTGGCTGT
5 AAAAATGAAAAGATAGCATTTATAATGGATGAATCTAATGTGTTA
GATTCTGGATTCCCTGGAGCGAATGAATACCCTTCTGGCCAATGGA
GAGGTGCCTGGTCTCTTTGAAGGAGACGAGTATGCCACCTTGATG
ACGCAGTGCAAAGAGGGGGCACAGAAGGAAGGCCTGATGCTGGAC
TCGCACGAGGAGCTCTACAAGTGGTTCACTAGCCAGGTTATCCGC
10 AACCTCCACGTCGTGTTCAACCATGAACCCGTCCTCGGAGGGACTC
AAGGACCGGGCAGCTACATCACCAGCACTTTTCAACAGGTGTGTG
TTGAATTGGTTTGGGAGACTGGTCCACCGAAGCACTGTATCAGGTT
GGCAAAGAATTACAAAGTAAGATGGATCTGGAGAAGCCAAATTAC
ATCGTGCCTGATTACATGCCAGTTGTGTATGATAAGCTGCCGCAG
15 CCACCATCCCATCGGGAAGCCATTGTGAACAGCTGTGTGTTTGT
CATCAGACTCTTCACCAGGCGAATGCTCGGCTAGCAAAGCGAGGC
GGCAGAACGATGGCCATCACCCCTCGCCACTACCTGGACTTCATC
AATCACTATGCCAACCTGTTCCACGAGAAGCGGAGCGAGCTGGAG
GAGCAGCAGATGCACTTGAACGTGGGGCTCAGGAAGATCAAAGAG
20 ACAGTCGACCAGGTAGAAGAACTGCGTCGTGACTTGAGGATAAAG
AGCCAAGAGCTGGAGGTGAAGAATGCAGCAGCCAATGACAAGCTG
AAAAGATGGTGAAAGACCAGCAGGAGGCTGAAAAGAAGAAGGTT
ATGAGCCAAGAAATCCAGGAACAGCTGCATAAGCAGCAGGAGGTA
ATTGCAGACAAACAGATGAGTGTCAAAGAAGATCTTGATAAGGTG
25 GAACCTGCCGTCATTGAGGCCCAGAATGCTGTGAAGTCGATCAAG
AAGCAGCACCTGGTGGAGGTGAGGTCCATGGCCAACCCTCCTGCT
GCTGTGAAGCTGGCGCTGGAGTCCATCTGCCTGCTGCTGGGGGAA
AGCACACAGACTGGAAGCAGATCCGCTCCATCATCATGCGGGAG
AACTTCATCCCCACCATCGTCAACTTCTCTGCAGAGGAGATCAGT
30 GACGCCATAAGGGAGAAGATGAAGAAAAATTACATGTCCAATCCA
AGTTACAATTATGAAATTGTGAATCGGGCTTCCCTGGCTTGCGGC
CCTATGGTGAAATGGGCAATTGCACAGCTTAACTATGCAGACATG
TTAAAGAGAGTGGAGCCCCTACGCAATGAGCTGCAGAAGCTGGAA
GATGACGCCAAGGACAACCAGCAGAAGGCCAACGAGGTGGAGCAG
35 ATGATCCGAGACCTGGAAGCCAGCATCGCCCGCTACAAGGAGGAA
TACGCCGTCCTGATCTCAGAGGCCCAGGCCATCAAGGCAGACCTG
GCAGCTGTGAGGCAAAAGTAAACCGGAGCACTGCTCTTCTGAAG
AGCTTGTCTGCTGAACGTGAACGATGGGAAAAACAAGTGAAACT
TTCAAAAACCAGATGTCCACCATTGCTGGGGACTGTCTCTTGTC
40 GCTGCGTTCATTGCCTACGCGGGTTACTTTGACCAGCAGATGCGT
CAGAACTTGTTCACTACCTGGTCCCATCACCTACAGCAAGCCAAC
ATCCAGTTCCGTACAGATATTGCCAGGACGGAATACCTTTCCAAT
GCTGATGAGCGTCTTCGCTGGCAGGCCAGCTCCTTGCCTGCTGAT
GACCTTTGCACAGAAAAATGCCATCATGCTGAAACGATTCAATAGG
45 TATCCGCTGATCATTGACCCCTCTGGACAGGCCACAGAATTCATT
ATGAATGAATATAAGGATCGTAAGATCACACGGACCAGCTTCCTG
GATGACGCCTTCAGAAAGAACTTAGAGAGTGCACTGAGATTCCGT
AACCCCTTCTGGTCCAGGATGTGGAAAGCTACGATCCAGTTTGT
AACCCGGTGCTGAACCGTGAAGTGCGGCGAACAGGGGGAGAGTG
50 CTGATCACTCTCGGGGACCAGGACATAGACCTGTGCGCCATCGTT
GTCATCTTCCCTGTCCACCCGGGATCCAACCTGTCGAGTTCCACCA
GATCTCTGTTCCCGGGTTACTTTTGTAACCTTCACAGTTACCCGT
AGCAGTTTACAAAGCCAGTGTCTAAATGAAGTACTTAAAGCAGAA
AGACCTGATGTGGACGAGAAACGATCTGATCTTCTTAAACTTCAA
55 GGGGAATTTAGCTCCGTTTTCGCTCAGCTGGAAAAATCTCTACTA
CAAGCTCTGAACGAGGTGAAAGGGCGCATTTTGGATGACGACACG

ATCATAACCACTCTGGAGAACCTGAAGAGAGAGGCTGCAGAGGTC
ACCAGGAAAGTTGAGGAGACGGACATTGTCATGCAGGAGGTGGAG
ACCGTGTCCCAGCAGTACCTCCCGCTCTCCACCGCCTGCAGCAGC
ATCTACTTCACCATGGAGTCCCTCAAGCAGATACACTTCTTGATC
5 CAGTACTCCCTCCAGTTTTTTCCTGGACATTTATCACAACGTCTTA
TACGAGAACCCGAACCTGAAGGGTGTACCGACCACACACAGCGC
CTGTCCATTATAACAAAGGACCTCTTCCAGGTGGCGTTTAACCGA
GTGGCTCGAGGCATGCTGCATCAGGACCACATTACCTTTGCCATG
10 CTGCTGGCAAGAATCAAACCTGAAGGGCACCGTGGGGGAGCCCACC
TACGATGCAGAATTCCAGCACTTCTTGAGAGGAAATGAGATTGTC
CTGAGTGCTGGCTCCACCCCCAGGATCCAGGGCCTGACTGTGGAG
CAGGCGGAGGCGGTGGTGAGGCTGAGCTGCCTTCCCGCGTTTAAG
GACTTGATTGCAAAGGTTCAAGGCAGACGAGCAATTTGGCATCTGG
CTGGACAGCAGCTCCCCGGAGCAGACTGTGCCCTACCTCTGGAGT
15 GAAGAAACACCTGCAACACCCATTGGCCAGGCCATCCACCGCCTG
CTCCTGATCCAGGCTTTCGGGCCCGATCGCCTGTTGGCCATGGCC
CACATGTTTGTTCACAAACCTTGGGGAGTCTTTCATGTCCATC
ATGGAGCAGCCGCTCGACCTGACCCACATTGTGGGCACAGAGGTG
AAGCCCAACACTCCTGTCTTAATGTGCTCTGTGCCTGGTTATGAT
20 GCCAGTGGACATGTCGAGGACCTTGCAGCCGAGCAGAACACGCAG
ATCACTTCAATTGCAATCGGCTCTGCAGAAGGCTTTAACCAAGCA
GATAAGGCAATAAACACCGCTGTAAAGTCGGGCAGGTGGGTGATG
CTGAAGAATGTGCATCTGGCCCCAGGGTGGCTGATGCAGCTGGAG
AAGAAGTTGCATTCCCTGCAGCCGCATGCCTGCTTCCGACTCTTC
25 CTACCATGGAGATCAACCCCAAGGTGCCTGTGAATCTGCTCCGT
GCGGGCCGCATCTTTGTGTTTCGAGCCACCGCCAGGGGTGAAGGCC
AACATGCTGAGGACGTTCAAGCAGCATTCCCGTCTCACGGATATGC
AAGTCTCCCAACGAGCGTGCCCGCTTGTACTTCTGCTGGCCTGG
TTTCATGCGATCATCCAAGAACGCTTACGATACGCACCACTGGGG
30 TGGTCAAAGAAGTATGAATTTGGAGAGTCTGACCTGCGGTGAGCT
TGCGATACGGTGGACACGTGGCTGGATGACACGGCCAAGGGCAGG
CAGAACATCTCACCGGATAAGATCCCGTGGTCTGCACTAAAGACC
TTAATGGCCCAGTCCATTTATGGCGGGCGCGTGGACAACGAGTTT
GACCAGCGTCTGCTCAACACCTTCTGGAGCGCCTGTTTACAACC
35 AGGAGTTTCGACAGTGAGTTTAAGCTGGCATGCAAGGTCGACGGA
CATAAAGACATTCAAATGCCAGATGGCATCAGGCGAGAGGAGTTT
GTGCAGTGGGTGGAGTTGCTCCCCGACACCCAGACGCCCTCCTGG
CTGGGCCTGCCCAACAACGCCGAGAGAGTCTCCTTACCACACAG
GGTGTGGACATGATCAGTAAATGCTGAAGATGCAGATGTTGGAG
40 GATGAGGACGACCTGGCCTACGCAGAGACTGAGAAGAAGACGAGG
ACAGACTCCACGTCCGACGGGCGCCCTGCCTGGATGCGGACACTG
CACACCACCGCGTCCAACCTGGCTGCACCTCATCCCCCAGACGCTG
AGCCACCTCAAGCGCACCGTGGAGAATATCAAGGATCCTTTGTTC
AGGTTCTTTGAGAGAGAAGTGAAGATGGGCGCAAAGCTGCTTCAG
45 GACGTTTCGCCAGGACCTTGCAGATGTCGTCCAGGTGTGCGAAGGA
AAGAAGAAGCAGACCAACTACTTGCACGCTGATCAACGAGCTA
GTGAAAGGGATCTTGCTCGGAGCTGGTCCCACTACACGGTGCCT
GCCGGCATGACCGTCATCCAGTGGGTGTCCGACTTCAGCGAGAGG
ATCAAACAGCTGCAGAACATCTCACTGGCAGCTGCATCTGGTGGC
50 GCCAAGGAGCTAAAGAACATCCACGTGTGCCTGGGTGGCCTGTTT
GTGCCTGAGGCGTACATCACTGCCACCAGGCAGTATGTGCCCCAG
GCCAACAGCTGGTCCCTGGAGGAGCTCTGCCTGGAAGTCAACGTC
ACCACCTCACAGGGCGCCACCCCTTGACGCTTGACGCTTCGGAGTC
ACGGGTTTGAACCTTCAAGGGGCCACGTGCAACAACAACAGCTG
55 TCACTGTCCAATGCCATCTCAACCGCCCTTCCCCTGACGCAGCTG
CGCTGGGTCAAGCAGACAAACACCGAGAAGAAGGCCAGTGTGGTA

ACCTTACCTGTCTACCTGAACTTCACCCGTGCAGACCTCATCTTC
ACCGTGGACTTCGAAATTGCTACAAAGGAGGATCCTCGCAGCTTC
TACGAGCGGGGTGTCGCAGTCTTGTGCACAGAGTAA

5

Other nucleic acid sequences that are contemplated as within the scope of this invention include sequences that hybridize to the nucleic acid sequences encoding cytoplasmic dynein heavy chain1 shown in SEQ ID NOS:1, 3, 5, and 17, other than those known in the prior art (as described above), with at least 75%, preferably at least
10 80%, more preferably at least 90%, even more preferably 95% and most preferably at least 99% sequence homology to the sequence of SEQ ID NOS: 1, 3, 5, or 17. Additionally, nucleic acid sequences that are degenerate with respect to the foregoing sequences are contemplated.

15

The nucleic acid sequences encoding cytoplasmic dynein heavy chain1 or mutant cytoplasmic dynein heavy chain1 of the invention may exist alone or in combination with other nucleic acids as, for example, vector molecules, such as plasmids, including expression or cloning vectors.

20

The term "nucleic acid sequence" as used herein refers to any contiguous sequence series of nucleotide bases, *e.g.*, a polynucleotide, and may be ribonucleic acid (RNA) or deoxy-ribonucleic acid (DNA). Preferably the nucleic acid sequence is cDNA.

25

The term "isolated nucleic acid molecule", as utilized herein, refers to a nucleic acid molecule that is separated from other nucleic acid molecules ordinarily present in the natural source of the nucleic acid. Preferably, an "isolated" nucleic acid is free of sequences which naturally flank the nucleic acid (*e.g.*, sequences located at the 5'- and 3'-termini of the nucleic acid) in the genomic DNA of the organism that is the natural
30 (wild type) source of the DNA.

Cytoplasmic dynein heavy chain1 molecules can be isolated using standard hybridization and cloning techniques, as described, for instance, in Sambrook *et al.* (eds.), *Molecular Cloning: A Laboratory Manual* (2nd Ed.) (Cold Spring Harbor
35 Laboratory Press, Cold Spring Harbor, NY, USA, 1989); and Ausubel *et al.* (eds.),

Current Protocols in Molecular Biology (John Wiley & Sons, New York, NY, USA, 1993).

A nucleic acid of the invention can be amplified using cDNA, mRNA or, alternatively, genomic DNA, as a template and appropriate oligonucleotide primers according to standard PCR amplification techniques. The nucleic acid so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis. Furthermore, oligonucleotides corresponding to cytoplasmic dynein heavy chain1 nucleotide sequences can be prepared by standard synthetic techniques, *e.g.*, using an automated DNA synthesizer.

As used herein, the term "oligonucleotide" refers to a series of linked nucleotide residues, which oligonucleotide has a sufficient number of nucleotide bases to be used in a PCR reaction. A short oligonucleotide sequence may be based on, or designed from, a genomic or cDNA sequence and is used to amplify, confirm, or reveal the presence of an identical, similar or complementary DNA or RNA in a particular cell or tissue. Generally, the term "oligonucleotide" is used to refer to a series of contiguous nucleotides (a polynucleotide) of about 100 nucleotides (nt) or less, *e.g.*, portions of a nucleic acid sequence of about 100 nt, 50 nt, or 20 nt in length, preferably nucleotide sequences of about 15 nt to 30 nt in length.

As used herein, the term "complementary" refers to Watson-Crick or Hoogsteen base pairing between nucleotide units of a nucleic acid molecule, and the term "binding" means the physical or chemical interaction between two polypeptides or compounds or associated polypeptides or compounds or combinations thereof.

25

The terms "homologous nucleic acid sequence" or "homologous amino acid sequence," or variations thereof, refer to sequences characterized by a homology at the nucleotide level or amino acid level, respectively. Homologous nucleotide sequences encode those sequences coding for isoforms of cytoplasmic dynein heavy chain1 polypeptides. Isoforms can be expressed in different tissues of the same organism as a result of, for example, alternative splicing of RNA. Alternatively, isoforms can be encoded by different genes.

30

As used herein, the phrase "stringent hybridization conditions" refers to conditions under which a probe, primer or oligonucleotide will hybridize to its target sequence, but to no other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures than shorter sequences. Generally, stringent conditions are selected to be about 5°C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. The T_m is the temperature (under defined ionic strength, pH and nucleic acid concentration) at which 50% of the probes complementary to the target sequence hybridize to the target sequence at equilibrium. Since the target sequences are generally present at excess, at T_m, 50% of the probes are occupied at equilibrium. Typically, stringent conditions will be those in which the salt concentration is less than about 1.0 M sodium ion, typically about 0.01 to 1.0 M sodium ion (or other salts) at pH 7.0 to 8.3, and the temperature is at least about 30°C for short probes, primers or oligonucleotides (*e.g.*, 10 nt to 50 nt) and at least about 60°C for longer probes, primers and oligonucleotides. Stringent conditions may also be achieved with the addition of destabilizing agents, such as formamide. Stringent conditions are known to those skilled in the art and can be found in Ausubel *et al.* (eds.), *Current Protocols in Molecular Biology* (John Wiley & Sons, New York, NY, USA, 1989) at 6.3.1-6.3.6. Preferably, the conditions are such that sequences at least about 65%, 70%, 75%, 85%, 90%, 95%, 98%, or 99% homologous to each other typically remain hybridized to each other. A non-limiting example of stringent hybridization conditions are hybridization in a high salt buffer comprising 6X SSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 mg/ml denatured salmon sperm DNA at 65°C, followed by one or more washes in 0.2X SSC, 0.01% BSA at 50°C.

As used herein, the term "ortholog" denotes a polypeptide or protein obtained from one species that is the functional counterpart of a polypeptide or protein from a different species. Sequence differences among orthologs are the result of speciation.

Amino Acids

The present invention also provides murine and human cytoplasmic dynein heavy chain1 amino acid sequences (wild type polypeptides and muteins). As used herein, the term "mutein" applies to a protein arising as a result of a mutation. The

wild type murine cytoplasmic dynein heavy chain1 amino acid sequence is shown in SEQ ID NO:2. A mutated version wherein Tyr at position 1055 has been mutated to a Cys is shown in SEQ ID NO:4. A preferred embodiment is of a human mutein with the same amino acid change at the corresponding position (native Tyr residue to mutant Cys residue at position 1057) in the sequence is shown in SEQ ID NO:6. Another preferred embodiment is the wild type human dynein heavy chain 1 amino acid sequence, as shown in SEQ ID NO:18.

Table 5. Accession Number AAF91078 (SEQ ID NO:2)

10 MSEPGGGEDGSAGLEVSAVQNVADVAVLQKHLRKLVPLLLEDGGD
APAALEAALEEKSALEQMRKFLSDPQVHTVLVERSTLKEDVGDEG
EEEEKEFISYNINIDIHYGVKSNSLAFIKRAPVIDADKPVSSQLRV
15 LTLSEDSPTYETLHSFISNAVAPFFKSYIRESKGADRDGDKMAPSV
EKKIAELEMGLLHLQONIEIPEISLPIHPITNVAKQCYERGEKP
KVTDFGDKVEDPTFLNQLQSGVNRWIREIQKVTKLDRDPASGTAL
QEISFWLNLERALYRIQEKRESPEVLLTLDILKHGKRFBHATVSFD
TDTGLKQALETVNDYNPLMKDFPLNDLLSATELTKIRQALVAIFT
HLRKIRNTKYPPIQRALRLVEAISRDLSQQLKVLGTRKLMHVAYE
20 EFEKVMVACFEVFQTDWDEYEKQLQVLLRDIVKRKREENLKMVWRI
NPAHRKLQARLDQMRKFRQHEQLRAVIVRVLRPQVTAVAQONQG
EAPFPQDMKVAEVLFDAADANTIEEVNLAYENVKEVDGLDVSKEG
TEAWEAAMKRYDERIDRVETRITARLRDQLGTAKNANEMFRIFSR
FNALFVRPHIRGAIREYQTQLIQRVKDDIESLHDKFKVQYPQSQA
25 CKMSHVRDLPPVSGSIIWAKQIDRQLTAYMKRVEDVLGKGWENHV
EGQKLKQDGDSEFRMKNLTQEIFDDWARKVQQRNLGVSGRIFTIES
ARVRGRTGNVLKLKVNFLPEIITLSKEVRNLKWLGRVPLAIVNK
AHQANQLYPFAISLIESVRTYERTCEKVEERNTISLLVAGLKKEV
QALIAEGIALVWESYKLDPPYVQRLAETVFNFQEKVDDLLIIEKI
30 DLEVRSLETCMYDHKTFSEILNRVQKAVDDLNLHSYSNLPWVVK
LDMEIERILGVRLQAGLRAWTQVLLGQAEDKAEVDMDTDAPQVSH
KPGGEPKIKNVVHELRTNQVIYLNPPIEECRYKLYQEMFAWKMV
VLSLPRIQSORYQVGVHYELTEEEKFYRNALTRMPDGPVAALESY
SAVMGIVTEVEQYVKVWLQYQCLWDMQAENIYNRLGEDLNKWQAL
35 LVQIRKARGTFDNAETKKEFGPVVIDYGKVQSKVNLKYDSWHKEV
LSKFGQMLGSGNMTEFHSQISKSQRQELEQHSVDASTSDAVTFITY
VQSLKRKIKQFEKQVELYRNGQRLLEKQRFQFPPSWLYIDNIEGE
WGAFNDDIMRRKDSAIQQQVANLQMKIVQEDRAVESRTTDLITDWE
KTKPVTGNLRPEEALQALTIYEGKFGRLKDDREKCAKAKEALELT
40 DTGLLSGSEERVQVALEELQDLKGVWSELSKVWEQIDQMKEQPWV
SVQPRKLRQNLQDGLLNQLKNFPARLRQYASYEYVQRLKGYMKIN
MLVIELKSEALKDRHWKQLMKRLHVNWVSELTLGQIWDVDLQKN
EAVVKDVLVLAQGGEMALEEFLKQIREVWNTYELDLVNYQNKRLI
RGWDDLNFNVKEHINSVSAMKLSPIYKVFEEDALSWEDKLNRI
45 LFDVWIDVQRRWVYLEGIFTGSADIKHLLPVETQRFQSI STEFLA
LMKKVSKSPLVMDVLNIQGVQRSLERLADLLGKIQKALGEYLERE
RSSFPFRFYFVGDEDLLEIIGNSKNVAKLQKHFKMFAGVSSIIIN
EDNSVVLGISSREGEVVMFKTPVSI TEHPKINEWLT LVEKEMRVT
LAKLLAESVTEVEIFGKATSIDPNTYITWIDKYQAQLVVLSAQIA
50 WSENVENALSNGGGGDVGPLQSVLSNVEVTNLNVLADSVLMEQPP

LRRRKLEHLITELVHQRDVTRS LIKSKI D NAKSFEWLSQMRFYFD
PKQTDVLOQLSIQMANAKFN YGFEYLGVDKLVQTPLTDRCYLTMT
TQALEARLGGS PF GPAGTGKTESVKALGHQLGRFVLVFNCDETFD
FQAMGRIFVGLCQVGAWGCFDEFNRLEERM LSAVSQQVQCIQEAL
5 REHSNP NYDKTSAPITCELLNKQVKVSPDMAIFITMNP GYAGRSN
LPDNLKKLFRSLAMTKPD RQLIAQVMLYSQGFRTAEVLANKI VPF
FKLCDEQLSSQSHYDFGLRALKSVLVSAGNVKRERIQKIKREKEE
RGEAVDEGEIAENLPEQEILIQSV CETMVPKLVAEDIPLLFSLLS
DVFPGVQYHRGEMTALREELKKVCQEMYLT YGDGEEVGGMWVEKV
10 LQLYQITQINHGLMMVGPSGSGKSMAWRVLLKALERLEGVEGVAH
IIDPKAISKDHL YGTLDPN TREWTDGLFTHVLRKIIDNVRGELQK
RQWIVFDGDVDPEWVENLNSVLDDNKLLTLPNGERLSLPPNVRIM
FEVQDLKYATLATVSR CGMVWFSEDLVSTDMILNNFLARLSIPL
DEGEDEAQRRRK GKEDEGEEAAS PMLQIQRDAATIMQPYFTSNGL
15 VTKALEHAFKLEHIMDLTRLRCLGSLF SMLHQACRNVAQYNANHP
DFPMQIEQLERYIQRYLVYAILWSLSGDSRLKMRAELGEYIRRIT
TVPLPTAPNPVPIIDYEVSISGEWSPWQAKVPQIEVETHKVAAPDV
VVPTLDTVRHEALLYTWLAEHKPLVLCGPPGSGKTM TLFSA LRAL
PDMEVVGLNFSSATTPE LLLKTFDHYCEYRRTPNGVV LAPVQLGK
20 WLVLFCDEINLPDMDKYGTQRVISFIRQMVEHGAFYRTSDQTWVK
LERIQFVGACNPPTDPGRKPLSHRFLRHVPVYVDYPGPASLTQI
YGTFNRAMLR LIPSLRTYAEPLTAAMVEFYTMSQERFTQDTQPHY
IYSPREMTRWVRGIF EALRPLETLPVEGLIRIWAHEALRLFKDRL
VEDEERRWTDENIDMVALKHFPNIDKEKAMSRPILYSNWLSKDYI
25 PVDQEELRDYVKARLKV FYEEELDVPLVLFNEVL DHVLRIDRIFR
QPQGHLLLLIGVSGAGKTTLSRFVAMNGLSVYQIKVHRKYTGEDF
DEDLRTVLR RSGCKNEKIAFIMDESNVLDSGF LERMNTLLANGEV
PGLFEGDEYATLMTQCKEGAQKEGLMLDSHEELYKWFTSQVIRNL
HVVFTMNPSS EGLKDRAATSPALFNRCVLNWFGDWSTEALYQVGK
30 EFTSKMDLEKPNYIVPDYMPVVYDKLPQPPHREAI VNSCVFVHQ
TLHQANARLAKRGGRTMAITPRHYLDFINHYANLFHEKRSELEEQ
QMHLNVGLRKIKETVDQVEELRRDLRIKSQELEVKNAAANDK LKK
MVKDQQEAEKKKVMSQEIQEQ LHKQQEV IADKQMSVKEDLDKVEP
AVIEAQNAVKS IKKQHLVEVRSMANPPAAVKLALESICLLLGEST
35 TDWKQIRSIIMRENFIPTIVNFS AEEISDAIREKMKNYMSNPSY
NYEIVNRASLACGPMVKWAI AQLN YADMLKRVEPLRNELOKLEDD
AKDNQQKANEVEQMIRDLEASIARYKEEYAVLISEAQAIKADLAA
VEAKVNRSTALLKSLSAERERWEKTSETFKNQMSTIAGDCLLSAA
FIAYAGYFDQQMRQNLFTTWSHHLQQANI QFRTDIARTEYLSNAD
40 ERLRWQASSLPADDLCTENAIMLKRFNRYPLIIDPSGQATEFIMN
EYKDRKITRTSFLDDAFRKNLESALRFGNPLLVDVESYDPVLNP
VLNREVRRTGGRVLITLGDQDIDLSPSFVIFLSTRDPTVEFPDDL
CSRVT FVNFTVTRSSLSQSQCLNEVLKAERP DVDEKRS DLLKLQGE
FQLRLRQLEKSL LQALNEVKGRILVDDTIIT TLENL KREAAEVTR
45 KVEETDIVMQEVETVSQQYLPLSTACSS IYFTMESLKQVHFLYQY
SLQFFLDIYHNVLYENPNLKGATDHTQRLSVITKDLFQVAFNRVA
RGMLHQDHITFAMLLARIKLGTVGEPTYDAEFQHFLRGKEIVLS
AGSTPKIQGLTVEQAEAVVRLSCLPAFKDLIAKVQADEQFGIWLD
SSSPEQTVPYLWSEETPTTPIGQAIHRLLLIQAFRPDRLLAMAHM
50 FVSTNLGESFMSIMEQPLDLTHIVGTEVKPNTPVL MCSVPGYDAS
GHVEDLAAEQNTQITSIAIGSAEGFNQADK AINTAVKSGRWVMLK
NVHLAPGWLMOLEKKLHSLQPHACFR LFLTMEINPKVPVNLLRAG
RIFVFEPPPGVKANMLRTFSSI PVS RICKSPNERARLYFLLAWFH
AIIQERLRYAPLGWSKKYEFGESDLRSACD TVDWTWLD T AKGRQN
55 ISPDKIPWSALKTLMAQSIYGGRV DNEFDQRLN TFLERLFTTRS
FDSEFKLACKVDGHKDIQMPDGIRREEFVQWVELLPDAQTPSWLG

LPNNAERVLLTTQGVDMISKMLKMOMLEDEDDLAYAETEEKKARTD
 STSDGRPAWMRTLHTTASNWLHLIPQTLSPKRTVENIKDPLFRF
 FEREVKMGAKLLQDVRQDLADVQVCEGKKKQTNYLRTLINELVK
 5 GILPRSWSHYTVPAGMTVIQWVSDFSERIKQLQNISQAAASGGAK
 ELKNIHVCLGGLFVPEAYITATRQYVAQANSWSLEELCLEVNVT
 SQSATLDACSFGVTGLKLQGATCSNNKLSLSNAISTVLPLTQLRW
 VKQTSAEKKASVVTLPVYLNFTRADLIFTVD FEIATKEDPRS FYE
 RGVAVLCTE

10 **Table 6.** Mutated murine cytoplasmic dynein heavy chain1 amino acid sequence
 (SEQ ID NO:4)

MSEPGGGEDGSAGLEVSAVQNVADVAVLQKHLRKLVP L L L E D G G D
 APAALEAALEEKSALEQMRKFLSDPQVHTVLVERSTLKEDVGDEG
 15 EEEKEFISYNINIDIHYGVKSNSLAFIKRAPVIDADKPVSSQLRV
 LTLSEDSPYETLHSFISNAVAPFFKSYIRESKGADRDGDKMAPSV
 EKKIAELEMGLLHLQONIEIPEISLPIHPITNVAKQCYERGEKP
 KVTDFGDKVEDPTFLNQLQSGVNRWIREIQKVTKLDRDPASGTAL
 QEISFWLNLERALYRIQEKRESPEVLLTLDILKHGKRFHATVSFD
 20 TDTGLKQALETVNDYNPLMKDFPLNDLLSATELTKIRQALVAIFT
 HLRKIRNTKYP IQRALRLVEAISRDLSQQLKVLGTRKLMHVAYE
 EFEKVMVACFEVFQTDWDEYEKLVLLRDIVKREENLKMVWRI
 NPAHRKLQARLDQMRKFRRQHEQLRAVIVRVLRPQVTAVAQONQG
 EAPFPQDMKVAEVLFDAADANTIEEVNLAYENVKEVDGLDVSKEG
 TEAWEAAMKRYDERIDRVETRITARLRDQLGTAKNANEMFRIFSR
 25 FNALFVRPHIRGAIREYOTQLIQRVKDDIESLHDKFKVQYPQSQA
 CKMSHVRDLPPVSGSIIWAKQIDRQLTAYMKRVEDVLGKGWENHV
 EGQKLKQDGD SFRMKLNTQEIFDDWARKVQQRNLGVSGRIFTIES
 ARVRGRTGNVLKLKVNFLPEIITLSKEVRNLKWLGRVPLAIVNK
 AHQANQLYPFAISLIESVRTYERTCEKVEERN TISLLVAGLKKEV
 30 QALIAEGIALVWESYKLDPPYVQRLAETVFN FQEKVDDLLIIEEKI
 DLEVRSL ETCMYDHKTFSEILNRVQKAVDDLNLHSYSNLPWVVK
 LDMEIERILGVRLQAGLRAWTQVLLGQAEDKAEVDMDTDA PQVSH
 KPGGEPKIKNVVHEL RITNQVIYLNPPIEECRYKLYQEMFAWKMV
 VLSLPRIQS QRYQVGVHYELTEEEKFYRNALTRMPDGPVALEESY
 35 SAVMGIVTEVEQYVKVWLOQCLWDMQAENIYNRLGEDLNKWQAL
 LVQIRKARGTFDNAETKKEFGPVVIDYGVQSKVNLKYDSWHKEV
 LSKFGQMLGSNMTEFHSQISKS RQELEQHSVD TASTSDAVTFITY
 VQSLKRKIKQFEKQVELYRNGQRLLEKQRFQFP PSWLYIDNIEGE
 WGA FN DIMRRKDSAIQQQVANLQMKIVQEDRAVESRTTDLTDWE
 40 KTKPVTGNLRPEEALQALTIYEGKFGR LKDDREKCAKAKEALELT
 DTGLLSGSEERVQVALEELQDLKGWSEL SKVWEQIDQMKEQPWV
 SVQPRKLRQNL DGLLNQLKNFPARLRQYAS YEFVQRLKGYMKIN
 MLVIELKSEALKDRHWKQLMKRLHVNWVSEL TLGQIWDVDLQKN
 EAVVKDVL LVAQGEMALEEFLKQIREVWNTYELDLVNYQNKCRLI
 45 RGWDDL FNKVKEHINSVSAMKLS PYYKVFEEDALSWEDKLN RIMA
 LFDVWIDVQRRWVYLEGIFTGSADIKHLLPVETQR FQSISTEFLA
 LMKKVS KSP LVM DV LNIQGVQRS LERLADLLGKI QKALGEYLERE
 RSSFP RFYFVGDEDLLEIIGNSKNVAKLQKHFKMFAGVSSIILN
 EDNSVVLGISSREGE EVMFKTPV SITEHPKINEWLT LVEKEMRVT
 50 LAKLLAESVTEVEIFGKATSIDPNTYITWIDKYQAQLVVLVLSAQIA
 WSENVENALSNVGGGGDVGPLQSVLSNVEVT LNVLADSVLMEQPP
 LRRRKLEHLITELVHQRDVTRS LIKSKIDNAKSFEWLSQMRFYFD
 PKQTDV LQQLSIQMANAKFNYGFEYLGVDKLVQTP LTRCYLTMT
 TQALEARLGGS PFGPAGTGKTESVKALGHQLGRFVLVFNCD E TFD

FQAMGRIFVGLCQVGAWGCFDEFNRLEERMLSAVSQQVQCIQEAL
REHSNPNYDKTSAPITCELLNKQVKVSPDMAIFITMNPYAGRSN
LPDNLKKLFRSLAMTKPDRQLIAQVMVLYSQGFRTAEVLANKIVPF
FKLCDEQLSSQSHYDFGLRALKSVLVSAGNVKRERIQKIKREKEE
5 RGEAVDEGEIAENLPEQEILIQSV CETMVPKLVAEDIPLLFSLLS
DVFPGVQYHRGEMTALREELKKVCQEMYLT YGDGEEVGGMWVEKV
LQLYQITQINHGLMMVGPSSGSKSMAWRVLLKALERLEGVEGVAH
IIDPKAISKDHLYGTLDPN TREWTDGLFTHVLRKIIDNVRGELQK
RQWIVFDGDVDPEWVENLNSVLDDNKLLTLPNGERLSLPPNVRIM
10 FEVQDLKYATLATVSR CGMVWFSE DVLSTDMILNNFLARLSIPL
DEGEDEAQRRRK GKEDEGEEAAS PMLQIQRDAATIMQPYFTSNGL
VTKALEHAFKLEHIMDLTRLRCLGSLF SMLHQACRNVAQYNANHP
DFPMQIEQLERYIQRYLVYAILWSLSGDSRLKMRAELGEYIRRIT
TVPLPTAPNPVPIIDYEVSISGEWSPWQAKVPQIEVETHKVAAPDV
15 VVPTLDTVRHEALLYTWLAEHKPLVLCGPPGSGKTM TLFSA LRAL
PDMEVVGLNFSSATTPELLLKTFDHYCEYRRTPNGVV LAPVQLGK
WLVLFCDEINLPDMDKYGTQRVISFIRQMVEHGA FYRTSDQTWVK
LERIQFVGACNPPTDPGRKPLSHRFLRHVPV VYVDYPGPASLTQI
YGTFNRAMLR LIPSLRTYAEPLTAAMVEFYTMSQERFTQDTQPHY
20 IYSPRETRWVRGIFEALRPLETLPVEGLIRIWAHEALRLFQDR L
VEDEERRWTDENIDMVALKHFPNIDKEKAMSRPILYSNWLSKDYI
PVDQEELRDYVKARLKV FYEEELDVPVLVLFNEVL DHVLRIDRIFR
QPQGHLLLLIGVSGAGKTTLSRFVAMNGLSVYQIKVHRKYTGEDF
DEDLRTVLR RSGCKNEKIAFIMDES NVLDSGFLERMNTLLANGEV
25 PGLEFEGDEYATLMTQCKEQAQEG LMLDSHEELYKWFTSQVIRNL
HVVFTMNPSS EGLKDRAATSPALFNRCVLNWFGDWSTEALYQVGK
EFTSKMDLEKPNYIVPDYMPVVYDKLPQPP THREAIVNSCVFVHQ
TLHQANARLAKRGGRTMAITPRHYLD FINHYANLFHEKRSELEEQ
QMHLNVGLRKIKETVDQVEELRRDLRIKSQELEVKNAAANDK LKK
30 MVKDQQEAEKKK VMSQEIQEQ LHKQQEVIADKQMSVKEDLDKVEP
AVIEAQNAVKS IKKQHLVEVRSMANPPAAVKLALESICLLLGEST
TDWKQIRSIIMRENFIPTIVNFS AEEISDAIREKMKNYMSNPSY
NYEIVNRASLACGPMVKWAI AQLNYADMLKRVEPLRNE LQKLEDD
AKDNQQKANEVEQMIRDLEASIARYKEEYAVLISEAQAIKADLAA
35 VEAKVNRSTALLKSLSAERERWEKTSETFKNQ MSTIAGDCLLSAA
FIAYAGYFDQ QMRQNLFTTWSHHLQQANIQFRTDIARTEYLSNAD
ERLRWQASSLPADDLCTENAIMLKRFNRYPLIIDPSGQATEFIMN
EYKDRKITRTSFLDDAFRKNLESALRFGNPLL VQDVESYDPVLNP
VLNREVRRTGGRVLITLGDQDIDLSPSFVIFLSTRDPTVEFPDL
40 CSRVTFTVNFTVTRSSLQSQCLNEVLKAERP DVDEKRSDDLKLQGE
FQLRLRQLEKSL LQALNEVKGRILVDDTIIT TLENL KREAAEVTR
KVEETDIVMQEVETVSQQYLPLSTACSS IYFTMESLKQVHFLYQY
SLOFFLDIYHNVLYENPNLKGATDHTQRLSVITKDLFQVAFNRVA
RGM LHQDHITFAMLLARIKLGTVGEPTYDAEFQHFLRGKEIVLS
45 AGSTPKIQGLTVEQAEAVVRLSCLPAFKDLIAKVQADEQFGIWLD
SSSPEQTVPYLWSEETPTTPIGQAIHRLLLIQAFRPDRLLAMAHM
FVSTNLGESFMSIMEQPLDLTHIVGTEVKPNTPVLMCSVPGYDAS
GHVEDLAAEQNTQITSIAIGSAEGFNQADK AINTAVKSGRWVMLK
NVHLAPGWLMOLEKKLHSLQPHACFR LFLTMEINPKVPVNLLRAG
50 RIFVFEPPPGVKANMLRTFSSIPVSRICKSPNERARLYFLLAWFH
AIIQERLRYAPLGWSKKYEFGESDLRSACD TVDTWLD DTA KGRQN
ISPDKIPWSALKTLMAQSIYGG RVDNEFDQRLNLTFLERLFTTRS
FDSEFKLACKVDGHKDIQMPDGI RREEFVQWV ELLPDAQTPSWLG
LPNNAERVLLTTQGVDMISKMLKMOMLEDEDD LAYAE TEKKARTD
55 STSDGRPAWMRTLHTTASNWLHLIPQ TLSPLKRTVENIKDPLFRF
FEREVKMGAKLLQDVRQDLADV VQVCEGKKKQTNYLRTLINELVK

GILPRSWSHYTVPAGMTVIQWVSDFSERIKQLQNISQAAAASGGAK
 ELKNIHVCLGGLFVPEAYITATRQYVAQANSWSLEELCLEVNVTA
 SQSATLDACSFGVTGLKLQGATCSNNKLSLSNAISTVLPLTQLRW
 VKQTSAEKKASVVTLPVYLNFTRADLIFTVD FEIATKEDPRS FYE
 5 RGVAVLCTE

**Table 7. Mutated human cytoplasmic dynein heavy chain1 amino acid sequence
 (SEQ ID NO:6)**

10 MSEPGGGGGEDGSAGLEVSAVQNVADVSVLQKHLRKLVP LLLLEDGGGEAP
 AALEAALEEKSALEQMRKFLSDPQVHTVLVERSTLKEDVGDEGEEKEF
 ISYNINIDIHYGVKSNSLAFIKRTPVIDADKPVSSQLRVLTLSEDSPYE
 TLHSFISNAVAPFFKSYIRES GKADRDGDKMAPSVEKKIAELEMGLLHL
 15 QONIEIPEISLPIHPMITNVAKQCYERGEKPKVTDFGDKVEDPTFLNQL
 QSGVNRWIREIQKVTCLDRDPASGTALQEISFWLNLERALYRIQEKRES
 PEVLLTLDILKHGKR FHATVSFDTDTGLKQALETVNDYNPLMKDFPLND
 LLSATEL DKIRQALVAIFTHLRKIRNTKYP IQRALRLVEAISRDLS SQL
 LKVLGTRKLMHVAYEEFEKVMVACFEVFQ TWDDDEYEKLQVLLRDIVKRK
 REENLKMVWRINPAHRKLQARLDQMRKFRRQHEQLRAVIVRVLRPQVTA
 20 VAQQNQGEVPEPQDMKVAEVLFDAAADANAIEEVNLAYENVKEVDGLDVS
 KEGTEAWEAAMKRYDERIDRVETRITARLRDQLGTAKNANEMFRIFSRF
 NALFVRPHIRGAIREYQTQLIQRVKDDIESLHDKFKVQYPQS QACKMSH
 VRDLPPVSGSIIWAKQIDRQLTAYMKRVEDVLGKGWENHVEGQKLKQDG
 DSFRMKLNTQEIFDDWARKVQQRNLGVSGRIFTIESTRVRGRTGNVLKL
 25 KVNFLPEIITLSKEVRNLKWLGFVRVPLAIVNKAHQANQLYPPFAISLIES
 VRTYERTCEKVEERNTISLLVAGLKKEVQALIAEGIALVWESYKLDPYV
 QRLAETVFNFOEKVDDLLIIEEKIDLEVRSL ETCMYDHKTFSEILNRVQ
 KAVDDLNLHSYSNLP IWVNKL DMEIERILGVRLQAGLRAWTQVLLGQAE
 DKAQVDMMDTDAPQVSHKPGGEPKIKNVVHEL RITNQVIYLNPPIEECRY
 30 KLYQEMFAWKMVVLSLPRIQSQR YQVG VHYELTEEEKFYRNALRMPDG
 PVALEESYSAVMGIVSEVEQYVKVWLQ⁶QCLWDMQAENIYNRLGEDLNK
 WQALLVQIRKARGTFD NAETKKEFGPVVIDY GKVQSKVNLKYDSWHKEV
 LSKFGQMLGSNMTEFHSQISKS RQELEQHSVDTASTSDAVTFITYVQSL
 KRKIKQFEKQVELYRNGQRLL EKQRFQFP PSWLYIDNIEGEWGAFNDIM
 35 RRKDSAIQQQVANLQMKIVQEDRAVESRTTDL L TDWEKTKPVTGNLRPE
 EALQALTIYEGKFGR LKDDREKCAKAKEALELTD TGLLSGSEERVQVAL
 EELQDLKGVWSELSKVWEQIDQMKEQPWVS VQPRKLRQNL DALLNQLKS
 FPARLRQYASYEFVQRLLKGYMKINMLVIELKSEALKDRHWKQLMKRLH
 VNWVVSELTLGQIWDVDLQKNEAIVKDVLLVAQ GEMALEEFLKQIREVW
 40 NTYELDLVNYQNKCR LIRGWDDL FNKVKEHINSVSAMKLSPPYKVFEEED
 ALSWEDKLN RIMALFDVWIDVQRRWVYLEGIFTGSADIKHLLPVETQRF
 QSISTEFLALMKKVS KSPLVMDVLNIQGVQ RSLERLADLLGKIQKALGE
 YLERERS SFPRFYFVGDEDLLEI IGNSKNVAKLQKHFKMFAGVSSIIL
 NEDNSVVLGISSREGE EVMFKTPVSITEHPKINEWLT LVEKEMRVTLAK
 45 LLAESVTEVEIFGKATSIDPNTYITWIDKYQAQLVVL SAQIAWSENVET
 ALSSMGGGGDAAPLH SVLSNVEVT LNVLADSVLMEQPPLRRRKLEHLIT
 ELVHQRDVTRSLIKSKIDNAKSFEWLSQMRFYFDPKQTDVLQQLSIQMA
 NAKFNYGFEYLGVDKLVQTPLTDRCYLTMTQALEARLGGSFPGPAGTG
 KTESVKALGHQLGRFVLVFNCD ETD FQAMGRIFVGLCQVGAWGCFDEF
 50 NRLEERMLSAVSQQVQCIQEALREHSNP NYDKTSAPITCELLNKQVKVS
 PDMAIFITMNPGYAGRSNLPDNLKKLFRSLAMTKPDRQLIAQVM LYSQG
 FRTAEVLANKIVPFFKLCDEQLSSQSHYDFGLRALKSVLVSAGNVKRER
 IQKIKREKEERGEAVDEGEIAENLPEQEILIQSV CETMVPKLVAEDIPL
 LFSLLSDVFPGVQYHRGEMTALREELKKVCQ EMYLTYGDGEEVGMWVE
 55 KVLQLYQITQINHGLMMVPSGSGKSMAWRVLLKALERLEGEVGVAHII
 DPKAISKDHLYGTLDPN TREWTDGLFTHVLRKIIDSVRGELQKRQWIVF
 DGDVDPEWVENLNSVLDDNKLLTL PNGERLSLPPNVRIMFEVQDLKYAT
 LATVSRCGMVWFSE DVLSTDMIFNNFLARLR SIPLDEGEDEAQR RRKKGK
 EDEGEEAASPMLQIQRDAATIMQPYFTS NGLVTKALEHAFQLEHIMDLT

5 RLRCLGSLFSLMLHQACRNVAQYNANHPDFPMQIEQLERYIQRYLVYAIL
 WSLSGDSRLKMRAELGEYIRRIITVPLPTAPNIPIDYEVSISGEWSPW
 QAKVPQIEVETHKVAAPDVVVPTLDTVRHEALLYTWLAEHKPLVLCGPP
 GSGKMTLFSALRALPDMEVVGLNFSSATTPELLLKTDFHYCEYRRTPN
 10 GVV LAPVQLGKWLVLFCDEINLPDMDKYGTQRVISFIRQMVEHGGFYRT
 SDQTWVKLERIQFVGACNPPTDPGRKPLSHRFLRHVPVYVDYFPGPASL
 TQIYGTFNRAMLRLIPSLRTYAEPLTAAMVEFYTMSQERFTQDTQPHYI
 YSPREMTRWVRGIFEALRPLETLPVEGLIRIWAHEALRLFQDRLVEDEE
 RRWTDENIDTVALKHFPNIDREKAMSRPILYSNWLSKDYIPVDQEELRD
 15 YVKARLKVFYEEELDVLPLVLFNEVLDHVLRIDRIFRQPQGHLLLLIGVSG
 AGKTTLRSFVAMNGLSVYQIKVHRKYTGEDFDEDLRTVLRSSGCKNEK
 IAFIMDESNVLD SGFLERMNTLLANGEVPGLFEGDEYATLMTQCKEGAQ
 KEGMLDSHEELYKWFTSQVIRNLHVFTMNPSSEGLKDRAATSPALFN
 RCVLWNWFGDWSTEALYQVGKEFTSKMDLEKPNYIVPDYMPVYDKLPQP
 20 PSHREAIVNSCVFVHQTLHQANARLAKRGGRTMAITPRHYLDFINHYAN
 LFHEKRSELEEQQMHNLVGLRKIKETVDQVEELRRDLRIKSQELEVKNA
 AANDKLKKMKVDQQEAEKKKMSQEIQEQQLHKQEQEVIADKQMSVKEDLD
 KVEPAVIEAQNAVKSIIKKQHLVEVRSMANPPAAVKLALESICLLLGEST
 TDWKQIRSIIMRENFIPTIVNFSAAEISDAIREKMKKNYMSNPSYNYEI
 25 VNRA SLACGPMVKWAIQAQLNYADMLKRVEPLRNELOKLEDDAKDNQOKA
 NEVEQMIRDLEASIARYKEEYAVLISEAQAIKADLA AVEAKVNRSTALL
 KSLSAERERWEKTSETFKNQ MSTIAGDCLLSAAFIAYAGYFDQQMRQNL
 FTTWSHHLQQANIQFRTDIARTEYLSNADERLRWQASSLPADDLC TENA
 IMLKRFNRYPLIIDPSGQATEFIMNEYKDRKITR TSFLDDAFRKNLESA
 30 LRFGNPLLVDVESYDPVLNPNVLRNREVRRTGGRVLITLGDQDIDLSPSF
 VIFLSTRDPTVEFPDLC SRVTFVNFTVTRSSLQSQC LNEVLKAERP DV
 DEKRSDLLKLQGEFQLRLRQLEKSL LQALNEVKGRILDDDTIIT TLENL
 KREAAEVTRKVEETDIVMQE VETVSQQYLPLSTACSS IYFTMESLKQIH
 FLYQYSLQFFLDIYHNVL YENPNLKGVT DHTQRLSIITKDLFQVAFNRV
 35 ARGMLHQDHITFAMLLARIK LKGTVG EPTYDAEFQHF LRGNEIVLSAGS
 TPRIQGLTVEQAEAVVRLSCLPAFKDLIAKVQADEQFGIWL DSSSPEQT
 VPYLWSEETPATPIGQAIHRL LLIQA FRPDRLLA MAHMFVSTNLGESFM
 SIMEQPLDLTHIVGTEVKP NTPVLMCSVPGYDASGHVEDLAAEQNTQIT
 SIAIGSAEGFNQADKAIN TAVKSGRWV MLKNVHLAPGWL MQLEKKLHSL
 40 QPHACFRFLTMEINPKVPV NLLRAGRIFVFEPPP GVKANMLRTFSSIP
 VSRICKSPNERARLYFL LAWFHAI IQERLRYAPLGWSKKYEFGESDLRS
 ACDTVDTWLD DTA KGRQNI SPDKIPWSALKTLMAQSIYGG RVDNEFDQR
 LLNTFLERLFTTRSF DSEFKLACKVDGHKDIQMPDGI RREEFVQWV ELL
 PDTQTPSWLGLPNNAER VLLTTQGVDMISKMLKMQMLED EDDLAYAETE
 45 KKTRTDSTSDGRPAWMRTL HTASNWLHLIPQTL SHLKRTVENIKDPLF
 RFFEREVKMGAKLLQDVRQDLADVVQVCEGKKKQTN YLRTLINELVKGI
 LPRSWSHYTPAGMTVIQWVSDFSERIKQLQNI SLAAASGGAKELKNIH
 VCLGGLFVPEAYITATRQYVAQANSWSLEELCLEVNVTTSQ GATLDACS
 FGV TGLKLQGATC NNNKLSLSNAISTALPLTQLRWVKQT NTEKKASVVT
 50 LPVYLNFTRADLI FTVD FEIATKEDPRS FYERGVAVLCTE

Table 8. Wild type human cytoplasmic dynein heavy chain1 amino acid sequence (SEQ ID NO:18)

50 MSEPGGGGGEDGSAGLEVS AVQNVADVSVLQKHLRKL VPLLLLEDG
 GEAPAALEAALEEKSALEQMRKFLSDPQVHTVLVERSTLKEDVGD
 EEEEEKEFISYNINIDIHYGVKSNSLAFIKRTPVIDADKPVSSQL
 RVLTLSEDSPYETLHSFISNAVAPFFKSYIRES GKADRDGDKMAP
 SVEKKIAELEMGLLHLQQNIEIPEISLP IHPMITNVAKQCYERGE
 55 KPKVTD FGDKVEDPTFLNQLQSGVNRWIREIQKVTKLDRDPASGT
 ALQEISFWLNLERALYRIQEKRESPEVLLTLDILKHGKR FHATVS
 FDTDTGLKQALETVNDYNPLMKDFPLNDLLSATELDKIRQALVAI

FTHLRKIRNTKYPIQRALRLVEAISRDLSQLLKVLGTRKLMHVA
YEEFEKVMVACFEVFQTDDEYEKQLQVLLRDIVKRRREENLKMVW
RINPAHRKLOARLDQMRKFRRQHEQLRAVIVRVLRPQVTAVAQQN
QGEVPEPQDMKVAEVLFDAADANAIEEVNLAYENVKEVDGLDVSK
5 EGTEAWEAAMKRYDERIDRVETRITARLRDQLGTAKNANEMFRIF
SRFNALFVRPHIRGAIREYQTQLIQRVKDDIESLHDKFKVQYPQS
QACKMSHVRDLPPVSGSIIWAKQIDRQLTAYMKRVEDVLGKGWEN
HVEGQKLKQDGDSFRMKNLTQEIFDDWARKVQQRN LGVSGRIFTI
ESTRVRGRTGNVLKLKVNFLPEIITLSKEVRNLKWLGRVPLAIV
10 NKAHQANQLYPFAISLIESVRTYERTCEKVEERNTISLLVAGLKK
EVQALIAEGIALVWESYKLDPYVQRLAETVFNFOEKVDDLLIEE
KIDLEVRSLCTCMYDHKTFSEILNRVQKAVDDNLNHSYSNLPiWV
NKLDMEIERILGVRLQAGLRAWTOVLLGQAEDKAEVDMDTDAPQV
SHKPGGEPKIKNVVHELRTNQVIYLNPPIEECRYKLYQEMFAWK
15 MVVLSLPRIQSORYQVGVHYELTEEEKFYRNALTRMPDGPVLEE
SYSAVMGIVSEVEQYVKVWLQYQCLWDMQAENIYNRLGEDLNKWQ
ALLVQIRKARGTFDNAETKKEFGPVVIDYGKVQSKVNLKYDSWHK
EVLSKFGQMLGSNMTEFHSQISKSQRQELEQHSVDTASTSDAVTFI
TYVQSLKRKIKQFEKQVELYRNGQRLLEKQRFQFPSPWLIDNIE
20 GEWGAFNDIMRRKDSAIQQQVANLQMKIVQEDRAVESRTDLLTD
WEKTKPVTGNLRPEEALQALTIYEGKFGRLKDDREKCAKAKEALE
LTDGTGLSGSEERVQVALEELQDLKGVWSEL SKVWEQIDQMKEQP
WVSVQPRKLRQNL DALLNQLKSFPARLRQYASYEFVQRLKGYMK
INMLVIELKSEALKDRHWKQLMKRLHVNWVSELTLGQIWDVLO
25 KNEAIVKDVLLVAQGE MALEEFKQIREVWNTYELDLVNYQNKCR
LIRGWDDL FNKVKEHINSVSAMKLSPIYKVFEE DALSWEDKLNRI
MALFDVWIDVQRRWVYLEGIFTGSADIKHLLPVETQRFOSISTEF
LALMKKVS KSPVMDVLNIQGVQRS LERLADLLGKIQKALGEYLE
RERSFPRFYFVGDEDLLEIIGNSKNVAKLQKHFKMFAGVSSII
30 LNE DNSVVLG ISSREG EVMFKTPVSITEHPKINEWLT LVEKEMR
VTLAKLLAESVTEVEIFGKATSIDPNTYITWIDKYQAQLVVL SAQ
IAWSENVETALSSMGGGGDAAPLHSVLSNVEVT LNVLADSVLMEQ
PPLRRRKLEHLITELVHQRDVTRSLIKSKIDNAKSFEWLSQMRFY
FDPKQTDVLQQLSIQMANAKFNYGFEYLGVDKLVQTPLTDRCYL
35 TMTQALEARLGGSFPGPAGTGKTESVKALGHQLGRFVLVFNCD ET
FDFQAMGRIFVGLCQVGAWGCFDEFNRLEERM LSAVSQQVQCIQE
ALREHSNPNYDKTSAPITCELLNKQVKVSPDMAIFITMNPGYAGR
SNLPDNLKKLFRSLAMTKPDRQLIAQVM LYSQGFRTAEVLANKIV
PFFKLCDEQLSSQSHYDFGLRALKSVLVSAGNVKRERIQKIKREK
40 EERGEAVDEGEIAENLPEQEILIQSV CETMVPKLVAEDIPLLFSL
LSDVFPGVQYHRGEMTALREELKKVCQEM YLTYGDGEEVGGMWVE
KVLQLYQITQINHGLMMVGPSGSGKSMAWRVLLKALERLEGVEGV
AHIIDPKAISKDHL YGTLDPNTREWTDGLFTHVLRKIIDSVRGEL
QKRQWIVFDGDVDPEWVENLSVLD DNKLLTLPNGERLSLPPNVR
45 IMFEVQDLKYATLATVSR CGMVWFSE DVLSTDMIFNNFLARLSI
PLDEGEDEAQR RRKKGKEDEGE EEAAS PMLQIQRDAATIMQPYFTSN
GLVTKALEHAFQLEHIMDLTRLRCLGSLF SMLHQACRNVAQYNAN
HPDFPMQIEQLERYIQRYLVYAILWSLSGDSRLKMRAELGEYIRR
ITTVPLPTAPNIPIIDYEVSISGEWSPWQAKVPQIEVETHKVAAP
50 DVVVPTLDTVRHEALLYTWLAEHKPLVLCGPPGSGKTM TLFSA LR
ALPDMEVVGLNFSSATTPELLLKTFDHYCEYRRTPNGVV LAPVQL
GKWLVLFCDEINLPDMDKYGTQRVISFIRQMVEHGGFYRTSDQTW
VKLERIQFVGACNPPTDPGRKPLSHRFLRHVPV VYVDYPGPASLT
QIYGTFNRA MLRLIPSLRTYAEPLTAAMVEFYTMSQERFTQDTQP
55 HYIYSPREMT RWVRGIF EALRPLETLPVEGLIRIWAHEALRLFQD
RLVEDEERRWTDENIDTVALKHFPNIDREKAMSRPILYSNWLSKD

YIPVDQEELRDYVKARLKVFYEEELDVPVLVLFNEVL DHVLRIDRI
 FRQPQGHLLLLIGVSGAGKTTL SRFVAMNGLSVYQIKVHRKYTGE
 DFDEDLRTVLRRSGCKNEKIAFIMDESNVLD SGFLERMNTLLANG
 5 EVPGLFEGDEYATLMTQCKEGAQKEGLMLDSHEELYKWFTSQVIR
 NLHVVFMTMNPSSSEGLKDRAATSPALFNRCVLNWF GDWSTEALYQV
 GKEFTSKMDLEKPNYIVPDYMPVVYDKLPQPPSHREAI VNSCVFV
 HQTLLHQANARLAKRGGRTMAITPRHYLDFINHYANLFHEKRSELE
 EQQMHLNVGLRKIKETVDQVEELRRDLRIKSQELEVKNAAANDKL
 10 KKMVKDQQEAEKKKVM SQEIQEQLHKQQEVIADKQMSVKEDLDKV
 EPAVIEAQNAVKSIIKKQHLVEVRS MANPPAAVKLALESICLLLGE
 STTDWKQIRSIIMRENFIPTIVNFSAE EISDAIREKMKKNYMSNP
 SYNYEIVNRASLACGPMVKWAI AQLNYADMLKRVEPLRNELOKLE
 DDAKDNQQKANEVEQMIRDLEASIARYKEEYAVLISEAQAIKADL
 15 AAVEAKVNRSTALLKSLSAERERWEKTSETFKNQMSTIAGDCLLS
 AAFIAYAGYFDQQMRQNLFTTWSHHLQQANI QFRTDIARTEYLSN
 ADERLRWQASSLPADDLCTENAIMLKR FNRYPLIIDPSGQATEFI
 MNEYKDRKITRTSFLDDAFRKNLESALRFGNPLLVDVESYDPVL
 NPVLNREVRRTGGRVLITLGDQDIDLSPSFVIFLSTRDPTVEFPP
 20 DLCSRVTFFVNFTVTRSSLSQCLNEVLKAERP DVDEKRSDLLKLQ
 GEFQLRLRQLEKSLLOALNEVKGRILDDDTIITLENL KREAAEV
 TRKVEETDIVMQEVETVSQQYLPLSTACSSIYFTMESLKQIHFLY
 QYSLQFFLDIYHNVLYENPNLKGVT DHTQRLSIITKDLFQVAFNR
 VARGMLHQDHITFAMLLARIKLGTVGEPTYDAEFQHFLRGNEIV
 25 LSAGSTPRIQGLTVEQAEAVVRLSCLPAFKDLIAKVQADEQFGIW
 LDSSSPEQTVPYLWSEETPATPIGQAIHRLLLIQA FRPDRL LAMA
 HMFVSTNLGESFMSIMEQPLDLTHIVGTEVKPNTPVLMCSVPGYD
 ASGHVEDLAAEQNTQITSIAIGSAEGFNQADK AINTAVKSGRWVM
 LKNVHLAPGWLMOLEKKLHSLQPHACFR LFLTMEINPKVPVNL LR
 30 AGRI FVFEP PPVGKANMLRTFSSIPVSRICKSPNERARLYFLLAW
 FHAI IQERLRYAPLGWSKKYEFGESDLRSACDTVDTWLDDTAKGR
 QNISPDKI PWSALKTLMAQSIYGG RVDNEFDQRLNNTFLERLFTT
 RSFDSEFKLACKVDGHKDIQMPDGIRREEFVQWV ELLPDTQTPSW
 LGLPNNAERVLLTTQGVDMISKMLKMOMLEDEDD LAYAETEKKTR
 35 TDSTSDGRPAWMRTLHTTASNWLHLIPQTL SHLKRTVENIKDPLF
 RFFEREVKMGAKLLQDVRQDLADV VQVCEGKKKQTNYLRTLINEL
 VKGILPRSWSHYTPAGMTVIQWVSDFSERIKQLQNI SLAAASGG
 AKELKNIHVCLGGLFVPEAYITATRQYVAQANSWSLEELCLEVNV
 40 TTSQGATLDACSGVGTGLKLQGATC NNNKLSLSNAISTALPLTQL
 RWVKQTNTEKKASVVTLPVYLNFTRADLIFTVD FEIATKEDPRSF
 YERGVAVLCTE

Preferably, the wild type residue of the modified human cytoplasmic dynein heavy chain1 protein is replaced by an amino acid with different size and/or polarity,
 45 *e.g.*, a non-conservative amino acid substitution.

Preferably, residue 1055 of murine cytoplasmic dynein heavy chain1 and residue 1057 of human cytoplasmic dynein heavy chain1 according to the present invention is replaced by an amino acid other than Trp or Phe and preferably is

replaced by an amino acid selected from Ala, Ser, Thr, Pro, Gly, Met, Leu, Ile, Val, or Cys, more preferably by Met, Leu, Ile, Val, or Cys, and most preferably by Cys.

In a most preferred embodiment the murine cytoplasmic dynein heavy chain1
5 mutein of the present invention has the amino acid sequence shown in SEQ ID NO:4. In another preferred embodiment the human cytoplasmic dynein heavy chain1 mutein of the present invention has the amino acid sequence shown in SEQ ID NO:6.

The present invention is not limited to muteins with a mutation of the residue
10 at, e.g., position 1055 of the amino acid sequence shown in SEQ ID NO: 4, and it is not limited to the mutation of the residue at, e.g., position 1057 of the amino acid sequence shown in SEQ ID NO: 6 or at a corresponding position in other dynein heavy chain proteins (especially cytoplasmic dynein heavy chain1 proteins from different species). Rather it encompasses additional muteins with modifications in the
15 amino acid sequence of the mouse or human cytoplasmic dynein heavy chain1 proteins as long as they impart a phenotype as described herein in connection with the animals. Such muteins, may comprise mutations, such as single or multiple further amino acid substitutions, deletions and insertions.

One embodiment of the invention relates to muteins wherein the amino acid
20 residue affected by the mutation, e.g., a substitution, deletion, or insertion, corresponds to a residue selected from the group of conserved amino acid residues between Leu302 (302L) and Phe1140 (1140F) of the cytoplasmic dynein heavy chain1 amino acid sequence, e.g., SEQ ID NO:2 (*Mus musculus*) specified in Table 19.

25 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 302L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 303K.

A preferred mutein of the invention is one wherein the conserved amino acid
30 affected by said mutation is the amino acid 305G.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 306K.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 307R.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 308F.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 309H.

5 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 310A.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 311T.

10 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 312V.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 314F.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 315D.

15 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 317D.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 319G.

20 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 320L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 321K.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 322Q.

25 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 324L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 327V.

30 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 329D.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 330Y.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 331N.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 333L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 334M.

5 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 335K.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 337F.

10 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 338P.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 342L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 344S.

15 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 345A.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 346T.

20 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 350K.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 354A.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 358I.

25 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 359F.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 361H.

30 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 362L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 363R.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 364K.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 366R.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 368T.

5 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 369K.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 370Y.

10 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 371P.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 373Q.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 374R.

15 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 376L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 378L.

20 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 380E.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 381A.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 382I.

25 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 383S.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 384R.

30 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 385D.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 386L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 389Q.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 390L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 391L.

5 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 392K.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 393V.

10 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 394L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 399L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 400M.

15 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 406E.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 407F.

20 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 411M.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 414C.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 418F.

25 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 421W.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 422D.

30 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 423D.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 424E.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 425Y.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 427K.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 431L.

5 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 432L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 433R.

10 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 434D.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 435I.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 437K.

15 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 439K.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 440R.

20 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 445K.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 448W.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 454H.

25 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 457L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 460R.

30 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 467F.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 468R.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 470Q.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 471H.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 472E.

5 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 473Q.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 475R.

10 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 477V.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 478I.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 480R.

15 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 481V.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 482L.

20 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 483R.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 484P.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 519E.

25 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 521V.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 524A.

30 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 525Y.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 526E.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 529K.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 531V.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 532D.

5 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 534L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 535D.

10 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 543A.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 544W.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 545E.

15 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 547A.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 549K.

20 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 550R.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 551Y.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 555I.

25 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 558V.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 559E.

30 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 560T.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 562I.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 563T.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 566L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 569Q.

5 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 570L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 575N.

10 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 577N.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 578E.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 579M.

15 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 580F.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 582I.

20 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 583F.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 584S.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 585R.

25 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 587N.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 588A.

30 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 589L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 590F.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 592R.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 593P.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 595I.

5 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 596R.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 597G.

10 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 598A.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 599I.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 601E.

15 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 602Y.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 603Q.

20 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 604T.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 606L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 607I.

25 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 609R.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 610V.

30 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 611K.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 613D.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 614I.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 617L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 621F.

5 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 639L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 640P.

10 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 641P.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 646W.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 655Q.

15 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 656L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 659Y.

20 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 661K.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 662R.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 663V.

25 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 664E.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 665D.

30 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 666V.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 667L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 668G.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 669K.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 671W.

5 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 672E.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 674H.

10 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 677G.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 680L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 681K.

15 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 683D.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 684G.

20 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 685D.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 687F.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 690F.

25 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 691L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 697F.

30 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 700W.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 704V.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 705N.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 715I.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 717T.

5 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 731L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 733L.

10 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 736N.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 744L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 746K.

15 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 747E.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 748V.

20 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 752K.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 755G.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 756F.

25 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 757R.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 758V.

30 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 759P.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 760L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 762I.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 763V.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 764N.

5 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 766A.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 767H.

10 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 768Q.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 769A.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 770N.

15 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 771Q.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 774P.

20 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 776A.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 778S.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 779L.

25 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 780I.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 781E.

30 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 784R.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 785T.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 802L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 804A.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 808K.

5 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 816E.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 817G.

10 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 820L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 822W.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 824S.

15 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 825Y.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 826K.

20 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 828D.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 830Y.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 834L.

25 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 836E.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 838V.

30 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 842Q.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 843E.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 848L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 849L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 862L.

5 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 865C.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 867Y.

10 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 871T.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 876L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 880Q.

15 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 883V.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 884D.

20 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 886L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 888L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 891Y.

25 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 892S.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 893N.

30 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 894L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 897W.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 898V.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 899N.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 901L.

5 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 902D.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 906E.

10 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 909L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 912R.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 920W.

15 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 921T.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 951P.

20 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 955N.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 957V.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 963T.

25 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 965Q.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 968Y.

30 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 971P.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 975E.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 977R.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 987W.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1001R.

5 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1003Q.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1017Y.

10 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1019N.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1021L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1025P.

15 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1027G.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1031L.

20 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1032E.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1035Y.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1048Y.

25 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1052W.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1053L.

30 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1055Y.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1056Q.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1058L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1059W.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1062Q.

5 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1063A.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1070L.

10 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1071G.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1077W.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1081L.

15 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1084I.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1088R.

20 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1091F.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1092D.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1096T.

25 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1102P.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1107Y.

30 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1109K.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1111Q.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1113K.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1117K.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1118Y.

5 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1119D.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1121W.

10 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1122H.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1123K.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1124E.

15 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1126L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1128K.

20 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1129F.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1130G.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1134G.

25 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1137W.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1140F.

30 It will be understood that human muteins of the cytoplasmic dynein heavy chain1 having mutations as described herein, e.g., carrying a substitution, deletion, or insertion at a position within the human amino acid sequence corresponding to any of the above individualized conserved amino acids of the mouse amino acid sequence, are likewise within the scope of the invention. The corresponding human amino acids

will, as they are conserved between, e.g. mouse and human, be identical while their relative position within the amino acid sequence may vary. The skilled person will be readily able to identify the corresponding human amino acids, e.g., within SEQ ID NO:18, or from Figures 9 or 10.

5

In addition to the mutant proteins described by SEQ ID NO:4, and SEQ ID NO:6, the skilled artisan will further appreciate that changes can be introduced by mutation into the nucleotide sequence encoding a dynein heavy chain polypeptide (e.g., the sequences of SEQ ID NO:3 and SEQ ID NO:5), thereby leading to changes
10 in the amino acid sequence of the encoded dynein heavy chain proteins without altering properties of the mutant dynein heavy chain proteins. For example, nucleotide substitutions leading to amino acid substitutions at "non-essential" amino acid residues can be made in the sequence of SEQ ID NO:3 and SEQ ID NO:5. A "non-essential" amino acid residue is a residue that can be altered from the wild-type
15 sequence of a dynein heavy chain polypeptide without altering the biological activity, whereas an "essential" amino acid residue is required for biological activity. For example, amino acid residues that are conserved among the cytoplasmic dynein heavy chain1 polypeptide or polypeptide fragments of the present invention are predicted to be particularly unamenable to alteration.

20

Preferably, such alterations replace an amino acid with one of similar size and polarity (e.g., conservative substitution). In one embodiment, the polypeptide has at least 75 %, preferably at least 80 %, more preferably at least 90 %, even more preferably 95% and most preferably at least 99 % sequence identity with the wild type
25 cytoplasmic dynein heavy chain1 sequence. In a particularly preferred embodiment, the polypeptide is identical with the wild type sequence except for a replacement of the Tyr residue at position 1055 of the amino acid sequence, as shown in SEQ ID NO: 4. In another particularly preferred embodiment, the polypeptide is identical to the wild type sequence except for a replacement of the Tyr residue at position 1057 of the
30 amino acid sequence, as shown in SEQ ID NO: 6 or at the corresponding position in other cytoplasmic dynein heavy chain1 sequences. Preferred modifications of the amino acid sequence, in addition to the replacement at, e.g., position 1055 of the amino acid sequence shown in SEQ ID NO: 4, and at, e.g., position 1057 of the amino acid sequence shown in SEQ ID NO: 6, or at a corresponding position in other dynein

heavy chains are at any of the positions which are conserved among the vertebrate dynein heavy chains as described in individualized manner in connection with the preferred muteins above.

5 Preferred modifications of the amino acid sequence, in addition to the replacement at position 1055 of the amino acid sequence shown in SEQ ID NO: 4, and at position 1057 of the amino acid sequence shown in SEQ ID NO: 6, or at a corresponding position in other dynein heavy chains are at positions which are not conserved among the vertebrate dynein heavy chains.

10

Amino acids in the cytoplasmic dynein heavy chain 1 proteins of the present invention that are essential for function can be identified by methods known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (Cunningham and Wells, Science 244:1081-1085, 1989). The latter procedure introduces single alanine
15 mutations at every residue in the molecule. The resulting mutant molecules are then tested for biological activity such as receptor binding or in vitro proliferative activity. Sites that are critical for ligand-receptor binding can also be determined by structural analysis such as crystallization, nuclear magnetic resonance or photoaffinity labeling (Smith et al., J. Mol. Biol. 224:899-904, 1992; de Vos et al., Science 255:306-312,
20 1992).

An "isolated" or "purified" polypeptide or protein or biologically-active portion thereof is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the polypeptide or protein is derived, or
25 substantially free from chemical precursors or other chemicals when chemically synthesized. The language "substantially free of cellular material" includes preparations of dynein heavy chain protein in which the protein is separated from cellular components of the cells from which it the protein is isolated or in which it is recombinantly produced.

30

Further as used herein, a "mature" form of a polypeptide or protein may arise from a step of post-translational modification other than a proteolytic cleavage event. Such additional processes include, by way of non-limiting example, glycosylation, myristoylation or phosphorylation. In general, a mature polypeptide or protein may

result from the operation of only one of these processes, or a combination of any of them.

To determine the percent homology of two amino acid sequences or of two
5 nucleic acids, the sequences are aligned for optimal comparison purposes (*e.g.*, gaps can be introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second comparison amino acid or nucleic acid sequence). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is
10 occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are homologous at that position (*e.g.*, as used herein amino acid or nucleic acid "homology" is equivalent to amino acid or nucleic acid "identity"). The nucleic acid sequence homology may be determined as the degree of identity between two sequences. The homology may be determined
15 using computer programs known in the art, such as GAP software provided in the GCG program package. See, Needleman and Wunsch (1970) J Mol Biol 48, 443-453. Using GCG GAP software with the following settings for nucleic acid sequence comparison: GAP creation penalty of 5.0 and GAP extension penalty of 0.3, the coding region of the analogous nucleic acid sequences referred to above exhibits a
20 degree of identity preferably of at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99%, with the CDS (encoding) part of the DNA sequence shown in SEQ ID NOS:1, 3, 5, and 17.

The term "sequence identity" refers to the degree to which two polynucleotide
25 or polypeptide sequences are identical on a residue-by-residue basis over a particular region of comparison. The term "percentage of sequence identity" is calculated by comparing two optimally aligned sequences over that region of comparison, determining the number of positions at which the identical nucleic acid base (*e.g.*, A, T, C, G, U, or I, in the case of nucleic acids) occurs in both sequences to yield the
30 number of matched positions, dividing the number of matched positions by the total number of positions in the region of comparison (*e.g.*, the window size), and multiplying the result by 100 to yield the percentage of sequence identity. The term "substantial identity" as used herein denotes a characteristic of a polynucleotide sequence, wherein the polynucleotide comprises a sequence that has at least 80

percent sequence identity, preferably at least 85 percent identity and often 90 to 95 percent sequence identity, more usually at least 99 percent sequence identity as compared to a reference sequence over a comparison region.

5 The phrases "percent identity" or "% identity" refer to the percentage of sequence similarity found in a comparison of two or more amino acid or nucleic acid sequences. Percent identity can be determined electronically, *e.g.*, by using the MEGALIGN program (DNASTAR, Inc., Madison WI, USA). The MEGALIGN
10 program can create alignments between two or more sequences according to different methods, *e.g.*, the clustal method (see, for example, Higgins and Sharp (1988) Gene 73:237-244. The clustal algorithm groups sequences into clusters by examining the distances between all pairs. The clusters are aligned pairwise and then in groups. The percentage similarity between two amino acid sequences, *e.g.*, sequence A and
15 sequence B, is calculated by dividing the length of sequence A, minus the number of gap residues in sequence A, minus the number of gap residues in sequence B, into the sum of the residue matches between sequence A and sequence B, times one hundred. Gaps of low homology or of no homology between the two amino acid sequences are not included in determining percentage similarity. Percent identity between nucleic
20 acid sequences can also be counted or calculated by other methods known in the art, *e.g.*, the method described in Hein (1990) Methods Enzymol 183, 626-645. Identity between sequences can also be determined by other methods known in the art, *e.g.*, by varying hybridization conditions.

25 The comparison of two or more amino acid or nucleic acid sequences to determine sequence identity can be performed between ortholog sequences, preferably between mouse and human, more preferably between mouse, rat, and human sequences. When a position of an amino acid or nucleotide in one ortholog sequence is occupied by the same amino acid or nucleotide in at least a second ortholog sequence, this amino acid or nucleotide is "evolutionary conserved" for the purpose of
30 this invention. The term "evolutionary conserved" also comprises amino acid substitutions, where an amino acid is replaced by another (*i.e.*, different) amino acid that represents a conservative substitution as defined below.

When, e.g., residue 1055 of SEQ ID NO:2, or residue 1057 of SEQ ID NO:18 or any of the residues corresponding to the conserved residues described in individualized manner in connection with the preferred muteins of the invention above is replaced by an amino acid with different size and/or polarity (excluding the wild type residue at this position), this is termed a non-conservative amino acid substitution. Non-conservative substitutions are defined as exchanges of an amino acid by another amino acid listed in a different group of the five standard amino acid groups shown below:

1. small aliphatic, nonpolar or slightly polar residues: Ala, Ser, Thr, (Pro), (Gly);
2. negatively charged residues and their amides: Asn, Asp, Glu, Gln;
3. positively charged residues: His, Arg, Lys;
4. large aliphatic, nonpolar residues: Met, Leu, Ile, Val, (Cys);
5. large aromatic residues: Phe, Tyr, Trp.

15

Conservative substitutions are defined as exchanges of an amino acid by another amino acid listed within the same group of the five standard amino acid groups shown above. Three residues are parenthesized because of their special role in protein architecture. Gly is the only residue without a sidechain and therefore imparts flexibility to the chain. Pro has an unusual geometry which tightly constrains the chain. Cys can participate in disulfide bonds.

In a preferred embodiment, the cytoplasmic dynein heavy chain1 expressed in the animal model of the present invention carries a mutation, which affects the conserved amino acids of the muteins described in individualized manner in connection with the preferred muteins of the invention above.

In the most preferred embodiment, the cytoplasmic dynein heavy chain1 expressed in the animal model of the present invention has the amino acid sequence shown in SEQ ID NO:4.

In another most preferred embodiment, the cytoplasmic dynein heavy chain1 expressed in the animal model of the present invention has an amino acid sequence selected from the sequences shown in SEQ ID NO:6 and SEQ ID NO:18.

The invention also provides novel chimeric or fusion proteins as used herein, a novel "chimeric protein" or "fusion protein" comprises a novel cytoplasmic dynein heavy chain1 polypeptide linked to a non-cytoplasmic dynein heavy chain1 polypeptide (e.g., a polypeptide that does not comprise cytoplasmic dynein heavy chain1 or a fragment thereof).

In one embodiment, the fusion protein is a GST-cytoplasmic dynein heavy chain1 fusion protein in which the cytoplasmic dynein heavy chain1 sequences are fused to the C-terminus of the GST (glutathione S-transferase) sequences. Such fusion proteins can facilitate the purification of recombinant cytoplasmic dynein heavy chain1 polypeptides.

In yet another embodiment, the fusion protein is a cytoplasmic dynein heavy chain1-immunoglobulin fusion protein in which the cytoplasmic dynein heavy chain1 sequences are fused to sequences derived from a member of the immunoglobulin protein family, especially Fc region polypeptides. Also contemplated are fusions of cytoplasmic dynein heavy chain1 sequences (mutant or wild type or functional fragments) fused to amino acid sequences that are commonly used to facilitate purification or labeling, e.g. polyhistidine tails (especially hexahistidine segments), FLAG tags, streptavidin.

The amino acid sequences of the present invention may be made by using peptide synthesis techniques well known in the art, such as solid phase peptide synthesis (see, for example, Fields *et al.* "Principles and Practice of Solid Phase Synthesis" in *Synthetic Peptides, A Users Guide*, Grant GA (ed.), (W.H. Freeman Co. New York NY, USA, 1992) at Chapter 3, pp. 77-183; Barlos K and Gatos D "Convergent Peptide Synthesis" in *FMOC Solid Phase Peptide Synthesis*, Chan WC and White PD (eds.), (Oxford University Press, New York NY, USA, 2000) at Chapter 9, pp. 215-228) or by recombinant DNA manipulations and recombinant expression. Techniques for making substitution mutations at predetermined sites in DNA having known sequence are well known and include, for example, M13 mutagenesis. Manipulation of DNA sequences to produce variant proteins which

manifest as substitution, insertion or deletion variants are conveniently described, for example, in Sambrook *et al.* (1989), *supra*.

Antibodies

5 Also included in the invention are antibodies to fragments of cytoplasmic dynein heavy chain1 polypeptides and muteins as described in individualized manner in connection with the preferred muteins of the invention above (including amino terminal fragments), as well as antibodies to fusion proteins containing cytoplasmic dynein heavy chain1 polypeptides or fragments of cytoplasmic dynein heavy chain1
10 polypeptides or muteins as described in individualized manner in connection with the preferred muteins of the invention above. The term "antibody" as used herein refers to immunoglobulin molecules and immunologically active portions of immunoglobulin (Ig) molecules, *e.g.*, molecules that contain an antigen binding site that specifically binds (immunoreacts with) an antigen. Such antibodies include, *e.g.*,
15 polyclonal, monoclonal, chimeric, single chain, F_{ab} , F_{ab}' and $F_{(ab)2}$ fragments, and an F_{ab} expression library. In general, an antibody molecule obtained from humans relates to any of the classes IgG, IgM, IgA, IgE and IgD, which differ from one another by the nature of the heavy chain present in the molecule. Certain classes have subclasses as well, such as IgG₁, IgG₂, and others. Furthermore, in humans, the light chain may
20 be a kappa chain or a lambda chain. Reference herein to antibodies includes a reference to all such classes, subclasses and types of human antibody species.

A cytoplasmic dynein heavy chain1 polypeptide 1 of the invention may be intended to serve as an antigen, or a portion or fragment thereof, and additionally can
25 be used as an immunogen to generate antibodies that immunospecifically bind the antigen, using standard techniques for polyclonal and monoclonal antibody preparation. Antigenic peptide fragments of the antigen for use as immunogens includes, *e.g.*, at least 7 amino acid residues of the amino acid sequence of the mutated region such as an amino acid sequence shown in SEQ ID NO:4 or SEQ ID NO:6, and
30 encompasses an epitope thereof such that an antibody raised against the peptide forms a specific immune complex with the full length protein or with any fragment that contains the epitope. Preferably, the antigenic peptide comprises at least 10 amino acid residues, or at least 15 amino acid residues, or at least 20 amino acid residues, or

at least 30 amino acid residues. Preferred epitopes encompassed by the antigenic peptide are regions of the protein that are located on its surface; commonly these are hydrophilic regions.

5 In certain embodiments of the invention, at least one epitope encompassed by the antigenic peptide is a region of cytoplasmic dynein heavy chain1 polypeptide that is located on the surface of the protein, *e.g.*, a hydrophilic region. A hydrophobicity analysis of a cytoplasmic dynein heavy chain1 polypeptide will indicate which regions of a cytoplasmic dynein heavy chain1 protein are particularly hydrophilic and, therefore, are likely to encode surface residues useful for targeting antibody production. As a means for targeting antibody production, hydropathy plots showing regions of hydrophilicity and hydrophobicity may be generated by any method well known in the art, including, for example, the Kyte Doolittle or the Hopp Woods methods, either with or without Fourier transformation. (See, for example, Hopp and Woods (1981) Proc Nat Acad Sci USA 78, 3824-3828; Kyte and Doolittle (1982) J Mol Biol 157, 105-142.) Antibodies that are specific for one or more domains within an antigenic protein, or derivatives, fragments, analogs or homologs thereof, are also provided herein.

20 A protein of the invention, or a derivative, fragment, analog, homolog or ortholog thereof, may be utilized as an immunogen in the generation of antibodies that immunospecifically bind these protein components.

Various procedures known within the art may be used for the production of polyclonal or monoclonal antibodies directed against a protein of the invention, or against derivatives, fragments, analogs homologs or orthologs thereof. (See, for example, Harlow and Lane *Antibodies: A Laboratory Manual*, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, USA, 1988).) Some of these antibodies are discussed below.

30

Polyclonal Antibodies

For the production of polyclonal antibodies, various suitable host animals (*e.g.*, rabbit, goat, mouse or other mammal) may be immunized by one or more injections with the protein of the invention, a synthetic variant thereof, or a derivative of the

foregoing. An appropriate immunogenic preparation can contain, for example, the naturally occurring immunogenic protein, a chemically synthesized polypeptide representing the immunogenic protein, or a recombinantly expressed immunogenic protein. Furthermore, the protein may be conjugated to a second protein known to be immunogenic in the mammal being immunized. Examples of such immunogenic proteins include but are not limited to keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin and soybean trypsin inhibitor.

The preparation can further include an adjuvant. Various adjuvants used to increase the immunological response include, but are not limited to, Freund's (complete and incomplete), mineral gels (*e.g.*, aluminum hydroxide), surface active substances (*e.g.*, lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, dinitrophenol, etc.), adjuvants usable in humans such as Bacille Calmette-Guerin and *Corynebacterium parvum*, or similar immunostimulatory agents. Additional examples of adjuvants which can be employed include MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate).

The polyclonal antibody molecules directed against the immunogenic protein can be isolated from the mammal (*e.g.*, from the blood) and further purified by well known techniques, such as affinity chromatography using protein A or protein G, which provide primarily the IgG fraction of immune serum. Subsequently, or alternatively, the specific antigen which is the target of the immunoglobulin sought, or an epitope thereof, may be immobilized on a column to purify the immune specific antibody by immunoaffinity chromatography. Purification of immunoglobulins is discussed, for example, by Wilkinson (Wilkinson (2000) *The Scientist*, 14, 25-28).

Monoclonal Antibodies

The term "monoclonal antibody" (MAb) or "monoclonal antibody composition", as used herein, refers to a population of antibody molecules that contain only one molecular species of antibody molecule consisting of a unique light chain gene product and a unique heavy chain gene product. In particular, the complementarity determining regions (CDRs) of the monoclonal antibody are identical in all the molecules of the population. MAbs thus contain an antigen binding

site capable of immunoreacting with a particular epitope of the antigen, the antigen binding site being characterized by its unique binding affinity for this epitope. Similarly, the epitope may be characterized by its binding affinity for antigen binding sites of one or more particular MAbs having binding sites directed towards that epitope.

Monoclonal antibodies can be prepared using hybridoma methods, such as those described by Kohler and Milstein (1975) Nature 256, 495. In a hybridoma method, a mouse, hamster, or other appropriate host animal, is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes can be immunized *in vitro*.

The immunizing agent will typically include the protein antigen, a fragment thereof or a fusion protein thereof. Generally, either peripheral blood lymphocytes are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired. The lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (Goding, *Monoclonal Antibodies: Principles and Practice* (Academic Press / Elsevier Science Sidcup, Kent, UK, 1986) at pp. 59-103). Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine and human origin. Usually, rat or mouse myeloma cell lines are employed. The hybridoma cells can be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine ("HAT medium"), which substances prevent the growth of HGPRT-deficient cells.

30

Preferred immortalized cell lines are those that fuse efficiently, support stable high level expression of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. More preferred immortalized cell lines are murine myeloma lines, which can be obtained, for instance, from the Salk Institute

Cell Distribution Center, San Diego, California and the American Type Culture Collection, Manassas, Virginia. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies (Kozbor (1984) J Immunol, 133, 3001; Brodeur *et al.*, *Monoclonal Antibody*
5 *Production Techniques and Applications* (Marcel Dekker, Inc., New York NY, USA, 1987) at pp. 51-63).

The culture medium in which the hybridoma cells are cultured can then be assayed for the presence of monoclonal antibodies directed against the antigen.
10 Preferably, the binding specificity of monoclonal antibodies produced by the hybridoma cells is determined by immunoprecipitation or by an *in vitro* binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA). Such techniques and assays are known in the art. The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of
15 Munson and Pollard (1980) Anal. Biochem., 107:220. Preferably, antibodies having a high degree of specificity and a high binding affinity for the target antigen are isolated.

After the desired hybridoma cells are identified, the clones can be subcloned
20 by limiting dilution procedures and grown by standard methods. Suitable culture media for this purpose include, for example, Dulbecco's Modified Eagle's Medium and RPMI-1640 medium. Alternatively, the hybridoma cells can be grown *in vivo* as ascites in a mammal.

25 The monoclonal antibodies secreted by the subclones can be isolated or purified from the culture medium or ascites fluid by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.

30 The monoclonal antibodies can also be made by recombinant DNA methods, such as those described in U.S. Patent No. 4,816,567. DNA encoding the monoclonal antibodies of the invention can be readily isolated and sequenced using conventional procedures (*e.g.*, by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). The

hybridoma cells of the invention serve as a preferred source of such DNA. Once isolated, the DNA can be placed into expression vectors, which are then transfected into host cells such as simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. The DNA also can be modified, for example, by substituting the coding sequence for human heavy and light chain constant domains in place of the homologous murine sequences (U.S. Patent No. 4,816,567; Morrison (1994) Nature 368, 812-13) or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide. Such a non-immunoglobulin polypeptide can be substituted for the constant domains of an antibody of the invention, or can be substituted for the variable domains of one antigen-combining site of an antibody of the invention to create a chimeric bivalent antibody.

15 Humanized Antibodies

The antibodies directed against the protein antigens of the invention can further comprise humanized antibodies or human antibodies. These antibodies are suitable for administration to humans without engendering an immune response by the human against the administered immunoglobulin. Humanized forms of antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab')₂ or other antigen-binding subsequences of antibodies) that are principally comprised of the sequence of a human immunoglobulin and contain minimal sequence derived from a non-human immunoglobulin. Humanization can be performed following the method of Winter and co-workers (Jones *et al.* (1986) Nature 321, 522-525; Riechmann *et al.* (1988) Nature 332, 323-327; Verhoeyen *et al.* (1988) Science 239, 1534-1536), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. (See also U.S. Patent No. 5,225,539.) In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies can also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the framework regions are those of a

human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin (Jones *et al.* (1986) Nature 321, 522-525; Riechmann *et al.* (1988) Nature 332, 323-327; and Presta (1992) Curr Op Struct Biol 2, 593-596).

Human Antibodies

Fully human antibodies relate to antibody molecules in which essentially the entire sequences of both the light chain and the heavy chain, including the CDRs, arise from human genes. Such antibodies are termed "human antibodies", or "fully human antibodies" herein. Human monoclonal antibodies can be prepared by the trioma technique; the human B-cell hybridoma technique (see Kozbor *et al.* (1983) Immunol Today 4, 72) and the EBV hybridoma technique to produce human monoclonal antibodies (see Cole *et al.* in: *Monoclonal Antibodies and Cancer Therapy* (Alan R. Liss, Inc., New York NY, USA, 1985) at pp. 77-96). Human monoclonal antibodies may be utilized in the practice of the present invention and may be produced by using human hybridomas (see Cote *et al.* (1983) Proc Natl Acad Sci USA 80, 2026-2030) or by transforming human B-cells with Epstein Barr Virus *in vitro* (see Cole *et al.* in: *Monoclonal Antibodies and Cancer Therapy* (Alan R. Liss, Inc., New York NY, USA, 1985) at pp. 77-96).

In addition, human antibodies can also be produced using additional techniques, including phage display libraries (Hoogenboom and Winter (1992) J Mol Biol 227, 381-388; Marks *et al.* (1991) J Mol Biol 222, 581-597). Similarly, human antibodies can be made by introducing human immunoglobulin loci into transgenic animals, *e.g.*, mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire. This approach is described, for example, in U.S. Patents No. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in Marks *et al.* (1992) Bio/Technology 10, 779-783; Lonberg *et al.* (1994) Nature 368, 856-859; Morrison (1994) Nature 368, 812-13; Fishwild *et al.* (1996) Nature Biotechnology 14, 845-51; Neuberger (1996) Nature

Biotechnology 14, 826; and Lonberg and Huszar (1995) Intern Rev Immunol 13, 65-93.

Human antibodies may additionally be produced using transgenic nonhuman
5 animals which are modified so as to produce fully human antibodies rather than the
animal's endogenous antibodies in response to challenge by an antigen (see PCT
publication WO94/02602). The endogenous genes encoding the heavy and light
immunoglobulin chains in the nonhuman host have been incapacitated, and active loci
10 encoding human heavy and light chain immunoglobulins are inserted into the host's
genome. The human genes are incorporated, for example, using yeast artificial
chromosomes containing the requisite human DNA segments. An animal which
provides all the desired modifications is then obtained as progeny by crossbreeding
intermediate transgenic animals containing fewer than the full complement of the
modifications. The preferred embodiment of such a nonhuman animal is a mouse, and
15 is termed the XenomouseTM as disclosed in PCT publications WO-A-96/33735 and
WO-A-96/34096. This animal produces B cells which secrete fully human
immunoglobulins. The antibodies can be obtained directly from the animal after
immunization with an immunogen of interest, as, for example, a preparation of a
polyclonal antibody, or alternatively from immortalized B cells derived from the
20 animal, such as hybridomas producing monoclonal antibodies. Additionally, the
genes encoding the immunoglobulins with human variable regions can be recovered
and expressed to obtain the antibodies directly, or can be further modified to obtain
analogs of antibodies such as, for example, single chain Fv molecules.

25 An example of a method of producing a nonhuman host, exemplified as a
mouse, lacking expression of an endogenous immunoglobulin heavy chain is
disclosed in U.S. Patent No. 5,939,598. Such a host can be obtained by a method
including deleting the J segment genes from at least one endogenous heavy chain
locus in an embryonic stem cell to prevent rearrangement of the locus and to prevent
30 formation of a transcript of a rearranged immunoglobulin heavy chain locus, the
deletion being effected by a targeting vector containing a gene encoding a selectable
marker; and producing from the embryonic stem cell a transgenic mouse whose
somatic and germ cells contain the gene encoding the selectable marker.

A method for producing an antibody of interest, such as a human antibody, is disclosed in U.S. Patent No. 5,916,771. The method includes introducing an expression vector that contains a nucleotide sequence encoding a heavy chain into one mammalian host cell in culture, introducing an expression vector containing a nucleotide sequence encoding a light chain into another mammalian host cell, and fusing the two cells to form a hybrid cell. The hybrid cell expresses an antibody containing the heavy chain and the light chain.

In a further improvement on this procedure, a method for identifying a clinically relevant epitope on an immunogen, and a correlative method for selecting an antibody that binds immunospecifically to the relevant epitope with high affinity, are disclosed in PCT publication WO-A-99/53049.

F_{ab} Fragments and Single Chain Antibodies

According to the invention, techniques can be adapted for the production of single-chain antibodies specific to an antigenic protein of the invention (see for example U.S. Patent No. 4,946,778). In addition, methods can be adapted for the construction of F_{ab} expression libraries (see for example Huse *et al.* (1989) Science 246, 1275-1281) to allow rapid and effective identification of monoclonal F_{ab} fragments with the desired specificity for a protein or derivatives, fragments, analogs or homologs thereof. Antibody fragments that contain the idiotype to a protein antigen may be produced by techniques known in the art including, but not limited to:

- (i) an F_{(ab)²} fragment produced by pepsin digestion of an antibody molecule;
- (ii) an F_{ab} fragment generated by reducing the disulfide bridges of an F_{(ab)²} fragment;
- (iii) an F_{ab} fragment generated by the treatment of the antibody molecule with papain and a reducing agent; and
- (iv) F_v fragments.

Bispecific Antibodies

Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens. In the

present case, one of the binding specificities is for an antigenic protein of the invention. The second binding target is any other antigen, and advantageously is a cell-surface protein or receptor or receptor subunit.

5 Methods for making bispecific antibodies are known in the art. Traditionally, the recombinant production of bispecific antibodies is based on the co-expression of two immunoglobulin heavy-chain/light-chain pairs, where the two heavy chains have different specificities (Milstein and Cuello (1983) *Nature* 305, 537-539). Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas
10 (quadromas) produce a potential mixture of ten different antibody molecules, of which only one has the correct bispecific structure. The purification of the correct molecule is usually accomplished by affinity chromatography steps. Similar procedures are disclosed in WO-A-93/08829 and in Traunecker *et al.* (1991) *EMBO J* 10, 3655-3659.

15

Antibody variable domains with the desired binding specificities (antibody-antigen combining sites) can be fused to immunoglobulin constant domain sequences. The fusion preferably is with an immunoglobulin heavy-chain constant domain, comprising at least part of the hinge, CH2, and CH3 regions. It is preferred to have
20 the first heavy chain constant region (CH1) containing the site necessary for light-chain binding present in at least one of the fusions. DNAs encoding the immunoglobulin heavy-chain fusions and, if desired, the immunoglobulin light chain are inserted into separate expression vectors and are co-transfected into a suitable host organism. For further details of generating bispecific antibodies see, for example,
25 Suresh *et al.* (1986) *Methods in Enzymology* 121, 210.

In accordance with another approach described in WO-A-96/27011, the interface between a pair of antibody molecules can be engineered to maximize the percentage of heterodimers which are recovered from recombinant cell culture. The
30 preferred interface comprises at least a part of the CH3 region of an antibody constant domain. In this method, one or more small amino acid side chains from the interface of the first antibody molecule are replaced with larger side chains (*e.g.* tyrosine or tryptophan). Compensatory "cavities" of identical or similar size to the large side chain(s) are created on the interface of the second antibody molecule by replacing

large amino acid side chains with smaller ones (e.g. alanine or threonine). This provides a mechanism for increasing the yield of the heterodimer over other unwanted end-products such as homodimers.

5 Bispecific antibodies can be prepared as full length antibodies or antibody fragments (e.g. $F(ab')_2$ bispecific antibodies). Techniques for generating bispecific antibodies from antibody fragments have been described in the literature. For example, bispecific antibodies can be prepared using chemical linkage. Brennan *et al.* ((1985) Science 229, 81) describe a procedure wherein intact antibodies are
10 proteolytically cleaved to generate $F(ab')_2$ fragments. These fragments are reduced in the presence of the dithiol complexing agent sodium arsenite to stabilize vicinal dithiols and prevent intermolecular disulfide formation. The Fab' fragments generated are then converted to thionitrobenzoate (TNB) derivatives. One of the Fab'-TNB derivatives is then reconverted to the Fab'-thiol by reduction with mercaptoethylamine
15 and is mixed with an equimolar amount of the other Fab'-TNB derivative to form the bispecific antibody. The bispecific antibodies produced can be used as agents for the selective immobilization of enzymes.

20 Additionally, Fab' fragments can be recovered directly from *E. coli* and chemically coupled to form bispecific antibodies. Shalaby *et al.* ((1992) J Exp Med 175, 217-225) describe the production of a fully humanized bispecific antibody $F(ab')_2$ molecule. Each Fab' fragment was secreted separately from *E. coli* and subjected to directed chemical coupling *in vitro* to form the bispecific antibody. The bispecific antibody thus formed was able to bind to cells overexpressing the ErbB2 receptor and
25 normal human T cells, as well as trigger the lytic activity of human cytotoxic lymphocytes against human breast tumor targets.

30 Various techniques for making and isolating bispecific antibody fragments directly from recombinant cell culture have also been described. For example, bispecific antibodies have been produced using leucine zippers. Kostelny *et al.* (1992) J Immunol 148, 1547-1553. The leucine zipper peptides from the Fos and Jun proteins were linked to the Fab' portions of two different antibodies by gene fusion. The antibody homodimers were reduced at the hinge region to form monomers and then re-oxidized to form the antibody heterodimers. This method can also be utilized

for the production of antibody homodimers. The "diabody" technology described by Hollinger *et al.* ((1993) Proc Natl Acad Sci USA 90, 6444-6448) has provided an alternative mechanism for making bispecific antibody fragments. The fragments comprise a heavy-chain variable domain (V_H) connected to a light-chain variable domain (V_L) by a linker which is too short to allow pairing between the two domains on the same chain. Accordingly, the V_H and V_L domains of one fragment are forced to pair with the complementary V_L and V_H domains of another fragment, thereby forming two antigen-binding sites. Another strategy for making bispecific antibody fragments by the use of single-chain Fv (sFv) dimers has also been reported (see Gruber *et al.* (1994) J Immunol 152, 5368-74.

Antibodies with more than two valencies are contemplated. For example, trispecific antibodies can be prepared (Tutt *et al.* (1991) J Immunol 147, 60-69).

Exemplary bispecific antibodies can bind to two different epitopes, at least one of which originates in the protein antigen of the invention. Alternatively, an anti-antigenic arm of an immunoglobulin molecule can be combined with an arm which binds to a triggering molecule on a leukocyte such as a T-cell receptor molecule (e.g. CD2, CD3, CD28, or B7), or Fc receptors for IgG (Fc R), such as Fc RI (CD64), Fc RII (CD32) and Fc RIII (CD16) so as to focus cellular defense mechanisms to the cell expressing the particular antigen. Bispecific antibodies can also be used to direct cytotoxic agents to cells which express a particular antigen. These antibodies possess an antigen-binding arm and an arm which binds a cytotoxic agent or a radionuclide chelator, such as EOTUBE, DPTA, DOTA, or TETA. Another bispecific antibody of interest binds the protein antigen described herein and further binds tissue factor (TF).

Heteroconjugate Antibodies

Heteroconjugate antibodies are also within the scope of the present invention. Heteroconjugate antibodies are composed of two covalently joined antibodies. Such antibodies have, for example, been proposed to target immune system cells to unwanted cells (U.S. Patent No. 4,676,980), and for treatment of HIV infection (WO-A-91/00360; WO-A-92/20373; EP-A3-0308936). It is contemplated that the antibodies can be prepared *in vitro* using known methods in synthetic protein

chemistry, including those involving crosslinking agents. For example, immunotoxins can be constructed using a disulfide exchange reaction or by forming a thioether bond. Examples of suitable reagents for this purpose include iminothiolate and methyl-4-mercaptobutyrimidate and those disclosed, for example, in U.S. Patent No. 4,676,980.

5

Effector Function Engineering

It can be desirable to modify the antibody of the invention with respect to effector function, so as to enhance, *e.g.*, the effectiveness of the antibody. For example, cysteine residue(s) can be introduced into the Fc region, thereby allowing
10 interchain disulfide bond formation in this region. The homodimeric antibody thus generated can have improved internalization capability and/or increased complement-mediated cell killing and antibody-dependent cellular cytotoxicity (ADCC) (see Caron *et al.* (1992) J Exp Med 176; 1191-1195 and Shopes (1992) J Immunol 148, 2918-2922). Homodimeric antibodies with enhanced anti-tumor activity can also be
15 prepared using heterobifunctional cross-linkers as described in Wolff *et al.* (1993) Cancer Res 53, 2560-2565. Alternatively, an antibody can be engineered that has dual Fc regions and can thereby have enhanced complement lysis and ADCC capabilities (see Stevenson *et al.* (1989) Anti-Cancer Drug Design 3, 219-230).

20 Immunoconjugates

The invention also pertains to immunoconjugates comprising an antibody conjugated to a cytotoxic agent such as a chemotherapeutic agent, toxin (*e.g.*, an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or fragments thereof), or a radioactive isotope (*e.g.*, a radioconjugate).

25

Enzymatically active toxins and fragments thereof that can be used include diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from *Pseudomonas aeruginosa*), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins, *Phytolacca americana* proteins
30 (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcumin, croton, saponaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and the tricothecenes. A variety of radionuclides are available for the production of radioconjugated antibodies. Examples include ^{212}Bi , ^{131}I , ^{131}In , ^{90}Y , and ^{186}Re .

Conjugates of the antibody and cytotoxic agent are made using a variety of bifunctional protein-coupling agents such as N-succinimidyl-3-(2-pyridyldithiol) propionate (SPDP), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as tolyene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). For example, a ricin immunotoxin can be prepared as described in Vitetta *et al.* (1987) Science 238, 1098-1104. Carbon-14-labeled 1-isothiocyanatobenzyl-3-methyldiethylene triaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugation of radionucleotide to the antibody (see WO-A-94/11026).

15

In another embodiment, the antibody can be conjugated to a "receptor" (such as streptavidin) for utilization in tumor pretargeting wherein the antibody-receptor conjugate is administered to the patient, followed by removal of unbound conjugate from the circulation using a clearing agent and then administration of a "ligand" (*e.g.*, avidin) that is in turn conjugated to a cytotoxic agent.

20

Vectors and Cells Expressing cytoplasmic dynein heavy chain1

Another aspect of the invention pertains to vectors, preferably expression vectors, containing a nucleic acid encoding a cytoplasmic dynein heavy chain1 protein or a mutein as described in individualized manner in connection with the preferred muteins of the invention above, or derivatives, fragments, analogs or homologs thereof. As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid", which refers to a circular double stranded circular DNA molecule into which additional DNA segments can be ligated. Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (*e.g.* bacterial vectors having a bacterial origin of replication and

25

30

episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively-linked.

5 Such vectors are referred to herein as "expression vectors".

A host cell of the invention, such as a prokaryotic or eukaryotic host cell in culture, can be used to produce (e.g., express) cytoplasmic dynein heavy chain1 protein or mutein as described in individualized manner in connection with the preferred muteins of the invention above. Accordingly, the invention further provides methods for producing cytoplasmic dynein heavy chain1 protein or mutein using the host cells of the invention. In one embodiment, the method comprises culturing the host cell of invention (into which a recombinant expression vector encoding cytoplasmic dynein heavy chain1 protein has been introduced) in a suitable medium such that cytoplasmic dynein heavy chain1 protein or mutein is produced. In another embodiment, the method further comprises isolating cytoplasmic dynein heavy chain1 protein or mutein from the medium or the host cell.

The host cells of the invention can also be used to produce non-human transgenic animals. For example, in one embodiment, a host cell of the invention is a fertilized oocyte or an embryonic stem cell into which cytoplasmic dynein heavy chain1 protein- or cytoplasmic dynein heavy chain1 mutein-coding sequences have been introduced. Such host cells can then be used to create non-human transgenic animals in which exogenous cytoplasmic dynein heavy chain1 sequences have been introduced into their genome or homologous recombinant animals in which endogenous cytoplasmic dynein heavy chain1 sequences have been altered. Such animals are useful for studying the function and/or activity of cytoplasmic dynein heavy chain1 protein and for identifying and/or evaluating modulators of cytoplasmic dynein heavy chain1 protein activity. As used herein, a "transgenic animal" is a non-human animal, preferably a mammal, more preferably a rodent such as a rat or mouse, which contains one or more cells bearing genetic information (a transgene), received, directly or indirectly, by deliberate genetic manipulation at the subcellular level, such as by microinjection or transfection with recombinant DNA, or infection with a recombinant virus. Other examples of transgenic animals include non-human

primates; ungulates such as cows, horses, goats, sheep; dogs, cats, and also chickens, amphibians, etc. Standard methods are known in the art that may be used in conjunction with the polynucleotides and of the invention and methods described herein to produce a transgenic animal expressing a modified cytoplasmic dynein heavy chain1 of the invention.

As used herein, a "transgene" is a foreign gene that has been artificially introduced into the genome of of an non human organism. A transgene present in germ cells is inherited by offspring. If such offspring in fact possesses the transgene, they too are transgenic animal.s

A transgene present only in somatic cells is nor passed on to the gametes.

As used herein, the term "transgenic" describes an organism whose genome incorporates and expresses genes from another species.

Animal Models

The present invention provides a non-human animal model which expresses a cytoplasmic dynein heavy chain1 protein modified as described herein, e.g. for the muteins described in individualized manner in connection with the preferred muteins above, as compared to the amino acid sequence of the wild type protein. The cytoplasmic dynein heavy chain1 expressed may have similarity in sequence and secondary structure to a vertebrate dynein heavy chain, including, but not limited to mammalian dynein heavy chain proteins, preferably of bovine, rat, and preferably mouse origin. The animal is preferably from a genus selected from the group consisting of *Mus* (e.g., mice), *Rattus* (e.g., rats), *Oryctologus* (e.g., rabbits) and *Mesocricetus* (e.g., hamsters). In a particularly preferred embodiment the animal is a mouse.

Animals carrying a mutated cytoplasmic dynein heavy chain1 allele expressing the modified cytoplasmic dynein heavy chain1 proteins of the invention, e.g. a mutein as described in individualized manner in connection with the preferred muteins above, exhibit a variety of phenotypical features including: myoclonic cramps (which are especially pronounced in the hindlimbs), movement hyperactivity, reduced muscle endurance, excitatory neuronal damage ("dark neurons") in the hippocampus (gyrus

dentatus, CA4, CA3) as well as in the upper layer of the cortex and in the Purkinje cell layer of the cerebellum.

5 Compared with heterozygous animals, homozygous individuals exhibit an elevated incidence of perinatal lethality (100% in homozygous animals, *versus* approximately 20% amongst heterozygous animals), accelerated neurondegeneration in the anterior horns of the spinal cord, and accelerated neurodegeneration in the dorsal root ganglia. Neurodegeneration in heterozygous animals is apparent at a much later stage, *i.e.* late adulthood.

10

The term "phenotype" according to the invention refers to a collection of morphological, physiological, behavioral and biochemical traits possessed by a cell or organism that results from the interaction of the genotype and the environment. Thus, the animal model of the present invention displays readily observable abnormalities.

15 In a preferred embodiment the animal of the invention shows at least 2, preferably at least 4, more preferably 6 and most preferably all of the above listed phenotypical features.

In the present invention, mice were generated carrying a point mutation in the thirteenth exon (exon 13) of the mouse cytoplasmic dynein heavy chain1 gene, which is illustrated in SEQ ID NO:1, thereby replacing the tyrosine residue at position 1055 in the N-terminal domain of the protein. This modification results in the above mentioned phenotypical features. Amino acid position 1055 according to the present invention refers to the non-mature cytoplasmic dynein heavy chain1 protein, as

20 numbered in SEQ ID NO:4. However, it will be appreciated by the person skilled in art that also the mature protein is encompassed by the present invention and may be expressed in the animal model of the present invention. A mature protein may result from a cleavage of several amino acids, and therefore may alter the numbering of the amino acids in the mature protein relative to the numbering of an unprocessed protein.

25 The tyrosine residue corresponding to the Tyr located at position 1055 in the amino acid sequence of SEQ ID NO:2 is conserved among the cytoplasmic dynein heavy chain proteins of different species as can be seen in the alignment in Table 9.

30

Table 9. Clustal W comparison of wild-type Dynein Heavy Chains

		1050	*	1060	1070	1080	1090	2000
	
5	gi 9717245 MOUSE	IVTEVEEQYVKVWLYQCCLWDMQAEINTYNRLGEDLNKWCALIVQIRKARGTFDPAETKKEF						
	SEQ ID NO:7							
	gi 729378 RAT	IVTEVEEQYVKVWLYQCCLWDMQAEINTYNRLGEDLSKWCALIVQIRKARGTFDPAETKKEF						
	SEQ ID NO:8							
	gi 7025519 HUMAN	IVSEVEEQYVKVWLYQCCLWDMQAEINTYNRLGEDLNKWCALIVQIRKARGTFDPAETKKEF						
10	SEQ ID NO:9							
	gi 17647333 DROSOPHILA	KVSEVRNYVDWELRYCSLWDLQADMLYGRIGEDVNLNIKCLNDIKQSEITFFDTSPTRRAN						
	SEQ ID NO:10							
	gi 987229 PARAMECIUM	ILEDMEQYVQTFNLNYCSLWELDIKQVEQILQDDIEKWCQMLTDIKQGEATFDNSTTEEF						
	SEQ ID NO:11							
15	gi 2494203 C.ELEGANS	IISDLIEEVLSEPLSYCSLWVLOAEQLFEMLGTSISKMMKTLMBELRGLVEDTQDTREVI						
	SEQ ID NO:12							

Thus, the non-human animal model of the present invention carries, e.g., a nucleic acid sequence encoding cytoplasmic dynein heavy chain1, whereby the codon for the amino acid at position 1055 of the amino acid sequence shown in SEQ ID NO:2 or the codon corresponding to said position in other dynein heavy chain proteins (especially cytoplasmic dynein heavy chain1 proteins), like position 1057 of the amino acid sequence shown in SEQ ID NO:18, which encodes a Tyr in the wild type, is mutated to encode a different amino acid. In a preferred embodiment, the animal model of the present invention expresses the amino acid sequence shown in SEQ ID NO:4.

In a preferred embodiment the animal model of the invention carries a modified cytoplasmic dynein heavy chain1 nucleic acid sequence derived from a vertebrate, preferably from a mammal, in particular from mouse, for example, a cytoplasmic dynein heavy chain1 nucleic acid sequence encoding a cytoplasmic dynein heavy chain1 mutein as described in individualized manner in connection with the preferred muteins of the invention above. In a particularly preferred embodiment the nucleic acid sequence is derived from the nucleic acid sequence of SEQ ID NO:1, 3, 5, or 17.

The animal model of the invention preferably expresses a modified cytoplasmic dynein heavy chain1 protein of the invention (e.g. as shown in SEQ ID

NO:4, or SEQ ID NO:6 or a mutein as described in individualized manner in connection with the preferred muteins above) in all of its cells, and particularly in the brain and spinal cord. However, animals which express the modified cytoplasmic dynein heavy chain1 protein in some, but not all cells, which are termed cellular
5 mosaic animals, are also contemplated.

The present invention further provides for inbred successive lines of animals carrying the mutant cytoplasmic dynein heavy chain1 nucleic acid of the present invention that offer the advantage of providing a virtually homogenous genetic
10 background. A genetically homogenous line of animals provides a functionally reproducible model system for disorders or symptoms associated with movement hyperactivity, hyperexcitability disorders (*e.g.* myoclonic cramping, epilepsy), excitotoxicity disorders and neurodegeneration; over-activity or undesirable activity of endogenous cytoplasmic dynein heavy chain1; over-expression, over-production or
15 undesirable production of endogenous cytoplasmic dynein heavy chain1; excessive or undesirable condition shown to be modulated by endogenous cytoplasmic dynein heavy chain1.

The animal model of the present invention may use any of the cytoplasmic
20 dynein heavy chain1 muteins described herein, *e.g.*, those described in an individualized manner in connection with the preferred muteins of the invention above, and is not limited to the modification of the residue at position 1055 of the amino acid sequence shown in SEQ ID NO:4 or at a corresponding position in other dynein heavy chain orthologs (*e.g.* position 1057 of the amino acid sequence shown in
25 SEQ ID NO:6) so long as the mutein used imparts the desired mutant dynein phenotype to the animal of the present invention. Suitable muteins include those with modifications in the amino acid sequence of the mouse or human cytoplasmic dynein heavy chain1 proteins so long as they impart a phenotype as described herein in connection with the animals of the invention. Such muteins may comprise mutations,
30 such as single or multiple further amino acid substitutions, deletions and insertions, particularly mutations that affect the conserved amino acids of mouse or human cytoplasmic dynein heavy chain1, as described, *e.g.*, in an individualized manner in connection with the preferred muteins of the invention above. Amino acid insertional derivatives of the present invention include amino and/or carboxyl terminal fusions as

well as intra-sequence insertions of single or multiple amino acids. Insertional amino acid sequence variants are those in which one or more amino acid residues are introduced into a predetermined site in the protein although random insertion is also possible with suitable screening of the resulting product. Deletional variants are characterized by the removal of one or more amino acids from the sequence. Substitutional amino acid variants are those in which at least one residue in the sequence has been removed and a different residue inserted in its place. Preferably, the cytoplasmic dynein heavy chain1 expressed in the animal model of the invention has a degree of identity preferably of at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or most preferably 99%, with the wild type cytoplasmic dynein heavy chain1 sequence from vertebrate, preferably from mammals, most preferably from bovine, and from rat and even most preferably from mouse (SEQ ID NO:2), excluding the wild type mouse cytoplasmic dynein heavy chain1 sequence itself. In another preferred embodiment, the cytoplasmic dynein heavy chain1 expressed in the animal model of the invention is human cytoplasmic dynein heavy chain1 (SEQ ID NO:18) or has a degree of identity preferably of at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or most preferably 99%, with the human cytoplasmic dynein heavy chain1 sequence in SEQ ID NO:18 (e.g. SEQ ID NO:6). The human wild type cytoplasmic dynein heavy chain1 sequence is a further embodiment of the invention.

20

In a particularly preferred embodiment the animal model expresses a polypeptide as shown in SEQ ID NO:4. Further preferred embodiments include the animal model of the invention, that expresses a polypeptide selected from those shown in SEQ ID NO:6 and SEQ ID NO:18. Preferred modifications of the cytoplasmic dynein heavy chain1 amino acid sequence in the animal models of the present invention, in addition to the modification at, e.g, position 1055 of the amino acid sequence shown in SEQ ID NO:4, (or in addition to the modification in the equivalent position 1057 of the amino acid sequence shown in SEQ ID NO:6) are at positions which are conserved among the vertebrate dynein heavy chain proteins (especially those conserved among vertebrate cytoplasmic dynein heavy chain1 proteins), as described in individualized manner in connection with the preferred muteins above.

25
30

Another preferred modification of the cytoplasmic dynein heavy chain1 amino acid sequence in the animal models of the present invention, in addition to the

modification at position 1055 of the amino acid sequence shown in SEQ ID NO:4, (or in addition to the modification in the equivalent position 1057 of the amino acid sequence shown in SEQ ID NO:6) are at positions which are not conserved among the vertebrate dynein heavy chain proteins (especially those not conserved among vertebrate cytoplasmic dynein heavy chain1 proteins), as described above.

It will be appreciated that the animal model of the invention may carry a mutated cytoplasmic dynein heavy chain1 nucleic acid according to the present invention derived from the same species or from a different species. Preferably, the mutated cytoplasmic dynein heavy chain1 nucleic acid of the present invention is homozygous in the animals of the present invention. Preferably, transcription of the mutated cytoplasmic dynein heavy chain1 gene of the present invention is under the control of the promoter sequence controlling transcription of the endogenous wild type cytoplasmic dynein heavy chain1 sequence of the animal, although a different promoter may be used.

The animals of the invention can be produced by using any technique known to the person skilled in the art; including but not limited to micro-injection, electroporation, cell gun, cell fusion, micro-injection into embryos of teratocarcinoma stem cells or functionally equivalent embryonic stem cells. The animals of the present invention may be produced by the application of procedures which result in an animal with a genome that incorporates and/or integrates exogenous genetic material in such a manner as to modify or disrupt the function of the normal cytoplasmic dynein heavy chain1 gene or protein. The preferred procedure for generating animal models of this invention as described in Example 1.

Alternatively, the procedure may involve obtaining genetic material, or a portion thereof, which encodes a cytoplasmic dynein heavy chain1. The isolated native sequence is then genetically manipulated by the insertion of a mutation appropriate to replace the residue at position 1055 of the amino acid sequence shown in SEQ ID NO:2. The manipulated construct may then be inserted into embryonic stem cells, e.g. by electroporation. The cells subjected to said procedure are screened to find positive cells, e.g. cells which have integrated into their genome the desired construct encoding an altered cytoplasmic dynein heavy chain1. The positive cells

may be isolated, cloned (or expanded) and injected into blastocysts obtained from a host animal of the same species or a different species. For example, positive cells are injected into blastocysts from mice, the blastocysts are then transferred into a female host animal and allowed to grow to term, following which the offspring of the female
5 are tested to determine which animals are transgenic, *e.g.* which animals have an inserted exogenous mutated DNA sequence. One method involves the introduction of the recombinant gene at the fertilized oocyte stage ensuring that the gene sequence will be present in all of the germ cells and somatic cells of the "founder" animal. The term "founder animal" as used herein means the animal into which the recombinant
10 gene was introduced at the one cell embryo stage.

The animals of the invention can also be used as a source of primary cells from a variety of tissues, for cell culture experiment, including but not restricted to, the production of immortalized cell lines by any methods known in the art, such as
15 retroviral transformation. Cells from the animals may advantageously exhibit desirable properties of both normal and transformed cultured cells, *e.g.* they will be normal or nearly normal morphologically and physiologically, but can be cultured for long, and perhaps indefinite periods of time. The present invention provides such primary cells and cell lines derived therefrom, obtained from the animals of the
20 present invention. These primary cells or cell lines derived thereof may be used for the construction of an animal model of the present invention.

In other embodiments cell lines may be prepared by the insertion of a nucleic acid construct comprising the nucleic acid sequence of the invention or a fragment
25 thereof comprising the codon imparting the above-described phenotype to the animal model of the invention (*vide infra*). Suitable cells for the insertion include primary cells harvested from an animal as well as cells which are members of an immortalized cell line. Recombinant nucleic acid constructs of the invention, described below, may be introduced into the cells by any method known in the art, including but not limited
30 to, transfection, retroviral infection, micro-injection, electroporation, transduction or DEAE-dextran. Cells which express the recombinant construct may be identified by, for example, using a second recombinant nucleic acid construct comprising a reporter gene which is used to produce selective expression. Cells that express the nucleic

acid sequence of the invention or a fragment thereof may be identified indirectly by the detection of reporter gene expression.

Pharmaceutical Compositions

5 The invention also includes pharmaceutical compositions containing mutein nucleic acids or proteins of the invention, e.g. those muteins as described in individualized manner in connection with the preferred muteins of the invention above, as well as pharmaceutical compositions containing antibodies to them. The compositions are preferably suitable for internal use and include an effective amount
10 of a pharmacologically active compound of the invention, alone or in combination, with one or more pharmaceutically acceptable carriers. The compounds are especially useful in that they have very low, if any toxicity.

 The mutated nucleic acid sequences and muteins of this invention, and
15 antibodies thereto, may be used in pharmaceutical compositions, when combined with a pharmaceutically acceptable carrier. As used herein, "pharmaceutically acceptable carrier" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. Suitable carriers are described
20 in the most recent edition of *Remington's Pharmaceutical Sciences* (e.g. currently the 18th edition), Alfonso R. Gennaro, ed. (Mack Publishing Co., Easton PA, USA, 1990), a standard reference text in the field, which is incorporated herein by reference. Preferred examples of such carriers or diluents include, but are not limited to, water, saline, finger's solutions, dextrose solution, and 5% human serum albumin.
25 Liposomes and non-aqueous vehicles such as fixed oils may also be used. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.

30

 A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g. intravenous, intradermal, subcutaneous, oral (e.g. inhalation), transdermal (e.g. topical), transmucosal, and rectal administration. Solutions or

suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; 5 antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid (EDTA); buffers such as acetates, citrates or phosphates, and agents for the adjustment of tonicity such as sodium chloride or dextrose. The pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, 10 disposable syringes or multiple dose vials made of glass or plastic.

Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For 15 intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, NJ, U.S.A.) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringeability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the 20 contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the 25 case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition. Prolonged 30 absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

For instance, for oral administration in the form of a tablet or capsule (e.g. a gelatin capsule), the active drug component can be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like. Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents and coloring agents can also be incorporated into the mixture. Suitable binders include starch, magnesium aluminum silicate, starch paste, gelatin, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, polyethylene glycol, waxes and the like. Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, silica, talcum, stearic acid, its magnesium or calcium salt and/or polyethyleneglycol and the like. Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum starches, agar, alginic acid or its sodium salt, or effervescent mixtures, and the like. Examples of diluents include, without limitation, lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycine.

Injectable compositions are preferably aqueous isotonic solutions or suspensions, and suppositories are advantageously prepared from fatty emulsions or suspensions. The compositions may be sterilized and/or contain adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or buffers. In addition, they may also contain other therapeutically valuable substances. The compositions are prepared according to conventional mixing, granulating or coating methods, respectively, and contain about 0.1 to 75%, preferably about 1 to 50%, of the active ingredient.

The compounds of the invention can also be administered in such oral dosage forms as timed release and sustained release tablets or capsules, pills, powders, granules, elixers, tinctures, suspensions, syrups and emulsions.

30

Liquid, particularly injectable compositions can, for example, be prepared by dissolving, dispersing, *etc.* The active compound is dissolved in or mixed with a pharmaceutically pure solvent such as, for example, water, saline, aqueous dextrose, glycerol, ethanol, and the like, to thereby form the injectable solution or suspension.

Additionally, solid forms suitable for dissolving in liquid prior to injection can be formulated. Injectable compositions are preferably aqueous isotonic solutions or suspensions. The compositions may be sterilized and/or contain adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or buffers. In addition, they may also contain other therapeutically valuable substances.

The compounds of the present invention can be administered in intravenous (both bolus and infusion), intraperitoneal, subcutaneous or intramuscular form, all using forms well known to those of ordinary skill in the pharmaceutical arts. Injectables can be prepared in conventional forms, either as liquid solutions or suspensions.

Parental injectable administration is generally used for subcutaneous, intramuscular or intravenous injections and infusions. Additionally, one approach for parenteral administration employs the implantation of a slow-release or sustained-released systems, which assures that a constant level of dosage is maintained, according to U.S. Pat. No. 3,710,795, incorporated herein by reference.

Furthermore, preferred compounds for the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in that art. To be administered in the form of a transdermal delivery system, the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen. Other preferred topical preparations include creams, ointments, lotions, aerosol sprays and gels, wherein the concentration of active ingredient would range from 0.1% to 15%, w/w or w/v.

For solid compositions, excipients include pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium carbonate, and the like may be used. The active compound defined above, may be also formulated as suppositories using for example, polyalkylene glycols, for example, propylene glycol, as the carrier. In some

embodiments, suppositories are advantageously prepared from fatty emulsions or suspensions.

5 The compounds of the present invention can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, containing cholesterol, stearylamine or phosphatidylcholines. In some embodiments, a film of lipid components is hydrated with an aqueous solution of drug to a form lipid layer encapsulating the drug, as described in U.S. Pat. No. 5,262,564.

10

Compounds of the present invention may also be delivered by the use of monoclonal antibodies as individual carriers to which the compound molecules are coupled. The compounds of the present invention may also be coupled with soluble polymers as targetable drug carriers. Such polymers can include
15 polyvinylpyrrolidone, pyran copolymer, polyhydroxypropyl-methacrylamide-phenol, polyhydroxyethylaspanamidephenol, or polyethyleneoxidepolylysine substituted with palmitoyl residues. Furthermore, the compounds of the present invention may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyepsilon caprolactone, polyhydroxy butyric
20 acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross-linked or amphipathic block copolymers of hydrogels.

If desired, the pharmaceutical composition to be administered may also contain minor amounts of non-toxic auxiliary substances such as wetting or emulsifying
25 agents, pH buffering agents, and other substances such as for example, sodium acetate, triethanolamine oleate, *etc.*

The dosage regimen utilizing the compounds is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of
30 the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular compound or salt thereof employed. An ordinarily skilled physician or veterinarian can readily determine and prescribe the effective amount of the drug required to prevent, counter or arrest the progress of the condition.

Oral dosages of the present invention, when used for the indicated effects, will range between about 0.05 to 1000 mg/day orally. The compositions are preferably provided in the form of scored tablets containing 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100.0, 250.0, 500.0 and 1000.0 mg of active ingredient. Effective plasma levels of the compounds of the present invention range from 0.002 mg to 50 mg per kg of body weight per day.

Compounds of the present invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three or four times daily.

Any of the above pharmaceutical compositions may contain 0.1-99%, preferably 1-70% of the cytoplasmic dynein heavy chain1 polypeptide.

15

If desired, the pharmaceutical compositions can be provided with an adjuvant. Adjuvants are discussed above. In some embodiments, adjuvants can be used to increase the immunological response, depending on the host species, include Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and *Corynebacterium parvum*. Generally, animals are injected with antigen using several injections in a series, preferably including at least three booster injections.

25

Assays and Diagnostics

The animals of the present invention present a phenotype whose characteristics are representative of many symptoms associated with disorders associated with dynein heavy chain deficiency (especially cytoplasmic dynein heavy chain1 deficiency), therefore making the animal model of the present invention a particularly suitable model for the study of these diseases including movement hyperactivity, hyperexcitability disorders (e.g. myoclonic cramping, epilepsy), excitotoxicity disorders and neurodegeneration; over-activity or undesirable activity of endogenous

30

cytoplasmic dynein heavy chain1; over-expression, over-production or undesirable production of endogenous cytoplasmic dynein heavy chain1; excessive or undesirable condition shown to be modulated by endogenous cytoplasmic dynein heavy chain1. In particular the animal model of the invention presents a phenotype
5 characterized by cramping, movement hyperactivity; excitatory neuronal damage in the CA3 and CA4 sector of the hippocampus, as well as in the upper layer of the cortex and in the Purkinje cell layer of the cerebellum and neurodegeneration. These are all phenotypical characteristics of human diseases related to hyperexcitability and neurodegeneration, such as epilepsy, Alzheimer's disease, Huntington's disease, and
10 Parkinson's disease. Therefore, the animals of the invention can be used to study diseases or symptoms associated with movement hyperactivity and impairment, hyperexcitability disorders (e.g. myoclonic cramping, epilepsy), excitotoxicity disorders, cognitive disorders and neurodegeneration in general.

15 The animals of the present invention can also be used to identify early diagnostic markers for diseases associated with cytoplasmic dynein heavy chain1 deficiency. Surrogate markers, including but not limited to ribonucleic acids or proteins, can be identified by performing procedures of proteomics or gene expression analysis known in the art. For example procedures of proteomics analysis include, but
20 are not restricted to, ELISA, 2D-gel, protein microarrays or mass spectrophotometric analysis of any organ or tissue samples, such as blood samples, or derivatives thereof, preferably plasma, at different age or stage of cytoplasmic dynein heavy chain1 activity deficiency associated disease development, or symptom thereof. As a further example, gene expression analysis procedures include, but are not restricted to,
25 differential display, cDNA microarrays, analysis of quality and quantity of ribonucleic acids species from any organ or tissue samples, such as blood samples, or derivatives thereof, at different age or stage of development of cytoplasmic dynein heavy chain1 activity deficiency associated disease, or symptom thereof.

30 The animal model of the present invention can be used to monitor the activity of agents useful in the prevention or treatment of the above-mentioned diseases and disorders. The agent to be tested can be administered to an animal of the present invention and various phenotypic parameters can be measured or monitored. In a further embodiment the animals of the invention may be used to test therapeutics

against any disorders or symptoms that have been shown to be associated with cytoplasmic dynein heavy chain1 deficiency or overexpression.

The animals of the present invention can also be used as test model systems for materials, including but not restricted to chemicals and peptides, particularly medical drugs, suspected of promoting or aggravating the above-described diseases associated with cytoplasmic dynein heavy chain1 deficiency. For example, the material can be tested by exposing the animal of the present invention to different time, doses and/or combinations of such materials and by monitoring the effects on the phenotype of the animal of the present invention, including but not restricted to movement activity; latency to fall in a hanging wire assay, motor coordination test assays, such as rotarod, stationary beam and coat hanger motor performance, excitatory neuronal damage in the hippocampus (CA3, CA4 and gyrus dentatus) and in the pyramidal area of the cortex, histopathological and biochemical parameters of motor neuron degeneration and spinal muscular atrophy, as well as tracer experiments to determine the functionality of the retrograd axonal transport.

Furthermore, the animals of the present invention may be used for the dissection of the molecular mechanisms of the cytoplasmic dynein heavy chain1 pathway, that is for the identification of downstream genes or proteins thereof regulated by cytoplasmic dynein heavy chain1 activity and deregulated in cytoplasmic dynein heavy chain1 activity deficiency associated disorders. For example, this can be done by performing differential proteomics analysis, using techniques including but not restricted to 2D gel analysis, protein chip microarrays or mass spectrophotometry, on tissues of the animal of the present invention which express cytoplasmic dynein heavy chain1 and which respond to cytoplasmic dynein heavy chain1 stimuli.

The animal model of the present invention can be used to identify and clone so-called modifier genes which are able to modify, aggravate, reduce or inhibit the phenotype associated with a cytoplasmic dynein heavy chain1 activity deficiency. Particularly, for this purpose, the animal model of the present invention can be mated to mice of different strains carrying a different genetic background, which gives the possibility to map the genes modifying the phenotype. For example, the animal model

of the present invention, when produced in an C3HeB/FeJ inbred strain background can be bred to C57B1/6Jico inbred mice. The hybrid animals of this progeny, are then further bred, either in back-cross strategy with C57B1/6Jico inbred mice again, or in an intercross strategy between each other. The modifier gene can be then mapped and
5 cloned by using microsattelites or a single nucleotide polymorphism (SNP) strategy on the mice resulting from the backcross or intercross breeding that have been grouped with respect to their phenotype intensity.

An exemplary method for detecting the presence or absence of cytoplasmic
10 dynein heavy chain1 in a biological sample, e.g. a mutein of the present invention, e.g., those described in individualized manner in connection with the preferred muteins of the invention above, involves obtaining a biological sample from a test subject and contacting the biological sample with a compound or an agent capable of detecting cytoplasmic dynein heavy chain1 protein, mutein, or nucleic acid (e.g.
15 mRNA, genomic DNA) that encodes cytoplasmic dynein heavy chain1 protein or mutein such that the presence of cytoplasmic dynein heavy chain1 is detected in the biological sample. An agent for detecting cytoplasmic dynein heavy chain1 mRNA or genomic DNA is a labeled nucleic acid probe capable of hybridizing to cytoplasmic dynein heavy chain1 mRNA or genomic DNA.

20

The diagnostic methods described herein can furthermore be utilized to identify subjects having or at risk of developing a disease or disorder associated with aberrant cytoplasmic dynein heavy chain1 expression or activity. For example, the assays described herein, such as the preceding diagnostic assays or the following
25 assays, can be utilized to identify a subject having or at risk of developing a disorder associated with cytoplasmic dynein heavy chain1 protein, nucleic acid expression or activity. Alternatively, the prognostic assays can be utilized to identify a subject having or at risk for developing a disease or disorder. Thus, the invention provides a method for identifying a disease or disorder associated with aberrant cytoplasmic
30 dynein heavy chain1 expression or activity in which a test sample is obtained from a subject and cytoplasmic dynein heavy chain1 protein or nucleic acid (e.g. mRNA, genomic DNA) is detected, wherein the presence of cytoplasmic dynein heavy chain1 protein or nucleic acid is diagnostic for a subject having or at risk of developing a disease or disorder associated with aberrant cytoplasmic dynein heavy chain1

expression or activity. As used herein, a "test sample" refers to a biological sample obtained from a subject of interest. For example, a test sample can be a biological fluid (e.g., blood, plasma, serum), cell sample, or tissue.

5 Furthermore, the prognostic assays described herein can be used to determine whether a subject can be administered an agent (*e.g.* an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate) to treat a disease or disorder associated with aberrant cytoplasmic dynein heavy chain1 expression or activity. For example, such methods can be used to
10 determine whether a subject can be effectively treated with an agent for a disorder.

 Agents, or modulators that have a stimulatory or inhibitory effect on cytoplasmic dynein heavy chain1 activity (*e.g.* cytoplasmic dynein heavy chain1 gene expression), as identified by a screening assay described herein can be administered to
15 individuals to treat (prophylactically or therapeutically) cytoplasmic dynein heavy chain1-mediated disorders. Differences in metabolism of therapeutics can lead to severe toxicity or therapeutic failure by altering the relation between dose and blood concentration of the pharmacologically active drug. Thus, the pharmacogenomics of the individual permits the selection of effective agents (*e.g.* drugs) for prophylactic or
20 therapeutic treatments based on a consideration of the individual's genotype. Such pharmacogenomics can further be used to determine appropriate dosages and therapeutic regimens. Accordingly, the activity of cytoplasmic dynein heavy chain1 protein, expression of cytoplasmic dynein heavy chain1 nucleic acid, or mutation content of cytoplasmic dynein heavy chain1 genes in an individual can be determined
25 to thereby select one or more appropriate agents for therapeutic or prophylactic treatment of the individual.

 The present invention also provides a diagnostic method for cytoplasmic dynein heavy chain1 activity deficiency. Patients' peptide material, particularly that in or from blood, serum or plasma, is subjected to analysis for one or more of the
30 amino acid sequences of the present invention. The peptide material may be analyzed directly or after extraction, isolation and/or purification by standard methods.

 In one embodiment of the invention, the diagnostic method comprises the identification of the modified cytoplasmic dynein heavy chain1, *e.g.*, modified as

described in individualized manner in connection with the preferred muteins of the invention above, whereby the modification is, e.g., associated with the replacement of an amino acid at a position corresponding to position 1055 in the amino acid sequence shown in SEQ ID NO:2. In another embodiment of the invention, the diagnostic method comprises the identification of the modified cytoplasmic dynein heavy chain1, e.g., the mutein as described in individualized manner in connection with the preferred muteins of the invention above, whereby the modification is, e.g., associated with the replacement of an amino acid at a position corresponding to position 1057 in the amino acid sequence shown in SEQ ID NO:18. In yet another embodiment of the invention, the diagnostic method comprises the identification of the modified cytoplasmic dynein heavy chain1, e.g., modified as described in individualized manner in connection with the preferred muteins of the invention above, wherein the modification is, e.g., associated with the replacement of an amino acid at a position that is conserved between the vertebrate cytoplasmic dynein heavy chain1 proteins. Such diagnostic methods include those employing detection of the modified cytoplasmic dynein heavy chain1 by its failure to activate a biological pathway. The diagnostic methods of the invention also include those employing detection of the modified cytoplasmic dynein heavy chain1 by its activity in competing with and blocking the action of native dynein heavy chain. Methods of identifying the modified cytoplasmic dynein heavy chain1 include any methods known in the art which are able to identify altered conformational properties of the amino acid sequence of the present invention compared to those of the wild type cytoplasmic dynein heavy chain1. These include, without limitation, the specific recognition of the modified protein by other proteins, particularly antibodies; individual or combined patterns of amino acid sequence digestion by known proteases or chemicals. In an additional, similar embodiment, the method exploits the failure of another protein to recognize the modified protein, examples being antibodies directed to an epitope of wild type cytoplasmic dynein heavy chain1 that incorporates residue 1055 of SEQ ID NO:2, or SEQ ID NO:18, and cytoplasmic dynein heavy chain1 receptors in which this portion of the molecular surface of wild type cytoplasmic dynein heavy chain1 is recognized or involved in cytoplasmic dynein heavy chain1 activation.

In a further embodiment of the present invention, the principle of the diagnostic method is the detection of a nucleic acid sequence encoding the modified

cytoplasmic dynein heavy chain1 of the invention. This includes, but is not restricted to any methods known in the art using nucleic acid hybridizing properties, such as Northern blot, Southern blot, nucleic acid (genomic DNA, cDNA, mRNA, synthetic oligonucleotides) standard methods employing microarrays, and patterns of nucleic acid digestion by known restriction enzymes.

Subunits of the Dynactin/Dynein Complex

As explained above, the present invention is not only concerned with the identification of neurodegenerative disease relevant mutations in the dynein heavy chain 1 gene, but is also based on the recognition that other components (hereinafter also referred to as "subunits") of the dynactin/dynein complex may likewise be subject to mutations that are involved in, or affect, the pathogenesis of such diseases.

When reference is made in the present specification to subunits of the dynactin/dynein complex, these subunits include in particular the cytoplasmic dynein heavy chain 1, cytoplasmic dynein intermediate chain 1, cytoplasmic dynein intermediate chain 2, cytoplasmic dynein light intermediate chain 1, cytoplasmic dynein light intermediate chain 2; cytoplasmic dynein 10 kDa light chain, cytoplasmic dynein light chain Tctex 1, cytoplasmic dynein light chain 2B, DCTN 1, DCTN 2, DCTN 3, DCTN 4, DCTN 5, DCTN 6, ARP1, ARP11, HAP1, and CLIP-170, preferably encoded by the genomic nucleic acid sequences identified in Table 25, or defined by the amino acid sequences identified in Tables 26, 27, and 29-35.

Table 25. Subunits of the Dynein Complex and their genomic sequences assigned as NCBI contig Accession Numbers (Gen Bank Acc. No., except where otherwise indicated) (NCBI contigs are derived from genomic sequence data assembled by NCBI staff)

Name of the Subunit	Gen Bank Accession Number	SEQ ID NO.:
Cytoplasmic dynein heavy chain 1	Mm NW_000055	28

Cytoplasmic dynein heavy chain 1	Hs AL118558	29
Cytoplasmic dynein intermediate chain 1	Mm NW_000272	30
Cytoplasmic dynein intermediate chain 1	Hs NT_023947	31
Cytoplasmic dynein intermediate chain 2	Mm NW_000176	32
Cytoplasmic dynein intermediate chain 2	Hs NT_005332.11	33
Cytoplasmic dynein light intermediate chain 1	Mm AC115796.2	34
Cytoplasmic dynein light intermediate chain 1	Hs NT_034532.2	35
Cytoplasmic dynein light intermediate chain 2	Mm AC118211.3	36
Cytoplasmic dynein light intermediate chain 2	Hs NT_010478.11	37
Cytoplasmic dynein 10kDa light chain	Mm NW_000236	38
Cytoplasmic dynein 10kDa light chain	Hs NT_009775	39
Cytoplasmic dynein light chain Tctex 1	Mm NW_000269	40
Cytoplasmic dynein light chain Tctex 1	Hs NT_007422	41
Cytoplasmic dynein light chain 2B	Hs NT_024797	42
DCTN 1	Mm NT_003134	43
DCTN 1	Hs NT_022184	44
DCTN 2	Mm MGI107733*	159

DCTN 2	Hs	NT_009509	45
DCTN 3	Mm	NW_000206	46
DCTN 3	Hs	NT_023974	47
DCTN 4	Mm	NW_000134	48
DCTN 4	Hs	NT_034779	49
DCTN 5	Mm	NT_036652	50
DCTN 6	Mm	NW_000340	51
DCTN 6	Hs	NT_007995	52
ARP1	Mm	NW_000148	53
ARP1	Hs	AL121928	54
ARP11	Mm	NW_000053	55
ARP11	Hs	AC005586	56
HAP1	Mm	NT_033680	57
HAP1	Hs	NT_010840	58
CLIP-170	Mm	NW_000236	59
CLIP-170	Hs	NT_009438	60

* Mouse Genome Informatics Tool of the Jackson Laboratory Accession No.

Table 26. Cytoplasmic dynein intermediate chain1 amino acid sequence (SEQ ID NO.: 61)

5

Gen Bank Accession No.: NP_034193.1(mouse)

MSDKSDLKAELEKQRLAQIREKKRKEEERKKKEADMQQKKEPVQDDSDLDRKRRETEALLQSIGIS
 PEPPLVPTMPSPSSKSVSTPSDAGSQDSGLGLTRTLQWDTPSVLQLQSDSELGRRHLKLGVSQVTQ
 10 VDFLPREVVSYSKETQTPLATHQSEDEEDEEMVEPKIGHDSELENQEKQETKEAPPRELTEEEKQOI
 LHSEEFLLIFFDRTIRVIERALAEEDSDIFFDYSGRELEEKDGDVQAGANLSFNRFYDEHWSKHRVVTCM
 DWSLQYPELMVASYSNNEDAPHEPDGVALVWNMFKKTTPEYVFHCQSSVMSVCFARFHPNLVVGGTYS
 GQIVLWDNRSHRRTPVQRTPLSAAATHPVYCVNVVGTHNARNLITVSTDGKMCSWSLDMSTPQESME
 LVYNKSKPVAVTGMAFPTGDVNNFVVGSEEGTVYTACRHGSKAGIGEVFEGHQGPVTGINCHMAVGPID
 15 FSHLEVTSSFDWTVKLWTTKHNPVYSSDNADYVDVMWSPVHPALFACVDGMGRDLWNLNSDTEVP
 TASVAIEGASALNRVRWAQGGKEVAVGDSEGRIFIYDVGELAVPHNDEWTRFARTLVEIRANRADSEEE
 GAVELAA

Table 27. Cytoplasmic dynein intermediate chain1 amino acid sequence (SEQ ID NO.: 62)

20

Gen Bank Accession No.: NP_004402.1(human)

MSDKSDLKAELEKQRLAQIREKKRKEEERKKKEADMQQKKEPVQDDSDLDRKRRETEALLQSIGIS
 PEPPLVQPLHFLTWDTCYFHYLVPTPMSPSSKSVSTPSEAGSQDSDLGPLTRTLQWDTDPSVLQLQSD
 SELGRRLHKLGVSKVTQVDFLPREVVSYSKETQTPLATHQSEDEEDEEMVESKVGQDSELENQDKKQE
 5 VKEAPPRELTEEEKQQILHSEEFLLIFFDRTIRVIERALAEEDSDIFFDYSGRELEEKDGDVQAGANLSFN
 RQFYDEHWSKHRVVT CMDWSLQYPELMVASYNNEADAPHEPDGVALVWNMKFKKTTPEYVFHCQSSVMS
 VCFARFHPNLVVG GTYSGQIVLWDNRSHRTPVQRTPLSAAAHTHPVYCVNVVGTQNAHNLTIVSTDGK
 MCSWLDMLSTPQESMELVYNKSKPVAVTGMAFPTGDVNNFVVGSEEGTVYTACRHGSKAGIGEVFEGH
 QGPVTGINCHMAVGPIDFSHLFTVTSFSDWTVKLWTTKHNKPLYSFEDNADYVYDVMWSPVHPALFACVD
 10 GMGRDLWNLNNDTEVPTASVAIEGASALNRVRWAQAGKEVAVGDSEGRIVVYDVGELAVPHNDEWTRF
 ARTLVEIRANRADSEEEGTVELSA

Table 29. Cytoplasmic dynein intermediate chain1 amino acid sequence (SEQ ID NO.: 63)

15

Gen Bank Accession No.: NP_062107.1(rat)

MSDKSDLKAELEKQRLAQIREKKRKEEERKKKEADMQQKKEPVQDDSDLDRKRRETEALLQSIGIS
 PEPPLVQPLHFLTWDTCYFHYLVPTPMSPSSKSVSTPSEAGSQDDLGLPLTRTLQWDTDPSVLQLQSDSE
 20 LGRRNLKLGVS KVTQVDFLPREVVSYSKETQTPLATHQSEDEEDEEMVEPKVGHDSLENQDKKQETK
 EAPPRELTEEEKQQILHSEEFLLIFFDRTIRVIERALAEEDSDIFFDYSGRELEEKDGDVQAGANLSFN
 FYDEHWSKHRVVT CMDWSLQYPELMVASYNNEADAPHEPDGVALVWNMKFKKTTPEYVFHCQSSVMSVC
 FARFHPNLVVG GTYSGQIVLWDNRSHRTPVQRTPLSAAAHTHPVYCVNVVGTQNAHNLTIVSTDGKMC
 SWSLDMLSTPQESMELVYNKSKPVAVTGMAFPTGDVNNFVVGSEEGTVYTACRHGSKAGIGEVFEGHQG
 25 PVTGINCHMAVGPIDFSHLFTVTSFSDWTVKLWTTKHNKPLYSFEDNADYVYDVMWSPVHPALFACVDGM
 GRDLWNLNNDTEVPTASVAIEGAYALNRVRWAQGGKEVAVGDSEGRIVIYDVGELAVPHNDEWTRFAR
 TLVEIRANRADSEEEGAVELAA

Table 30. Cytoplasmic dynein intermediate chain 2 amino acid sequence (SEQ ID NO.: 64)

30

Gen Bank Accession No.: NP_034194.1(mouse)

MSDKSDLKAELEKQRLAQIREKKRKEEERKKKETDQKKEAAVSVQEEEDLEKKRREAEALLQSMGL
 35 TTDSPIVPPPMSPSSKSVSTPSEAGSQDSDGAVGSRGPIKLGMAKITQVDFPPREIVTYTKETQTPV
 TAQPKEDDEEEDDVATPKPPVEPEEEKTLKKDEENDSKAPPHELTEEEKQQILHSEEFLLFFDHSTRIV
 ERALSEQINIFFDYSGRDLEDKEGEIQAGAKLSLNQFFDERWSKHRVVSCLDWSSQYPELLVASYNNE
 EEAPHEPDGVALVWNMKYKKTTPPEYVFHCQSAVMSATFAKFHPNLVVG GTYSGQIVLWDNRNKRTPVQ
 RTPLSAAAHTHPVYCVNVVGTQNAHNLTIVSTDGKICSWSLDMLSHPDQSMELVHKQSKAVAVTSMSFP
 40 VGDVNNFVVGSEEGSVYTACRHGSKAGISEMFEGHQGPITGIHCHAAVAVDFSHLFTVTSFSDWTVKLW

TTKNNKPLYSFEDNSDYVDVMWSPTHPALFACVDGMGRDLWNLNNDTEVPTASISVEGNPALNRVRW
THSGREIAVG DSEGQIV IYDVGEQIAVPRNDEWARFGRTLAEINANRADAEEEEAATRI PA

Table 31. Cytoplasmic dynein intermediate chain 2 amino acid sequence (SEQ ID NO.: 65)

Gen Bank Accession No.: NP_001369.1(human)

MSDKSELKAELEKQRLAQIREKKRKEEERKKKETDQKKEAVAPVQESDLEKKRREAEALLQSMGL
TPESPIVFSEYWVPPMSPSSKSVSTPSEAGSQDSGDGAVGSRTLHWDTPSVLQLHSDSDLGRGPIKL
GMAKITQVDFPPREIVTYTKETQTPVMAQPKEDDEEDDDVAPKPPIEPEEEKTLKKDEENDSKAPPHE
LTEEEKQQILHSEEFSLFFDHSTRIVERALSEQINIFFDYSGRDLEDKEGEIQAGAKLSLNRQFFDERW
SKHRVVSCLDWSSQYPELLVASYNNEEDAPHEPDGVALVWNMKYKKTTPYVVFHCQSAVMSATFAKFHP
NLVVG GTYSGQIVLWDNRSNK RTPVQRTPLSAAAH THPVYCVNVVGTQNAHNLISISTDGKICSWSLDM
LSHPQDSMELVHKQSKAVAVTSMSFPVGDVNNFVVGSEEGSVYTACRHGSKAGISEMFEGHQGPITGIH
CHAAVGAVDFSHLFTSSFDWTVKLWTTKNNKPLYSFEDNADYVDVMWSPTHPALFACVDGMGRDLW
NLNNDTEVPTASISVEGNPALNRVRWTHSGREIAVG DSEGQIV IYDVGEQIAVPRNDEWARFGRTLAEI
NANRADAEEEEAATRI PA

Table 32. Cytoplasmic dynein intermediate chain 2 amino acid sequence (SEQ ID NO.: 66)

Gen Bank Accession No.: NP_446332.1(rat)

MSDKSELKAELEKQRLAQIREKKRKEEERKKKETDQKKEAAVSVQESDLEKKRREAEALLQSMGL
TTDSPIVFSEHWVPPMSPSSKSVSTPSEAGSQDSGDGAVGSRTLHWDTPSALQLHSDSDLGRGPIKL
GMAKITQVDFPPREIVTYTKETQTPVTAQPKEDDEEDDDVAAPKPPVEPEEEKILKKDEENDSKAPPHE
LTEEEKQQILHSEEFSLFFDHSTRIVERALSEQINIFFDYSGRDLEDKEGEIQAGAKLSLNRQFFDERW
SKHRVVSCLDWSSQYPELLVASYNNEEAPHEPDGVALVWNMKYKKTTPYVVFHCQSAVMSATFAKFHP
NLVVG GTYSGQIVLWDNRSNK RTPVQRTPLSAAAH THPVYCVNVVGTQNAHNLISISTDGKICSWSLDM
LSHPQDSMELVHKQSKAVAVTSMSFPVGDVNNFVVGSEEGSVYTACRHGSKAGISEMFEGHQGPITGIH
CHAAVGAVDFSHLFTSSFDWTVKLWSTKNNKPLYSFEDNSDYVDVIGSPTHPALFACVDGMGRDLW
NLNNDTEVPTASISVEGNPALNRVRWTHSGREIAVG DSEGQIV IYDVGEQIAVPRNDEWARFGRTLAEI
NASRADAEEEEAATRI PA

35

Table 33. DCTN1; Dynactin subunit p150 amino acid sequence (SEQ ID NO.: 67)

Gen Bank Accession No.: NP_031861.1 p150 (mouse)

MAQSRHRMSSRTPSGSRMSTEASARPLRVGSRVEVIGKGRGTVAIVGATLFATGKWVGVLDEAKGKN
 DGTVOGRKYFTCDEGHGIFVRQSQIQVFEDGADTTSPETPDSSASKVLKREGADAAAKTSKLRGLKPKK
 APTARKTTTTRPKPTRPASTGVAGPSSSLGPSGSASAGELSSSEPSTPAQTPLAAPIIPTPALTSFGAA
 PPLSPSPKEEEGLRAQVRDLEEKLETLRLKRSEDKAKLKELEKHKIQLEQVQEWKSKMQEQQADLQRRRL
 5 KEARKEAKEALEAKERYMEEMADTADAIEMATLDKEMAEERAESLQQEVEALKERVDELTTDLEILKAE
 IEEKSGDGAASSYQLKQLEEQNARLKDALVRMRDLSSSEKQEHVKLQKLMEKKNQELEVVRRQQRERLQE
 ELSQAESTIDELKEQVDAALGAEEMVEMLTDRNLNLEEKVRELRETVGDLEAMNEMNDXLQENARETEL
 ELREQLDMAGARVREAQKRVEAAQETVADYQQTICKYRQLTAHLQDVNRELTNQQEASVERQQQPPPET
 FDFKIKFAETKAHAKAIEMELRQMEVAQANRHMSLLTAFMPDSFLRPGGDHDCVLVLLMPRLICKAEL
 10 IRKQAQEKFDLSENCSERPGLRGAAGEQLSFAAGLVYSLSLQATLHRYEHALSQCSVDVYKKVGSLYP
 EMSAHERSLDFLIELLHKDQLDET VNVEPLNKGIKYYQHLYRIHLAEQPEDSTMQLADHIKFTQSALDC
 MGVEVGRRLRAFLQGGQEQATDIALLLRDLETSCSDTRQFCKKIRRRMPGTDAPGIPAALAFGSQVSDTLL
 DCRKHLTWVAVLQEVAAAAAQLIAPLAENEGLPVAALEELAFKASEQIYGSPSSSPYECLRQSCITILI
 STMNKLATAMQEGEYDAERPPSKPPPVELRAALRAEITDAEGLGLKLEDRETVIKELKKSLLKIKGEEL
 15 SEANVRXSLLEKKLDSAAKDADERIEKVQTRLEDETQTLRKKEKDFEETMDALQADIDQLEAEKAEKQ
 RLNSQSKRTIEGLRGPPPSGIATLVSGIAGEEPQRGGAPGQAPGALPGPGLVKDSPLLLQQISAMRLHI
 SQLQHENSILRGAQMKASLALPPLHVAKLSLPPHEGPGGNLVAGALYRKTSQLEKLNQLSTHTHVVD
 ITRSSPAAKSPSAQLMEQVAQLKSLSDTIEKLKDEVKETVTQRPATVPTDFATFPSSAFLRAKEEQQ
 DDTVYMGKVTFSCAAGLGQRHRLVLTQEQLHQLHSRLIS

20

Table 34. DCTN1; Dynactin subunit p150 amino acid sequence (SEQ ID NO.: 68)

Gen Bank Accession No.: AAD55811.1(human)

MAQSKRHVYSRTPSGSRMSAEASARPLRVGSRVEVIGKGRGTVAIVGATLFATGKWVGVLDEAKGKN
 DGTVOGRKYFTCDEGHGIFVRQSQIQVFEDGADTTSPETPDSSASKVLKREGDTTAKTSKLRGLKPKK
 APTARKTTTTRPKPTRPASTGVAGASSSLGPSGSASAGELSSSEPSTPAQTPLAAPIIPTPVLTSPGAV
 PPLSPSPKEEEGLRAQVRDLEEKLETLRLKRAEDKAKLKELEKHKIQLEQVQEWKSKMQEQQADLQRRRL
 KEARKEAKEALEAKERYMEEMADTADAIEMATLDKEMAEERAESLQQEVEALKERVDELTTDLEILKAE
 30 IEEKSGDGAASSYQLKQLEEQNARLKDALVRMRDLSSSEKQEHVKLQKLMEKKNQELEVVRRQQRERLQE
 ELSQAESTIDELKEQVDAALGAEEMVEMLTDRNLNLEEKVRELRETVGDLEAMNEMNDELQENARETEL
 ELREQLDMAGARVREAQKRVEAAQETVADYQQTICKYRQLTAHLQDVNRELTNQQEASVERQQQPPPET
 FDFKIKFAETKAHAKAIEMELRQMEVAQANRHMSLLTAFMPDSFLRPGGDHDCVLVLLMPRLICKAEL
 IRKQAQEKFELSENCSERPGLRGAAGEQLSFAAGLVYSLSLQATLHRYEHALSQCSVDVYKKVGSLYP
 35 EMSAHERSLDFLIELLHKDQLDET VNVEPLTKAIKYYQHLYSIHLAEQPEDCTMQLADHIKFTQSALDC
 MSVEVGRRLRAFLQGGQEQATDIALLLRDLETSCSDIRQFCKKIRRRMPGTDAPGIPAALAFGPQVSDTLL
 DCRKHLTWVAVLQEVAAAAAQLIAPLAENEGLLVAALEELAFKASEQIYGTSPSSSPYECLRQSCNILI
 STMNKLATAMQEGEYDAERPPSKPPPVELRAALRAEITDAEGLGLKLEDRETVIKELKKSLLKIKGEEL
 SEANVRLSLEKKLDSAAKDADERIEKVQTRLEETQALLRKKEKEFEETMDALQADIDQLEAEKAEKQ
 40 RLNSQSKRTIEGLRGPPPSGIATLVSGIAGEEQQRGAI PGQAPGSVPGPGLVKDSPLLLQQISAMRLHI
 SQLQHENSILKGAQMKASLASLPLHVAKLSHEGPGSEL PAGALYRKTSQLETLNQLSTHTHVVDITR

TS PAAKSPSAQLMEQVAQLKSLSDTVEKLKDEV LKETVSQRPGATVPTDFATFPSSAFLRAKEEQDDT
VYMGKVTFS CAAGFGQRHRLVLTQEQLHQLHSRLIS

Table 35. DCTN1; Dynactin subunit p150 amino acid sequence (SEQ ID NO.: 69)

5

Gen Bank Accession No.: NP_077044.1 (rat)

MAQSKRHMYNRTPSGSRMSTEASARPLRVGSRVEVIGKGHRTVAYVGATLFATGKWVG VILDEAKGKN
DGT VQGRKYFTCDEGHGIFVRQSQIQVFEDGADTTSPETPDSSASKILKREGADAAAKTSKLRGLKPKK
10 APTARKTTTTRPKPTRPASTGVAGPSSSLGPSGSASAGELSSSEPSTPAQTPLAAPIIPTPALTSPGAA
PPLPSPSKEEEGLRDQVRDLEEKLET LRLKRSEDKAKLKELEKHKIQLEQVQEWKSKMQEQQADLQRR L
KEAKEAKEALEAKERYMEEMADTADAIEMATLDKEMAEERAESLQQEVEALKERVDELTTDLEILKAEI
EEKGSDGAASSYQLKQLEEQNARLKDALVRMRDLSSSEKQEHVKLQKLMEKKNQELEVVRRQRRERLQEE
LSQAESTIDELKEQVDAALGAEEMVEMLTDRNLNLEEKVRELRET VGDLEAMNEMNDELQENARETELE
15 LREQLDMAGARVREAQKRVEAAQETVADYQQT IKKYRQLTAHLQDVNREL TNQOEASVERQQQPPPETF
DFKIKFAETKAHAKAIEMELRQMEVAQANRHMSLLTAFMPDSFLRPGGDHDCVLVLLLMPRLICKAELI
RKQAQEKFDLSENC SERPGLRGAAGEQLSFAAGLVYSLSLQATLHRYEHALSQCSVDVYKVKVGS LYPE
MSAHERSLDFLIELLHKDQLDET VNVEPLTKAIKYYQHLYSIHLAEQPEESTMQ LADHIKFTQSALDCM
SVEVGR LRAFLQGGQEATDIALLLRDLETSCSDIRQFCKKIRRRMPGTDAPGIPAALAFGSQVSDTLLD
20 CRKHLTWVVAVLQEVAAAAAQLIAPLAENEGLPVAALEELAFKASEQIYGSPSSSPYECLRQSCSILIS
TMNKLATAMQEGEYDAERPPSKPPPVEPWPAALRAEITDAEGLGLKLEDRET VIKELKKSLKIKGEELS
EANVRLSLEKKLDSAAKDADERIEKVQTRLEETQTLLRKKEKEFEETMDALQADIDQLEAEKTELKQR
LNSQSKRTIEGLRGPPPSGIATLVSGIAGEEQQRGGTPGQAPGALPGPGPVKDSPLLLQQISAMRLHIS
QLQHENSILRGAQMKASLAALPPLHVAKFSLPPHEGPGGNLLSGALYRKTSQ LLEKLNQLSTYTHVVDI
25 TRSSPACKSPSAQLMEQVAQLKSLSDTIEKLKDEV LKETVTQRPGATVPTDFATFPSSAFLRAKEEQDD
DTVYMGKVTFS CAAGLGQRHRLVLTQEQLHQLHGRLIS

Methods of Screening for Disease-Relevant Mutations in Proteins, which are a
30 **Subunit of the Dynactin/Dynein Complex**

The invention *inter alia* relates to the identification of a protein or a nucleic acid marker indicative of an increased risk of a mammalian subject, particularly a human subject, of developing a neurodegenerative disease or of an association of a
35 neurodegenerative disease in a mammalian subject, particularly a human subject, with a mutation which leads to a neurodegenerative disease.

Preferably the above-mentioned neurodegenerative diseases are Alzheimer's Disease, Parkinson's Disease, or Huntington's Disease. In a preferred embodiment the neurodegenerative disease is a motoneuron degenerative disease. In an even more preferred embodiment, the motoneuron degenerative disease is Amyotrophic Lateral Sclerosis, Spinal Muscular Atrophy, Bulbo-Spinal Muscular Atrophy, Progressive Bulbar Palsy, Progressive Muscular Atrophy, and Primary Lateral Sclerosis.

In a preferred embodiment, the mutation selectively affects cell types associated with or suspected to be involved in neurodegenerative diseases. In a more preferred embodiment, these cell types are motoneurons. In an even more preferred embodiment, the motoneurons are α -motoneurons. In another preferred embodiment, the mutation affects cellular processes, e.g., neuronal axonal transport, cellular transport, proliferation, differentiation, or apoptosis. In another preferred embodiment, the mutation leads to a deficiency or malfunction, e.g. an alteration in the functional interaction or a disruption of the dynactin/dynein complex in neurons, preferably in motoneurons.

On a molecular basis, said mutation results in a deletion of an amino acid or an insertion of an additional amino acid not normally present in the amino acid sequence of the protein encoded by said allele or in a substitution by another amino acid of an amino acid encoded by said allele. In a preferred embodiment, said deletion, substitution, or insertion is encoded by both alleles of the gene coding for said protein and/or occurs in an evolutionary conserved region of said protein. In another preferred embodiment, the substitution of an amino acid which is identical between the corresponding mouse and human, preferably between the corresponding mouse, rat, and human protein encoded by said allele, by another amino acid, preferably by a non-conservative amino acid and/or the substitution of the amino acid occurs by a naturally occurring amino acid.

In another embodiment of the invention, the amino acid affected by the mutation is encoded by a codon within the open reading frame of a nucleic acid sequence, preferably by an exon, as set forth in the following tables.

Table 36. Mouse cytoplasmic dynein intermediate chain1 (GenBank Acc. No.: NM 010063) (SEQ ID NO.: 70)

Exon1 (nucleotide)

5 ATGTCTGACAAGAGCGACCTAAAGGCCGAGCTGGAGCGCAAAAAGCAGCGCTTAGCACAGATAAGAGAG
GAGAAGAAACGGAAGGAAGAGGAGAGGAAGAAGAAAGAG

Table 37. Mouse cytoplasmic dynein intermediate chain1 (GenBank Acc. No.: NM 010063) (SEQ ID NO.: 71)

10

Exon2 (nucleotide)

GCAGATATGCAGCAAAAGAAAGAGCCCGTTCAAGATGACTCCGATCTGGATCGCAAACGACGGGAGACA
GAAGCTTTGCTTCAGAGCATTGGCATATCACCGGAGCCCCCTCTAG

15 **Table 38. Mouse cytoplasmic dynein intermediate chain1 (GenBank Acc. No.: NM 010063) (SEQ ID NO.: 72)**

Exon3 (nucleotide)

20 TCCCAACCCCTATGTCTCCCTCTTCGAAATCAGTGAGCACTCCCAGTGATGCTGGAAGCCAAGACTCGG
GCGATCTGGGGCCATTAACAAG

Table 39. Mouse cytoplasmic dynein intermediate chain1 (GenBank Acc. No.: NM 010063) (SEQ ID NO.: 73)

25 Exon4 (nucleotide)

GACCCTGCAGTGGGACACAGACCCCTCAGTGCTCCAGCTGCAGTCAGACTCAGAACTTGG

Table 40. Mouse cytoplasmic dynein intermediate chain1 (GenBank Acc. No.: NM 010063) (SEQ ID NO.: 74)

30

Exon1 to 4 (nucleotide)

ATGTCTGACAAGAGCGACCTAAAGGCCGAGCTGGAGCGCAAAAAGCAGCGCTTAGCACAGATWAGAGAG
GAGAAGAAACGGAAGGAAGAGGAGAGGAAGAAGAAAGAGGCAGATATGCAGCARAAGAAAGAGCCCGTT
CAAGATGACTCCGATCTGGATCGCAAACGACGGGAGACAGAAGCTTTGCTTCAGAGCATTGGCATATCA
35 CCGGAGCCCCCTCTAGTCCCAACCCCTATGTCTCCCTCTTCGAAATCAGTGAGCACTCCAGTGATGCT
GGAAGCCAAGACTCGGGCGATCTGGGGCCATTAACAAGGACCCTGCAGTGGGACACAGACCCCTCAGTG
CTCCAGCTGCAGTCAGACTCAGAACTTGG

Table 41. Mouse cytoplasmic dynein intermediate chain1 (GenBank Acc. No.: NM 010063) (SEQ ID NO.:75)

Exon5 (nucleotide)

5 GAGACGACTGCACAAGCTGGGCGTGTCAAAGGTGACCCAGGTGGATTTCCTGCCTAGGGAAGTAGTATC
CTACTCCAAGGAGACACAGACTCCTCTTGCAACACATCAGTCTGAAG

Table 42. Mouse cytoplasmic dynein intermediate chain1 (GenBank Acc. No.: NM 010063) (SEQ ID NO.: 76)

10

Exon7 (nucleotide)

CCCCTCCAAGAGAGTTGACGGAGGAAGAAAAACAGCAGATCCTGCACTCAGAAGAATTCCTCATCTTCT
TTGACCGGACAATCCGAGTAATTGAAAGAGCTCTTGCAAGAGGACTCGGACATCTTTTTTGAAGTACAGCG
GTCGAGAGCTGGAGGAGAAAGATGG

15

Table 43. Mouse cytoplasmic dynein intermediate chain1 (GenBank Acc. No.: NM 010063) (SEQ ID NO.: 77)

Exon8 (nucleotide)

20 GGATGTGCAGGCTGGAGCCAACCTGTCTTTCAACCGTCAGTTCTACGATGAACATTGGTCTAAGCATCG
GGTGGTCACATGTATGGACTGGTCTCTCCAG G

Table 44. Mouse cytoplasmic dynein intermediate chain1 (GenBank Acc. No.: NM 010063) (SEQ ID NO.: 78)

25

Exon9 (nucleotide)

TACCCTGAGCTGATGGTTGCTTCTTATAGCAACAACGAAGATGCTCCCCACGAGCCAGATGGAGTGGCC
TTGGTTTGAACATGAAGTTCAAGAAAACACACCAGAATATGTCTTCCACTGTCAG

Table 45. Mouse cytoplasmic dynein intermediate chain1 (GenBank Acc. No.: NM 010063) (SEQ ID NO.: 79)

Exon7 to 9 (nucleotide)

35 CCCCTCCAAGAGAGTTGACGGAGGAAGAAAAACAGCAGATCCTGCACTCAGAAGAATTCCTCATCTTCT
TTGACCGGACAATCCGAGTAATTGAAAGAGCTCTTGCAAGAGGACTCGGACATCTTTTTTGAAGTACAGCG
GTCGAGAGCTGGAGGAGAAAGATGGGGATGTGCAGGCTGGAGCCAACCTGTCTTTCAACCGTCAGTTCT
ACGATGAACATTGGTCTAAGCATCGGGTGGTCACATGTATGGACTGGTCTCTCCAGGTACCCTGAGCTG
ATGGTTGCTTCTTATAGCAACAACGAAGATGCTCCCCACGAGCCAGATGGAGTGGCCTTGGTTTGAAC
ATGAAGTTCAAGAAAACACACCAGAATATGTCTTCCACTGTCAG

Table 46. Human cytoplasmic dynein intermediate chain1 (GenBank NM_004411) (SEQ ID NO.: 80)

5 Exon1 (nucleotide)

TCCAAGGAAACCAACATGTCTGACAAAAGTGACTTAAAAGCTGAGCTAGAGCGCAAAAAGCAGCGCTTA
GCACAGATAAGAGAAGAGAAGAAACGGAAGGAAGAGGAGAGGAAAAAGAAAGAG

10 **Table 47. Human cytoplasmic dynein intermediate chain1 (GenBank NM_004411) (SEQ ID NO.: 81)**

Exon2 (nucleotide)

GCTGATATGCAGCAGAAGAAAGAACCCGTTTCAGGACGACTCTGATCTGGATCGCAAACGACGAGAGACA
GAGGCTTTGCTGCAAAGCATTGGTATCTCACCGGAGCCGCCTCTAG

15

Table 48. Human cytoplasmic dynein intermediate chain1 (GenBank NM_004411) (SEQ ID NO.: 82)

Exon3 (nucleotide)

20 TGCAGCCGCTGCATTTTTTAACATGGGATACCTGTTATTTTCATTATTTAGTCCCAACCCCTATGTCTC
CCTCCTCGAAATCAGTGAGCACTCCCAGTGAAGCTGGAAGCCAAGACTCAGGCGATCTGGGGCCATTAA
CAAG

25 **Table 49. Human cytoplasmic dynein intermediate chain1 (GenBank NM_004411) (SEQ ID NO.: 83)**

Exon4 (nucleotide)

GACCCTGCAGTGGGACACAGACCCCTCAGTGCTCCAGCTGCAGTCAGACTCAGAACTTGG

30 **Table 50. Human cytoplasmic dynein intermediate chain1 (GenBank NM_004411) (SEQ ID NO.: 84)**

Exon 1 to4 (nucleotide)

35 TCCAAGGAAACCAACATGTCTGACAAAAGTGACTTAAAAGCTGAGCTAGAGCGCAAAAAGCAGCGCTTA
GCACAGATAAGAGAAGAGAAGAAACGGAAGGAAGAGGAGAGGAAAAAGAAAGAGGCTGATATGCAGCAG
AAGAAAGAACCCGTTTCAGGACGACTCTGATCTGGATCGCAAACGACGAGAGACAGAGGCTTTGCTGCAA
AGCATTGGTATCTCACCGGAGCCGCCTCTAGTGCAGCCGCTGCATTTTTTAACATGGGATACCTGTTAT
TTTCATTATTTAGTCCCAACCCCTATGTCTCCCTCCTCGAAATCAGTGAGCACTCCCAGTGAAGCTGGA

AGCCAAGACTCAGGCGATCTGGGGCCATTAACAAGGACCCTGCAGTGGGACACAGACCCTCAGTGCTC
CAGCTGCAGTCAGACTCAGAACTTGG

**Table 51. Human cytoplasmic dynein intermediate chain1 (GenBank
5 NM_004411) (SEQ ID NO.: 85)**

Exon5 (nucleotide)

AAGAAGACTGCATAAACTGGGCGTGTCAAAGGTCACCCAAGTGGATTTCCTGCCAAGGGAAGTAGTGTC
CTACTCAAAGGAGACCCAGACTCCTCTTGCCACGCATCAGTCTGAAG

10

**Table 52. Human cytoplasmic dynein intermediate chain1 (GenBank
NM_004411) (SEQ ID NO.: 86)**

15 Exon7 (nucleotide)

CCCCCTCCAAGAGAGTTGACAGAGGAAGAAAAACAGCAGATCCTTCATTCAGAGGAATTTCTCATCTTTT
TTGACCGGACAATACGGGTAATTGAAAGAGCCCTGGCTGAAGATCCGACATCTTTTTTGACTACAGCG
GCCGAGAGTTAGAGGAAAAAGATGG

**20 Table 53. Human cytoplasmic dynein intermediate chain1 (GenBank
NM_004411) (SEQ ID NO.: 87)**

Exon8 (nucleotide)

GGATGTTCAAGGCTGGAGCCAATCTTTCTTTCAATCGTCAGTTCTATGATGAACATTGGTCCAAGCATCG
25 AGTGGTCACTTGTATGGACTGGTCCCTCCAG

**Table 54. Human cytoplasmic dynein intermediate chain1 (GenBank
NM_004411) (SEQ ID NO.: 88)**

30 Exon9 (nucleotide)

TACCCTGAGCTGATGGTGGCTTCTTACAACAACAATGAAGATGCTCCCCATGAACCAGATGGAGTGGCC
TTGGTTTGGAACATGAAGTTTAAGAAAACACACCAGAATACGTCTTCCACTGTCAG

**Table 55. Human cytoplasmic dynein intermediate chain1 (GenBank
35 NM_004411) (SEQ ID NO.: 89)**

Exon7 to 9 (nucleotide)

CCCCCTCCAAGAGAGTTGACAGAGGAAGAAAAACAGCAGATCCTTCATTCAGAGGAATTTCTCATCTTTT
TTGACCGGACAATACGGGTAATTGAAAGAGCCCTGGCTGAAGATCCGACATCTTTTTTGACTACAGCG

-130-

GCCGAGAGTTAGAGGAAAAAGATGGGGATGTTTCAGGCTGGAGCCAATCTTTCTTTCAATCGTCAGTTCT
ATGATGAACATTGGTCCAAGCATCGAGTGGTCACTTGTATGGACTGGTCCCTCCAGTACCCTGAGCTGA
TGGTGGCTTCTTACAACAACAATGAAGATGCTCCCCATGAACCAGATGGAGTGGCCTTGTTTGAACA
TGAAGTTTAAGAAAACACACCAGAATACGTCTTCCACTGTCAG

5

Table 56. Mouse cytoplasmic dynein intermediate chain2 (GenBank Acc. No. NM 010064) (SEQ ID NO.: 90)

Exon2 (nucleotide)

10

GTCACAACCATGTCGGACAAAAGTGATTTAAAAGCTGAGTTGGAACGTAAGAAGCAACGGTTGGCCCAA
ATCAGAGAAGAAAAGAAGAGGAAAGAAGAGGAAAGGAAAAAAAAGGAA

Table 57. Mouse cytoplasmic dynein intermediate chain2 (GenBank Acc. No. NM 010064) (SEQ ID NO.: 91)

15

Exon3 (nucleotide)

ACTGATCAGAAGAAGGAAGCTGCTGTTTCTGTACAAGAAGAGTCTGATCTTGAAAAAAAAGAAGAGAA
GCTGAGGCATTGCTTCAAAGCATGGGACTAACTACGGACTCCCCTATTG

Table 58. Mouse cytoplasmic dynein intermediate chain2 (GenBank Acc. No. NM 010064) (SEQ ID NO.: 92)

Exon4 (nucleotide)

20

TCCCTCCTCTATGTCTCCATCCTCCAAGTCGGTGAGCACGCCAAGTGAAGCTGGAAGCCAGGATTCTG
GAGATGGCGCCGTGGGATCTAG

Table 59. Mouse cytoplasmic dynein intermediate chain2 (GenBank Acc. No. NM 010064) (SEQ ID NO.: 93)

30

Exon5 (nucleotide)

ACGAGGACCTATTAACTTGAATGGCCAAAATTACTCAAGTTGACTTTCCCCCTCGAGAAATCGTCAC
ATACACAAAGGAACTCAGACCCCGTTACAGCTCAACCCAAAGAAG

Table 60. Mouse cytoplasmic dynein intermediate chain2 (GenBank Acc. No. NM 010064) (SEQ ID NO.: 94)

35

Exon2 to 5 (nucleotide)

GTCACAACCATGTCGGACAAAAGTGATTTAAAAGCTGAGTTGGAACGTAAGAAGCAACGGTTGGCCCAA
ATCAGAGAAGAAAAGAAGAGGAAAGAAGAGGAAAGGAAAAAAAAGGAAACTGATCAGAAGAAGGAAGCT

GCTGTTTCTGTACAAGAAGAGTCTGATCTTGAAAAAAAAAGAAGAGAAGCTGAGGCATTGCTTCAAAGC
ATGGGACTAACTACGGACTCCCCTATTGTCCCTCCTCCTATGTCTCCATCCTCCAAGTCGGTGAGCACG
CCAAGTGAAGCTGGAAGCCAGGATTCTGGAGATGGCGCCGTGGGATCTAGACGAGGACCTATTAAACTT
GGAATGGCCAAAATTACTCAAGTTGACTTTCCCCTCGAGAAATCGTCACATACACAAAGGAACTCAG
5 ACCCCGGTTACAGCTCAACCCAAAGAAG

Table 61. Mouse cytoplasmic dynein intermediate chain2 (GenBank Acc. No. NM 010064) (SEQ ID NO.: 95)

10 Exon7 (nucleotide)
CTCCACCTCATGAACTAACTGAAGAAGAAAAGCAACAGATTTTACACTCAGAAGAATTTTAAAGTTTCT
TTGACCATTCTACGAGAATTGTAGAAAGAGCCCTTTCTGAGCAGATTAACATCTTCTTTGACTACAGTG
GGAGAGACTTGGAAGACAAAGAAGG

15 **Table 62. Mouse cytoplasmic dynein intermediate chain2 (GenBank Acc. No. NM 010064) (SEQ ID NO.: 96)**

Exon8 (nucleotide)
GGAGATTCAAGCAGGTGCTAAGCTGTCATTAAATCGACAGTTCTTTGATGAGCGTTGGTCAAAGCATCG
20 AGTTGTTAGTTGTTTGGATTGGTCATCCAG

Table 63. Mouse cytoplasmic dynein intermediate chain2 (GenBank Acc. No. NM 010064) (SEQ ID NO.: 97)

25 Exon9 (nucleotide)
TATCCAGAATTACTTGTGGCTTCCTATAATAACAATGAAGAGGCTCCTCATGAGCCTGATGGTGTGGCC
CTCGTGTGGAATATGAAGTACAAAAAACTACCCAGAGTATGTGTTCCACTGCCAG

30 **Table 64. Mouse cytoplasmic dynein intermediate chain2 (GenBank Acc. No. NM 010064) (SEQ ID NO.: 98)**

Exon7 to 9 (nucleotide)
CTCCACCTCATGAACTAACTGAAGAAGAAAAGCAACAGATTTTACACTCAGAAGAATTTTAAAGTTTCT
TTGACCATTCTACGAGAATTGTAGAAAGAGCCCTTTCTGAGCAGATTAACATCTTCTTTGACTACAGTG
35 GGAGAGACTTGGAAGACAAAGAAGGGGAGATTCAAGCAGGTGCTAAGCTGTCATTAAATCGACAGTTCT
TTGATGAGCGTTGGTCAAAGCATCGAGTTGTTAGTTGTTTGGATTGGTCATCCAGTATCCAGAATTAC
TTGTGGCTTCCTATAATAACAATGAAGAGGCTCCTCATGAGCCTGATGGTGTGGCCCTCGTGTGGAATA
TGAAGTACAAAAAACTACCCAGAGTATGTGTTCCACTGCCAG

Table 65. Human cytoplasmic dynein intermediate chain2, transcript 2
(GenBank Acc. No. NM 001378) (SEQ ID NO.: 99)

Exon1 (nucleotide)

5 ATGTCAGACAAAAGTGAATTAAAGGCTGAGTTGGAACGTAAGAAGCAGCGACTGGCCCAAATCAGAGAG
GAAAAGAAGAGAAAAGAAGAAGAAAGGAAAAAAAAAGAAACAG

Table 66. Human cytoplasmic dynein intermediate chain2, transcript 2
(GenBank Acc. No. NM 001378) (SEQ ID NO.: 100)

10

Exon2 (nucleotide)

ACCAGAAGAAGGAAGCTGTTGCTCCTGTGCAAGAAGAATCAGATCTTGAAAAAAAAAGGAGAGAAGCTG
AAGCATTGCTTCAAAGCATGGGGCTAACTCCAGAATCCCCCATTG

15 **Table 67. Human cytoplasmic dynein intermediate chain2 (GenBank Acc. No.**
NM 001378) (SEQ ID NO.: 101)

Exon3 (nucleotide)

TCCCTCCTCTATGTCTCCATCCTCCAAATCTGTGAGCACTCCAAGTGAAGCTGGAAGCCAAGACTCTG
20 GAGATGGCGCCGTGGGATCTAG

Table 68. Human cytoplasmic dynein intermediate chain2 (GenBank Acc. No.
NM 001378) (SEQ ID NO.: 102)

25 Exon4 (nucleotide)

ACGAGGACCTATTAACTTGAATGGCTAAAATCACGCAAGTCGACTTTCCTCCTCGAGAAATTGTCAC
GTATACAAAGGAACTCAGACTCCAGTTATGGCTCAACCCAAAGAAG

30 **Table 69. Human cytoplasmic dynein intermediate chain2 (GenBank Acc. No.**
NM 001378) (SEQ ID NO.: 103)

Exon1 to 4 (nucleotide)

ATGTCAGACAAAAGTGAATTAAAGGCTGAGTTGGAACGTAAGAAGCAGCGACTGGCCCAAATCAGAGAG
GAAAAGAAGAGAAAAGAAGAAGAAAGGAAAAAAAAAGAAACAGACCAGAAGAAGGAAGCTGTTGCTCCT
35 GTGCAAGAAGAATCAGATCTTGAAAAAAAAAGGAGAGAAGCTGAAGCATTGCTTCAAAGCATGGGGCTA
ACTCCAGAATCCCCCATTGTCCCTCCTCTATGTCTCCATCCTCCAAATCTGTGAGCACTCCAAGTGAA
GCTGGAAGCCAAGACTCTGGAGATGGCGCCGTGGGATCTAGACGAGGACCTATTAACTTGAATGGCT
AAAATCACGCAAGTCGACTTTCCTCCTCGAGAAATTGTCACGTATACAAAGGAACTCAGACTCCAGTT
ATGGCTCAACCCAAAGAAG

Table 70. Human cytoplasmic dynein intermediate chain2 (GenBank Acc. No. NM 001378) (SEQ ID NO.: 104)

5 Exon6 (nucleotide)

CTCCCCCTCATGAGCTGACTGAAGAAGAAAAGCAACAAATCCTGCACTCTGAGGAATTTTAAAGTTTCT
TTGACCATTCTACAAGAATTGTAGAAAGAGCTCTTCTGAGCAGATTAACATCTTCTTTGACTATAGTG
GGAGAGATTTGGAAGACAAAGAAGG

10 **Table 71. Human cytoplasmic dynein intermediate chain2 (GenBank Acc. No. NM 001378) (SEQ ID NO.: 105)**

Exon7 (nucleotide)

AGAGATTCAAGCAGGTGCTAAACTGTCATTAAATCGACAATTTTTTGACGAACGTTGGTCAAAGCATCG
15 GGTGGTTAGTTGTTTGGATTGGTCATCTCAG

Table 72. Human cytoplasmic dynein intermediate chain2 (GenBank Acc. No. NM 001378) (SEQ ID NO.: 106)

20 Exon8 (nucleotide)

TATCCGGAGTTACTCGTGGCTTCTCTATAACAACAATGAAGATGCCCCCTCATGAGCCTGATGGTGTGGCC
CTTGATGGAATATGAAATACAAAAAACTACCCAGAGTATGTGTTTCACTGCCAG

25 **Table 73. Human cytoplasmic dynein intermediate chain2 (GenBank Acc. No. NM 001378) (SEQ ID NO.: 107)**

Exon6 to 8 (nucleotide)

CTCCCCCTCATGAGCTGACTGAAGAAGAAAAGCAACAAATCCTGCACTCTGAGGAATTTTAAAGTTTCT
TTGACCATTCTACAAGAATTGTAGAAAGAGCTCTTCTGAGCAGATTAACATCTTCTTTGACTATAGTG
30 GGAGAGATTTGGAAGACAAAGAAGGAGAGATTCAAGCAGGTGCTAAACTGTCATTAAATCGACAATTTT
TTGACGAACGTTGGTCAAAGCATCGGGTGGTTAGTTGTTTGGATTGGTCATCTCAGTATCCGGAGTTAC
TCGTGGCTTCTCTATAACAACAATGAAGATGCCCCCTCATGAGCCTGATGGTGTGGCCCTTGATGGAATA
TGAAATACAAAAAACTACCCAGAGTATGTGTTTCACTGCCAG

35

Table 74. Mouse Dctn1 (P150) protein (SEQ ID NO.: 108)

Exon1 (nucleotide)

-134-

ATGGCCCAGAGCAGGAGGCACATGTCCAGTCGGACGCCGAGTGGCAGCAGGATGAGTACGGAGGCAAGC
GCCCCGCCCCCTGCGGGTTGGCTCCCGCGTGGAGGTGATTGGGAAGGGCCACCGAGGCACTGTGGCCTAT
GTTGGAGCCACACTCTTTGCCACTGGCAAATGGGTGGGCGTGATTCTGGATGAAGCAAAAGGCAAAAAT
GATGGCACTGTCCAGGGAAGGAAGTATTTACATGTGATGAAGGCCACGGCATCTTTGTACGCCAGTCC
5 CAG

Table 75. Mouse Dctn1 (P150) protein (SEQ ID NO.: 109)

Exon2 (nucleotide)
10 ATCCAAGTATTTGAAGATGGAGCAGATACTACTTCCCCAGAGACTCCTGATTCTTCTGCTTCAAAGGTC
CTCAAGAGAG

Table 76. Mouse Dctn1 (P150) protein (SEQ ID NO.: 110)

15 Exon3 (nucleotide)
AGGGAGCCGATGCAGCTGCAAAGACCAGCAAAC TG

Table 77. Mouse Dctn1 (P150) protein (SEQ ID NO.: 111)

20 Exon4 (nucleotide)
ACCACAAC TCGACGGCCCAAG

Table 78. Mouse Dctn1 (P150) protein (SEQ ID NO.: 112)

25 Exon1 to 4 (nucleotide)
ATGGCCCAGAGCAGGAGGCACATGTCCAGTCGGACGCCGAGTGGCAGCAGGATGAGTACGGAGGCAAGC
GCCCCGCCCCCTGCGGGTTGGCTCCCGCGTGGAGGTGATTGGGAAGGGCCACCGAGGCACTGTGGCCTAT
GTTGGAGCCACACTCTTTGCCACTGGCAAATGGGTGGGCGTGATTCTGGATGAAGCAAAAGGCAAAAAT
GATGGCACTGTCCAGGGAAGGAAGTATTTACATGTGATGAAGGCCACGGCATCTTTGTACGCCAGTCC
30 CAGATCCAAGTATTTGAAGATGGAGCAGATACTACTTCCCCAGAGACTCCTGATTCTTCTGCTTCAAAG
GTCCTCAAGAGAGAGGGAGCCGATGCAGCTGCAAAGACCAGCAAAC TCGGGGACTGAAGCCTAAGAAG
GCACCGACAGCCCGAAAGACCACAAC TCGACGGCCCAAG

Table 80. Mouse Dctn1 (P150) protein (SEQ ID NO.: 114)

35 Exon5 (nucleotide)
CCTACTCGCCCAGCCAGCACTGGGGTGGCTGGGCCCAGTAGCTCCCTTGGCCCCCTCTGGCTCAGCGTCA
GCCGGGGAACTAAGCAGCAGTGAGCCCAGCACCCCAGCTCAGACTCCGCTGGCAGCACCCATCATCCCC
ACACCGGCCCTCACCTCTCTTGAGCAGCACCCCCACTTCCATCTCCCTCTAAG
40

Table 81. Mouse Dctn1 (P150) protein (SEQ ID NO.: 115)

Exon6 (nucleotide)

GAAGAGGAAGGGCTGAGGGCTCAGGTACGGGACCTGGAGGAGAAGCTGGAGACCCGCGCCTAAAACGC
5 TCAGAAGACAAAGCAAAGCTGAAAGAGCTGGAGAAGCACAAGATCCAGCTGGAGCAGGTGCAGGAATGG
AAGAGCAAATGCAGGAGCAGCAGGCAGACCTGCAGCGGCGCCTCAAGGAGGCTCGGAAG

Table 82. Mouse Dctn1 (P150) protein (SEQ ID NO.: 116)

10 Exon7 (nucleotide)

GAAGCCAAGGAGGCGCTAGAGGCAAAGGAACGCTACATGGAGGAGATGGCCGACACAGCCGACGCTATC
GAGATGGCCACTCTGGACAAGGAGATGGCTGAAGAGCGCGCTGAGTCTCTGCAGCAAGAGGTGGAGGCA
CTGAAGGAACGGGTAGACGAGCTCACCACAGACCTGGAGATTCTCAAGGCTGAAATCGAAGAGAAAG

15 **Table 83. Mouse Dctn1 (P150) protein (SEQ ID NO.: 117)**

Exon8 (nucleotide)

GCTCTGATGGGGCCGCATCAAGCTACCAGCTCAAGCAGCTGGAGGAGCAGAATGCCCGCCTGAAGGATG
CCCTGGTGAG

20

Table 84. Mouse Dctn1 (P150) protein (SEQ ID NO.: 118)

Exon9 (nucleotide)

GATGCGAGACCTCTCTTCCTCAGAGAAGCAGGAGCACGTGAAGCTGCAGAACTCATGGAAAAGAAAAA
25 CCAGGAGCTGGAGGTCTGTGCGGCAGCAGCGGAGCGTCTTCAGGAGGAGCTGAGCCAGGCTGAGAGCAC
CATCGATGAGCTCAAAGAGCAG

Table 85. Mouse Dctn1 (P150) protein (SEQ ID NO.: 119)

30 Exon10 (nucleotide)

GTGGACGCCGCTCTGGGAGCCGAGGAGATGGTGGAGATGCTGACCGACCGGAACCTGAATCTAGAGGAG
AAAGTGCGGGAGTTACGGGAGACTGTGGGGGACTTG

Table 86. Mouse Dctn1 (P150) protein (SEQ ID NO.: 120)

35

Exon11 (nucleotide)

GAAGCCATGAACGAGATGAACGATGAGCTGCAGGAGAACGCACGGGAGACGGAGCTGGAACCTCCGAGAG
CAGCTGGACATGGCGGGCGCCGAGTGAGGGAAGCGCAGAAGCGAGTGGAAGCCGCCAGGAGACAGTC
GCCGACTACCAGCAGACCATCAAGAAGTACCGCCAGTTGACTGCCCCACCTACAG

Table 87. Mouse Dctn1 (P150) protein (SEQ ID NO.: 121)

Exon12 (nucleotide)

5 GATGTCAATCGGGAGCTGACAAACCAGCAGGAAGCGTCTGTAGAGAGGCAGCAGCAGCCGCCGAGAG
ACTTTTGATTTCAAATCAAGTTTGCTGAGACCAAGGCTCATGCCAAG

Table 88. Mouse Dctn1 (P150) protein (SEQ ID NO.: 122)

10 Exon13(nucleotide)

GCCATTGAGATGGAGTTGAGACAGATGGAAGTTGCCAGGCCAACCGGCACATGTCCCTGCTGACAGCC
TTTATGCCTGACAGCTTCCTTCGGCCAGGTGGAGACCACGACTGTGTCCTGGTGCTGCTGCTCATGCCC
CGACTCATTTGCAAG

15 **Table 89. Mouse Dctn1 (P150) protein (SEQ ID NO.: 123)**

Exon14 (nucleotide)

GCAGAGCTCATCCGGAAGCAGGCCAGGAGAAGTTTGACCTGAGCGAGAACTGTTCCGAGCGGCCCCGGG
CTGCGGGGAGCTGCCGGGGAGCAGCTGAGCTTTGCTGCTGGACTGGTGTACTCGCTGAGTCTGCTGCAG
20 GCCACGCTGCACCGCTATGAGCA

Table 90. Mouse Dctn1 (P150) protein (SEQ ID NO.: 124)

Exon15 (nucleotide)

25 TGCCCTCTCTCAGTGCAGTGTGGACGTGTATAAGAAGGTCGGCAGCCTGTACCCCGAGATGAGCGCCCA
CGAGCGCTCCTTAGATTTCTCATTGAGCTGCTGCACAAGGATCAGCTGGATGAGACTGTCAACGTGGA
GCCCCCTACCAAGGCCATCAAGTATTACCAG

Table 91. Mouse Dctn1 (P150) protein (SEQ ID NO.: 125)

30

Exon16 (nucleotide)

TGCCCTCTCTCAGTGCAGTGTGGACGTGTATAAGAAGGTCGGCAGCCTGTACCCCGAGATGAGCGCCCA
CGAGCGCTCCTTAGATTTCTCATTGAGCTGCTGCACAAGGATCAGCTGGATGAGACTGTCAACGTGGA
GCCCCCTACCAAGGCCATCAAGTATTACCAG

35

Table 92. Mouse Dctn1 (P150) protein (SEQ ID NO.: 126)

Exon17 (nucleotide)

TGCCCTCTCTCAGTGCAGTGTGGACGTGTATAAGAAGGTCGGCAGCCTGTACCCCGAGATGAGCGCCCA
CGAGCGCTCCTTAGATTTCCCTCATTGAGCTGCTGCACAAGGATCAGCTGGATGAGACTGTCAACGTGGA
CCCCCTACCAAGGCCATCAAGTATTACCAG

5 **Table 93. Mouse Dctn1 (P150) protein (SEQ ID NO.: 127)**

Exon18 (nucleotide)

GGTGGGCAGGAGGCAACAGATATTGCCCTTCTTCTCCGAGACCTGGAAACATCATGTAGTGACACCCGT
CAGTTCTGCAAGAAGATCCGAAGGCGGATGCCGGGGACGGATGCTCCTGGGATCCCAGCAGCGCTGGCC
10 TTTGGCTCACAG

Table 94. Mouse Dctn1 (P150) protein (SEQ ID NO.: 128)

Exon19 (nucleotide)

15 GTATCCGACACACTCCTGGACTGCAGGAAGCACTTGACGTGGGTGGTAGCTGTTCTGCAGGAGGTGGCA
GCTGCAGCCGCCAGCTTATTGCCCCCTTGGCAGAGAACGAGGGGCTGCCTGTGGCTGCACTGGAGGAG
CTGGCCTTCAAAGCAAGCGAGCAG

Table 95. Mouse Dctn1 (P150) protein (SEQ ID NO.: 129)

20

Exon20 (nucleotide)

ATCTACGGGAGCCCCCTCCAGCAGCCCCCTATGAGTGTCTACGCCAGTCATGCACCATCCTCATCAGCACG
ATGAACAAGCTGGCCACAGCCATGCAAGAAGGCGAGTATGACGCAGAGCGACCCCCGAGCAAG

25 **Table 96. Mouse Dctn1 (P150) protein (SEQ ID NO.: 130)**

Exon3 to 20 (nucleotide)

AGGGAGCCGATGCAGCTGCAAAGACCAGCAAAGTGCAGGGGACTGAAGCCTAAGAAGGCACCGACAGCCC
GAAAGACCACAAGTGCAGCGGCCCAAGCCTACTCGCCAGCCAGCACTGGGGTGGCTGGGCCCAGTAGCT
30 CCCTTGCCCCCTCTGGCTCAGCGTCAGCCGGGGAACTAAGCAGCAGTGAGCCCAGCACCCCAGCTCAGA
CTCCGCTGGCAGCACCCATCATCCCCACACCGGCCCTCACCTCTCCTGGAGCAGCACCCCCACTTCCAT
CTCCCTCTAAGGAAGAGGAAGGGCTGAGGGCTCAGGTACGGGACCTGGAGGAGAAGCTGGAGACCCTGC
GCCTAAACGCTCAGAAGACAAAGCAAAGCTGAAAGAGCTGGAGAAGCACAAGATCCAGCTGGAGCAGG
TGCAGGAATGGAAGAGCAAAATGCAGGAGCAGCAGGCAGACCTGCAGCGGCGCCTCAAGGAGGCTCGGA
35 AGGAAGCCAAGGAGGCGCTAGAGGCAAAGGAACGCTACATGGAGGAGATGGCCGACACAGCCGACGCTA
TCGAGATGGCCACTCTGGACAAGGAGATGGCTGAAGAGCGCGCTGAGTCTCTGCAGCAAGAGGTGGAGG
CACTGAAGGAACGGGTAGACGAGCTCACCACAGACCTGGAGATTCTCAAGGCTGAAATCGAAGAGAAAG
GCTCTGATGGGGCCGCATCAAGCTACCAGCTCAAGCAGCTGGAGGAGCAGAATGCCCCCCTGAAGGATG
CCCTGGTGAGGATGCGAGACCTCTCTTCTCAGAGAAGCAGGAGCACGTGAAGCTGCAGAACTCATGG
40 AAAAGAAAACCAGGAGCTGGAGGTCGTGCGGCAGCAGCGGAGCGTCTTCAGGAGGAGCTGAGCCAGG

CTGAGAGCACCATCGATGAGCTCAAAGAGCAGGTGGACGCCGCTCTGGGAGCCGAGGAGATGGTGGAGA
TGCTGACCGACCGGAACCTGAATCTAGAGGAGAAAGTGCGGGAGTTACGGGAGACTGTGGGGGACTTGG
AAGCCATGAACGAGATGAACGATGAGCTGCAGGAGAACGCACGGGAGACGGAGCTGGAACCTCCGAGAGC
AGCTGGACATGGCGGGCGCCCGAGTGAGGGAAGCGCAGAAGCGAGTGGAAGCCGCCAGGAGACAGTCG
5 CCGACTACCAGCAGACCATCAAGAAGTACCGCCAGTTGACTGCCCACCTACAGGATGTCAATCGGGAGC
TGACAAACCAGCAGGAAGCGTCTGTAGAGAGGCAGCAGCAGCCGCCGAGAGACTTTTGATTTCAAAA
TCAAGTTTGCTGAGACCAAGGCTCATGCCAAGGCCATTGAGATGGAGTTGAGACAGATGGAAGTTGCCC
AGGCCAACCGGCACATGTCCCTGCTGACAGCCTTTATGCCTGACAGCTTCCTTCGGCCAGGTGGAGACC
ACGACTGTGTCTGGTGCTGCTGCTCATGCCCCGACTCATTTGCAAGGCAGAGCTCATCCGGAAGCAGG
10 CCCAGGAGAAGTTTGACCTGAGCGAGAACTGTTTCGGAGCGGCCCGGGCTGCGGGGAGCTGCCGGGGAGC
AGCTGAGCTTTGCTGCTGGACTGGTGTACTCGCTGAGTCTGCTGCAGGCCACGCTGCACCGCTATGAGC
ATGCCCTCTCTCAGTGCAGTGTGGACGTGTATAAGAAGGTCGGCAGCCTGTACCCCGAGATGAGCGCCC
ACGAGCGCTCCTTAGATTTCTCATTGAGCTGCTGCACAAGGATCAGCTGGATGAGACTGTCAACGTGG
AGCCCCCTCAMCAAGGSCATCAAGTATTACCAGCATCTGTACAGSATCCACCTCGCTGAACAACCCGAGG
15 ACTCCACCATGCAGCTGGCTGACCACATCAAGTTCACCCAGAGTGCCCTGGACTGCATGGGCGTGGAGG
TGGGGCGGCTGCGTGCTTCTTGCAAGGTGGGCAGGAGGCAACAGATATTGCCCTTCTTCTCCGAGACC
TGGAACATCATGTAGTGACACCCGTCAGTTCTGCAAGAAGATCCGAAGGCGGATGCCGGGGACGGATG
CTCCTGGGATCCCAGCAGCGCTGGCCTTTGGCTCACAGGTATCCGACACACTCCTGGACTGCAGGAAGC
ACTTGACGTGGGTGGTAGCTGTTCTGCAGGAGGTGGCAGCTGCAGCCGCCAGCTTATTGCCCCCTTGG
20 CAGAGAACGAGGGGCTGCCTGTGGCTGCACTGGAGGAGCTGGCCTTCAAAGCAAGCGAGCAGATCTACG
GGAGCCCCCTCCAGCAGCCCCCTATGAGTGTCTACGCCAGTCATGCACCATCCTCATCAGCACGATGAACA
AGCTGGCCACAGCCATGCAAGAAGGCGAGTATGACGCAGAGCGACCCCCGAGCAAG

Table 97. Mouse Dctn1 (P150) protein (SEQ ID NO.: 131)

25

Exon22 (nucleotide)

GGAGAGGAGCTGAGTGAGGCCAACGTGCGGCTCAGCCTCCTGGAGAAGAAGTTGGACAGCGCTGCCAAG
GATGCAGACGAGCGAATCGAGAAAGTTAGACACGGCTGGACGAGACTCAGACCCTGCTGCGGAAGAAG
GAGAA

30

Table 98. Mouse Dctn1 (P150) protein (SEQ ID NO.: 132)

Exon23 (nucleotide)

AGACTTTGAGGAGACAATGGACGCACTCCAGGCTGACATCGACCAGCTGGAGGCAGAGAAGGCAGAGCT
35 CAAGCAGCGCCTGAACAGCCAGTCCAAGCGCACAATCGAGGGGCTCCGGGGCCCCCTCCGTCAGGCAT
CGCTACCCTGGTCTCTGGCATCGCTGGTG

Table 99. Mouse Dctn1 (P150) protein (SEQ ID NO.: 133)

40 Exon 22 to 23 (nucleotide)

GGAGAGGAGCTGAGTGAGGCCAACGTGCGGCTCAGCCTCCTGGAGAAGAAGTTGGACAGCGCTGCCAAG
GATGCAGACGAGCGAATCGAGAAAGTTCAGACACGGCTGGACGAGACTCAGACCCTGCTGCGGAAGAAG
GAGAAAGACTTTGAGGAGACAATGGACGCACTCCAGGCTGACATCGACCAGCTGGAGGCAGAGAAGGCA
GAGCTCAAGCAGCGCCTGAACAGCCAGTCCAAGCGACAATCGAGGGGCTCCGGGGCCCCCTCCGTCA
5 GGCATCGCTACCCTGGTCTCTGGCATCGCTGGTG

Table 100. Human DCTN 1 (P150) protein (SEQ ID NO.: 134)

Exon 2 (nucleotide)

10 ACGCCAGCGGCAGCAGGATGAGTGCGGAGGCAAGCGCCCGGCCTCTGCGGGTGGGCTCCCGTGTAGAG
GTGATTGGAAAAGGCCACCGAGGCACTGTGGCCTATGTTGGAGCCACACTGTTTGCCACTGGCAAATGG
GTAGGCGTGATTCTGGATGAAGCAAAGGGCAAAAATGATGGAAGTGTTCAGGCAGGAAGTACTTCACT
TGTGATGAAGGGCATGGCATCTTTGTGCGCCAGTCCCG

15 **Table 101. Human DCTN 1 (P150) protein (SEQ ID NO.: 135)**

Exon3 (nucleotide)

ATCCAGGTATTTGAAGATGGAGCAGATACTACTTCCCCAGAGACACCTGATTCTTCTGCTTCAAAAGTC
CTCAAAAGAG

20

Table 102. Human DCTN 1 (P150) protein (SEQ ID NO.: 136)

Exon4 (nucleotide)

25 AGGGAAGTGAACAAGTCAAAGACTAGCAAAGT

Table 103. Human DCTN 1 (P150) protein (SEQ ID NO.: 137)

Exon5 (nucleotide)

30 ACCACAAGTGGCGACCCAAG

Table 104. Human DCTN 1 (P150) protein (SEQ ID NO.: 138)

Exon2 to 5 (nucleotide)

35 ACGCCAGCGGCAGCAGGATGAGTGCGGAGGCAAGCGCCCGGCCTCTGCGGGTGGGCTCCCGTGTAGAG
GTGATTGGAAAAGGCCACCGAGGCACTGTGGCCTATGTTGGAGCCACACTGTTTGCCACTGGCAAATGG
GTAGGCGTGATTCTGGATGAAGCAAAGGGCAAAAATGATGGAAGTGTTCAGGCAGGAAGTACTTCACT
TGTGATGAAGGGCATGGCATCTTTGTGCGCCAGTCCCAGATCCAGGTATTTGAAGATGGAGCAGATACT
ACTTCCCCAGAGACACCTGATTCTTCTGCTTCAAAAGTCCTCAAAAGAGAGGGAAGTGAACAAGTGA

AAGACTAGCAAACCTGCGGGGACTGAAGCCTAAGAAGGCACCGACAGCCCGAAAGACCACAACCTCGGCGA
CCCAAG

Table 105. Human DCTN 1 (P150) protein (SEQ ID NO.: 139)

5

Exon6 (nucleotide)

CCCACGCGCCAGCCAGTACTGGGGTGGCTGGGGCCAGTAGCTCCCTGGGCCCCTCTGGCTCAGCGTCA
GCAGGTGAGCTGAGCAGCAGTGAGCCCAGCACCCCGGCTCAGACTCCGCTGGCAGCACCCATCATCCCC
ACGCCGGTCCTCACCTCTCTGGAGCAGTCCCCCGCTTCCTTCCCCATCCAAG

10

Table 106. Human DCTN 1 (P150) protein (SEQ ID NO.: 140)

Exon7 (nucleotide)

GAGGAGGAGGGACTAAGGGCTCAGGTGCGGGACCTGGAGGAGAACTAGAGACCCTGAGACTGAAACGG
15 GCAGAAGACAAAGCAAAGCTAAAAGAGCTGGAGAAACACAAAATCCAGCTGGAGCAGGTGCAGGAATGG
AAGAGCAAAATGCAGGAGCAGCAGGCCGACCTGCAGCGGCGCCTCAAGGAGGCGAGAAAG

Table 107. Human DCTN 1 (P150) protein (SEQ ID NO.: 141)

20

Exon8 (nucleotide)

GAAGCCAAGGAGGCGCTGGAGGCAAAGGAACGCTATATGGAGGAGATGGCTGATACTGCTGATGCCATT
GAGATGGCCACTTTGGACAAGGAGATGGCTGAAGAGCGGGCTGAGTCCCTGCAGCAGGAGGTGGAGGCA
CTGAAGGAGCGGGTGGACGAGCTCACTACTGACTTAGAGATCCTCAAGGCTGAGATTGAAGAGAAGG

25

Table 108. Human DCTN 1 (P150) protein (SEQ ID NO.: 142)

Exon9 (nucleotide)

GCTCAGATGGCGCTGCATCCAGTTATCAGCTCAAGCAGCTTGAGGAGCAGAATGCCGCCTGAAGGATG
CCCTGGTGAG

30

Table 109. Human DCTN 1 (P150) protein (SEQ ID NO.: 143)

Exon10 (nucleotide)

GATGCGGGATCTTTCTTCCTCAGAGAAGCAGGAGCATGTGAAGCTCCAGAAGCTCATGGAAAAGAAGAA
35 CCAAGAGCTGGAAGTTGTGAGGCAACAGCGGGAGCGTCTGCAGGAGGAGCTAAGCCAGGCAGAGAGCAC
CATTGATGAGCTCAAGGAGCAG

Table 110. Human DCTN 1 (P150) protein (SEQ ID NO.: 144)

Exon11 (nucleotide)

GTGGATGCTGCTCTGGGTGCTGAGGAGATGGTGGAGATGCTGACAGATCGGAACCTGAATCTGGAAGAG
AAAGTGC GCGAGTTGAGGGAGACTGTGGGAGACTTG

5 **Table 112. Human DCTN 1 (P150) protein (SEQ ID NO.: 145)**

Exon12 (nucleotide)

GAAGCGATGAATGAGATGAACGATGAGCTGCAGGAGAATGCACGTGAGACAGAACTGGAGCTGCGGGAG
CAGCTGGACATGGCAGGCGCGGGTTCGTGAGGCCAGAACGCTGTGGAGGCAGCCAGGAGACGGTT
10 GCAGACTACCAGCAGACCATCAAGAAGTACCGCCAGCTGACCGCCCATCTACAG

Table 113. Human DCTN 1 (P150) protein (SEQ ID NO.: 146)

Exon13(nucleotide)

15 GATGTGAATCGGGAACCTGACAAACCAGCAGGAAGCATCTGTGGAGAGGCAACAGCAGCCACCTCCAGAG
ACCTTTGACTTCAAAATCAAGTTTGCTGAGACTAAGGCCCATGCCAAG

Table 114. Human DCTN 1 (P150) protein (SEQ ID NO.: 147)

20 Exon14 (nucleotide)

GCAATTGAGATGGAATTGAGGCAGATGGAGGTGGCCAGGCCAATCGACACATGTCCCTGCTGACAGCC
TTCATGCCTGACAGCTTCCTTCGGCCAGGTGGGGACCATGACTGCGTTCTGGTGCTGTTGCTCATGCCT
CGTCTCATTTGCAAG

25 **Table 115. Human DCTN 1 (P150) protein (SEQ ID NO.: 148)**

Exon15 (nucleotide)

GCAGAGCTGATCCGGAAGCAGGCCAGGAGAAGTTTGAACCTAAGTGAGAACTGTTGAGAGCGGCCTGGG
CTGCGAGGAGCTGCTGGGGAGCAACTCAGCTTTGCTGCTGGACTGGTGTACTCGCTGAGCCTGCTGCAG
30 GCCACGCTACACCGCTATGAGCA

Table 116. Human DCTN 1 (P150) protein (SEQ ID NO.: 149)

Exon16 (nucleotide)

35 TGCCCTCTCTCAGTGCAGTGTGGATGTGTATAAGAAAGTGGGCAGCCTGTACCCTGAGATGAGTGCCCA
TGAGCGCTCCTTGATTTCCTCATTGAACTGCTGCACAAGGATCAGCTGGATGAGACTGTCAATGTGGA
GCCTCTCACCAAGGCCATCAAGTACTATCAG

Table 117. Human DCTN 1 (P150) protein (SEQ ID NO.: 150)

Exon17 (nucleotide)

CATCTGTACAGCATCCACCTTGCCGAACAGCCTGAGGACTGTACTATGCAGCTGGCTGACCACATTAAG

5 **Table 118. Human DCTN 1 (P150) protein (SEQ ID NO.: 151)**

Exon18 (nucleotide)

TTCACGCAGAGTGCTCTGGACTGCATGAGTGTGGAGGTAGGACGGCTGCGTGCCTTCTTGAG

10 **Table 119. Human DCTN 1 (P150) protein (SEQ ID NO.: 152)**

Exon19 (nucleotide)

GGTGGGCAGGAGGCTACAGATATTGCCCTCCTGCTCCGGGATCTGGAACTTCATGCAGTGACATCCGC
CAGTTCTGCAAGAAGATCCGAAGGCGAATGCCAGGGACAGATGCTCCTGGGATCCCAGCTGCACTGGCC
15 TTTGGACCAÇAG**Table 120. Human DCTN 1 (P150) protein (SEQ ID NO.: 153)**

Exon20 (nucleotide)

20 GTATCTGACACGCTCCTAGACTGCAGGAAACACTTGACGTGGGTCGTGGCTGTGCTGCAGGAGGTGGCA
GCTGCTGCTGCCAGCTCATTGCCCCACTGGCAGAGAATGAGGGGCTACTTGTGGCTGCTCTGGAGGAA
CTGGCTTTCAAAGCAAGCGAGCAG**Table 121. Human DCTN 1 (P150) protein (SEQ ID NO.:154)**

25

Exon21 (nucleotide)

ATCTATGGGACCCCCTCCAGCAGCCCCCTATGAGTGTCTGCGCCAGTCATGCAACATCCTCATCAGTACC
ATGAACAAGCTGGCCACAGCCATGCAGGAGGGGGAGTATGATGCAGAGCGGCCCCCAGCAAG30 **Table 122. Human DCTN 1 (P150) protein (SEQ ID NO.: 155)**

Exon4 to 21 (nucleotide)

AGGGAAC TGATACTGCAAAGACTAGCAAAC TCGGGGACTGAAGCCTAAGAAGGCACCGACAGCCC
GAAAGACCACAAC TCGGCGACCCAAGCCCACGCGCCAGCCAGTACTGGGGTGGCTGGGGCCAGTAGCT
35 CCCTGGGCCCCCTCTGGCTCAGCGTCAGCAGGTGAGCTGAGCAGCAGTGAGCCCAGCACCCCGGCTCAGA
CTCCGCTGGCAGCACCCATCATCCCCACGCCGGTCCTCACCTCTCCTGGAGCAGTCCCCCGCTTCCTT
CCCCATCCAAGGAGGAGGAGGGACTAAGGGCTCAGGTGCGGGACCTGGAGGAGAACTAGAGACCCTGA
GACTGAAACGGGCAGAAGACAAAGCTAAAAGAGCTGGAGAAACACAAAATCCAGCTGGAGCAGG
TGCAGGAATGGAAGAGCAAAATGCAGGAGCAGCAGGCCGACCTGCAGCGGCGCTCAAGGAGGCGAGAA
40 AGGAAGCCAAGGAGGCGCTGGAGGCAAAGGAACGCTATATGGAGGAGATGGCTGATACTGCTGATGCCA

TTGAGATGGCCACTTTGGACAAGGAGATGGCTGAAGAGCGGGCTGAGTCCCTGCAGCAGGAGGTGGAGG
CACTGAAGGAGCGGGTGGACGAGCTCACTACTGACTTAGAGATCCTCAAGGCTGAGATTGAAGAGAAGG
GCTCAGATGGCGCTGCATCCAGTTATCAGCTCAAGCAGCTTGAGGAGCAGAATGCCCCGCTGAAGGATG
CCCTGGTGAGGATGCGGGATCTTTCTTCCTCAGAGAAGCAGGAGCATGTGAAGCTCCAGAAGCTCATGG
5 AAAAGAAGAACCAAGAGCTGGAAGTTGTGAGGCAACAGCGGGAGCGTCTGCAGGAGGAGCTAAGCCAGG
CAGAGAGCACCATTGATGAGCTCAAGGAGCAGGTGGATGCTGCTCTGGGTGCTGAGGAGATGGTGGAGA
TGCTGACAGATCGGAACCTGAATCTGGAAGAGAAAGTGCGCGAGTTGAGGGAGACTGTGGGAGACTTGG
AAGCGATGAATGAGATGAACGATGAGCTGCAGGAGAATGCACGTGAGACAGAACTGGAGCTGCGGGAGC
AGCTGGACATGGCAGGCGCGCGGGTTTCGTGAGGCCCAGAAGCGTGTGGAGGCAGCCAGGAGACGGTTG
10 CAGACTACCAGCAGACCATCAAGAAGTACCGCCAGCTGACCGCCCATCTACAGGATGTGAATCGGGAAC
TGACAAACCAGCAGGAAGCATCTGTGGAGAGGCAACAGCAGCCACCTCCAGAGACCTTTGACTTCAAAA
TCAAGTTTGCTGAGACTAAGGCCCCATGCCAAGGCAATTGAGATGGAATTGAGGCAGATGGAGGTGGCCC
AGGCCAATCGACACATGTCCCTGCTGACAGCCTTCATGCCTGACAGCTTCCTTCGGCCAGGTGGGGACC
ATGACTGCGTTCTGGTGCTGTTGCTCATGCCTCGTCTCATTTGCAAGGCAGAGCTGATCCGGAAGCAGG
15 CCCAGGAGAAGTTTGAACATAAGTGAGAACTGTTTCAGAGCGGCCTGGGCTGCGAGGAGCTGCTGGGGAGC
AACTCAGCTTTGCTGCTGGACTGGTGTACTCGCTGAGCCTGCTGCAGGCCACGCTACACCGCTATGAGC
ATGCCCTCTCTCAGTGCAGTGTGGATGTGTATAAGAAAGTGGGCAGCCTGTACCCTGAGATGAGTGCCC
ATGAGCGCTCCTTGATTTTCCTCATTGAAGTGTGCACAAGGATCAGCTGGATGAGACTGTCAATGTGG
AGCCTCTCACCAAGGCCATCAAGTACTATCAGCATCTGTACAGCATCCACCTTGCCGAACAGCCTGAGG
20 ACTGTACTATGCAGCTGGCTGACCACATTAAGTTACGCAGAGTGCTCTGGACTGCATGAGTGTGGAGG
TAGGACGGCTGCGTGCCCTTCTTGCAAGGTGGGCAGGAGGCTACAGATATTGCCCTCCTGCTCCGGGATC
TGGAAACTTCATGCAGTGACATCCGCCAGTTCTGCAAGAAGATCCGAAGGCGAATGCCAGGGACAGATG
CTCCTGGGATCCCAGCTGCACTGGCCTTTGGACCACAGGTATCTGACACGCTCCTAGACTGCAGGAAAC
ACTTGACGTGGGTGCTGGCTGTGCTGCAGGAGGTGGCAGCTGCTGCTGCCAGCTCATTGCCCCACTGG
25 CAGAGAATGAGGGGCTACTTGTGGCTGCTCTGGAGGAACTGGCTTCAAAGCAAGCGAGCAGATCTATG
GGACCCCTCCAGCAGCCCTATGAGTGTCTGCGCCAGTCATGCAACATCCTCATCAGTACCATGAACA
AGCTGGCCACAGCCATGCAGGAGGGGGAGTATGATGCAGAGCGGGCCCCCAGCAAG

Table 123. Human DCTN 1 (P150) protein (SEQ ID NO.: 156)

30

Exon23 (nucleotide)

GGAGAGGAGCTAAGTGAGGCCAATGTGCGGCTGAGCCTCCTGGAGAAGAAGTTGGACAGTGCTGCCAAG
GATGCAGATGAGCGCATCGAGAAAGTCCAGACTCGGCTGGAGGAGACCCAGGCACTGCTGCGAAAGAAG
GAGAA

35

Table 124. Human DCTN 1 (P150) protein (SEQ ID NO.: 157)

Exon24 (nucleotide)

AGAGTTTGAGGAGACAATGGATGCACTCCAGGCTGACATCGACCAGCTGGAGGCAGAGAAGGCAGAACT
40 AAAGCAGCGTCTGAACAGCCAGTCCAAACGCACGATTGAGGGACTCCGGGGCCCTCCTCCTTCAGGCAT
TGCTACTCTGGTCTCTGGCATTGCTGGTG

Table 125. Human DCTN 1 (P150) protein (SEQ ID NO.: 158)

Exon 23 to 24 (nucleotide)

5 GGAGAGGAGCTAAGTGAGGCCAATGTGCGGCTGAGCCTCCTGGAGAAGAAGTTGGACAGTGCTGCCAAG
 GATGCAGATGAGCGCATCGAGAAAGTCCAGACTCGGCTGGAGGAGACCCAGGCACTGCTGCGAAAGAAG
 GAGAAAGAGTTTGAGGAGACAATGGATGCACTCCAGGCTGACATCGACCAGCTGGAGGCAGAGAAGGCA
 GAACTAAAGCAGCGTCTGAACAGCCAGTCCAAACGCACGATTGAGGGACTCCGGGGCCCTCCTCCTTCA
 GGCATTGCTACTCTGGTCTCTGGCATTGCTGGTG

10

In another embodiment, the amino acid affected by the mutation is located in a domain of said protein, which is capable of binding to another subunit of the dynactin/dynein complex. Specifically, said domain comprises amino acids 147-157, amino acids 243-314, amino acids 140-157, or amino acids 1-123 of SEQ ID NO.: 61, in case the protein is mouse cytoplasmic dynein intermediate chain 1, or, in case the protein is human cytoplasmic dynein intermediate chain 1 amino acids 1-140, amino acids 157-174, amino acids 164-174, or amino acids 260-331 of SEQ ID NO.: 62. In case the protein is mouse cytoplasmic dynein intermediate chain 2, said domain comprises amino acids 1-123, amino acids 122-139, amino acids 129-130, or amino acids 226-297 of SEQ ID NO.: 64, or, in case the protein is human cytoplasmic dynein intermediate chain 2 amino acids 1-149, amino acids 148-165, amino acids 155-165, or amino acids 252-323 of SEQ ID NO.: 65. In case the protein is mouse DCTN 1 (SEQ ID NO.: 67), said domain comprises amino acids 39-150, amino acids 1006-1021, or amino acids 133-899 of SEQ ID NO.: 67, or, in case the protein is human DCTN 1 amino acids 39-150, amino acids 133-899, or amino acids 1006-1021 of SEQ ID NO.: 68.

In another preferred embodiment, the amino acid affected by the mutation is any one as described in individualized manner in connection with the preferred mutants of the invention above, e.g., those specified in Tables 19, 20, 21, 22 or 24.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is amino acid 39G.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is amino acid 40H.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is amino acid 41R.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is amino acid 42G.

5 In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is amino acid 43T.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is amino acid 44V.

10 In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 45A.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 46Y.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 47V.

15 In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 48G.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 49A.

20 In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 50T.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 51L.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 52F.

25 In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 53A.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 54T.

30 In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 55G.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 56K.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 57W.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 58V.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 59G.

5 In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 60V

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 61I.

10 In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 62L.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 63D.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 64E.

15 In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 65A.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 66K.

20 In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 67G.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 68K.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 69N.

25 In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 70D.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 71G.

30 In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 72T.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 73V.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 74Q.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 75G.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 76R.

5 In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 77K.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 78Y.

10 In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 79F.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 80T.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 81C.

15 In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 82D.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 83E.

20 In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 84G.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 85H.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 86G.

25 In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 87I.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 88F.

30 In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 89V.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 90R.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 91Q.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 92S.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 93Q.

5 In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 94I.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 95Q.

10 In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 96V.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 97F.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 98E.

15 In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 99D.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 100G.

20 In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 101A.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 102D.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 103T.

25 In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 104T.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 105S.

30 In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 106P.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 107E.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 108T.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 109P.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 110D.

5 In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 111S.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 112S.

10 In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 113A.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 114S.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 115K.

15 In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 117L.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 118K.

20 In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 119R.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 120E.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 121G.

25 In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 123D.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 126A.

30 In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 127K.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 128T.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 129S.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 130K.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 131L.

5 In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 132R.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 133G.

10 In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 134L.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 135K.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 136P.

15 In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 137K.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 138K.

20 In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 139A.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 140P.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 141T.

25 In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 142A.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 143R.

30 In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 144K.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 145T.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 146T.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 147T.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 148R.

5 In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 149R.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 150P.

10 The method of identifying a protein or nucleic acid marker indicative of an increased risk of a mammalian subject of developing a neurodegenerative disease, or the method of identifying a protein or nucleic acid marker indicative of an association of a neurodegenerative disease in a mammalian subject with a mutation in an allele of a gene coding for a protein, which is a subunit of the dynactin/dynein complex
15 comprise the step of analyzing a test sample derived from said subject for the presence of a difference compared to a similar test sample if derived from a subject of the same species that is unaffected by, or known not to be at risk of, developing said disease, wherein said difference is indicative of the presence of a mutation in an allele of the gene coding for a protein, which is a subunit of the dynactin/dynein complex.

20

In the above methods, the test sample derived from a mammalian subject, particularly a human subject, may be directly obtained from said subject. It may, however, also be a sample that has been obtained previously. Also included test samples according to the invention are, for example, cDNA preparations that have
25 been prepared from mRNA obtained from a tissue sample from a human subject at an earlier stage. It may also be cloned or PCR-amplified DNA that originates from DNA contained in such tissue sample obtained at an earlier stage.

According to the claimed method, the test sample will be analyzed for a difference to a similar test sample derived from a human subject unaffected by or
30 known not to be at risk of developing a neurological disease. While the method may include actually deriving or directly obtaining a test sample from such a mammalian subject, particularly a human subject, for comparative purposes, the necessary information regarding the relevant structural features and properties of such similar test sample to be used for comparison will often already be available. Thus, it will

often be sufficient for the purposes of the above methods of the invention to perform an analysis for a difference to a similar test sample as it would be observed if said similar test sample were in fact obtained from a subject of the same species, which subject is unaffected by or known not to be at risk of developing the above medical
5 condition.

The test sample may be a nucleic acid sample, e.g., mRNA (or cDNA derived therefrom), or genomic DNA.

10 It may also be a protein sample. In a preferred embodiment the nucleic acid sample or the protein sample comprises one or more of the nucleic acids coding for proteins or the proteins itself, which are subunits of the dynactin/dynein complex, preferably the cytoplasmic dynein heavy chain 1, e.g. according to SEQ ID NOS.: 28 or 29, the cytoplasmic dynein intermediate chain 1, e.g. according to SEQ ID NOS.:
15 30 or 31, the cytoplasmic dynein intermediate chain 2, e.g. according to SEQ ID NOS.: 32 or 33, the cytoplasmic dynein light intermediate chain 1, e.g. according to SEQ ID NOS.: 34 or 35, the cytoplasmic dynein light intermediate chain 2, e.g. according to SEQ ID NOS.: 36 or 37; the cytoplasmic dynein 10 kDa light chain, e.g. according to SEQ ID NOS.: 38 or 39, the cytoplasmic dynein light chain Tctex 1, e.g.
20 according to SEQ ID NOS.: 40 or 41, the cytoplasmic dynein light chain 2B, e.g. according to SEQ ID NO.: 42, DCTN 1, e.g. according to SEQ ID NOS.: 43 or 44, DCTN 2, e.g. according to SEQ ID NO.: 45, DCTN 3, e.g. according to SEQ ID NOS.: 46 or 47), DCTN 4, e.g. according to SEQ ID NOS.: 48 or 49, DCTN 5, e.g. according to SEQ ID NO.: 50, DCTN 6, e.g. according to SEQ ID NOS.: 51 or 52),
25 ARP1, e.g. according to SEQ ID NOS. 53 or 54, ARP11, e.g. according to SEQ ID NOS. 55 or 56), HAP1, e.g. according to SEQ ID NO. 57 or 58, and CLIP-170, e.g. according to SEQ ID NOS.: 59 or 60), more preferably the cytoplasmic dynein heavy chain 1, cytoplasmic dynein intermediate chain 1, cytoplasmic dynein intermediate chain 2, and/or DCTN 1, e.g., according to the above-mentioned corresponding SEQ
30 ID NOS.

The difference analyzed may furthermore be one relating to the expression level of said nucleic acid or protein. Alternatively, it may be analyzed whether there is a difference in terms of the nucleotide or the amino acid sequence level.

The step of analysis for differences between the test samples may comprises the partial or complete determination of the sequence of the nucleic acid, or a PCR-amplified portion of the nucleic acid, of the test sample, and optionally also of the
5 nucleic acid or at PCR-amplified portion of the nucleic acid of the similar test sample (or the similar test samples).

Accordingly, another embodiment of the invention relates to oligonucleotides suitable for identifying a mutation in an allele coding for a protein, which is a subunit
10 of the dynactin/dynein complex. In a preferred embodiment, the nucleic acid sequence of the oligonucleotide corresponds to one within said allele, which contains a mutation as defined above. In another preferred embodiment the oligonucleotide is suitable for hybridizing to the nucleic acid of said allele or a portion of its nucleic acid under stringent conditions. In another preferred embodiment, the oligonucleotide is suitable
15 as primer for amplifying the nucleic acid of said allele or a portion of its nucleic acid.

Suitable methods for the determination of partial or complete nucleic acid sequences, and thus, detection of the above-mentioned differences, are well known to the skilled artisan. They include, for example, Southern blotting, TGGE (temperature
20 gradient gel electrophoresis), DGGE (denaturing gradient gel electrophoresis), SCCP (single chain conformation polymorphism) detection, and the like. High throughput sequence analysis methods such as those described by Kristensen et al. (Kristensen et al., BioTechniques 30 (2001), 318-332), which is incorporated herein by reference in its entirety, are likewise suitable, and hence, contemplated in connection with the
25 present invention.

One embodiment of the present invention relates to the determination whether the above-mentioned differences are present in one or both alleles of the gene coding for the protein, which is a subunit of the dynactin/dynein complex, i.e., whether the
30 mammalian subject (or certain cell samples derived therefrom) is (are) homozygous or heterozygous with respect to said mutation. In a preferred embodiment, the portion of the allele to be tested is PCR-amplified and digested with a suitable restriction enzyme and the resulting restriction pattern obtained from the amplified portion is compared to the restriction pattern obtained from the corresponding amplified portion of the

similar sample or the similar samples (see Example (8)). In another preferred embodiment, the above-mentioned determination whether differences are present in one or both alleles of the gene coding for said protein is TGCE, as explained below.

5 Another preferred embodiment of the invention relates to the separation of PCR-amplified portions of the allele via electrophoresis through a gradient of increasing temperature via TGCE (see Example 20). Differences in the amplified portion of the allele compared to amplified portions of the alleles contained in the similar test sample(s) are indicated by a difference in migration during
10 electrophoresis.

As mentioned above, the invention *inter alia* relates to high throughput screening methods. Preferably, the oligonucleotides according to the invention, used in these high throughput methods, are fixed on a solid support to form an array. The
15 solid support can comprise microplates, standard blotting membranes, or glass chips. In a preferred embodiment, the solid support is a glass chip with a modified surface capable of covalently binding to said oligonucleotides. Nucleic acid samples, preferably genomic DNA, are tagged, e.g. with a fluorescent marker, and allowed to interact with said oligonucleotides bound to the solid support. Hybridization will occur
20 at complementary sequences between nucleic acid sample and oligonucleotide, which is indicative for the presence of a mutation in said nucleic acid sample. Hybridization is then determined by scanning with a laser beam and analyzing the signal on a computer.

25 Suitable methods for the determination of partial or complete amino acid sequences are likewise well known, and include, for example, detection of particular epitopes within a protein sample via specific antibodies in dot blot, slot blot, or Western blot assays, or via ELISAs or RIAs, or partial amino acid sequence determination on a sequencer via Edman degradation. Also, high-throughput methods
30 may again be employed.

A further aspect of the present invention is represented by a method for identifying a predisposition of a mammalian subject, particularly a human subject, for developing a neurodegenerative disease, said method comprising the step of

determining whether a test sample derived from said subject indicates the presence of a mutation in an allele of the gene coding for a protein, which is a subunit of the dynactin/dynein complex, indicative of an increased risk of said human subject of developing said neurodegenerative disease.

5

Also contemplated in connection with the present invention is a method for determining whether a neurodegenerative disease in a mammalian subject, particularly a human subject, which is associated with a mutation in an allele of a gene coding for a protein, which is a subunit of the dynactin/dynein complex, said method comprising
10 the step of determining whether a test sample derived from said subject indicates the presence of a mutation in an allele of the gene coding for said protein.

As in the case of the methods described above, the test sample may also be a sample that has been obtained previously. Furthermore, suitable test samples
15 according to the invention are, for example, cDNA preparations that have been prepared from mRNA obtained from a tissue sample from a mammalian subject, particularly a human subject, at an earlier stage. It may also again be cloned or PCR-amplified DNA that originates from DNA contained in such tissue sample obtained at an earlier stage.

20

Again, the previously mentioned methods of determining partial or complete nucleic acid or amino acid sequences may be employed for the step of determining whether the test sample (which may be a nucleic acid or protein test sample as previously defined) indicates the presence of said mutation.

25

According to the above methods of identifying a predisposition in a mammalian subject, particularly a human subject, of developing a neurodegenerative disease, or determining a potential association between such a neurodegenerative disease and certain mutations, the test sample is analyzed for the presence of a
30 mutation in an allele of a gene of a protein, which is a subunit of the dynactin/dynein complex, which mutation is indicative of an increased risk of developing such a neurodegenerative disease.

On the molecular level, said methods would comprise analyzing said sample for the presence of a mutation, which would indicate an altered expression or function of said protein. It will be appreciated that such mutations are *inter alia* those referred to herein in connection with the proteins and nucleic acids according to the invention, and that mutations of this kind may be readily identified, for example, by *in vitro* assays. Such *in vitro* assays to determine whether the mutation in an allele of a gene coding for said protein affects the function of the complex may comprise the quantitative and/or qualitative determination of the binding of the subunits to each other within the complex. Qualitative methods may comprise SDS-PAGE and subsequent Western blotting of homogenates of, e.g. the spinal cord, using antibodies specific for the dynactin/dynein subunits. Disruption of the dynactin/dynein complex by a mutation in said proteins can be determined by, e.g. a difference in migration of the subunits compared to proteins derived from homogenates of similar tissue comprising the corresponding proteins without mutation (LaMonte *et al.*, see above.).

In another embodiment of the invention, disruption, or at least functional alteration of the dynactin/dynein complex due to mutations in its subunits, may be analyzed by affinity chromatography as described in Karki *et al.* (J Biol Chem 270, 28806-28811, 1995) or co-precipitation experiments as described in Paschal *et al.* (J Biol Chem 268, 15318-23, 1993). Quantitative methods to determine quantitative binding of the subunits within the complex to each other are, e.g. those using surface plasmon resonance (SPR), such as, for example, the Biacore technology (Biacore AB, Uppsala, Sweden) (see also Example 18). Further suitable *in vitro* assays comprise the step of determining whether a mutation in one or more subunits of the dynactin/dynein complex affects dynein motility. Such tests comprise, e.g. immunohistology with appropriate antibodies. To determine an effect of the mutation on axonal transport, antibodies directed against tubulin or synaptotagmin may be suitable (Martin *et al.*, 1999, Mol Biol Cell 10, 3717-3728).

In another embodiment of the invention, dynein motility may be determined by analysis of single-lipid-droplet motility as described by Welte *et al.* (Cell 92: 547-557, 1998) or a microtubule gliding assay (see Example 16). In another embodiment, the *in vitro* assays may comprise tests to determine whether the mutation in an allele of a gene coding for said protein affects the expression of the protein. In this regard, quantitative analysis of the mRNA expression levels may be applicable. These

methods may comprise, for example, Northern blotting or quantitative Polymerase Chain Reaction, which are well known to those skilled in the art.

In a further embodiment of the present invention, the above-mentioned
5 mutations may be readily identified, for example, by an animal model (see Example 1).

The above-mentioned mutations may also be identified by any of the aforementioned methods of screening for disease-relevant alleles of said proteins.

10

The invention further comprises a kit for identifying a predisposition of a mammalian subject, particularly a human subject, for developing a neurodegenerative disease, or for identifying an association of a neurodegenerative disease of said subject with a mutation in an allele coding for a protein, which is a subunit of the
15 dynactin/dynein complex. The kit according to the invention comprises one or more of the above-mentioned oligonucleotides suitable for identifying a mutation in an allele of a gene coding for a protein which is a subunit of the dynactin/dynein complex. In one preferred embodiment, the kit comprises oligonucleotide(s), the nucleotide sequence of which correspond(s) to a nucleotide sequence within said allele, which
20 contains a mutation. In another preferred embodiment, the oligonucleotide(s) is(are) suitable for hybridizing to the nucleic acid of said allele or a portion of its nucleic acid under stringent conditions. In another preferred embodiment, the oligonucleotide(s) is(are) suitable as primer(s) for amplifying the nucleic acid of said allele or a portion of its nucleic acid. In another preferred embodiment, the kit further comprises
25 instructions to use the oligonucleotide or the oligonucleotides for identifying said predisposition in said subject or said association of the neurodegenerative disease of said subject with said mutation.

The invention further comprises a solid support, wherein at least two oligonucleotides are individually fixed to separate areas of the solid support to form
30 an array. Preferably the oligonucleotides fixed on the solid support are suitable for identifying a mutation in an allele of a gene coding for a protein, which is a subunit of the dynactin/dynein complex. Preferably, the oligonucleotides fixed on the solid support have a nucleotide sequence, which corresponds to a nucleotide sequence within said allele, which contains a mutation and are suitable for hybridizing to the

nucleic acid of said allele or a portion of its nucleic acid under stringent conditions. The solid support can be a microplate or standard blotting membranes, such as nylon or nitrocellulose membranes. In a preferred embodiment, the solid support is a glass chip, preferably a glass chip with a modified surface. The surface of the glass chip is modified as to bind nucleic acids, preferably oligonucleotides, more preferably oligonucleotides with a nucleotide sequence, which corresponds to a nucleotide sequence within said allele, which contains a mutation.

A further embodiment of the present invention comprises the use of the previously mentioned oligonucleotides, or the previously mentioned kit, or the above-mentioned solid support, in a method for identifying a predisposition of a mammalian subject, particularly a human subject, for developing a neurodegenerative disease or in a method for determining whether a neurodegenerative disease in a mammalian subject, particularly a human subject, is associated with a mutation in an allele of a gene coding for a protein, which is a subunit of the dynactin/dynein complex as mentioned previously.

The invention will be further described in the following examples, which do not limit the scope of the invention described in the claims. The following examples are offered for illustrative purposes only, and are not intended to limit the scope of the present invention in any way.

EXAMPLE 1: Production of Animals of the Invention and Breeding Strategies

To produce mouse mutants, a C3HeB/FeJ male mouse (The Jackson Laboratory, Bar Harbor ME, USA) was injected intraperitoneally three times in weekly intervals between 8–10 weeks of age with ethyl-nitroso-urea (ENU) (Serva Electrophoresis GmbH, Heidelberg, Germany) at 90mg/kg body weight.

30 Generation of F1 Progeny:

50 days after the last injection the injected male mouse was mated to wild type C3HeB/FeJ female partners. The F1 progeny (up to 100 offspring) were then analyzed for phenotypes of dominant traits.

Generation of F2 Progeny-genetic confirmation of dominant phenotype:

Affected F1 individuals were mated to wild type C3HeB/FeJ mice and the resulting F2 progeny was screened for the identical pathological phenotype as identified in F1 generation.

Generation of F3 Progeny:

For maintenance purposes affected F2 individuals were mated to wild type C3HeB/FeJ mice. Affected F2 individuals were intercrossed to produce homozygous F3 individuals, which undergo perinatal lethality: therefore fetal tissues of these animals were analyzed. Heterozygous F3 individuals were used for the histochemical, neurological and physiological characterization of the Cra1 phenotype.

EXAMPLE 2: First Identification of Phenotype

The Cra1 mouse mutant was identified by the observation of hind limb cramping during manual tail suspension in the heterozygous condition (Figure 1). Adult mice were manually suspended by their tails for one minute. During this period it was observed whether the mice display cramping of their hind limbs. In all tests, the observation of hind limb cramping was invariably correlated to the heterozygous Cra1/+ genotype.

A broad range of standard physiological values were tested, but were within wild type (control) ranges.

EXAMPLE 3: Analysis of Muscle Endurance and Motor Coordination

A semi-quantitative evaluation of the phenotype was accomplished by the application of the hanging wire assay (for results see Figure 3), as a tool for measuring muscle endurance. Muscle endurance of adult heterozygous Cra1 individuals (Cra1/+) was measured in comparison to wildtype individuals by placing individual mice on a wire grid, mildly shaking the grid to cause the mouse to grip the wires with their paws, and then inverting the grid. The grid was held stationary in the inverted position and the time elapsed until the mouse fell was recorded as the latency to fall.

Both sexes of *Cra1* mice exhibit a significantly reduced latency to fall off the grid in comparison to wild type mice.

A reduction in motor coordination was subsequently suggested by a reduced performance in the coat hanger and stationary beam assays. In a coat hanger assay a single heterozygous *Cra1* animal was placed in the middle of the horizontal part of a metal coat hanger. The movements of the animal were observed for 45 seconds and assessed in comparison to movements of a wildtype mice in a separate assay. The following classification was used to describe the performance of the animal: "normal", the mouse climbs up the wire (horizontal and vertical movements); "abnormal", the mouse displays only horizontal movements or it does not display any movements (freeze) or it falls from the metal coat hanger.

In the stationary beam assay, a heterozygous mouse was placed in the middle of a stationary beam, which was divided into fourteen 5 cm zones. The animal was observed for 45 seconds. The following classification was used to describe the performance of the animal: "normal", the mouse moves between at least 3 zones; "abnormal", the mouse moves within less than 3 zones, or the mouse is falls from the stationary beam.

EXAMPLE 4: Determination of Movement Activity

To determine movement activity during an 24 hour interval, individual heterozygous *Cra1* or wild type mice were monitored with a photobeam activity system (San Diego Instruments, San Diego, CA, USA), according to the manufacturer's instructions. A single animal was transferred into a type 3 mouse cage, with a photobeam frame assembled. Beam breaks caused by a moving mouse were counted automatically using a software package "SDI PAS Photobeam System V2" following the instructions of the manufacturer's handbook. Data were collected over a period of 24 hours after the animals had been acclimatized to the cages for 48 hours.

Figure 2 indicates that heterozygous *Cra1* mice exhibit increased ambulatory activity in the early dark phase of an alternating 12 hour light/dark cycle.

EXAMPLE 5: Necropsy and Organ Histology of Mutant Animals

For sampling of organs, adult animals were perfusion fixed with 4% paraformaldehyde. Muscle samples were collected from anaesthetised mice and cryopreserved in liquid nitrogen cooled isopentane at -50°C . Embryos were
5 immersion fixed in paraformaldehyde. Tissues were sampled and processed to paraffin wax. Sections were cut at 5 microns and stained according to subsequent usage.

1. Heterozygotes

The following histopathological aberrations were observed in adult Cra1/+ (as
10 compared to wild type mice)

in I). Brain:

Slight enlargement of the lateral and 3rd ventricles.

Neuronal eosinophilic inclusions in the arcuate and the preoptic nuclei of the hypothalamus.

15 Excitatory neuronal damage ("dark neurons") in hippocampus (gyrus dentatus, CA4, CA3), some areas of the upper cortex and the Purkinje cell layer of the cerebellum (see Figure 4A: hippocampus):

This type of neuronal damage is reversible: it can be evoked by challenging the individuals by tail suspension for two minutes immediately before sacrifice by
20 cervical dislocation, and can be demonstrated as follows. Brains were removed immediately, immersion fixed in paraformaldehyde and processed for paraffin embedding using standard histopathological techniques. Coronal sections of 5 μm were mounted on glass slides and stained with hematoxylin and eosin by standard histological protocols. The phenomenon of dark neurons after acute neuronal cell
25 stress is well recognized since some years in the neuropathological literature and resembles a fixation effect by aldehyde fixation. This cellular pathomorphology is not accompanied by astro- or microglial activation, it occurs under normal neuronal cell count, and it is only detectable after aldehyde fixation, but not by cryosectioning.

in II). Muscle:

30 Decreasing numbers of α -motor neurons and altered composition of musculus vastus fibre types. Muscle samples were processed according to standard protocols

and were cut at 5 μ m. Staining of NeuN protein was performed by immunohistochemical analysis with an anti NeuN antibody Mab377 (Chemicon Int. Inc., Temecula, CA, USA), detecting decreasing numbers of α -motor neurons. Periodic acid-Schiff (PAS) staining was performed according to standard protocols,
5 detecting an altered composition of musculus vastus fiber tybes (see Fig. 4B).

2. Homozygotes

The following preliminary histopathological observations were made in organs of E17.5

Cral/Cral fetus as compared to wild type individuals: Neurodegeneration in
10 the anterior horns of the spinal cord:

Mature motor neurons were sparse in the anterior horn region of homozygotes when compared to heterozygote or wildtype littermates. From a histomorphological aspect approximately 50 % of motor neuros were missing, the remaining neurons were smaller of size and did not have a normal mature aspect.

15 Detection of apoptotic cell death within the anterior horns of the spinal cord:

Apoptosis detection was performed as follows: deparaffinized and rehydrated paraffin sections were treated with proteinase K (20 μ g/ml) for 15 minutes at room temperature. Apoptotic cells were detected in situ by the TUNEL (terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling) assay using the
20 Roche *in situ* cell death detection kit POD (Roche Diagnostics GmbH, Mannheim, Germany), according to the manufacturer's instructions, and using diaminobenzidine as a staining dye. The percentage of TUNEL positive cells was clearly increased in the anterior horn region of the homozygous embryos when compared to heterozygote and wildtype littermates, where only few positive neuronal cells were detected.

25

EXAMPLE 6: Mapping and Cloning of the Mutation in Mutant Animals of the Invention

1. Generation of F3- and F4-Hybrids

F3-hybrids were generated by mating affected F2-individuals to C57BL/6J
30 wildtype mice. F3 hybrids were designated as DO1. DO1 individuals were screened for the Cral phenotype directly after weaning. For mapping and positional cloning of the mutated gene affected F3-hybrids were either intercrossed to generate F4

intercross individuals, designated as DIC individuals, or outcrossed to C57BL/6J wildtype mice to generate F4-individuals, designated as DO2 individuals.

2. DNA Isolation from Rodent Tails and Macromapping

5 Mouse genomic DNA was purified from 1 cm long pieces of tails of DIC or DO2 mice by using the "DNeasy 96 Tissue Kit" (Qiagen, Hilden, Germany) according to the manufacturer's protocol.

10 For chromosomal mapping of the mutant locus in the Cral mouse line standard outcross/backcross and outcross/intercross strategies in strain C57Bl/6Jico (Ifacredo, France) were used in combination with microsatellite markers specific for the C3HeB/FeJ and C57Bl/6Jico strains equally distributed over all 19 mouse chromosomes.

15 Oligonucleotides were obtained from MWG-Biotech AG (Ebersberg, Germany). PCR reactions were performed with fluorescent-labeled primers, whose sequences were taken from Schalkwyk et al., 1999, <http://www-genome.wi.mit.edu/> (site maintained by the Whitehead Institute for Genome Research, Cambridge MA, USA). The PCR reactions were performed in a MJ tetrad thermocycler PTC 225
20 device (MJ Research, Inc., Waltham MA, USA) in 25µl reaction volumes, using BioTherm-DNA-polymerase (Genecraft, Germany). A four minute denaturation step was then followed by 28 amplification cycles, each comprising 30 seconds denaturation and 30 seconds annealing at the respective temperatures given in Schalkwyk et al., see above, and 30 seconds extension at 72°C. Samples were
25 amplified with different dyes and products were separated on an ABI 3700 DNA sequencing device (PE Applied Biosystems, Foster City, USA) using internal length standards in every lane. Analysis was performed with Genescan version 3.0 and Genotyper version 2.1 software from ABI. We macromapped the locus of the mutation by identifying a chromosomal region having an increased allele frequency of
30 markers representing the C3H founder strain.

Our analysis of DO2 and DIC mice indicated that the Cral mutation cosegregates with the marker D12Mit141 on chromosome 12.

3. Fine Mapping

A detailed haplotype analysis of affected and non-affected Cra1 mice using identified single nucleotide polymorphisms (SNPs) located in the critical region demonstrated, that the mutation was located between SNP markers in the Ppp2r5c
5 gene (encoding the protein phosphatase 2, regulatory subunit B (B56), gamma isoform) and the Traf3 gene (encoding the Tnf receptor-associated factor 3).

4. PCR Amplification of Cytoplasmic Dynein Heavy Chain1 Gene

Oligonucleotides were obtained from MWG-Biotech AG (Ebersberg, Germany). The PCR reactions were performed in a MJ tetrad thermocycler PTC 225 device (MJ Research, Inc., Waltham MA, USA) in 25µl reaction volumes using BioTherm-DNA-polymerase (Genecraft, Germany). A four minute denaturation step was then followed by 28 amplification cycles comprising each 30 seconds
15 denaturation and 30 seconds annealing at the respective temperatures given in Schalkwyk *et al.* (1999), and 30 seconds extension at 72°C. A total of 77 exon sequences of the murine Dnchc1 gene were identified by sequence alignment of the full-length mouse Dnchc1 cDNA sequence (GenBank Acc. No. AY004877) and mouse BAC clone RPCI-23-134O19 (GenBank Acc. No. AL596265) using
20 Sequencher™ Version 4.0.5 (Gene Codes Corp., Ann Arbor MI, USA). Exon specific primers located in the flanking intronic sequences were designed using Primer3, maintained by the Whitehead Institute for Biomedical Research.

All 77 exons of the Dnchc1 gene were amplified using a DNA pool of 4
25 affected pups (Cra1/Cra1) as well as C3H and C57 control DNA as PCR templates.

5. DNA Sequence Analysis

PCR amplicons were purified by using the QIAquick PCR Purification Kit (Qiagen, Hilden, Germany) according to the manufacturers protocol. PCR products
30 were sequenced using forward/reverse PCR primers and "Big Dye" thermal cycle

sequencing Kit (ABI PRISM, Applied Biosystems, Foster City CA, USA). The reaction products were analyzed on an ABI 3700 DNA sequencing device.

The sequences were edited manually and contig assembly for mutation
5 detection was performed using Sequencher version 4.0.5 (Gene Codes Corp., Ann Arbor MI, USA). The sequence analysis detected an A to G (codon TAC to TGC) transition in exon 13 of the mouse gene, at a location corresponding to nucleotide position 3328 (position +3164 of the coding sequence) in the Dnchc1 mRNA sequence (GenBank Acc. No. AY004877, SEQ ID NO:1) The PCR amplicons with 364 bp in
10 size, and including exon 13, were generated by PCR amplification with oligonucleotide Dnchc 1-25 (5'-TCCAAGACTTTGAAGTGAGGTTC; located in intron 12, SEQ ID NO:15) and with oligonucleotide Dnchc1-26 (5'-CAGGGCCAAACACCAATACT; located in intron 13, SEQ ID NO 16). The PCR amplicons generated contain either the wild type sequence (SEQ ID NO:13) or the
15 mutated sequence (SEQ ID NO:14), as listed in Tables 10 and 11, respectively.

Table 10. Wild type Dnchc1 364 bp PCR Amplicon (SEQ ID NO:13)

wild type:

20 TCCAAGACTTTGAAGTGAGGTTCCTAATGGTGTGAAGACATGGA
CTGTTGACATGGTGGGTTCTAGCATATTAATAGTCTACAGCACTG
CAGACTAGAATTGAGCTGTGTTTCCTTTGCAGGTTTGGCTTCAGT
ACCAGTGTTTGTGGGATATGCAGGCAGAAAACATTTACAACAGGC
TAGGGGAAGATCTCAACAAGTGGCAAGCTCTCCTGGTCCAGATAA
25 GGAAAGCCAGAGGAACCTTTGACAATGCGGAAACCAAGAAAGAGT
TTGGTCCGGTGGTGATAGATTACGGCAAGGTGAGCTTGGCTTGTT
GTCAAAAGGCACCAGGCAGCCGTAAGATCAGTATTGGTGTGTTGGC
CCTG

30

Table 11. Mutant Dnchc1 364 bp PCR Amplicon (SEQ ID NO:14)

mutant:

35 TCCAAGACTTTGAAGTGAGGTTCCTAATGGTGTGAAGACATGGA
CTGTTGACATGGTGGGTTCTAGCATATTAATAGTCTACAGCACTG
CAGACTAGAATTGAGCTGTGTTTCCTTTGCAGGTTTGGCTTCAGT
GCCAGTGTTTGTGGGATATGCAGGCAGAAAACATTTACAACAGGC
TAGGGGAAGATCTCAACAAGTGGCAAGCTCTCCTGGTCCAGATAA
GGAAAGCCAGAGGAACCTTTGACAATGCGGAAACCAAGAAAGAGT
TTGGTCCGGTGGTGATAGATTACGGCAAGGTGAGCTTGGCTTGTT
40 GTCAAAAGGCACCAGGCAGCCGTAAGATCAGTATTGGTGTGTTGGC
CCTG

The A to G transition (see nucleotide exchange underlined in SEQ ID NO:14) results in an Tyr (Y) to Cys (C) amino acid exchange at aa position 1055 in SEQ ID NO:2.

The mutation was confirmed by sequence analysis of 13 adult $\text{Cra1}^{+/+}$ mice and 5 $\text{Cra1}^{-/-}$ pups, respectively. The complete nucleic acid sequence of the mutant transcript (SEQ ID NO:3) and the complete amino acid sequence of the mutant protein (SEQ ID NO:4) are shown above.

EXAMPLE 7: Method for Production of Mutant Animals of the Invention by Gene Targeting Technology

10 The construction of a recombinant targeting vector to insert a point mutation in exon 13 of the mouse *Dnchc1* gene may be performed according to well known techniques: for example by the Lambda-KO-*Sfi* system of Nehls and Wattler, WO-A2-01/75127.

1. Vector construction

15 In a first step, a 1,5kbp genomic DNA fragment was PCR amplified, representing the left arm of homology of the targeting vector to be constructed. After subsequent subcloning of the PCR fragment into a plasmid vector, for example *pCR 2.1-TOPO* (K4500-01, Invitrogen Corp., Carlsbad, California, USA), according to the manufacturer's instructions, plasmid DNA, bearing the correct *Dnchc1* insert is subject
20 to site-directed mutagenesis, using a *QuickChange Site-Directed Mutagenesis Kit* (200518, Stratagene, La Jolla CA, USA), as outlined in the manufacturer's instructions. The plasmid vector (parental DNA template) and two oligonucleotide primers, each primer complementary to opposite strands of the vector insert and containing the desired point mutation (exon 13, position 3169 of *Dnchc1*cDNA), were
25 denatured and subject to PCR amplification with a proof-reading DNA polymerase (*Pfu* Turbo), provided in the kit. Using the non-strand displacing action of *Pfu* Turbo DNA polymerase, mutagenic primers were incorporated and extended, resulting in nicked circular DNA strands. In a restriction digest with *DpnI*, only the methylated parental parental DNA template was susceptible to *DpnI* digestion. After
30 transformation in XL1-Blue supercompetent cells, provided with the kit, nicks in the mutated (point mutation) plasmid DNA were repaired. Mutation positive colonies were selected and plasmid DNA was isolated, according to the manufacturer's instructions (Stratagene, La Jolla CA, USA).

Plasmid DNA, bearing the point mutation in exon 13, as described in the present invention, was subject to PCR amplification with primers, bearing *Sfi*C and *Sfi*A sequence overhangs, respectively, as described in the published patent application WO-A2-01/75127. The PCR fragment, representing the left arm of homology was further processed as described in the aforementioned patent application. The vector described in WO-A2-01/75127, includes a linear lambda vector (lambda-KO-*Sfi*) that comprises a stuffer fragment, an *E. coli* origin of replication, an antibiotic resistance gene for bacteria selection, two negative selection markers suitable for use in mammalian cells, and LoxP sequences for cre-recombinase mediated conversion of linear lambda phages into high copy plasmids. In a final lambda targeting vector, the stuffer fragment was replaced by *Sfi* A,B,C,D ligation of the left arm of homology (bearing the Dnchc1 point mutation in exon 13), an ES cell selection cassette, and a right arm of homology, as described in the aforementioned patent application. In-vitro packaging of the ligation products, plating of a phage library, plasmid conversion, and DNA isolation of the homologous recombination plasmid vector is performed according to standard procedures known to persons skilled in the art.

2. ES Cell Transformation and Production of Mice

Targeting vectors containing the point mutation were used for mouse ES cell transformation and to producing chimeric mice by blastocyst injection and transfer using standard methodology, well known in the art. The chimeras were bred to wild type mice to determine germline transmission. Heterozygotes and subsequently homozygotes were generated according to well-known techniques.

EXAMPLE 8: Method for the Detection of Nucleic Acid of the Present Invention: Mutation Detection using a Polymorphic *Rsa*I Restriction Site

The nucleotide transition A to G in the nucleic acid sequence of the Dnchc1 gene results in the disappearance of a restriction site for the restriction enzyme *Rsa*I. As a result, the restriction pattern of the nucleic acid sequence of Dnchc1 will differ between the wild type and the mutant sequence. Diagnostic analysis was applied on amplified fragments from nucleic acids extracted from mutant and wild type mice as

already described in the example. PCR and restriction steps were performed as follows.

The PCR reactions were carried out on 10ng genomic DNAs using primers
5 Dnchc1-25

(5'-TCCAAGACTTTGAAGTGAGGTTC, located in intron 12, SEQ ID NO:15) and Dnchc1-26 (5'-CAGGGCCAAACACCAATACT, located in intron 13, SEQ ID NO:16), generating PCR products of either SEQ ID NO:13 (including the wild type exon 13 sequence) or SEQ ID NO:14 (including the mutant exon 13
10 sequence). The products have a size of 364 bp.

PCR reactions were performed in 25 µl using *Taq*-DNA polymerase (SIGMA, Deisenhofen, Germany) according to the manufacturer's protocol. A further 4 minute denaturation step was followed by 28 cycles of denaturation at 94°C for 30 seconds;
15 annealing at 55°C for 30 seconds; and 90 seconds extension at 72°C or the enzymatic digestion, 7 µl of PCR reaction, 10 µl H₂O, 2 µl NEB buffer 1 and 1 unit *RsaI* (New England BioLabs, Inc., Beverly MA, USA) were incubated at 37°C for 2 hours. Restriction fragments were size separated by electrophoresis on 2% agarose gels (SeaKem ME agarose, Biozym Diagnostik GmbH, Hess. Oldenburg, Germany) with
20 0.5 µg ethidium bromide ml⁻¹ agarose. Gels were photographed after 2 hours electrophoresis at 3 V m⁻¹. The presence of the point mutation deletes the *RsaI* site present in the PCR product of the wild type. This results in the appearance of a non-restricted fragment of 364 bp in the *Cra1*^{-/-} mutant samples in contrast to two restriction fragments of 136 bp and 228 bp in the wild type. This procedure even
25 allows the discrimination of heterozygous and homozygous *Cra1* mutants.

EXAMPLE 9: Identification of the Full-Length cDNA Sequence of Human DNCH1

No full-length cDNA sequences of the human DNCH1 gene have been
30 published. Here, we disclose a full-length cDNA sequence of the human DNCH1 gene, which has the highest homology to the coding sequence of the orthologous mouse gene, Dnchc1 (mRNA sequence published as Genbank Accession No. AY004877).

Although incomplete human DNCH1 mRNA sequences, and several EST sequences containing partial sequences of human DNCH1, have been published, construction of the correct, full-length sequence for human DNCH1 cDNA has not
5 previously been achieved, perhaps as a consequence of the large size of the transcript, approximately 14.5 kb. Sequencing of several full-length cDNA clones generated from RNA of various human tissues obtained from independent sources confirms the sequence disclosed herein as SEQ ID NO:17. Particular attention is required to prevent RNA degradation, especially in those tissues known to exhibit high RNase
10 activity (*e.g.* brain tissues); the use of fresh tissue being especially important.

EXAMPLE 10: Comparison of the Full-Length cDNA Sequences of Human DNCH1 and Mouse Dnchc 1

An exon structure comparison, as schematically depicted in Fig. 7, indicates an
15 almost perfect identity in exon number and exon lengths between the mouse cytoplasmic dynein heavy chain1 (Dnchc 1) and the human cytoplasmic dynein heavy chain1 (DNCH 1) cDNAs. Exonic sequences were aligned with Sequencher software (version 4.0.5, GeneCodes Corp., Ann Arbor MI, USA).

20 Figure 8 exhibits a comparative listing of all mouse (MmDnchc1) and human (Hs DNCH1) cytoplasmic dynein heavy chain1 gene exons. The size of each exon is indicated in length by basepairs (bp). The human gene consists of 78 exons, and the mouse gene consists of 77 exons. The difference is caused by an additional RNA splice event in human, separating exon 67 (61 bp) and exon 68 (124 bp). The total
25 lengths of the cDNAs are 13.941 bp in human DNCH 1, and 13.935 bp in mouse Dnchc 1.

EXAMPLE 11: Characteristics of Human and Mouse Cytoplasmic Dynein Heavy Chain1 Protein

30 The human ortholog of the mouse cytoplasmic dynein heavy chain1 protein, human cytoplasmic dynein heavy chain1 protein, has a length of 4646 amino acid residues (in comparison to 4644 for the corresponding mouse protein). Figure 9 represents an amino acid alignment of human DNCH 1 and mouse Dnchc 1, with

black boxes indicating amino acid identity, and grey boxes indicating amino acid similarity. The amino acid identity is 97%, indicating that these are true orthologs.

EXAMPLE 12: Detection of Transcriptionally Deregulated Genes Expressed in the Brain

A series of genes selected for their putative biological relevance to cytoplasmic dynein heavy chain1 function were analysed for altered RNA expression levels in the brain of homozygous Cra1 mice, in comparison to expression levels in brain of wild type mice.

Significantly altered expression levels were found for those genes listed in Figure 6. Transcriptional deregulation was determined by quantitative PCR-Light Cycler technology (Roche Diagnostics GmbH, Mannheim, Germany), according to the manufacturer's instructions.

EXAMPLE 13: Exons 12 and 13

Exon 13 is critical for activity of the cytoplasmic dynein heavy chain1, as demonstrated by the altered activity of the mouse protein bearing the amino acid substitution at position 1055, encoded by exon 13, the causative point mutation being located close to the 5' end of exon 13. The nucleotide sequence of exon 13 of the mouse wild type Dnchc 1 is provided as SEQ ID NO:19.

Table 12. Nucleotide sequence of mouse exon 13 (SEQ ID NO:19)

```
GT TTGGCTTCAGTACCA GTGTTTGTGGGATATGCAGGCAGAAAAC
ATTTACAACAGGCTAGGGGAAGATCTCAACAAGTGGCAAGCTCTC
CTGGTCCAGATAAGGAAAGCCAGAGGAACCTTTGACAATGCGGAA
ACCAAGAAAGAGTTTGGTCCGGTGGTGATAGATTACGGCAAG
```

As the causative point mutation is close to the 5' end of exon 13, it is probable that the amino acid sequence encoded by exon 12 also has a significant influence on the activity of the protein.

SEQ ID NO:20 indicates the nucleotide sequence of exons 12 plus 13 of the mouse wild type Dnchc 1.

Table 13. Nucleotide sequence of mouse exon12 and 13 (SEQ ID NO:20)

GTGGGAGTGCATTACGAGTTGACAGAGGAAGAGAAGTTCTATCGG
AATGCACTGACAAGGATGCCCCGACGGCCCTGTCGCCCTGGAAGAG
5 TCCTACTCTGCGGTCATGGGCATAGTGACTGAAGTTGAGCAGTAT
GTTAAGGTTTGGCTTCAGTACCAGTGTTTGTGGGATATGCAGGCA
GAAAACATTTACAACAGGCTAGGGGAAGATCTCAACAAGTGGCAA
GCTCTCCTGGTCCAGATAAGGAAAGCCAGAGGAACCTTTGACAAT
GCGGAAACCAAGAAAGAGTTTGGTCCGGTGGTGATAGATTACGGC
10 AAG

The amino acid sequences encoded by exons 12 plus 13 are located within a region known to be important for heavy chain dimerization (Tynan *et al.* (2000) J Biol Chem 275, 32769-32774). Therefore these amino acid sequences, and the peptide
15 sequences encoded by the corresponding exons in other mammalian systems, may be used as targets for inactivation of the protein by small molecules, antibodies, antibody fragments, aptamers and other molecules designed to bind thereto.

20 **Table 14. Amino acid sequence encoded in-frame by nucleotide sequences of mouse exon 13 (SEQ ID NO:21)**

VWLQYQCLWDMQAENIYNRLGEDLNKWQALLVQIRKARGTFDNAE
TKKEFGPVVIDYGK
25

Table 15. Amino acid sequence encoded in-frame by nucleotide sequences of mouse exon 12 and 13 (SEQ ID NO:22)

30 VGVHYELTEEEKFYRNALTRMPDGPVALEESYSAVMGIVTEVEQY
VKVWLQYQCLWDMQAENIYNRLGEDLNKWQALLVQIRKARGTFDN
AETKKEFGPVVIDYGK

The corresponding human peptide sequences, encoded by human exon 13 (SEQ ID NO:23), or human exon 12 and 13 (SEQ ID NO:24), are preferred embodiments of the invention.

5

Table 16. Amino acid sequence encoded in-frame by nucleotide sequences of human exon 13 (SEQ ID NO:23)

VWLQYQCLWDMQAENIYNRLGEDLNKWQALLVQIRKARGTFDNAE
10 TKKEFGPVVIDYGK

Table 17. Amino acid sequence encoded in-frame by nucleotide sequences of human exon 12 and 13 (SEQ ID NO:24)

15

VGVHYELTEEEKFYRNALTRMPDGPVALEESYSAVMGIVSEVEQY
VKVWLQYQCLWDMQAENIYNRLGEDLNKWQALLVQIRKARGTFDN
AETKKEFGPVVIDYGK

Table 18. Amino acid sequence encoded in-frame by nucleotide sequences of human exon 12 and 13 (SEQ ID NO:24)

VGVHYELTEEEKFYRNALTRMPDGPVALEESYSAVMGIVSEVEQY
VKVWLQYQCLWDMQAENIYNRLGEDLNKWQALLVQIRKARGTFDN
25 AETKKEFGPVVIDYGK

EXAMPLE 14: Gene Therapy

A number of viruses, including retroviruses, adenoviruses, herpes viruses, and
30 pox viruses, have been developed as live viral vectors for gene therapy. A nucleic acid that codes for mutated cytoplasmic dynein heavy chain1 protein (e.g. SEQ ID NO:4, SEQ ID NO:6) is inserted into the genome of a parent virus to allow it to be expressed by that parent virus. This task is accomplished by first constructing a DNA donor vector for *in vivo* recombination with a parent virus.

The DNA donor vector contains:

- (i) a prokaryotic origin of replication, so that the vector may be amplified in a prokaryotic host;
- 5 (ii) a gene encoding a marker which allows selection of prokaryotic host cells that contain the vector (*e.g.* a gene encoding antibiotic resistance);
- (iii) at least one gene encoding a desired protein located adjacent to a transcriptional promoter capable of directing the expression of the gene; and
- (iv) DNA sequences homologous to the region of the parent virus genome
- 10 where the foreign gene or genes will be inserted, flanking the construct of element (iii).

The donor vector further contain additional genes which encodes one or more marker which will allow identification of recombinant viruses containing inserted

15 foreign DNA. The marker genes to be used include genes that encode antibiotic or chemical resistance (*e.g.* see Spyropoulos *et al.* (1988) J Virol 62, 1046-1054; Falkner and Moss (1988) J Virol 62, 1849-1854; Franke *et al.* (1985) Mol Cell Biol 5, 1918-1924), as well as genes such as the *E. coli lacZ* gene, that permit identification of recombinant viral plaques by calorimetric assay (Panicali *et al.* (1986) Gene 47,

20 193-199).

Homologous recombination between donor plasmid DNA and viral DNA in an infected cell are made using standard techniques. The recombination results in the formation of recombinant viruses that incorporate the nucleic acid encoding SEQ ID

25 NO:4. Appropriate host cells for *in vivo* recombination are eukaryotic cells that can be infected by the virus and transfected by the plasmid vector such as, for example, chick embryo fibroblasts, HuTK143 cells (human cells), and CV-1 and BSC-40 cells (both monkey kidney cells). Infection of cells by the virus and transfection of these cells with plasmid vectors is accomplished by techniques standard in the art.

30

Following *in vivo* recombination, recombinant viral progeny are identified by co-integration of a gene encoding a marker or indicator gene with the foreign gene or genes of interest, which, in this case, is the β -galactosidase gene. The presence of the β -galactosidase gene is selected using the chromogenic substrate 5-bromo-4-chloro-3-

indolyl- β -D-galactosidase (Panicali *et al.* (1986) Gene 47, 193). Recombinant virus appears as blue plaques in a lawn of the host cells. Expression of the polypeptide encoded by the inserted gene is further confirmed by *in situ* enzyme immunoassay performed on viral plaques and confirmed by Western blot analysis, radioimmunoprecipitation assay (RIPA), and/or enzyme immunoassay (EIA). Positive viruses are cultured and expanded and stored.

In gene therapy, B cells are collected from peripheral blood of a patient and infected at MOI of 1, 2, 4, 8, 10 and 20. Expression of the cytoplasmic dynein heavy chain1 is assayed 24 hours post-infection. Wild type virus is used as the negative control. The percent of cells transduced as a function of MOI and days after infection was determined by antibody and chromogenic substrate assays described above. B cells tranfected at high efficiency are reintroduced into the patient.

EXAMPLE 15: Transgenic animal model bearing transgenic cytoplasmic dynein heavy chain1

Transgenic mice carrying a mammalian dynein heavy chain 1 transgene are generated by either using the embryonic stem cell method, or the pronucleus method, both of them well-known methods in the art; preferably using the method of Nehls and Wattler, as described in WO-A2-01/75127. For transgenic methods see also US patents US6436701, US6018097, US5942435, US5824837, US5731489, and US5523226.

EXAMPLE 16: In vitro dynein motility assay

Abnormalities in axonal transport are described in the human disease ALS (Sasaki and Iwata (1996) Neurology 47, 535-540). Such abnormalities are also observed in several mouse models with motor neuron degeneration, *e.g.* the wobbler mouse (Mitsumoto *et al.* (1986) Ann Neurol 19, 36-43) and transgenic mice overexpressing the heavy chain of neurofilament protein (Collard *et al.* (1995) Nature 375, 61-64), SOD-1 (Zhang *et al.* (1997) J Cell Biol 139, 1307-1315) and dynamitin (LaMonte *et al.* (2002) Neuron 34, 715-727). Studies in *Drosophila* have shown that mutations in the cytoplasmic dynein heavy chain (cDhc64c) lead to a disruption of axonal organelle transport in both directions and as a consequence to axonal swelling and posterior paralysis (Martin *et al.* (1999) Mol Biol Cell 10, 3717-3728).

A microtubule gliding assay is performed based on a commercial assay offered by Cytoskeleton, Inc. (Denver, CO, USA). In brief, the assay involves coating a glass slide with the protein of interest and then examining, by time-lapse or by real time
5 microscopy, the protein's ability to translocate microtubules in the presence of ATP. Cytoplasmic dynein heavy chain 1 proteins, carrying non-conserved amino acid substitutions at residue positions as highlighted in Figures 9 and 10, and listed in Example 19, are over-expressed either in a bacterial, or in an eucaryotic expression system. A preferred method is the cDNA subcloning into expression vectors of the
10 Gateway cloning and expression system (Invitrogen, California, USA), according to the manufacturer's instructions. Purification of recombinant dynein heavy chain 1 from host cells can be performed using standard methods well-known to those skilled in the art. For standard references, see in Sambrook et al. (eds.), MOLECULAR CLONING: A LABORATORY MANUAL (2nd Ed.), Cold Spring Harbor Laboratory Press,
15 Cold Spring Harbor, NY, 1989; and Ausubel et al. (eds.), CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, NY, 1993.

Differences in proteins ability to translocate microtubules in the presence of ATP, whereby the proteins carry particular non-conserved amino acid substitution, are indicative of functional domains of dynein heavy chain 1 in axonal transport.

20

EXAMPLE 17: Interaction of the dynein complex with the EAAT2 glutamate transporter

A direct link between the Cra1 mouse line and the excitotoxicity hypothesis
25 for ALS, as described in the background of the Invention, is the excitatory neuronal damage detected in the brains of heterozygote Cra1 animals. Comparable defects have been found in the brains of mice lacking EAAT2, an glutamate transporter (Tanaka et al., Science vol.276, 1699-1702, june 1997).

Co-immunoprecipitation studies using antibodies raised against the
30 cytoplasmic dynein heavy chain 1, the 74 kDa intermediate chain, the dynactin p150 component and against the EAAT2 transporter in various combinations are performed using brain homogenates of wild type mice, Cra1 homozygotes, and Cra1 heterozygotes. Anti dynein heavy chain 1 antibodies are raised against epitopes, which carry non-conserved amino acid substitutions of those amino acid residues highlighted

in Figures 9 and 10, and listed in Example 19. Protein expression vectors and antibodies are generated as described, in example, in Ausubel et al., Current protocols in Molecular Biology, Massachusetts general Hospital, Harvard Medical School, 1996 by John Wiley and Sons, Inc.). Antibodies raised against the 74 kDa intermediate chain, the dynactin p150 component and against the EAAT2 transporter are commercially available (anti-EAAT2 antibody from Accurate Chemical and Scientific Corp; anti-74 kDa intermediate chain antibody from Chemicon Int. Corp.; anti-dynactin p150 antibody from BD Transduction Laboratories). Co-Immunoprecipitation studies are well known in the art and are performed as described, for example, in Ausubel et al., Current protocols in Molecular Biology, Massachusetts general Hospital, Harvard Medical School, 1996 by John Wiley and Sons, Inc.).

The results of the assay are indicative for dynein heavy chain 1 function in EAAT2 glutamate transporter/dynein motor complex interaction. Functional amino acid residues are identified.

EXAMPLE 18: Quantitative Binding Study

To investigate a possible influence of an cytoplasmic dynein heavy chain 1 mutation on the whole dynein complex, which might result in an impaired transport process, quantitative binding studies are performed. Surface plasmon resonance (SPR) spectroscopy, such as, in example, in the Biacore technology (Biacore AB, Uppsala, Sweden) is an appropriate tool. By this method the interaction of two molecules binding each other is described by two rate parameters, the association rate parameter $k(a)$ and the dissociation rate parameter $k(d)$. Under standardized conditions these kinetic parameters can be determined by analysis of their interaction in an affinity-based biosensor system. The association rate describes the collision frequency and the attraction between two molecules. The dissociation rate describes the stability of the complex.

30

Using the SPR technique, the affinity of mutated dynein heavy chain domains, carrying non-conserved amino acid substitutions of the residues highlighted in Figures 9 and 10, and listed in Example 19, to other components of the dynein complex are analysed.

In similar studies the influence of mutations on protein – protein affinities have been studied (Hobba et al., J Biol Chem 273(31):19691-19698) 1998; Starling et al., J Exp Med 185(8):1487-1492, 1997).

5

EXAMPLE 19: Characterization of dynactin/dynein complex proteins from different species – amino acid conservation

Inter-species comparison of mouse and human dynein heavy chain 1, dynein intermediate chain 1, dynein intermediate chain 2, and DCTN 1 amino acids was performed. The degree of identity and the degree of similarity are summarized in the following table:

10

Protein of the dynactin/dynein complex	Degree of Identity	Degree of Similarity
Dynein heavy chain1	97%	98%
Dynein intermediate chain 1	88%	89%
Dynein intermediate chain 2	94%	95%
DCTN 1	97%	98%

The high degree of amino acid identity and similarity is indicative for highly conserved residues between the species indicating functional significance of these conserved residues in the proteins compared in this Example, see Figures 9, 11, 13 and 15. The amino acid being exchanged in dynein heavy chain 1 (1055Y to C, as described in the invention herein) is conserved between the species compared, as indicated in Figure 9.

15

20

In an inter-species comparison of mouse, human, and rat dynein heavy chain 1, dynein intermediate chain 1, dynein intermediate chain 2, and DCTN 1 amino acids was performed, the degree of identity and the degree of similarity are summarized in the following table:

25

Protein of the dynactin/dynein complex	Degree of Identity	Degree of Similarity
---	--------------------	----------------------

Dynein heavy chain1	95%	96%
Dynein intermediate chain 1	87%	88%
Dynein intermediate chain 2	93,5%	94,5%
DCTN 1	95%	96%

The high degree of amino acid identity and similarity is indicative for highly conserved residues between the species indicating functional significance of these conserved residues in the proteins compared in this Example, see Figure 10, 12, 14, and 16. The amino acid being exchanged in dynein heavy chain 1 (1055Y to C, as described in the invention herein) is conserved between the species compared, as indicated in Figure 10.

For several subunits of the dynactin/dynein complex, several binding domains are predicted, with which the individual proteins of the dynactin/dynein complex binds to other subunits of the complex. The binding domains of several proteins, which are subunits of the dynactin/dynein complex are summarized in respect to the amino acids positions:

a) With respect to mouse Dnchc1 the following domains and binding sites are predicted, which are summarized in respect to the amino acid positions of the mouse Dnchc1 protein:

heavy chain dimerization domain (Hcd) between amino acids 300 and 1140; 74 kDa intermediate chains binding domain (Icd) between amino acids 446 and 701; 53-59 kDa light intermediate chains binding domains (Lcds) between amino acids 649 and 800 (Tynan *et al.* (2000) J Biol Chem. 275, 32769-32774).

b) With respect to cytoplasmic dynein intermediate chain 1 the following binding domains are predicted, which are summarized in respect to the amino acid positions of the mouse cytoplasmic dynein intermediate chain 1 protein:

10 kDa light chain binding domain (10kDad) between amino acids 147 and 157 (Lo *et al.*, J.Biol. Chem. 276(17):14059-14066, 2000); light chain 2B binding domain (2Bd) between amino acids 243 and 314 (Susalka *et al.*, J. Biol. Chem. 277(36):32939-32946, 2002); Tctex1 binding domain (Tctex1d) between amino acid 140 and 157 (Mok *et al.* J. Biol. Chem. 276(17):14067-14074, 2001); p150 binding

domain (p150d) between amino acid 1 and 123 (see in Susalka et al., J. Biol. Chem. 277(36):32939-32946, 2002).

c) For mouse cytoplasmic dynein intermediate chain 2 several binding
5 domains are predicted, which are summarized in respect to the amino acid positions of the mouse cytoplasmic dynein intermediate chain 2 protein:

10 kDa light chain binding domain (10kDad) between amino acids 129 and 139; light chain 2B binding domain (2Bd) between amino acids 226 and 297; Tctex1 binding domain (Tctex1d) between amino acid 122 and 139; p150 binding domain
10 (p150d) between amino acid 1 and 123 (see in Susalka et al., J. Biol. Chem. 277(36):32939-32946, 2002).

d) For mouse p150 (DCTN 1) several binding domains are predicted, which are summarized in respect to the amino acid positions of the mouse p150
15 protein:

microtubule binding domain (Microtd) between amino acids 39 and 150 (Waterman-Storer et al, P.N.A.S. 92:1634-1638, 1995); ARP1 binding domain (ARP1d) between amino acids 1006 and 1021 (see in Waterman-Storer et al, P.N.A.S. 92:1634-1638, 1995); cytoplasmic dynein intermediate chain binding domain (Dicd)
20 between amino acid 133 and 899 (Karki and Holzbaur, J. Biol. Chem. 270:28806-28811, 1995).

In an inter-species comparison of the amino acids of the corresponding mouse and human proteins, the degree of conserved (i.e. identical and similar) amino acids in
25 these domains and binding sites is summarized in the following tables:

Cytoplasmic dynein heavy chain 1	
Binding site to	Degree of conservation
Hcd	99,5%
Icd	99%
Lcds	99,5%

Cytoplasmic dynein intermediate chain 1

Binding site to	Degree of conservation
10kDad	100%
2Bd	98,6%
Tctex1d	100%
P150d	86,2%

Cytoplasmic dynein intermediate chain 2	
Binding site to	Degree of conservation
10kDad	90%
2Bd	98,6%
Tctex1d	94%
P150d	74%

P150 (DCTN 1)	
Binding site to	Degree of conservation
Microd	98%
ARP1d	100%
Dicd	98,5%

In an inter-species comparison of the amino acids of the corresponding mouse,
 5 rat, and human proteins, the degree of conserved (i.e. identical and similar) amino
 acids in these domains and binding sites is summarized in the following tables:

Cytoplasmic dynein heavy chain 1	
Binding site to	Degree of conservation
Hcd	99%
Icd	99%
Lcds	99%

Cytoplasmic dynein intermediate chain 1	
Binding site to	Degree of conservation
10kDad	100%
2Bd	98,6%

-181-

Tctex1d	100%
P150d	85,3%

Cytoplasmic dynein intermediate chain 2*	
Binding site to	Degree of conservation
10kDad	90%
2Bd	98,6%
Tctex1d	94%
P150d	74%

*(mouse and rat amino acid sequences are 100% identical for cytoplasmic dynein intermediate chain 2)

P150 (DCTN 1)	
Binding site to	Degree of conservation
Microd	98%
ARP1d	100%
Dicd	98,7%

- 5 In an inter-species comparison of cytoplasmic dynein heavy chain 1 amino acid sequences of the species mouse, human, rat, *Drosophila*, and *C. elegans*, the degree of conserved (i.e., identical and similar) amino acids in these domains and binding sites is the following:

Cytoplasmic dynein heavy chain 1	
Binding site to	Degree of conservation
Hcd	64%
Icd	70%
Lcds	61%

10

Conserved amino acid residues within the defined binding domains of the individual proteins are listed in Table 19, 20, 21, and 22.

15

Evolutionary pressure has conserved these residues at their particular locations in the molecule. It is predicted that any non-conservative amino acid substitution will modify the protein's normal biological function in a manner analogous to that observed in the present invention. Hence, identification of such an abnormal cytoplasmic dynein intermediate chain 1 protein sequence in a biological sample, or of the a DNA encoding such an abnormal cytoplasmic dynein intermediate chain 1 protein, will be indicative of an increased probability of developing the phenotype of the present invention.

EXAMPLE 20: Mutation Detection at Human Patient Samples by Heteroduplex Analysis using Temperature Gradient Capillary Electrophoresis (TGCE) – Mutation Detection in Exon 13 of Human Cytoplasmic Dynein Heavy Chain 1 (DNCH1)

Assay Description: Human genomic DNA is isolated and is subject to PCR amplification according to standard methods in the art, in example, as described in Example 6. For detection of mutations with unknown positions in PCR amplified DNA fragments, double-stranded (ds) DNA is electrophoresed through a temporal gradient of increasing temperature (Temperature Gradient Capillary Electrophoresis (TGCE); RevealSystem, SCE9610, by SpectruMedix LLC, State College, PA, USA). Because retardation of dsDNA during electrophoresis is greatest at the temperature of partial denaturation, DNA fragments of the same size can be separated according to their thermodynamic stabilities. Base mismatches within dsDNA molecules (heteroduplices) lead to a significant destabilization resulting in significant differences in melting temperatures (T_m) between heteoduplices and perfectly paired dsDNA (homoduplices). Such differences in T_m allow the separation of heteroduplices from homoduplices in a temperature gradient electrophoresis and serve as the basis for mutation detection by TGCE.

Detection of point mutations in exon 13: For detection of homo- or heterozygous mutations, an equimolar mixture of chromosomal DNA from 5 to 10 healthy individuals is prepared. An equimolar amount of this template DNA (healthy individuals) is added to each sample DNA (patient), and the target region is amplified

-183-

using a standard PCR reaction with gene specific primers. For analysis of human DNCH1 exon 13, a 290 bp DNA fragment containing all exon 13 DNA sequence, was generated with the following intronic primers:

5	<u>primer</u>	<u>sequence</u>	<u>location in intron no.</u>
	hDnchc1-21 (SEQ ID NO: 26)	5'-TGTGAACATAAGAGGTGCCAGT	12
	hDnchc1-22 (SEQ ID NO: 27)	5'-CTACCCGTGACACCTTTCAA	13

10 Following the manufacturers instructions, hybrids of wildtype and mutant sequences are formed in a denaturation/renaturation step, transforming base pair exchanges into heteroduplices with lower thermal stability. A typical temperature profile for denaturation/renaturation is:

- 15 • heat sample to 95°C and hold for 3 min
- decrease from 95°C to 80°C at 3°C/min
- decrease from 80°C to 55°C at 1°C/min
- hold 20 min at 55°C
- decrease from 55°C to 45°C at 1°C/min
- 20 • decrease from 45°C to 25°C at 2°C/min

 Depending on the DNA concentration obtained in the PCR reaction the sample is diluted in a range of 1:10 to 1:50 and subjected to TGCE. Washing, dilution and running buffers are supplied by the manufacturer. Typical operation parameters for

25 TGCE are:

- Prerun: 25 min
- Injection voltage: 3-8 kV
- Injection time: 3-10 sec.
- 30 • Running voltage: 10 kV
- Electrophoresis time: 60 min

The applied temperature gradient during electrophoresis depends on the base composition (G+C content) of the analyzed fragment and ranges from 55°C to 70°C. For the 290 bp exon 13 fragment of hDNCH1 a temperature gradient from 55°C to 65°C with a ramp time of 21 min was applied.

5

Upon completion the obtained electrophoresis pattern is analyzed for additional bands resulting from decreased mobility of heteroduplices during TGCE, using the manufacturers software program Revelation 2.10. Candidate fragments are further analyzed by DNA sequencing, using the method described in Example 6,

10 Section DNA Sequence Analysis.

Table 19. Conserved amino acid residues in binding domains Hcd, Icd, and Lcd of Dnchc1 of mouse (*M. musculus*), rat (*R. norvegicus*), human (*H. sapiens*), *Drosophila melanogaster*, and *Caenorhabditis elegans*:

- conserved residues numbered as mouse Dnchc1 amino acid positions.

302L	303K	305G	306K	307R	308F	309H	310A	311T	312V	314F	315D	317D	319G
320L	321K	322Q	324L	327V	329D	330Y	331N	333L	334M	335K	337F	338P	342L
344S	345A	346T	350K	354A	358I	359F	361H	362L	363R	364K	366R	368T	369K
370Y	371P	373Q	374R	376L	378L	380E	381A	382I	383S	384R	385D	386L	389Q
390L	391L	392K	393V	394L	399L	400M	406E	407F	411M	414C	418F	421W	422D
423D	424E	425Y	427K	431L	432L	433R	434D	435I	437K	439K	440R	445K	448W
454H	457L	460R	467F	468R	470Q	471H	472E	473Q	475R	477V	478I	480R	481V
482L	483R	484P	519E	521V	524A	525Y	526E	529K	531V	532D	534L	535D	543A
544W	545E	547A	549K	550R	551Y	555I	558V	559E	560T	562I	563T	566L	569Q
570L	575N	577N	578E	579M	580F	582I	583F	584S	585R	587N	588A	589L	590F
592R	593P	595I	596R	597G	598A	599I	601E	602Y	603Q	604T	606L	607I	609R
610V	611K	613D	614I	617L	621F	639L	640P	641P	646W	655Q	656L	659Y	661K
662R	663V	664E	665D	666V	667L	668G	669K	671W	672E	674H	677G	680L	681K
683D	684G	685D	687F	690F	691L	697F	700W	704V	705N	715I	717T	731L	733L
736N	744L	764K	747E	748V	752K	755G	756F	757R	758V	759P	760L	762I	763V
764N	766A	767H	768Q	769A	770N	771Q	774P	776A	778S	779L	780I	781E	784R
785T	802L	804A	808K	816E	817G	820L	822W	824S	825Y	826K	828D	830Y	834L
836E	838V	842Q	843E	848L	849L	862L	865C	867Y	871T	876L	880Q	883V	884D
886L	888L	891Y	892S	893N	894L	897W	898V	899N	901L	902D	906E	909L	912R
920W	921T	951P	955N	957V	963T	965Q	968Y	971P	975E	977R	987W	1001R	1003Q
1017Y	1019N	1021L	1025P	1027G	1031L	1032E	1035Y	1048Y	1052W	1053L	1055Y	1056Q	1058L
1059W	1062Q	1063A	1070L	1071G	1077W	1081L	1084I	1088R	1091F	1092D	1096T	1102P	1107Y
1109K	1111Q	1113K	1117K	1118Y	1119D	1121W	1122H	1123K	1124E	1126L	1128K	1129F	1130G
1134G	1137W	1140F											

5

Explanation of amino acid single letter code:

A=Ala C=Cys D=Asp E=Glu F=Phe G=Gly H=His I=Ile N=Asn
P=Pro Q=Gln R=Arg S=Ser T=Thr V=Val K=Lys L=Leu M=Met
W=Trp Y=Trp

Binding Domains

P150d = binding domain for p150 protein
Tctex1d = binding domain for Tctex1 protein
10kDad = binding domain for 10kDa light chain
2Bd = binding domain for 2B light chain protein

Table 20. Conserved amino acid residues in binding domains p150d, Tctex1d, 10kDad, and 2Bd of cytoplasmic dynein intermediate chain1 of mouse (*Mus musculus*), rat (*Rattus norvegicus*), and human (*Homo sapiens*)

conserved residues numbered as human cytoplasmic dynein heavy chain 1 amino acid positions

A. Conserved amino acid residues in binding domain p150d

1M	2S	3D	4K	5S	6D	7L	8K	9A	10E	11L	12E	13R	14K
15K	16Q	17R	18L	19A	20Q	21I	22R	23E	24E	25K	26K	27R	28K
29E	30E	31E	32R	33K	34K	35K	36E	37A	38D	39M	40Q	41Q	42K
43K	44E	45P	46V	48D	49D	50S	51D	52L	53D	54R	55K	56R	57R
58E	59T	60E	61A	62L	63L	64Q	65S	66I	67G	68I	69S	70P	71E
72P	73P	74L	75V	93P	94T	95P	96M	97S	98P	99S	100S	101K	102S
103V	104S	105T	106P	107S	109A	110G	111S	112Q	113D	116D	117L	118G	119P
120L	121T	122R	123T	124L	125Q	126W	127D	128T	129D	130P	131S	132V	133L
134Q	135L	136Q	137S	138D	139S	140E							

5

B. Conserved amino acid residues in binding domain Tctex1d

157F	158L	159P	160R	161E	162V	163V	164S	165Y	166S	167K	168E	169T	170Q
171T	172P	173L	174A										

C. Conserved amino acid residues in binding domain 10kDad

164S	165Y	166S	167K	168E	169T	170Q	171T	172P	173L	174A

10

D. Conserved amino acid residues in binding domain 2Bd

260L	261E	262E	263K	264D	265G	266D	267V	268Q	269A	270G	271A	272N	273L
274S	275F	276N	277R	278Q	279F	280Y	281D	282E	283H	284W	285S	286K	287H
288R	289V	290V	291T	292C	293M	294D	295W	296S	297L	298Q	299Y	300P	301E
302L	303M	304V	305A	306S	307Y	309N	310N	311E	312D	313A	314P	315H	316E
317P	318D	319G	320V	321A	322L	323V	324W	325N	326M	327K	328F	329K	330K
331T													

Explanation of amino acid single letter code:

A=Ala C=Cys D=Asp E=Glu F=Phe G=Gly H=His I=Ile N=Asn
P=Pro Q=Gln R=Arg S=Ser T=Thr V=Val K=Lys L=Leu M=Met
W=Trp Y=Tyr

Binding Domains

P150d = binding domain for p150 protein
Tctex1d = binding domain for Tctex1 protein
10kDad = binding domain for 10kDa light chain
2Bd = binding domain for 2B light chain protein

Table 21. Conserved amino acid residues in binding domains p150d, Tctex1d, 10kDad, and 2Bd of cytoplasmic dynein intermediate chain 2 of mouse (*Mus musculus*), rat (*Rattus norvegicus*), and human (*Homo sapiens*)

conserved residues numbered as human cytoplasmic dynein heavy chain 2 amino acid positions

A. Conserved amino acid residues in binding domain p150d

1M	2S	3D	4K	5S	7L	8K	9A	10E	11L	12E	13R	14K	15K
16Q	17R	18L	19A	20Q	21I	22R	23E	24E	25K	26K	27R	28K	29E
30E	31E	32R	33K	34K	35K	36E	37T	38D	39Q	40K	41K	42E	43A
47V	48Q	49E	50E	51S	52D	53L	54E	55K	56K	57R	58R	59E	60A
61E	62A	63L	64L	65Q	66S	67M	68G	69L	70T	73S	74P	75I	76V
77P	84P	85P	86M	87S	88P	89S	90S	91K	92S	93V	94S	95T	96P
97S	98E	99A	100G	101S	102Q	103D	104S	105G	106D	107G	108A	109V	110G
111S	112R	133R	134G	135P	136I	137K	138L	139G	140M	141A	142K	143I	144T
145Q	146V	147D	148F	149P									

B. Conserved amino acid residues in binding domain Tctex1

148F	149P	150P	151R	152E	153I	154V	155T	156Y	157T	158K	159E	160T	161Q
162T	163P	164V	165M										

10

C. Conserved amino acid residues in binding domain 10kDad

155T	156Y	157T	158K	159E	160T	161Q	162T	163P	164V	165M
------	------	------	------	------	------	------	------	------	------	------

D. Conserved amino acid residues in binding domain 2Bd

252L	253E	254D	255K	256E	257G	258E	259I	260Q	261A	262G	263A	264K	265L
266S	267L	268N	269R	270Q	271F	272F	273D	274E	275R	276W	277S	278K	279H
280R	281V	282V	283S	284C	285I	286D	287W	288S	289S	290Q	291Y	291P	293E
294L	295L	296V	297A	298S	299Y	300N	301N	302N	303E	305A	306P	307h	308E
309P	310D	311G	312V	313A	314L	315V	316W	317N	318M	319K	320Y	321K	322K
323T													

Explanation of amino acid single letter code:

A=Ala C=Cys D=Asp E=Glu F=Phe G=Gly H=His I=Ile N=Asn
P=Pro Q=Gln R=Arg S=Ser T=Thr V=Val K=Lys L=Leu M=Met
W=Trp Y=Tyr

Binding Domains

P150d = binding domain for p150 protein
Tctex1d = binding domain for Tctex1 protein
10kDad = binding domain for 10kDa light chain
2Bd = binding domain for 2B light chain protein

Table 22. Conserved amino acid residues in binding domains Microd, Arp1d, and Dcd of p150 of mouse (*M. musculus*), rat (*rattus norvegicus*) and human (*Homo sapiens*).

conserved residues numbered as human p150 amino acid positions

A. Conserved amino acid residues in binding domain Microd

39G	40H	41R	42G	43T	44V	45A	46Y	47V	48G	49A	50T	51L	52F
53A	54T	55G	56K	57W	58V	59G	60V	61I	62L	63D	64E	65A	66K
67G	68K	69N	70D	71G	72T	73V	74Q	75G	76R	77K	78Y	79F	80T
81C	82D	83E	84G	85H	86G	87I	88F	89V	90R	91Q	92S	93Q	94I
95Q	95Q	96V	97F	98E	99D	100G	101A	102D	103T	104T	105S	106P	107E
107E	108T	109P	110D	111S	112S	113A	114S	115K	117L	118K	119R	120E	121G
123D	126A	127K	128T	129S	130K	131L	132R	133G	134L	135K	136P	137K	138K
139A	140P	141T	142A	143R	144K	145T	146T	147T	148R	149R	150P		

5

B. Conserved amino acid residues in binding domain ARP1

1006R	1007K	1008K	1009E	1010K	1012F	1013E	1014E	1015T	1016M	1017D	1018A	1019L
1020Q	1021A											

C. Conserved amino acid residues in binding domain Dcd.

133G	134L	135K	136P	137K	138K	139A	140P	141T	142A	143R	144K	145T	146T
147T	148R	149R	150P	151K	152P	153T	154R	155P	156A	157S	158T	159G	160V
161A	162G	164S	165S	166S	167L	168G	169P	170S	171G	172S	173a	174S	175A
176G	177E	178L	179S	180S	181S	182E	183P	184S	185T	186P	187A	188Q	189T
190P	191L	192A	193A	194P	195I	196I	197P	198T	199P	201L	202T	203S	204P
205G	206A	208P	209P	210L	211P	212S	213P	214S	215K	216E	217E	218E	219G
220L	221R	223Q	224V	225R	226D	227L	228E	229E	230K	231L	232E	233T	234L
235R	236L	237K	238R	240E	241DE	242K	243A	244K	245L	246K	247E	248L	249E
250K	251H	252K	253I	254Q	255L	256E	257Q	258V	259Q	260E	261W	262K	263S
264K	265M	266Q	267E	268Q	269Q	270A	271D	272L	273Q	274R	275R	276L	277K
278E	279A	281K	282E	283A	284K	285E	286A	287L	288E	289A	290K	291E	292R
293Y	294M	295E	296E	297M	298A	299D	300T	301A	302D	303A	304I	305E	306M
307A	308T	309L	310D	311K	312E	313M	314A	315E	316E	317R	318A	319E	320S
321L	322Q	323Q	324E	325V	326E	327A	328L	329K	330E	331R	332V	333D	334E
335L	336T	337T	338D	339L	340E	341I	342L	343K	344A	345E	346I	347E	348E
349K	350G	351S	352D	353G	354A	355A	356S	357S	358Y	359Q	360L	361K	362Q
363L	364E	365E	366Q	367N	368A	369R	370L	371K	372D	373A	374L	375V	376R
377M	378R	379D	380L	381S	382S	383S	384E	385K	386Q	387E	388H	389V	390K
391L	392Q	393K	394L	395M	396E	397K	398K	399N	400Q	401E	402L	403E	404V
405V	406R	407Q	408Q	409R	410E	411R	412L	413q	414E	415E	416L	417S	418Q
419A	420E	421S	422T	423I	424D	425E	426L	427K	428E	429Q	430V	431D	432A
433A	434L	435G	436A	437E	438E	439M	440V	441E	442M	443L	444T	445D	446R
447N	448L	449N	450L	451E	452E	453K	454V	455R	456E	457L	458R	459E	460T
461V	462G	463D	464L	465E	466A	467M	468N	469E	470M	471N	472D	474L	475Q

476E	477N	478A	479R	480E	481T	482E	483L	484E	485L	486R	487E	488Q	489L
490D	491M	492A	493G	494A	495R	496V	497R	498E	499A	500Q	501K	502R	503V
504E	505A	506A	507Q	508E	509T	510V	511A	512D	513Y	514Q	515Q	516T	517I
518K	519K	520Y	521R	522Q	523L	524T	525A	526H	527L	528Q	529D	530V	531NR
532R	533E	534L	535T	536N	537Q	538Q	539E	540A	541S	542V	543E	544R	545Q
546Q	547Q	548P	549P	550P	551E	552T	553F		554D	555F	556K	557I	558K
559F	560A	561E	562T	563K	564A	565H	566A	567K	568A	569I	570E	571M	572E
573L	574R	575Q	576M	577E	578V	579A	580Q	581A	582N	583R	584H	585M	586S
587L	588L	589T	590A	591F	592M	593P	594D	595S	596F	597L	598R	599P	600G
601G	602D	603H	604D	605C	606V	607L	608V	609L	610L	611L	612M	613P	614R
615L	616I	617C	618K	619A	620E	621L	622I	623R	624K	625Q	626A	627Q	628E
629K	630F	632L	633S	634E	635N	636C	637S	638E	639R	640P	641G	642L	643R
644G	645A	646A	647G	648E	649Q	650L	651S	652F	653A	654A	655G	656L	657V
658Y	659S	660L	661S	662L	663L	664Q	665A	666T	667L	668H	669R	670Y	671E
672H	673A	674L	675S	676Q	677C	678S	679V	680D	681V	682Y	683K	684K	685V
686G	687S	688L	689Y	690P	691E	692M	693S	694A	695H	696E	697R	698S	699L
700D	701F	702L	703I	704E	705L	706L	707H	708K	709D	710Q	711L	712D	713E
714T	715V	716N	717V	718E	719P	720L	722K	724I	725K	726Y	727Y	728Q	729H
730L	731Y	733I	734H	735L	736A	737E	738Q	739P	740E	743T	744M	745Q	746L
747A	748D	749H	750I	751K	752F	753T	754Q	755S	756A	757L	758D	759C	760M
762V	763E	764V	765G	766R	767L	768R	769A	770F	771L	772Q	773G	774G	775Q
776E	777A	778T	779D	780I	781A	782L	783L	784L	785R	786D	787L	788E	789T
790S	791C	792S	793D	795R	796Q	797F	798C	799K	800K	801I	802R	803R	804R
805M	806P	807G	808T	809D	810A	811P	812G	813I	814P	815A	816A	817L	818A
819F	820G	822Q	823V	824S	825D	826T	827I	828L	829D	830C	831R	832K	833H
834L	835T	836W	837V	838V	839A	840V	841L	842Q	843E	844V	845A	846A	847A
848A	849A	850Q	851L	852I	853A	854P	855L	856A	857E	858N	859E	860G	861L
863V	864A	865A	866L	867E	868E	869L	870A	871F	872K	873A	874S	875E	876Q
877I	878Y	879G	881P	882S	883S	884S	885P	886Y	887E	888C	889L	890R	891Q
892S	893C	895I	896L	897I	898S	899T							

Explanation of amino acid single letter code:

A=Ala C=Cys D=Asp E=Glu F=Phe G=Gly H=His I=Ile N=Asn
 P=Pro Q=Gln R=Arg S=Ser T=Thr V=Val K=Lys L=Leu M=Met
 W=Trp Y=Tyr

Binding Domains

P150d = binding domain for p150 protein
 Tctex1d = binding domain for Tctex1 protein
 10kDad = binding domain for 10kDa light chain
 2Bd = binding domain for 2B light chain protein

-190-

This invention has been described in detail including the preferred embodiments thereof. However, it will be appreciated that those skilled in the art, upon consideration of this disclosure, may make modifications and improvements thereon without departing from the spirit and scope of the invention as set forth in the
5 claims. All references, patents, patent applications and Genbank references recited in this patent application is hereby incorporated by reference in their entirety.

Table 23. List of certain sequences provided in this application

SEQ ID NO:	Description
1	Coding sequence (cDNA) of wild type mouse cytoplasmic dynein heavy chain1.
2	Amino acid sequence of wild type mouse cytoplasmic dynein heavy chain1.
3	Coding sequence (cDNA) of mutant mouse cytoplasmic dynein heavy chain1.
4	Amino acid sequence of mutant mouse cytoplasmic dynein heavy chain1.
5	Coding sequence (cDNA) of mutant human cytoplasmic dynein heavy chain1.
6	Amino acid sequence of mutant human cytoplasmic dynein heavy chain1.
7	ClustalW mouse sequence cytoplasmic dynein heavy chain1.
8	ClustalW rat sequence dynein heavy chain.
9	ClustalW human sequence cytoplasmic dynein heavy chain1.
10	ClustalW <i>Drosophila</i> sequence dynein heavy chain.
11	ClustalW <i>Paramecium</i> sequence dynein heavy chain.
12	ClustalW <i>C. elegans</i> sequence dynein heavy chain.
13	Wildtype PCR amplicon of Dnchc1, exon 13.
14	Mutant PCR amplicon of Dnchc1, exon 13.
15	Primer Dnchc1-25.
16	Primer Dnchc1-26.
17	Coding sequence (cDNA) of wild type human cytoplasmic dynein heavy chain1.
18	Amino acid sequence of wild type human cytoplasmic dynein heavy chain1.
19	Nucleotide sequence of wild type mouse cytoplasmic dynein heavy chain1, exon 13.
20	Nucleotide sequence of wild type mouse cytoplasmic dynein heavy chain1, exons 12 and 13.

21	In-frame amino acid sequence derived from SEQ ID NO:19.
22	In-frame amino acid sequence derived from SEQ ID NO:20.
23	In-frame amino acid sequence derived from human Dchc1 exon13.
24	In-frame amino acid sequence derived from human Dchc1 exons 12 + 13.
25	Amino acid sequence of residues positioned within ten residues of Tyr 1055 in wild type cytoplasmic dynein heavy chain1 of mouse, rat and human.
26	Primer hDnchc1-21
27	Primer hDnchc1-22

We Claim:

1. A modified cytoplasmic dynein heavy chain1 polypeptide, wherein:
 - 5 (a) the amino acid sequence of said modified cytoplasmic dynein heavy chain1 differs from the corresponding wild type sequence by substitution, deletion, or insertion of at least one amino acid in the wild type cytoplasmic dynein heavy chain1 sequence;
 - 10 (b) a biological activity of said modified cytoplasmic dynein heavy chain1 polypeptide is altered by at least 10% in comparison to the activity of the wild type cytoplasmic dynein heavy chain1 polypeptide.
2. The modified cytoplasmic dynein heavy chain1 polypeptide of claim 1 wherein said biological activity is altered by at least 50% in comparison to the activity of the wild type cytoplasmic dynein heavy chain1 polypeptide.
- 15 3. The modified cytoplasmic dynein heavy chain1 polypeptide of claim 1 wherein said biological activity is altered by at least 75% in comparison to the activity of the wild type cytoplasmic dynein heavy chain1 polypeptide.
4. The modified cytoplasmic dynein heavy chain1 polypeptide of any of claims 1 to 3, wherein the alteration of said biological activity is a reduction of activity.
- 20 5. The modified cytoplasmic dynein heavy chain1 polypeptide of any of claims 1 to 3, wherein the alteration of said biological activity is an increase of activity.
6. The modified cytoplasmic dynein heavy chain1 polypeptide of any of claims 1 to 5, wherein the alteration of said biological activity is demonstrated by a method selected from the group consisting of:
 - 25 (a) determining the relative proportions of cytoplasmic dynein heavy chain1 dimer and cytoplasmic dynein heavy chain1 monomer in a test sample;

- 5 (b) quantifying the proportion of cytoplasmic dynein complex that is fully assembled from its subunits in an *in vitro* assembly assay;
- (c) quantifying the proportion of cytoplasmic dynein complex subunits that remain unassembled in an *in vitro* assembly assay;
- (d) quantifying the proportion of cytoplasmic dynein heavy chain1 that binds to microtubules *in vitro*;
- (e) assaying the rate of dimerization of the cytoplasmic dynein heavy chain1 polypeptide *in vitro*;
- 10 (f) assaying the rate of assembly of the cytoplasmic dynein complex from constituent subunits *in vitro*;
- (g) assaying the rate of binding of cytoplasmic dynein heavy chain1 to microtubules *in vitro*;
- (h) assaying motor activity of the cytoplasmic dynein complex *in vitro*;
- (i) assaying motor activity of the cytoplasmic dynein heavy chain1 *in vitro*;
- 15 (j) quantifying binding of cytoplasmic dynein heavy chain1 polypeptide to an antibody having an epitope specific for cytoplasmic dynein heavy chain1; and

20 wherein the method compares the results provided by said modified cytoplasmic dynein heavy chain1 polypeptide to those provided by the corresponding wild type cytoplasmic dynein heavy chain1 polypeptide.

7. The modified cytoplasmic dynein heavy chain1 polypeptide of claim 6, wherein said antibody is selected from the following group;

- 25 (a) an antibody binding an epitope situated within the dimerization domain of the cytoplasmic dynein heavy chain1;
- (b) an antibody binding an epitope situated within a binding domain of the cytoplasmic dynein heavy chain1 the binds a subunit of the cytoplasmic dynein complex;

- (c) an antibody binding an epitope located in exon 12 of cytoplasmic dynein heavy chain1;
 - (d) an antibody binding an epitope located in exon 13 of cytoplasmic dynein heavy chain1;
 - 5 (e) an antibody binding an epitope located in exons 12 plus 13 of cytoplasmic dynein heavy chain1;
 - (f) an antibody binding an epitope formed by the intact dimer of cytoplasmic dynein heavy chain1, but not by the individual monomers.
8. The modified cytoplasmic dynein heavy chain1 polypeptide of claim 6,
10 wherein motor activity of the cytoplasmic dynein heavy chain1 is determined *in vitro* by at least one parameter selected from the group consisting of:
- (a) rate of total protein transport through cellular Golgi apparatus;
 - (b) axonal transport;
 - (c) retrograde axonal transport;
 - 15 (d) microtubule gliding rate;
 - (e) phagosome movement along microtubules;
 - (f) rate of intracellular trafficking of membranous organelles;
 - (g) nuclear migration rate;
 - (h) prometaphase chromosome movement.
- 20 9. The modified cytoplasmic dynein heavy chain1 polypeptide according to any one of claims 1 to 8 wherein expression of the protein within a non-human animal model heterozygous for the modified and wild type cytoplasmic dynein heavy chain1 gene results in the animal developing at least one of the following phenotypical features:
- 25 (a) epilepsy;
 - (b) myoclonic cramping;
 - (c) neuronal excitotoxicity;

- (d) cell damage in hippocampus;
 - (e) cell damage in cerebellum;
 - (f) neurodegenerative disease;
 - (g) under-activity or undesirable activity of endogenous cytoplasmic dynein heavy chain1;
 - (h) under-expression, under-production or undesirable production of endogenous cytoplasmic dynein heavy chain1; and
 - (i) undesirable medical condition shown to be modulated by endogenous cytoplasmic dynein heavy chain1.
- 10 10. The modified cytoplasmic dynein heavy chain1 polypeptide according to claim 9 wherein the phenotypical features developed by said non-human animal model comprise at least one feature selected from the following group:
- (a) myoclonic cramping of the fore limbs;
 - (b) myoclonic cramping of the hind limbs;
 - (c) cell damage in CA3 and CA4 sectors of hippocampus;
 - (d) cell damage in gyrus dentatus;
 - (e) neuronal damage in the upper layer of the cortex and in the Purkinje cell layer of the cerebellum;
 - (f) motor neuron impairment;
 - (g) Alzheimer's disease;
 - (h) Parkinson's disease;
 - (i) amyotrophic lateral sclerosis;
 - (j) spinal muscular atrophy; and
 - (k) fiber type grouping in *Musculus tibialis anterior*.
- 25 11. A modified cytoplasmic dynein heavy chain1 polypeptide, wherein:

- (a) the amino acid sequence of said modified cytoplasmic dynein heavy chain1 differs from the corresponding wild type sequence by substitution, deletion, or insertion of at least one amino acid residue in the wild type cytoplasmic dynein heavy chain1 sequence;
- 5 (b) the position of said amino acid residue in the cytoplasmic dynein heavy chain1 sequence is selected from the group consisting of:
- (i) those positions at which, in each of the wild type cytoplasmic dynein heavy chain1 reference sequences, the identity of the wild type amino acid residue is restricted to conservative amino acid substitutions; and
- 10 (ii) those positions at which, in each of the wild type cytoplasmic dynein heavy chain1 reference sequences, the identity of the wild type amino acid residue is conserved; and
- (c) said wild type cytoplasmic dynein heavy chain1 reference sequences
- 15 consist of:
- (i) SEQ ID NO:18 (*Homo sapiens*);
- (ii) Genbank Accession No. NP_062099 (*Rattus norvegicus*); and
- (iii) Genbank Accession No. NP_084514 (*Mus musculus*).
12. The modified cytoplasmic dynein heavy chain1 polypeptide of claim 11
- 20 wherein said the position of said amino acid residue is a position at which, in all of the wild type cytoplasmic dynein heavy chain1 reference sequences, the identity of the wild type amino acid residue is conserved.
13. The modified cytoplasmic dynein heavy chain1 polypeptide of any of claims 11 to 12, wherein said wild type cytoplasmic dynein heavy chain1 reference
- 25 sequences consist of:
- (i) SEQ ID NO:18 (*Homo sapiens*);
- (ii) Genbank Accession No. NP_062099 (*Rattus norvegicus*);
- (iii) Genbank Accession No. NP_084514 (*Mus musculus*);

- (iv) Genbank Accession No. NP_523929 (*Drosophila melanogaster*); and
- (v) Genbank Accession No. NP_084514 (*Caenorhabditis elegans*).

14. The modified cytoplasmic dynein heavy chain1 polypeptide of any of claims 11 to 13 wherein said amino acid residue corresponds to a residue selected from the group of conserved amino acid residues between Leu302 (302L) and Phe1140 (1140F) of SEQ ID NO:2 (*Mus musculus*) specified in Table 19.
15. The modified cytoplasmic dynein heavy chain1 polypeptide of any of claims 11 to 14 wherein said amino acid residue is positioned in a cytoplasmic dynein heavy chain1 domain capable of binding a subunit of the cytoplasmic dynein complex selected from the group consisting of:
- (a) cytoplasmic dynein heavy chain1;
 - (b) cytoplasmic dynein intermediate chain;
 - (c) cytoplasmic dynein light intermediate chain; and
 - (d) cytoplasmic dynein light intermediate chain.
16. The modified cytoplasmic dynein heavy chain1 polypeptide of any of claims 11 to 15 wherein said amino acid residue is positioned in the cytoplasmic dynein heavy chain1 dimerization binding domain.
17. The modified cytoplasmic dynein heavy chain1 polypeptide of any of claims 11 to 16 wherein said amino acid residue is located in a sequence selected from the group consisting of:
- (a) sequences encoded by cytoplasmic dynein heavy chain1 exon 13;
 - (b) SEQ ID NO:21;
 - (c) SEQ ID NO:23;
 - (d) sequences encoded by cytoplasmic dynein heavy chain1 exons 12 and 13
 - (e) SEQ ID NO:22;

(f) SEQ ID NO:24.

18. The modified cytoplasmic dynein heavy chain1 polypeptide of any of claims 11 to 17 wherein said amino acid residue is located in a position corresponding to a residue selected from the group consisting of:

- 5 (a) in SEQ ID NO:2 (*Mus musculus*),
- (i) residue 300 to residue 1140;
 - (ii) residue 416 to residue 701;
 - (iii) residue 649 to residue 800;
- (b) in SEQ ID NO:18 (*Homo sapiens*);
- 10 (i) residue 302 to residue 1142;
- (ii) residue 418 to residue 703;
 - (iii) residue 651 to residue 802.

19. The modified cytoplasmic dynein heavy chain1 polypeptide of claim 18 wherein said amino acid residue is located in a position corresponding to a residue selected from the group consisting of:

15

- (a) in SEQ ID NO:2 (*Mus musculus*), residue 649 to residue 701;
- (b) in SEQ ID NO:18 (*Homo sapiens*), residue 651 to residue 703.

20. The modified cytoplasmic dynein heavy chain1 polypeptide of any of claims 11 to 19, wherein the amino acid sequence of said modified cytoplasmic dynein heavy chain1 differs from the corresponding wild type sequence by substitution, deletion, or insertion of two or more of said amino acid residues in the wild type cytoplasmic dynein heavy chain1 sequence and wherein said amino acid residues are contiguous amino acid residues.

20

21. The modified cytoplasmic dynein heavy chain1 polypeptide of any of claims 11 to 20, wherein the amino acid sequence of said modified cytoplasmic dynein heavy chain1 differs from the corresponding wild type sequence by substitution, deletion, or insertion of at least ten of said amino acid residues.
- 5 22. The modified cytoplasmic dynein heavy chain1 polypeptide of any of claims 11 to 21, wherein the amino acid sequence of said modified cytoplasmic dynein heavy chain1 differs from the corresponding wild type sequence by substitution, deletion, or insertion of at least ten of said amino acid residues.
- 10 23. The modified cytoplasmic dynein heavy chain1 polypeptide of any of claims 11 to 18 and 20 to 22, wherein said amino acid residue is selected from the following group:
- (a) a residue at a position within ten residues of position 1055 of the amino acid sequence as shown in SEQ ID NO:2;
 - (b) a residue at a position within ten residues of position 1057 of the amino acid sequence as shown in SEQ ID NO:18;
 - (c) a residue corresponding to one of the residues of the amino acid sequence
- VEQYVKVWLQYQCLWDMQAEN.
- 20 24. The modified cytoplasmic dynein heavy chain1 polypeptide of any of claims 11 to 18 and 20 to 22, wherein said amino acid residue corresponds to a residue in SEQ ID NO:2 selected from the group consisting of: 1035Y; 1036S; 1037A; 1038V; 1039M; 1040G; 1041I; 1042V; 1044E; 1045V; 1046E; 1047Q; 1048Y; 1049V; 1050K; 1052W; 1053L; 1054Q; 1055Y; 1056Q; 1058L; 1059W; D1060D; 1061M; 1062Q; 1063A; 1064E; and 1065N.
- 25 25. The modified cytoplasmic dynein heavy chain1 polypeptide of claim 24 wherein said amino acid residue corresponds to a residue in SEQ ID NO:2 selected from the group consisting of: 1044E; 1045V; 1046E; 1047Q; 1048Y;

1049V; 1050K; 1052W; 1053L; 1054Q; 1055Y; 1056Q; 1058L; 1059W;
1060D; 1061M; 1062Q; 1063A; 1064E; and 1065N.

26. The modified cytoplasmic dynein heavy chain1 polypeptide of claim 24 wherein said amino acid residue corresponds to a residue in SEQ ID NO:2 selected from the group consisting of: 1052W; 1053L; 1054Q; 1055Y; and 1056Q.
27. A modified cytoplasmic dynein heavy chain1 polypeptide wherein the modification is an amino acid substitution in the wild type cytoplasmic dynein heavy chain1 sequence at a position selected from the group consisting of:
- (a) a position corresponding to position 1055 of the amino acid sequence as shown in SEQ ID NO:2; and
- (b) a position corresponding to position 1057 of the amino acid sequence as shown in SEQ ID NO:19.
28. The modified cytoplasmic dynein heavy chain1 polypeptide according to any of claims 1 to 27 wherein the modified cytoplasmic dynein heavy chain1 polypeptide is a mammalian cytoplasmic dynein heavy chain1 polypeptide.
29. The modified cytoplasmic dynein heavy chain1 polypeptide according to claim 28 wherein the cytoplasmic dynein heavy chain1 polypeptide is selected from the group consisting of:
- (a) human cytoplasmic dynein heavy chain1 polypeptide;
- (b) murine cytoplasmic dynein heavy chain1 polypeptide;
- (c) rat cytoplasmic dynein heavy chain1 polypeptide.
30. The modified cytoplasmic dynein heavy chain1 polypeptide of any of claims 1 to 29, wherein said modified cytoplasmic dynein heavy chain1 protein is a recombinant protein.

31. The modified cytoplasmic dynein heavy chain1 polypeptide of any of claims 1 to 30 wherein said substitution, deletion, or insertion of at least one amino acid residue in the wild type cytoplasmic dynein heavy chain1 sequence is located within a region of the polypeptide selected from the group consisting of:
- 5 (a) the region encoded by exon 12;
- (b) the region encoded by exon 13;
- (c) the cytoplasmic dynein heavy chain1 dimerization domain;
- (d) a cytoplasmic dynein heavy chain1 binding domain for a subunit of the cytoplasmic dynein complex distinct from cytoplasmic dynein heavy chain1.
- 10
32. The modified cytoplasmic dynein heavy chain1 polypeptide of any of claims 1 to 31 wherein said deletion is of more than one amino acid residue in the wild type cytoplasmic dynein heavy chain1 sequence and extends into a region of the polypeptide selected from the group consisting of:
- 15 (a) exon 12;
- (b) exon 13;
- (c) the cytoplasmic dynein heavy chain1 dimerization domain;
- (d) a cytoplasmic dynein heavy chain1 binding domain for a subunit of the cytoplasmic dynein complex distinct from cytoplasmic dynein heavy chain1.
- 20
33. The modified cytoplasmic dynein heavy chain1 polypeptide according to any of claims 1 to 32 wherein the amino acid substitution replaces a Tyr residue.
34. The modified cytoplasmic dynein heavy chain1 polypeptide according to any of claims 1 to 33 wherein said amino acid substitution is with an amino acid residue selected from the group consisting of Met, Leu, Ile, Val and Cys.
- 25

35. The modified cytoplasmic dynein heavy chain1 polypeptide according to claim 34 wherein the amino acid substitution is with a Cys residue.
36. The modified cytoplasmic dynein heavy chain1 polypeptide according to claim 35 wherein the modified cytoplasmic dynein heavy chain1 polypeptide has an amino acid sequence selected from the group consisting of SEQ ID NO:4 and SEQ ID NO:6.
37. A cytoplasmic dynein heavy chain1 polypeptide comprising the polypeptide according to any one of claims 1 to 36.
38. A murine cytoplasmic dynein heavy chain1 polypeptide having an amino acid sequence of SEQ ID NO:4.
39. A human cytoplasmic dynein heavy chain1 polypeptide having an amino acid sequence selected from the group consisting of:
- (a) the amino acid sequence as shown in SEQ ID NO:6; and
 - (b) the amino acid sequence as shown in SEQ ID NO:18.
40. A cytoplasmic dynein heavy chain1 chimeric protein, comprising a cytoplasmic dynein heavy chain1 polypeptide according to any one of claims 1 to 39, conjugated or fused with a non-cytoplasmic dynein heavy chain1 polypeptide.
41. The cytoplasmic dynein heavy chain1 chimeric protein of claim 40, which comprises a cytoplasmic dynein heavy chain1 polypeptide according to any one of claims 37 to 39, conjugated or fused with a non-cytoplasmic dynein heavy chain1 polypeptide.
42. A monoclonal antibody capable of binding specifically to a cytoplasmic dynein heavy chain1 polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:4 and SEQ ID NO:6 in preference to a

cytoplasmic dynein heavy chain1 polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:2 and SEQ ID NO:18.

43. A monoclonal antibody capable of binding specifically to a cytoplasmic dynein heavy chain1 polypeptide having an amino acid sequence of SEQ ID NO:6 in preference to the cytoplasmic dynein heavy chain1 polypeptide of SEQ ID NO:18.
44. A composition comprising:
- (a) a polypeptide selected from the group consisting of:
- (i) the cytoplasmic dynein heavy chain1 polypeptide of any of claims 1 to 37;
 - (ii) the murine cytoplasmic dynein heavy chain1 polypeptide of claim 38;
 - (iii) the in-frame amino acid sequence derived from exon 12 of Dchc;
 - (iv) the in-frame amino acid sequence derived from exon 13 of Dchc;
 - (v) the in-frame amino acid sequence derived from exons 12 and 13 of Dchc;
 - (vi) the human cytoplasmic dynein heavy chain1 polypeptide of claim 39;
 - (vii) the cytoplasmic dynein heavy chain1 chimeric protein of any of claims 40 to 41; and
 - (viii) the monoclonal antibody of any of claims 42 to 43; and
- (b) a pharmaceutically acceptable carrier.
45. The composition of claim 44 wherein the amino acid sequence of said polypeptide is selected from the group consisting of:
- (a) SEQ ID NO:2;

- (b) SEQ ID NO:18;
- (c) SEQ ID NO:21;
- (d) SEQ ID NO:22;
- (e) SEQ ID NO:23; and
- 5 (f) SEQ ID NO:24.
46. A nucleic acid sequence encoding a cytoplasmic dynein heavy chain1 polypeptide selected from the group consisting of:
- (a) the cytoplasmic dynein heavy chain1 polypeptide according to any one of claims 27 to 39; and
- 10 (b) the cytoplasmic dynein heavy chain1 chimeric protein of claim 40.
47. A polynucleotide, preferably isolated, comprising the nucleic acid sequence according to claim 46.
48. A polynucleotide, preferably isolated, comprising a nucleic acid sequence encoding a polypeptide comprising the amino acid sequence shown in SEQ ID
- 15 NO:18.
49. A polynucleotide, preferably isolated, comprising a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence selected from the following group:
- (a) SEQ ID NO:21;
- 20 (b) SEQ ID NO:22;
- (c) SEQ ID NO:23; and
- (d) SEQ ID NO:24.
50. A nucleic acid vector comprising a polynucleotide selected from the following group:
- 25 (a) the polynucleotide of claim 47;

- (b) the polynucleotide of claim 48;
 - (c) the polynucleotide of claim 49;
 - (d) a polynucleotide comprising a nucleic acid sequence encoding a polypeptide comprising the amino acid sequence SEQ ID NO:23; and
 - 5 (e) a polynucleotide comprising a nucleic acid sequence encoding a polypeptide comprising the amino acid sequence SEQ ID NO:24.
51. An expression vector comprising the polynucleotide of any one of claims 47 to 48 operably linked to an expression control sequence suitable for directing transcription and translation of the polynucleotide in a selected host cell.
- 10 52. A host cell transformed with the vector of claim 51.
53. An antisense nucleic acid of length sufficient to inhibit the expression of a mutant cytoplasmic dynein heavy chain1 protein and total cellular cytoplasmic dynein heavy chain1 protein biological activity, wherein said antisense nucleic acid is complementary to a mammalian cytoplasmic dynein heavy chain1
- 15 nucleic acid sequence.
54. The antisense nucleic acid according to claim 53 wherein said mammalian cytoplasmic dynein heavy chain1 nucleic acid sequence is selected from the group consisting of human, bovine, equine, porcine, ovine, canine, feline, rat and murine cytoplasmic dynein heavy chain1 nucleic acid sequences.
- 20 55. The antisense nucleic acid according to any of claims 53 to 54 wherein said mammalian cytoplasmic dynein heavy chain1 nucleic acid sequence is selected from the group consisting of human cytoplasmic dynein heavy chain1 sequences corresponding to SEQ ID NO:6 and SEQ ID NO:18 and mouse cytoplasmic dynein heavy chain1 sequences corresponding to SEQ ID NO:2
- 25 and SEQ ID NO:4.

56. The antisense nucleic acid of any of claims 53 to 55, wherein the inhibitor of cytoplasmic dynein heavy chain1 biological activity inhibits a condition selected from the group consisting of:
- (a) epilepsy;
 - 5 (b) myoclonic cramping;
 - (c) neuronal excitotoxicity;
 - (d) cell damage in hippocampus;
 - (e) cell damage in cerebellum;
 - (f) neurodegenerative disease;
 - 10 (g) under-activity or undesirable activity of endogenous cytoplasmic dynein heavy chain1;
 - (h) under-expression, under-production or undesirable production of endogenous cytoplasmic dynein heavy chain1; and
 - (i) 15 undesirable medical condition shown to be modulated by endogenous cytoplasmic dynein heavy chain1.
57. The antisense nucleic acid according to claim 56, wherein the inhibitor of cytoplasmic dynein heavy chain1 biological activity inhibits a condition selected from the group consisting of:
- (a) myoclonic cramping of the fore limbs;
 - 20 (b) myoclonic cramping of the hind limbs;
 - (c) cell damage in CA3 and CA4 sectors of hippocampus;
 - (d) cell damage in gyrus dentatus;
 - (e) neuronal damage in the upper layer of the cortex and in the Purkinje cell layer of the cerebellum;
 - 25 (f) motor neuron impairment;
 - (g) Alzheimer's disease;
 - (h) Parkinson's disease;

- (i) amyotrophic lateral sclerosis;
- (j) spinal muscular atrophy;
- (k) fiber type grouping in *Musculus tibialis anterior*.

58. The antisense nucleic acid of any of claims 53 to 56, wherein the inhibitor of cytoplasmic dynein heavy chain1 biological activity inhibits a condition selected from the group consisting of:

- (a) over-activity or undesirable activity of endogenous cytoplasmic dynein heavy chain1;
- (b) over-expression, over-production or undesirable production of endogenous cytoplasmic dynein heavy chain1; and
- (c) undesirable medical condition shown to be modulated by endogenous cytoplasmic dynein heavy chain1.

59. The antisense nucleic acid according to claim 58, wherein the inhibitor of cytoplasmic dynein heavy chain1 biological activity inhibits a condition selected from the group consisting of:

- (a) undesirable cell division;
- (b) tumorigenesis.

60. A ribozyme comprising a hybridising region and a catalytic region wherein the hybridizing region is capable of hybridizing to at least part of a target mRNA sequence transcribed from a genomic gene corresponding to SEQ ID NO:1, 3, 5 or 17, wherein the catalytic domain is capable of cleaving the target mRNA sequence to reduce or inhibit a cytoplasmic dynein heavy chain1 mediated disorder.

61. A pharmaceutical composition comprising a nucleic acid molecule that inhibits or otherwise reduces a cytoplasmic dynein heavy chain1 mediated disorder wherein the nucleic acid comprises at least about ten nucleotides and hybridizes to or forms a heteroduplex with an mRNA molecule directed from a

gene encoding cytoplasmic dynein heavy chain1, the composition further comprising one or more pharmaceutically acceptable carriers.

62. The pharmaceutical composition of claim 61 for topical administration.

63. A medicament for the prevention, treatment or amelioration in a mammal of at least one medical condition selected from the group consisting of:

- (a) epilepsy;
- (b) myoclonic cramping;
- (c) neuronal excitotoxicity;
- (d) cell damage in hippocampus;
- 10 (e) cell damage in cerebellum;
- (f) neurodegenerative disease;
- (g) under-activity or undesirable activity of endogenous cytoplasmic dynein heavy chain1;
- (h) under-expression, under-production or undesirable production of
15 endogenous cytoplasmic dynein heavy chain1; and
- (i) undesirable medical condition shown to be modulated by endogenous cytoplasmic dynein heavy chain1;

wherein said medicament comprises a polypeptide selected from the group consisting of:

- 20 (i) a cytoplasmic dynein heavy chain1 polypeptide;
- (ii) the in-frame amino acid sequence derived from exon 12 of mouse or human Dhc;
- (iii) the in-frame amino acid sequence derived from exon 13 of mouse or human Dhc;
- 25 (iv) the in-frame amino acid sequence derived from exons 12 and 13 of mouse or human Dhc;

- (v) the chimeric protein according to any of claims 40 to 41; and
- (vi) the monoclonal antibody according to any of claims 42 to 43.

64. The medicament according to claim 63 wherein said medical condition comprises at least one feature selected from the following group:

- 5 (a) myoclonic cramping of the fore limbs;
- (b) myoclonic cramping of the hind limbs;
- (c) cell damage in CA3 and CA4 sectors of hippocampus;
- (d) cell damage in gyrus dentatus;
- (e) neuronal damage in the upper layer of the cortex and in the Purkinje
10 cell layer of the cerebellum;
- (f) motor neuron impairment;
- (g) Alzheimer's disease;
- (h) Parkinson's disease;
- (i) amyotrophic lateral sclerosis;
- 15 (j) spinal muscular atrophy;
- (k) fiber type grouping in *Musculus tibialis anterior*.

65. The medicament according to claims 63 to 64, wherein said polypeptide is a wild type mammalian cytoplasmic dynein heavy chain1 polypeptide.

20 66. The medicament according to claim 65, wherein said polypeptide is human cytoplasmic dynein heavy chain1 polypeptide.

67. The medicament according to claims 63 to 66, wherein said polypeptide has an amino acid sequence selected from the following group:

- (i) SEQ ID NO:2;
- (ii) SEQ ID NO:18;
- 25 (iii) SEQ ID NO:21;

- (iv) SEQ ID NO:22;
- (v) SEQ ID NO:23; and
- (vi) SEQ ID NO:24.

68. A medicament for the prevention, treatment or amelioration in a mammal of at
5 least one medical condition selected from the group consisting of:

- (a) over-activity or undesirable activity of endogenous cytoplasmic dynein heavy chain1;
- (b) over-expression, over-production or undesirable production of endogenous cytoplasmic dynein heavy chain1; and
- 10 (c) undesirable medical condition shown to be modulated by endogenous cytoplasmic dynein heavy chain1;

wherein the medicament comprises a polypeptide selected from the group consisting of:

- 15 (i) a cytoplasmic dynein heavy chain1 polypeptide according to any of claims 1 to 39;
- (ii) the in-frame amino acid sequence derived from exon 12 of mouse or human Dhc;
- (iii) the in-frame amino acid sequence derived from exon 13 of mouse or human Dhc;
- 20 (iv) the in-frame amino acid sequence derived from exons 12 and 13 of mouse or human Dhc;
- (v) the chimeric protein according to any of claims 40 to 41; and
- (vi) the monoclonal antibody according to any of claims 42 to 43.

69. The medicament according to claim 68 wherein said medical condition is
25 selected from the following group:

- (a) undesirable cell division;

(b) tumorigenesis.

70. The medicament according to any of claims 68 to 69, wherein said polypeptide has an amino acid sequence selected from the following group:

- (a) SEQ ID NO:4;
- (b) SEQ ID NO:6;
- (c) SEQ ID NO:21;
- (d) SEQ ID NO:22;
- (e) SEQ ID NO:23; and
- (f) SEQ ID NO:24.

71. The medicament according to any of claims 68 to 70, wherein said polypeptide is a dynein heavy chain1 polypeptide according to any of claims 11 to 39.

72. A medicament for the prevention, treatment or amelioration in a mammal of at least one medical condition selected from the group consisting of:

- (a) epilepsy;
- (b) myoclonic cramping;
- (c) neuronal excitotoxicity;
- (d) cell damage in hippocampus;
- (e) cell damage in cerebellum;
- (f) neurodegenerative disease;
- (g) under-activity or undesirable activity of endogenous cytoplasmic dynein heavy chain1;
- (h) under-expression, under-production or undesirable production of endogenous cytoplasmic dynein heavy chain1; and
- (i) undesirable medical condition shown to be modulated by endogenous cytoplasmic dynein heavy chain1;

wherein the medicament comprises the polynucleotide of any of claims 47 to 49, or the vector of any one of claims 50 to 51.

73. The medicament according to claim 72 wherein said medical condition comprises at least one feature selected from the following group:

- 5 (a) myoclonic cramping of the fore limbs;
- (b) myoclonic cramping of the hind limbs;
- (c) cell damage in CA3 and CA4 sectors of hippocampus;
- (d) cell damage in gyrus dentatus;
- (e) neuronal damage in the upper layer of the cortex and in the Purkinje
10 cell layer of the cerebellum;
- (f) motor neuron impairment;
- (g) Alzheimer's disease;
- (h) Parkinson's disease;
- (i) amyotrophic lateral sclerosis;
- 15 (j) spinal muscular atrophy;
- (k) fiber type grouping in *Musculus tibialis anterior*.

74. The medicament according to claim 73, wherein said polynucleotide comprises a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence selected from the following group:

- 20 (a) SEQ ID NO:2;
- (b) SEQ ID NO:18;
- (c) SEQ ID NO:21;
- (d) SEQ ID NO:22;
- (e) SEQ ID NO:23; and
- 25 (f) SEQ ID NO:24.

75. A medicament for the prevention, treatment or amelioration in a mammal of at least one medical condition selected from the group consisting of:

- (a) over-activity or undesirable activity of endogenous cytoplasmic dynein heavy chain1;
- 5 (b) over-expression, over-production or undesirable production of endogenous cytoplasmic dynein heavy chain1; and
- (c) undesirable medical condition shown to be modulated by endogenous cytoplasmic dynein heavy chain1;

10 wherein the medicament comprises a polynucleotide selected from the group consisting of:

- (i) a polynucleotide according to claim 47;
- (ii) a polynucleotide comprising a nucleic acid sequence encoding an in-frame amino acid sequence selected from exon 12 of mouse or human Dhc;
- 15 (iii) a polynucleotide comprising a nucleic acid sequence encoding an in-frame amino acid sequence selected from exon 13 of mouse or human Dhc;
- (iv) a polynucleotide comprising a nucleic acid sequence encoding an in-frame amino acid sequence selected from exons 12 and 13 of mouse or
20 human Dhc.

76. The medicament according to claim 73, wherein said polynucleotide comprises a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence selected from the following group:

- (a) SEQ ID NO:4;
- 25 (b) SEQ ID NO:6;
- (c) SEQ ID NO:21;
- (d) SEQ ID NO:22;
- (e) SEQ ID NO:23; and

(f) SEQ ID NO:24.

77. A medicament for the prevention, treatment or amelioration in a mammal of at least one medical condition selected from the group consisting of:

- 5
- (a) over-activity or undesirable activity of endogenous cytoplasmic dynein heavy chain1;
 - (b) over-expression, over-production or undesirable production of endogenous cytoplasmic dynein heavy chain1; and
 - (c) undesirable medical condition shown to be modulated by endogenous cytoplasmic dynein heavy chain1;

10 wherein the medicament comprises a vector selected from the group consisting of:

- (i) a nucleic acid vector comprising a polynucleotide encoding a polypeptide comprising an amino acid sequence selected from SEQ ID NO:4, 6, 21, 22, 23 and 24; and
- 15 (ii) an expression vector comprising a polynucleotide operably inked to an expression control sequence suitable for directing transcription and translation of said polynucleotide in a selected host cell, wherein said polynucleotide encodes a polypeptide comprising an amino acid sequence selected from SEQ ID NO:4, 6, 21, 22, 23 and 24.

20 78. A process for preparing a cytoplasmic dynein heavy chain1 polypeptide comprising:

- (a) growing a culture of the host cell of claim 52 in a suitable culture medium; and
 - (b) recovering the cytoplasmic dynein heavy chain1 polypeptide from the culture.
- 25

79. A method for the prevention, treatment or amelioration of a cytoplasmic dynein heavy chain1-mediated medical condition in a mammalian subject,

particularly a human subject, comprising the step of administering to the subject a cytoplasmic dynein heavy chain1 polypeptide selected from the group consisting of:

- 5 (a) the modified cytoplasmic dynein heavy chain1 polypeptide of claims 1 to 10;
- (b) the modified cytoplasmic dynein heavy chain1 polypeptide of claims 11 to 26;
- (c) the modified cytoplasmic dynein heavy chain1 polypeptide of claims 27 to 36;
- 10 (d) the cytoplasmic dynein heavy chain1 polypeptide of claim 37; and
- (e) the cytoplasmic dynein heavy chain1 polypeptide of claims 38 or 39.

80. A method of prevention, treatment or amelioration of a cytoplasmic dynein heavy chain1-mediated medical condition in a mammalian subject, particularly a human subject, comprising the step of administering to the subject a protein
15 selected from the group consisting of:

- (a) the chimeric protein of any of claims 40 to 41; and
- (b) the monoclonal antibody of claim 42 to 43.

81. A method of preventing, treating or ameliorating a cytoplasmic dynein heavy chain1-mediated medical condition in a mammalian subject, particularly a
20 human subject, comprising the step of administering to the subject a composition selected from the following group:

- (a) the composition of claim 44; and
- (b) the composition of claim 45.

25 82. A method of diagnosing in a mammalian subject, particularly a human subject, at least one of:

- (a) cytoplasmic dynein heavy chain1-mediated medical condition;
- (b) a susceptibility to develop a cytoplasmic dynein heavy chain1-mediated medical condition;

wherein the method comprises the steps of:

- 5 (i) isolating a biological sample from the subject;
- (ii) comparing expression levels of cytoplasmic dynein heavy chain1 in the subject sample against a reference value.

83. The method of claim 82 wherein said reference value is obtained by performing the method with a wild type sample equivalent to the biological sample from the subject.

84. The method of claims 82 or 83 wherein a positive diagnosis is indicated by determining a cytoplasmic dynein heavy chain1 expression level in the subject sample that differs from that in the wild type sample by a factor selected from the group consisting of:

- 15 (a) expression in subject sample being less than 50% of expression in wild type sample;
- (b) expression in subject sample being less than 20% of expression in wild type sample;
- (c) expression in subject sample being less than 5% of expression in wild type sample;

and wherein the expression level of cytoplasmic dynein heavy chain1 in the subject sample is at least 0.5% of that in the wild type sample.

85. The method of any of claims 82 to 84, wherein said abnormal expression is delimited the alteration in expression of cytoplasmic dynein heavy chain1 is determined by detecting the existence of a mutation in a nucleic acid sequence

controlling the level of expression of the cytoplasmic dynein heavy chain1 polypeptide.

86. A method of diagnosing in a mammalian subject, particularly a human subject, at least one of:

- 5 (a) cytoplasmic dynein heavy chain1-mediated medical condition;
- (b) a susceptibility to develop a cytoplasmic dynein heavy chain1-mediated medical condition;

wherein the method comprises the steps of:

- (i) isolating a sample of nucleic acid from the subject; and
- 10 (ii) determining that said sample comprises a mutation in the nucleic acid sequence of a polynucleotide encoding the cytoplasmic dynein heavy chain1 polypeptide, wherein said mutation is responsible for a substitution, deletion or insertion of at least one amino acid residue in the encoded polypeptide.

15 87. The method of claim 86 wherein said method comprises the additional step of identifying said mutation.

88. The method of claim 87 wherein the method is capable of detecting a point mutation.

20 89. The method of claims 86 or 87 wherein the method comprises the additional step of determining that the cytoplasmic dynein heavy chain1 encoded by said polynucleotide is a modified cytoplasmic dynein heavy chain1 polypeptide selected from the group consisting of:

- (a) the modified cytoplasmic dynein heavy chain1 polypeptide of claims 1 to 10;
- 25 (b) the modified cytoplasmic dynein heavy chain1 polypeptide of claims 11 to 26;

- (c) the modified cytoplasmic dynein heavy chain1 polypeptide of claims 27 to 36.

90. The method of any of claims 86 to 89 wherein the method includes the additional step of amplification and subsequent sequencing of nucleic acid, and said mutation is identified by the sequence of the amplified nucleic acid.

91. The method of any of claims 86 to 90, wherein said method comprises the additional step of confirming that said mutation is associated with at least one of:

- (a) cytoplasmic dynein heavy chain1-mediated medical condition;
- (b) a susceptibility to develop a cytoplasmic dynein heavy chain1-mediated medical condition;

wherein said confirmation is obtained by generating a non-human animal model selected from the group consisting of:

- (i) a non-human animal model expressing the corresponding mutation in the animal's cytoplasmic dynein heavy chain1, as a heterozygote;
- (ii) a non-human animal model expressing the corresponding mutation in the animal's cytoplasmic dynein heavy chain1, as a homozygote;
- (iii) a transgenic non-human animal model expressing the corresponding mutation in human cytoplasmic dynein heavy chain1, as a heterozygote; and
- (iv) a transgenic non-human animal model expressing the corresponding mutation in human cytoplasmic dynein heavy chain1, as a heterozygote;

and observing the phenotype of said non-human animal.

92. The method of any of claims 86 to 91, wherein said method comprises the additional step of confirming that said mutation is associated with at least one of:

- (a) cytoplasmic dynein heavy chain1-mediated medical condition;
- 5 (b) a susceptibility to develop a cytoplasmic dynein heavy chain1-mediated medical condition;

wherein said confirmation is obtained by an analysis selected from the group consisting of:

- 10 (i) a structural analysis of cytoplasmic dynein heavy chain1 comprising said mutation;
- (ii) assaying a biological function of cytoplasmic dynein heavy chain1 comprising said mutation.

93. The method of claim 92 wherein said analysis comprises at least one method selected from the group consisting of:

- 15 (a) assaying whether the cytoplasmic dynein heavy chain1 comprising said mutation is capable of dimerization;
- (b) assaying whether the cytoplasmic dynein heavy chain1 comprising said mutation binds a recombinantly produced peptide corresponding to the dimerization domain of cytoplasmic dynein heavy chain1, preferably
20 corresponding to the dimerization domain of human cytoplasmic dynein heavy chain1;
- (c) assaying whether the cytoplasmic dynein heavy chain1 comprising said mutation binds other components of the dynein complex selected from the group comprising:
 - 25 (i) dynein intermediate chain;
 - (ii) dynein light intermediate chain;

- (iii) dynein light chain;
 - (iv) dynactin;
 - (v) dynamitin;
- 5 (d) assaying whether the cytoplasmic dynein heavy chain1 comprising said mutation is capable of integration into an intact dynein complex;
- (e) assaying whether formation of intact dynein complex is inhibited in the presence of the cytoplasmic dynein heavy chain1 comprising said mutation;
- 10 (f) assaying whether the cytoplasmic dynein heavy chain1 comprising said mutation is capable of actin movement; and
- (g) assaying whether the cytoplasmic dynein heavy chain1 comprising said mutation is capable of axonal transport.
94. The method of any of claims 86 to 93, wherein said method comprises database comparison, wherein the database comprises mutations in cytoplasmic
- 15 dynein heavy chain 1 that are associated with at least one medical condition selected from the group consisting of:
- (a) epilepsy;
 - (b) myoclonic cramping;
 - (c) neuronal excitotoxicity;

20 (d) cell damage in hippocampus;

 - (e) cell damage in cerebellum;
 - (f) neurodegenerative disease;
 - (g) under-activity or undesirable activity of endogenous cytoplasmic dynein heavy chain1;

25 (h) under-expression, under-production or undesirable production of endogenous cytoplasmic dynein heavy chain1; and

- (i) undesirable medical condition shown to be modulated by endogenous cytoplasmic dynein heavy chain1.

95. A database according to claim 94 wherein said database comprises mutations
5 in cytoplasmic dynein heavy chain 1 that are associated to at least one feature
selected from the group consisting of:
- (a) myoclonic cramping of the fore limbs;
 - (b) myoclonic cramping of the hind limbs;
 - (c) cell damage in CA3 and CA4 sectors of hippocampus;
 - 10 (d) cell damage in gyrus dentatus;
 - (e) neuronal damage in the upper layer of the cortex and in the Purkinje
cell layer of the cerebellum;
 - (f) motor neuron impairment;
 - (g) Alzheimer's disease;
 - 15 (h) Parkinson's disease;
 - (i) amyotrophic lateral sclerosis;
 - (j) spinal muscular atrophy;
 - (k) fiber type grouping in *Musculus tibialis anterior*.
96. The method of any of claims 86 to 95 wherein the mutation is located the
20 nucleic acid sequence encoding cytoplasmic dynein heavy chain 1, wherein
cytoplasmic dynein heavy chain 1 is selected from SEQ ID NO:17.
97. The method of any of claims 86 to 96 wherein the mutation is located in a
selected region of the nucleic acid sequence encoding cytoplasmic dynein
heavy chain 1, wherein said selected region is selected from the group of:
- 25 (a) exon 12;
 - (b) exon 12 and exon 13;

(c) the dimerization binding site of cytoplasmic dynein heavy chain1.

98. The method of claim 97 wherein the mutation is located in cytoplasmic dynein heavy chain1, wherein said selected region comprises the amino acid sequences, selected from the group of:

- 5 (a) SEQ ID NO:23
 (b) SEQ ID NO:24
 (c) residues 302 to residues 1142 in SEQ ID NO:18.

99. The method of any of claims 86 to 98, wherein said medical condition is a neurodegenerative disease.

10 100. The method of claim 99 wherein said neurodegenerative disease is a progressive neurodegenerative disease and is selected from the group of Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and spinal muscular atrophy.

15 101. A method of gene delivery and expression in a target cell of a mammal, comprising the step of introducing a viral vector into the target cell, wherein the viral vector is derived from a virus that has a low replicative efficiency in the target cell and has at least one insertion site containing a nucleic acid of any of claims 47, 53, 54, 55, 56, 57, 58 and 59, and the nucleic acid is operably linked to a promoter capable of expression in the host.

20 102. The method of claim 101, wherein the viral vector is a non-lytic viral vector.

103. A method of gene delivery and expression in a target cell of a mammal comprising the steps of:

- (a) providing an isolated nucleic acid fragment of claims 47, 53, 54, 55, 56, 57, 58 and 59;

- (b) selecting a viral vector derived from a virus that has a low replicative efficiency in the target cell, wherein the vector has at least one insertion site for insertion of said isolated nucleic acid fragment operably linked to a promoter capable of expression in the target cells;
 - 5 (c) inserting the isolated nucleic acid fragment into the insertion site; and
 - (d) introducing the vector into said target cell wherein said gene is expressed at detectable levels.
104. The method of any of claims 101 to 103 wherein the virus is selected from the group consisting of retrovirus, adenovirus, iridoviruses, coronaviruses, 10 togaviruses, caliciviruses and picornaviruses.
105. The method of any of claims 101 to 104 wherein the virus is selected from the group consisting of retrovirus, adenovirus, and pox virus.
106. The method of claim 105 wherein the pox virus is vaccinia.
107. The method of any of claims 101 to 106, wherein the virus is a strain that has 15 been genetically modified or selected to be non-virulent in a host.
108. A non-human animal model expressing a modified cytoplasmic dynein heavy chain1 polypeptide selected from the group consisting of:
- (a) the modified cytoplasmic dynein heavy chain1 polypeptide of claims 1 to 10;
 - 20 (b) the modified cytoplasmic dynein heavy chain1 polypeptide of claims 11 to 26;
 - (c) the modified cytoplasmic dynein heavy chain1 polypeptide of claims 27 to 36.
109. The non-human animal model according to claim 108 which is a mammalian 25 non-human animal model.

110. The non-human animal model according to claim 109 which is selected from the group consisting of bovine, equine, porcine, ovine, canine, feline, rat and murine non-human animal models.
111. The non-human animal model according to any one of claims 108 to 110 wherein the modified cytoplasmic dynein heavy chain1 is encoded by a nucleic acid sequence which is heterozygous in the animal model.
112. The non-human animal model according to any one of claims 108 to 111 wherein the animal exhibits at least one of the following phenotypical features:
- (a) epilepsy;
 - (b) myoclonic cramping;
 - (c) neuronal excitotoxicity;
 - (d) cell damage in hippocampus;
 - (e) cell damage in cerebellum;
 - (f) neurodegenerative disease;
 - (g) under-activity or undesirable activity of endogenous cytoplasmic dynein heavy chain1;
 - (h) under-expression, under-production or undesirable production of endogenous cytoplasmic dynein heavy chain1; and
 - (i) undesirable medical condition shown to be modulated by endogenous cytoplasmic dynein heavy chain1.
113. The non-human animal model according to claim 112 wherein the phenotypical features exhibited by the animal include at least one feature selected from the following group:
- (a) myoclonic cramping of the fore limbs;
 - (b) myoclonic cramping of the hind limbs;
 - (c) cell damage in CA3 and CA4 sectors of hippocampus;

- (d) cell damage in gyrus dentatus;
 - (e) neuronal damage in the upper layer of the cortex and in the Purkinje cell layer of the cerebellum;
 - (f) motor neuron impairment;
 - 5 (g) Alzheimer's disease;
 - (h) Parkinson's disease;
 - (i) amyotrophic lateral sclerosis;
 - (j) spinal muscular atrophy; and
 - (k) fiber type grouping in *Musculus tibialis anterior*.
- 10 114. A transgenic non-human animal model expressing a human cytoplasmic dynein heavy chain1.
115. A transgenic non-human animal model according to claim 114 wherein the human cytoplasmic dynein heavy chain1 has an amino acid sequence selected from SEQ ID NO:6 or SEQ ID NO:18.
- 15 116. The non-human animal model according to any of claims 108 to 115 wherein the animal is a mouse.
117. An animal model according to any one of claims 108 to 116 utilized for the study of diseases or symptoms associated with cytoplasmic dynein heavy chain1 activity deficiency.
- 20 118. An animal model according to any one of claims 108 to 116 utilized for the identification of early diagnostic markers for diseases associated with cytoplasmic dynein heavy chain1 activity deficiency.
119. An animal model according to any one of claims 108 to 116 utilized for monitoring the activity of agents useful in the prevention or treatment of

diseases or symptoms associated with cytoplasmic dynein heavy chain1 activity deficiency.

120. An animal model according to any one of claims 108 to 116 utilized as a model system for testing agents suspected of promoting or aggravating diseases associated with cytoplasmic dynein heavy chain1 activity deficiency by administering or applying such agents to the model and monitoring at least one effect thereof.
121. A primary cell or cell lines derived from the animal model according to any one of claims 108 to 116.
122. A method of identifying a protein or nucleic acid marker indicative of an increased risk of a mammalian subject, particularly a human subject, of developing a neurodegenerative disease, said method comprising the step of analyzing a test sample derived from said subject for the presence of a difference compared to a similar test sample if derived from a subject of the same species unaffected by or known not to be at risk of developing said disease, wherein said difference is indicative of the presence of a mutation in an allele of a gene coding for a protein, which is a subunit of the dynactin/dynein complex.
123. A method of identifying a protein or nucleic acid marker indicative of an association of a neurodegenerative disease in a mammalian subject, particularly a human subject, with a mutation in an allele of a gene coding for a protein, which is a subunit of the dynactin/dynein complex, said method comprising the step of analyzing a test sample derived from said subject for the presence of a difference compared to a similar test sample if derived from a subject of the same species, unaffected by or known not to be at risk of developing said disease, wherein said difference is indicative of the presence of a mutation in an allele of a gene coding for a protein, which is a subunit of the dynactin/dynein complex.

124. The method of claim 122 or 123, wherein said test sample is analyzed for a difference compared to similar test samples if derived from a group of mammalian subjects of the same species as said subject, which subjects are unaffected by, or known not to be at risk of developing, said neurodegenerative disease.
125. The method according to any one of claims 122 to 124, wherein said mammalian subject whose test sample is analyzed has a neurodegenerative disease or is known or suspected to be at risk of developing a neurodegenerative disease.
126. The method of any one of claims 122 to 125, further comprising the step of obtaining said similar test sample or said similar test samples from said mammalian subject or group of mammalian subjects.
127. The method according to any one of claims 122 to 126, wherein said neurodegenerative disease is selected from the group consisting of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease.
128. The method according to any one of claims 122 to 126, wherein said neurodegenerative disease is a motoneuron degenerative disease.
129. The method according to claim 128, wherein said motoneuron degenerative disease is selected from the group consisting of Amyotrophic Lateral Sclerosis, Spinal Muscular Atrophy, Bulbo-Spinal Muscular Atrophy, Progressive Bulbar Palsy, Progressive Muscular Atrophy, and Primary Lateral Sclerosis.
130. The method according to any one of claims 122 to 129, wherein said test sample is a nucleic acid sample.
131. The method according to claim 130, wherein said nucleic acid is selected from the group consisting of mRNA, cDNA and genomic DNA.

132. The method according to any of claims 130 or 131, wherein the nucleic acid is selected from the group consisting of nucleic acids coding for the cytoplasmic dynein heavy chain 1, e.g. SEQ ID NOS.: 28 or 29, the cytoplasmic dynein intermediate chain 1, e.g. SEQ ID NOS.: 30 or 31, the cytoplasmic dynein intermediate chain 2, e.g. SEQ ID NOS.: 32 or 33, the cytoplasmic dynein light intermediate chain 1, e.g. SEQ ID NOS.: 34 or 35, the cytoplasmic dynein light intermediate chain 2, e.g. SEQ ID NOS.: 36 or 37; the cytoplasmic dynein 10 kDa light chain, e.g. SEQ ID NOS.: 38 or 39, the cytoplasmic dynein light chain Tctex 1, e.g. SEQ ID NOS.: 40 or 41, the cytoplasmic dynein light chain 2B, e.g. SEQ ID NO.: 42, DCTN 1, e.g. SEQ ID NOS.: 43 or 44, DCTN 2, e.g. SEQ ID NOS.: 159 or 45, DCTN 3, e.g. SEQ ID NOS.: 46 or 47, DCTN 4, e.g. SEQ ID NOS.: 48 or 49, DCTN 5, e.g. SEQ ID NO.: 50, DCTN 6, e.g. SEQ ID NOS.: 51 or 52, ARP1, e.g. SEQ ID NOS.: 53 or 54, ARP11, e.g. SEQ ID NOS.: 55 or 56, HAP1, e.g. SEQ ID NOS.: 57 or 58, and CLIP-170, e.g. SEQ ID NOS.: 59 or 60, preferably the cytoplasmic dynein heavy chain 1, cytoplasmic dynein intermediate chain 1, cytoplasmic dynein intermediate chain 2, and/or DCTN 1, e.g. according to the above-mentioned corresponding SEQ ID NOS.
133. The method according to any of claims 122 to 132, wherein the step of analyzing said nucleic acid sample comprises amplifying at least a portion of its nucleic acid via the polymerase chain reaction, and optionally also amplifying via the polymerase chain reaction at least a portion of the nucleic acid of said similar sample or said similar samples.
134. The method according to any of claims 122 to 133, wherein the step of analyzing further comprises the step of determining whether said allele is homozygous or heterozygous with respect to said mutation.
135. The method according to claim 122 or 134, wherein the step of analyzing further comprises the separation of the amplified portion of said sample and optionally said similar sample or said similar samples by electrophoresis.

136. The method according to any of claims 122 to 135, wherein the step of analyzing comprises the partial or complete determination of the sequence of the nucleic acid or the amplified portion of the nucleic acid of said sample, and optionally also of the nucleic acid or the amplified portion of the nucleic acid of said similar sample or said similar samples.
137. The method according to any one of claims 122 to 129, wherein said test sample is a protein sample.
138. The method according to claim 137, wherein said protein sample comprises a protein selected from the group consisting of the cytoplasmic dynein heavy chain 1, e.g. encoded by SEQ ID NOS.: 28 or 29, the cytoplasmic dynein intermediate chain 1, e.g. encoded by SEQ ID NOS.: 30 or 31, the cytoplasmic dynein intermediate chain 2, e.g. encoded by SEQ ID NOS.: 32 or 33, the cytoplasmic dynein light intermediate chain 1, e.g. encoded by SEQ ID NOS.: 34 or 35, the cytoplasmic dynein light intermediate chain 2, e.g. encoded by SEQ ID NOS.: 36 or 37; the cytoplasmic dynein 10 kDa light chain, e.g. encoded by SEQ ID NOS.: 38 or 39, the cytoplasmic dynein light chain Tctex 1, e.g. encoded by SEQ ID NOS.: 40 or 41, the cytoplasmic dynein light chain 2B, e.g. encoded by SEQ ID NO.: 42, DCTN 1, e.g. encoded by SEQ ID NOS.: 43 or 44, DCTN 2, e.g. encoded by SEQ ID NOS.: 159 or 45, DCTN 3, e.g. encoded by SEQ ID NOS.: 46 or 47, DCTN 4, e.g. encoded by SEQ ID NOS.: 48 or 49, DCTN 5, e.g. encoded by SEQ ID NO.: 50, DCTN 6, e.g. encoded by SEQ ID NOS.: 51 or 52, ARP1, e.g. encoded by SEQ ID NOS.: 53 or 54, ARP11, e.g. encoded by SEQ ID NOS.: 55 or 56, HAP1, e.g. encoded by SEQ ID NOS.: 57 or 58, and CLIP-170, e.g. encoded by SEQ ID NOS.: 59 or 60, preferably the cytoplasmic dynein heavy chain 1, cytoplasmic dynein intermediate chain 1, cytoplasmic dynein intermediate chain 2, and/or DCTN 1, e.g. encoded by the above-mentioned corresponding SEQ ID NOS.
139. The method according to any one of claims 122 to 138, wherein said mutation selectively affects cell types associated with or suspected to be involved in a neurodegenerative disease.

140. The method according to any one of claims 122 to 139, wherein said mutation selectively affects motoneurons, preferably α -motoneurons.
141. The method according to any of claims 122 to 140, wherein said mutation affects a cellular process selected from the group of processes consisting of neuronal axonal transport, cellular transport, proliferation, differentiation and apoptosis.
142. The method according to any of claims 122 to 141, wherein said mutation leads to a disruption of, or alteration in the functional interaction within the dynactin/dynein complex in neurons, preferably in motoneurons.
143. The method according to any one of claims 122 to 142, wherein said mutation results in a deletion or substitution by another amino acid of an amino acid encoded by said allele, or an insertion of additional amino acids not normally present in the amino acid sequence of the protein encoded by said allele.
144. The method according to claim 143, wherein said deletion, substitution, or insertion is encoded by both alleles of the gene coding for said protein.
145. The method according to claim 143 or 144, wherein said deletion, substitution, or insertion of the amino acid occurs in an evolutionary conserved region of said protein.
146. The method according to any of claims 122 to 145, wherein said mutation results in the substitution of an amino acid which is identical between the corresponding mouse and human, preferably between the corresponding mouse, rat, and human protein encoded by said allele, by another amino acid.
147. The method according to any one of claims 143 to 146, wherein said amino acid is substituted by a naturally occurring amino acid.

148. The method according to any of claims 143 to 147, wherein said amino acid is encoded by a codon within the open reading frame of a nucleic acid sequence selected from the group consisting of SEQ ID NOS.: 70 to 112 or SEQ ID NOS.: 114 to 158.
- 5 149. The method according to any of claims 143 to 148, wherein said amino acid is located in a domain of said protein, which is capable of binding to another subunit of the dynactin/dynein complex.
150. The method according to claim 149, wherein said domain is defined by an amino acid sequence selected from the group of sequences consisting of
- 10 in case the protein is mouse cytoplasmic dynein intermediate chain 1 (SEQ ID NO.: 61):
- i) amino acids 147-157;
 - ii) amino acid 243-314;
 - iii) amino acids 140-157; and
- 15 amino acids 1-123;
- in case the protein is human cytoplasmic dynein intermediate chain 1 (SEQ ID NO.: 62):
- v) amino acids 164-174;
 - vi) amino acids 260-331;
 - 20 vii) amino acids 157-174; and
 - viii) amino acids 1-140;
- in case the protein is mouse cytoplasmic dynein intermediate chain 2 (SEQ ID NO.: 64):
- i) amino acids 1-123;
 - 25 ii) amino acids 122-139;

iii) amino acids 129-130; and

iv) amino acids 226-297;

in case the protein is human cytoplasmic dynein intermediate chain 2 (SEQ ID NO.: 65):

5 v) amino acids 155-165;

vi) amino acids 252-323;

vii) amino acids 148-165; and

viii) amino acids 1-149;

in case the protein is mouse DCTN 1 (SEQ ID NO.: 67):

10 i) amino acids 39-150;

ii) amino acids 1006-1021; and

iii) amino acids 133-899; or

in case the protein is human DCTN1 (SEQ ID NO.: 68):

iv) amino acids 39-150;

15 v) amino acids 1006-1021; and

vi) amino acids 133-899.

151. The method according to claim 150, wherein

20 a) if the protein is cytoplasmic dynein intermediate chain 1 (SEQ ID NO.: 61 or 62), said amino acid is any one of the amino acids specified in Table 20;

b) if the protein is cytoplasmic dynein intermediate chain 2 (SEQ ID NO.: 64 or 65), said amino acid is any one of the amino acids specified in Table 21;

25 c) if the protein is DCTN 1 (SEQ ID NO.: 67 or 68), said amino acid is any one of the amino acids specified in Table 22.

152. A method for identifying a predisposition of a mammalian subject, particularly a human subject, for developing a neurodegenerative disease, said method comprising the step of determining whether a test sample derived from said subject indicates the presence of a mutation in an allele of a gene coding for a protein, which is a subunit of the dynactin/dynein complex, indicative of an increased risk of said subject of developing said neurodegenerative disease.
153. The method according to claim 152, further comprising the step of assigning a certain risk of developing said neurodegenerative disease to said subject.
154. A method for determining whether a neurodegenerative disease in a mammalian subject, particularly a human subject, is associated with a mutation in an allele of a gene coding for a protein, which is a subunit of the dynactin/dynein complex, said method comprising the step of determining whether a test sample derived from said subject indicates the presence of a mutation in an allele of a gene coding for said protein.
155. The method according to any of claims 152 to 154, wherein said neurodegenerative disease is selected from the group consisting of Alzheimer's Disease, Parkinson's Disease, and Huntington's Disease.
156. The method according to any one of claims 152 to 154, wherein said neurodegenerative disease is a motoneuron degenerative disease.
157. The method according to claim 156, wherein said motoneuron degenerative disease is selected from the group consisting of: Amyotrophic Lateral Sclerosis, Spinal Muscular Atrophy, Bulbo-Spinal Muscular Atrophy, Progressive Bulbar Palsy, Progressive Muscular Atrophy, and Primary Lateral Sclerosis.
158. The method according to any one of claims 152 to 157, wherein said test sample is a nucleic acid sample.

159. The method according to claim 158, wherein said nucleic acid is selected from the group consisting of mRNA, cDNA and genomic DNA.
160. The method according to claim 158 or 159, wherein the nucleic acid is selected from the group consisting of nucleic acids coding for the cytoplasmic dynein heavy chain 1, e.g. SEQ ID NOS.: 28 or 29, the cytoplasmic dynein intermediate chain 1, e.g. SEQ ID NOS.: 30 or 31, the cytoplasmic dynein intermediate chain 2, e.g. SEQ ID NOS.: 32 or 33, the cytoplasmic dynein light intermediate chain 1, e.g. SEQ ID NOS.: 34 or 35, the cytoplasmic dynein light intermediate chain 2, e.g. SEQ ID NOS.: 36 or 37; the cytoplasmic dynein 10 kDa light chain, e.g. SEQ ID NOS.: 38 or 39, the cytoplasmic dynein light chain Tctex 1, e.g. SEQ ID NOS.: 40 or 41, the cytoplasmic dynein light chain 2B, e.g. SEQ ID NO.: 42, DCTN 1, e.g. SEQ ID NOS.: 43 or 44, DCTN 2, e.g. SEQ ID NOS.: 159 or 45, DCTN 3, e.g. SEQ ID NOS.: 46 or 47, DCTN 4, e.g. SEQ ID NOS.: 48 or 49, DCTN 5, e.g. SEQ ID NO.: 50, DCTN 6, e.g. SEQ ID NOS.: 51 or 52, ARP1, e.g. SEQ ID NOS.: 53 or 54, ARP11, e.g. SEQ ID NOS.: 55 or 56, HAP1, e.g. SEQ ID NOS.: 57 or 58, and CLIP-170, e.g. SEQ ID NOS.: 59 or 60, preferably the cytoplasmic dynein heavy chain 1, cytoplasmic dynein intermediate chain 1, cytoplasmic dynein intermediate chain 2, and/or DCTN 1, e.g. according to the above-mentioned corresponding SEQ ID NOS.
161. The method according to any one of claims 152 to 157, wherein said test sample is a protein sample.
162. The method of claim 161, wherein said protein sample comprises a protein selected from the group consisting of the cytoplasmic dynein heavy chain 1, e.g. encoded by SEQ ID NOS.: 28 or 29, the cytoplasmic dynein intermediate chain 1, e.g. encoded by SEQ ID NOS.: 30 or 31, the cytoplasmic dynein intermediate chain 2, e.g. encoded by SEQ ID NOS.: 32 or 33, the cytoplasmic dynein light intermediate chain 1, e.g. encoded by SEQ ID NOS.: 34 or 35, the cytoplasmic dynein light intermediate chain 2, e.g. encoded by SEQ ID NOS.: 36 or 37; the cytoplasmic dynein 10 kDa light chain, e.g. encoded by SEQ ID

- 5 NOS.: 38 or 39, the cytoplasmic dynein light chain Tctex 1, e.g. encoded by
SEQ ID NOS.: 40 or 41, the cytoplasmic dynein light chain 2B, e.g. encoded
by SEQ ID NO.: 42, DCTN 1, e.g. encoded by SEQ ID NOS.: 43 or 44, DCTN
2, e.g. encoded by SEQ ID NOS.: 159 or 45, DCTN 3, e.g. encoded by SEQ
ID NOS.: 46 or 47, DCTN 4, e.g. encoded by SEQ ID NOS.: 48 or 49, DCTN
5, e.g. encoded by SEQ ID NO.: 50, DCTN 6, e.g. encoded by SEQ ID NOS.:
51 or 52, ARP1, e.g. encoded by SEQ ID NOS.: 53 or 54, ARP11, e.g.
10 encoded by SEQ ID NOS.: 55 or 56, HAP1, e.g. encoded by SEQ ID NOS.: 57
or 58, and CLIP-170, e.g. encoded by SEQ ID NOS.: 59 or 60, preferably the
cytoplasmic dynein heavy chain 1, cytoplasmic dynein intermediate chain 1,
cytoplasmic dynein intermediate chain 2, and/or DCTN 1, e.g. encoded by the
above-mentioned corresponding SEQ ID NOS.
- 15 163. The method according to any one of claims 152 to 162, wherein said mutation
selectively affects cell types associated with or suspected to be involved in
developing a neurodegenerative disease.
164. The method according to any one of claims 152 to 163, wherein said mutation
selectively affects motoneurons, preferably α -motoneurons.
- 20 165. The method according to any of claims 152 to 164, wherein said mutation
affects a cellular process selected from the group of processes consisting of
neuronal axonal transport, cellular transport, proliferation, differentiation and
apoptosis.
166. The method according to any of claims 152 to 165, wherein said mutation
leads to a disruption of, or alteration in the functional interaction within the
dynactin/dynein complex in neurons, preferably in motoneurons.
- 25 167. The method according to any one of claims 152 to 166, wherein said mutation
results in a deletion or substitution by another amino acid of an amino acid
encoded by said allele, or an insertion of additional amino acids not normally
present in the amino acid sequence of said protein, encoded by said allele.

168. The method according to claim 167, wherein said deletion, substitution, or insertion is encoded by both alleles of the gene coding for said protein.
169. The method according to any of claims 167 or 168, wherein said deletion, substitution, or insertion occurs in an evolutionary conserved region of said protein.
170. The method according to any of claims 152 to 169, wherein said mutation results in the substitution of an amino acid which is identical between the corresponding mouse and human protein, preferably between the corresponding mouse, rat, and human protein encoded by said allele, by another amino acid.
171. The method according to any of claims 167 to 170, wherein said amino acid is substituted by a naturally occurring amino acid.
172. The method according to any of claims 167 to 171, wherein said amino acid is encoded by a codon within the open reading frame of a nucleic acid sequence selected from the group consisting of SEQ ID NO.: 70-112 or SEQ ID NO.: 114-158.
173. The method according to any of claims 167 to 172, wherein said amino acid is located in a domain of said protein, which is capable of binding to another subunit of the dynactin/dynein complex.
174. The method according to claim 173, wherein said domain is defined by an amino acid sequence selected from the group of sequences consisting of
- in case the protein is mouse cytoplasmic dynein intermediate chain 1 (SEQ ID NO.: 61):
- i) amino acids 147-157;
 - ii) amino acid 243-314;

iii) amino acids 140-157; and

iv) amino acids 1-123;

in case the protein is human cytoplasmic dynein intermediate chain 1 (SEQ ID NO.: 62):

5 v) amino acids 164-174;

vi) amino acids 260-331;

vii) amino acids 157-174; and

viii) amino acids 1-140;

10 in case the protein is mouse cytoplasmic dynein intermediate chain 2 (SEQ ID NO.: 64):

i) amino acids 1-123;

ii) amino acids 122-139;

iii) amino acids 129-130; and

iv) amino acids 226-297;

15 in case the protein is human cytoplasmic dynein intermediate chain 2 (SEQ ID NO.: 65):

v) amino acids 155-165;

vi) amino acids 252-323;

vii) amino acids 148-165; and

20 viii) amino acids 1-149;

in case the protein is mouse DCTN 1 (SEQ ID NO.: 67):

i) amino acids 39-150;

ii) amino acids 1006-1021; and

iii) amino acids 133-899; or

in case the protein is human DCTN1 (SEQ ID NO.: 68):

- iv) amino acids 39-150;
- v) amino acids 1006-1021; and
- vi) amino acids 133-899.

5 175. The method according to claim 174, wherein

- a) if the protein is cytoplasmic dynein intermediate chain 1 (SEQ ID NOS.: 61 or 62), said amino acid is any one of the amino acids specified in Table 20;
- b) if the protein is cytoplasmic dynein intermediate chain 2 (SEQ ID
10 NOS.: 64 or 65), said amino acid is any one of the amino acids specified in Table 21;
- c) if the protein is DCTN 1 (SEQ ID NOS.: 67 or 68), said amino acid is any one of the amino acids specified in Table 22.

15 176. An oligonucleotide suitable for identifying a mutation in an allele of a gene coding for a protein, which is a subunit of the dynactin/dynein complex.


177. An oligonucleotide according to claim 176, the nucleotide sequence of which corresponds to a nucleotide sequence within said allele, which contains a mutation as defined in any of claims 139 to 151.

20 178. An oligonucleotide according to claim 176 or 177, which is suitable for hybridizing to the nucleic acid of said allele or a portion of its nucleic acid under stringent conditions.

179. An oligonucleotide according to any of claims 176 to 178, which is suitable as primer for amplifying the nucleic acid of said allele or a portion of its nucleic acid.

180. A kit for identifying a predisposition of a mammalian subject, particularly a human subject, for developing a neurodegenerative disease, or for identifying an association of a neurodegenerative disease of said subject with a mutation in an allele coding for a protein, which is a subunit of the dynactin/dynein complex, said kit comprising one or more oligonucleotides according to any of claims 176 to 178.
181. A kit for identifying a predisposition of a mammalian subject, particularly a human subject, for developing a neurodegenerative disease or for an association of a neurodegenerative disease of said subject with a mutation in an allele coding for a protein, which is a subunit of the dynactin/dynein complex, said kit comprising at least two oligonucleotides according to claim 179.
182. The kit according to claims 180 or 181, further comprising instructions to use the oligonucleotide or the oligonucleotides for identifying said predisposition in said subject or said association of the neurodegenerative disease of said subject with said mutation.
183. A solid support, wherein at least two oligonucleotides according to any of claims 176 to 178 are individually fixed to separate areas of the solid support to form an array.
184. The solid support according to claim 183, which is a glass chip, preferably a glass chip with a modified surface.
185. Use of the oligonucleotides of any of claims 176 to 179, or the kit of any of claims 180 to 182, or the solid support of claim 183 or 184, in a method according to any one of claims 122 to 136, 139 to 160, or 163 to 175.

Figure 1. Muscle cramping of the Cral mouse.



Cral/+

+/+

Figure 2. Increased ambulatory activity of
Cra1 mice during the night.





Figure 3. Reduced muscle endurance of Cra1 mice.

Mouse #	Sex	Genotype	Latency to Fall [in seconds]
1	female	+/+	810
2	male	+/+	280
3	male	+/+	845
4	female	Cra1/+	110
5	female	Cra1/+	15
6	female	Cra1/+	35
7	male	Cra1/+	14
8	male	Cra1/+	20
9	male	Cra1/+	20

Figure 4. Excitatory neuronal damage in the hippocampus of the *Cral*^{1/+} mouse.

Cral^{1/+}



+/+




Figure 5. Neurodegeneration in the anterior horns of the spinal cord and the dorsal root ganglia of homozygous Cra1 embryos.




Figure 5.2: Progressive impairment of muscle function and motor coordination is associated with decreasing numbers of a-motor neurons and altered composition of muscle fibre types.




Figure 6. Transcriptionally deregulated genes in the brain of homozygous Cral embryos.

Gene symbol	Gene description	Deregulation	Biological significance
Rasgrp2	RAS, guanyl releasing protein 2	Up	Brain-enriched guanine nucleotide exchange factor, is stimulated by calcium and diacylglycerol and activates small GTPases (e.g. Ras); expressed in the striatal projection neurons (cf. Toki et al. 2001, J Comp Neurol 437, 398-407)
Vdac2	voltage-dependent anion channel 2	Down	Voltage dependent anion channel of the outer mitochondrial membrane; controls the permeability of outer mitochondrial membrane for anions (eg ATP); probably part of the permeability transition pore (involved in apoptosis regulation); KO mouse displays immobile sperms and infertility (axonal defects of the sperms) as well as deficits in long and short term synaptic plasticity, fear conditioning and spatial learning (cf. Waagepetersen et al. 2002, J Biol Chem 277, 18891-18897).
Ttic3	tetratricopeptide repeat domain	Down	Domain on transcription factors that allows them to bind to an acceptor site on the ubiquitous hsp90 protein; some of these transcription factors bind to cytoplasmic dynein; the complex of the hsp90-GR (glucocorticoid receptor)-FKBP52 is targeted to the nucleus by binding of the latter to dynein (cf. Harrell et al. 2002, 41, 5581-5587)
Rab6	RAB6, member RAS oncogene family	Down	Rab proteins are molecular switches or timers regulating the transport of vesicles between compartments of the cell (eg golgi and ER); they impact the recruitment of dynein to the intracellular vesicles which have to be transported (cf. Smythe 2002, Mol. Cell 9, 205-206; Seabra et al 2002, Trends Mol Med 8, 23-30)
Rab2	RAB2, member RAS oncogene family	Down	Rab proteins are molecular switches or timers regulating the transport of vesicles between compartments of the cell (eg golgi and ER); they impact the recruitment of dynein to the intracellular vesicles which have to be transported (cf. Smythe 2002, Mol. Cell 9, 205-206; Seabra et al 2002, Trends Mol Med 8, 23-30)
Pak3	p21 (CDKN1A)-activated kinase 3	Down	PAK proteins (p21 activating kinases) are downstream effectors that link Rho-GTPases to the actin cytoskeleton and to MAP kinase cascades, including the c-Jun amino-terminal kinase (JNK) and p38. Recently it has been shown, that the presence of mutations in Pak3 is associated with X-linked non-specific mental retardation (Blanchard, T. et al 2000, Am J Med Genet. 93, 294-298)
Mark3	MAP/microtubule affinity-regulating kinase 3	Down	Belongs to a family of kinases which phosphorylates microtubule-associated proteins (e.g. tau) and trigger microtubule disruption (cf. Drewes et al 1997, Cell 89, 297-308); tau is hyperphosphorylated in several neurodegenerative diseases including Alzheimers disease (cf. Schneider et al. 1999, Biochemistry 38, 3549-3558)
Kif3b	kinopsin family member 3b	Down	Component of the axonemal dynein motor kinesin (Yamazaki et al 1995, J Cell Biol 130, 1387-1399)
Drg1	developmentally regulated GTP binding protein 1	Down	DRG is a developmentally regulated GTP-binding protein from the central nervous system of mouse (Li and Trueb, 2000, Biochim Biophys Acta 1491, 196-204)
Cicn3	chloride channel 3	Down	Cic3 chloride channel is expressed in nervous tissue; the KO mouse displays blindness, motor coordination deficit, spontaneous hypertrophy of retinal and hippocampal degeneration; the observed phenotype seems to be due to an accumulation of the neuronal ceroid lipofuscin
Bcan	brevican	Down	Brevican is an extracellular matrix molecule (proteoglycan) which is overexpressed in human gliomas (Lawless et al 1996, Cancer Research 56, 2293-2298). It seems to inhibit neurite outgrowth thereby contributing to axon guidance in development and regenerative processes (cf. Deller et al. 2001, Restor Neurol Neurosci 19, 159-167)

Figure 7. Exon Structure Comparison between the Human DNCH1 and the Mouse Dnchc1 Genes.




Figure 8. Comparison of mouse and human dynein heavy chain 1 exon numbers and exon lengths.

Exon No.	Mm Dnchc1 (bp)	Hs DNCH1 (bp)	Exon No.	Mm Dnchc1 (bp)	Hs DNCH1 (bp)
1	250	256	40	122	122
2	88	88	41	166	166
3	174	174	42	164	164
4	256	256	43	130	130
5	187	187	44	134	134
6	272	272	45	115	115
7	228	228	46	162	162
8	1078	1078	47	215	215
9	180	180	48	205	205
10	150	150	49	174	174
11	147	147	50	120	120
12	141	141	51	121	121
13	177	177	52	196	196
14	111	111	53	118	118
15	120	120	54	216	216
16	240	240	55	213	213
17	156	156	56	128	128
18	114	114	57	154	154
19	111	111	58	147	147
20	210	210	59	151	151
21	147	147	60	254	254
22	167	167	61	135	135
23	174	174	62	95	95
24	166	166	63	175	175
25	189	189	64	76	76
26	195	195	65	161	161
27	283	283	66	112	112
28	101	101	67	185	61
29	160	160	68	114	124
30	244	244	69	171	114
31	184	184	70	218	171
32	213	213	71	104	218
33	239	239	72	212	104
34	157	157	73	154	212
35	228	228	74	143	154
36	231	231	75	169	143
37	141	141	76	128	169
38	234	234	77	129	128
39	207	207	78		129

Figure 9. Amino Acid Alignment of Human DNCH1 and Mouse Dnchc1 Proteins.

Hs_DNCH1	1	MSRPGGGGEGDSAGLEVSANQNVADVS	VLOKHRLKRLVPLLEDGGG	APAALEALEEKSALAEQMRKFLSDPQVHTVIVERTLKEDVGDGEGEEKEFTIS
Mm_Dnchc1	1	MSRPGGGG..EDGSAGLEVSANQNVADVA	VLOKHRLKRLVPLLEDGGG	APAALEALEEKSALAEQMRKFLSDPQVHTVIVERTLKEDVGDGEGEEKEFTIS
Hs_DNCH1	101	YNINIDHYGVKSNLSLAFIKRTPVIDADKPVSSQRLVLT	SEDSPYETLHSFTISNAVAPFFKSYI	RESGADRDRGDKWAPSVEKKIAELEMGLLHLQONI
Mm_Dnchc1	99	YNINIDHYGVKSNLSLAFIKRAEVIDADKPVSSQRLVLT	SEDSPYETLHSFTISNAVAPFFKSYI	RESGADRDRGDKWAPSVEKKIAELEMGLLHLQONI
Hs_DNCH1	201	EIPEISLPIHEIITWAKOCYERGERKPVTDGDKVEDP	TFNLQOSGVNRWIREIQKVTIKIDRDPASGVALQEI	SPWNLERALYRIQEKRESPEVLLT
Mm_Dnchc1	199	EIPEISLPIHEIITWAKOCYERGERKPVTDGDKVEDP	TFNLQOSGVNRWIREIQKVTIKIDRDPASGVALQEI	SPWNLERALYRIQEKRESPEVLLT
Hs_DNCH1	301	LDILKHGRFRHATVSFDTDTGLKQALFTVNDYNPLMKDF	PLNDLSATELDKIRQALVAI	FTHLRKIRNTKYPITORAURLVEAISRDLSQLLKVLTGRK
Mm_Dnchc1	299	LDILKHGRFRHATVSFDTDTGLKQALFTVNDYNPLMKDF	PLNDLSATELDKIRQALVAI	FTHLRKIRNTKYPITORAURLVEAISRDLSQLLKVLTGRK
Hs_DNCH1	401	LMHVAEENEFKVMVACFEVQVWDDVEYKIQVLLRDI	VKKRKEENLKWWRINPAHRKLOARLDQHRKFR	RQHQDLRAVI
Mm_Dnchc1	399	LMHVAEENEFKVMVACFEVQVWDDVEYKIQVLLRDI	VKKRKEENLKWWRINPAHRKLOARLDQHRKFR	RQHQDLRAVI
Hs_DNCH1	501	EPQDMKVAEVLFDAAADANAEEVNLA	YENKVEDGLDVSKEGTEAMEAAKRYDERIDR	VEPTRITARLRDQJGTAKANAMERI
Mm_Dnchc1	499	EPQDMKVAEVLFDAAADANAEEVNLA	YENKVEDGLDVSKEGTEAMEAAKRYDERIDR	VEPTRITARLRDQJGTAKANAMERI
Hs_DNCH1	601	IREYQTQLIQRVKDDIESLHDKFKVQVQSQACKRSHVRDL	PPVSGSI	IWAKQIDROLTAYMKRVEDVLGKGWENHVEGQKLDQGDSPFKMLNTQELFD
Mm_Dnchc1	599	IREYQTQLIQRVKDDIESLHDKFKVQVQSQACKRSHVRDL	PPVSGSI	IWAKQIDROLTAYMKRVEDVLGKGWENHVEGQKLDQGDSPFKMLNTQELFD
Hs_DNCH1	701	DWARKVQQRNLGVSGRIFTTIESNRVGRGTGNVLKLVNLP	PELITLSKEVRNLKWLGFGRVPLAI	VNKAHQANQLYPPFALSIESVRYTERTCEKVEERNY
Mm_Dnchc1	699	DWARKVQQRNLGVSGRIFTTIESNRVGRGTGNVLKLVNLP	PELITLSKEVRNLKWLGFGRVPLAI	VNKAHQANQLYPPFALSIESVRYTERTCEKVEERNY
Hs_DNCH1	801	ISLLVAGLKKEVQALTAEGTALVMSYKLDPPYVQRLAETV	FNFEQEKVDDLLI	IEEKIDLEVRSLFCMYDHTTSEILNRVOKAVDDDLNLHYSNLP
Mm_Dnchc1	799	ISLLVAGLKKEVQALTAEGTALVMSYKLDPPYVQRLAETV	FNFEQEKVDDLLI	IEEKIDLEVRSLFCMYDHTTSEILNRVOKAVDDDLNLHYSNLP
Hs_DNCH1	901	NKLDMEIERILGVRLQAGLRATQVLLGQAEKAEVDMDTDA	FOVSHKPGGEPKIKNVVHELRI	TNQVIYINPPIEECRKYLYQEMFAWKWVLSLPRIO
Mm_Dnchc1	899	NKLDMEIERILGVRLQAGLRATQVLLGQAEKAEVDMDTDA	FOVSHKPGGEPKIKNVVHELRI	TNQVIYINPPIEECRKYLYQEMFAWKWVLSLPRIO
Hs_DNCH1	1001	SQRVQGVHYTEEBEKFYRNALTRMPDGPVVALESYS	SAVMGTVHEVEQVKKVLQYQCLNDQNAENI	YNRLGEDLNKQALVQIRKARGTFDNAETKK
Mm_Dnchc1	999	SQRVQGVHYTEEBEKFYRNALTRMPDGPVVALESYS	SAVMGTVHEVEQVKKVLQYQCLNDQNAENI	YNRLGEDLNKQALVQIRKARGTFDNAETKK
Hs_DNCH1	1101	EFGPVVTDYGVKQSVNLA	YDSHKEVL	SKFGQMLGSMNTEFHSQJLSKSRQELSHSVDTASTSDAVTFITYVOSLRKRIKQEKOVELYRNGORLLEKO
Mm_Dnchc1	1099	EFGPVVTDYGVKQSVNLA	YDSHKEVL	SKFGQMLGSMNTEFHSQJLSKSRQELSHSVDTASTSDAVTFITYVOSLRKRIKQEKOVELYRNGORLLEKO
Hs_DNCH1	1201	RFQPPSPSWLYTDNI	EGEWGA	FNDIMRRKDSAIQQOVANI
Mm_Dnchc1	1199	RFQPPSPSWLYTDNI	EGEWGA	FNDIMRRKDSAIQQOVANI

(Figure 9 continued)

Hs_DNCH1 1301 KEALDELDTGLSGSERVQVVALEELQDLKGWSELKSWEQIQDKMEQPVWSVOPRKLQRNDLILNQLKSEFARLQYASVEFVQRLKGYMKINMLV
 Mm_Dnchc1 1299 KEALDELDTGLSGSERVQVVALEELQDLKGWSELKSWEQIQDKMEQPVWSVOPRKLQRNDLILNQLKSEFARLQYASVEFVQRLKGYMKINMLV
 Hs_DNCH1 1401 IELKSEALKDRHMKQLMKRLHVNWVSELTIGQIVNDVLDQKNEALVKDVLVLAQCEMALEEFKQIREVNTYELDLVNYQNKCRILRGHDDLFNKVKREH
 Mm_Dnchc1 1399 IELKSEALKDRHMKQLMKRLHVNWVSELTIGQIVNDVLDQKNEALVKDVLVLAQCEMALEEFKQIREVNTYELDLVNYQNKCRILRGHDDLFNKVKREH
 Hs_DNCH1 1501 INSVSAMKLSPPYKVFEDALSWEDKLNRIWALFDVWIDVQRWVYLEGITGSADIKHLLPVETQRFQSIISTEFALMKKVKSPVMDVNLNIQGVQVS
 Mm_Dnchc1 1499 INSVSAMKLSPPYKVFEDALSWEDKLNRIWALFDVWIDVQRWVYLEGITGSADIKHLLPVETQRFQSIISTEFALMKKVKSPVMDVNLNIQGVQVS
 Hs_DNCH1 1601 LERLADLGGIKQKALGEYLERERSSFRPFYVGDLDLLELIGNKKNVAKQKHFKKFAGVSSIIINEDNSVVLGSSREGGEVMTKTPVSIITGHPKINE
 Mm_Dnchc1 1599 LERLADLGGIKQKALGEYLERERSSFRPFYVGDLDLLELIGNKKNVAKQKHFKKFAGVSSIIINEDNSVVLGSSREGGEVMTKTPVSIITGHPKINE
 Hs_DNCH1 1701 WLTIVKEMRVTLAKLLAESVTEVEIFGKATSIDNTYITWIDKYQOLVVLVLSAQIAWSENVEFALSNMGGGGVAPLQSVLSNVETLVNVLADSVLMEQ
 Mm_Dnchc1 1699 WLTIVKEMRVTLAKLLAESVTEVEIFGKATSIDNTYITWIDKYQOLVVLVLSAQIAWSENVEFALSNMGGGGVAPLQSVLSNVETLVNVLADSVLMEQ
 Hs_DNCH1 1801 PPLRRRKLHLLTELVDHQRDVTRSLIKSIDNAKSEFELSQMRFYFDPKQFDVQLQSLIQMANAKFNKGFEYLGVDKLQVQPLTDRCYLTMTQALEARL
 Mm_Dnchc1 1799 PPLRRRKLHLLTELVDHQRDVTRSLIKSIDNAKSEFELSQMRFYFDPKQFDVQLQSLIQMANAKFNKGFEYLGVDKLQVQPLTDRCYLTMTQALEARL
 Hs_DNCH1 1901 GSGFPGAGTGTESVKALGHQGRFVLVFNCDDETFDQAMGRI FVGLQVQVANGCFFENRLEERLRSVQVQVQCIQEAALREHSNPNYDKTSAPITCE
 Mm_Dnchc1 1899 GSGFPGAGTGTESVKALGHQGRFVLVFNCDDETFDQAMGRI FVGLQVQVANGCFFENRLEERLRSVQVQVQCIQEAALREHSNPNYDKTSAPITCE
 Hs_DNCH1 2001 LLNKKQVKSPOWALFTTMNPGYAGRSNLPDLNKKLFRSLAMTKPDRQLIAQVMLYSQGFRTAEVLANKIVPFFKLCDQLSSQSHVDFGLRALKSVLVA
 Mm_Dnchc1 1999 LLNKKQVKSPOWALFTTMNPGYAGRSNLPDLNKKLFRSLAMTKPDRQLIAQVMLYSQGFRTAEVLANKIVPFFKLCDQLSSQSHVDFGLRALKSVLVA
 Hs_DNCH1 2101 GNVKRERIKIKRKEERGEAVDEGEAENIPEQILLIQSVCTWVPKVAEDIPLLESLSDVFPVQVHRGEMTALREELKVKCOEMVLTGDBGEEVG
 Mm_Dnchc1 2099 GNVKRERIKIKRKEERGEAVDEGEAENIPEQILLIQSVCTWVPKVAEDIPLLESLSDVFPVQVHRGEMTALREELKVKCOEMVLTGDBGEEVG
 Hs_DNCH1 2201 GNVVEKVLQLYQITQINHGIMWVGPSSGSGKSMARVLLKALERLEGEVGAHIIDPKAISKDHLYGTLDNTRNTWTDGLFTHVLRKIIDNVRGELQKQW
 Mm_Dnchc1 2199 GNVVEKVLQLYQITQINHGIMWVGPSSGSGKSMARVLLKALERLEGEVGAHIIDPKAISKDHLYGTLDNTRNTWTDGLFTHVLRKIIDNVRGELQKQW
 Hs_DNCH1 2301 LVFDGVDPEWENLNSVLDNKLTLTPNGERLSLPPNVRIMEVQDLKYATLATVSRCGWVWFSDVLTDMIFNNFLARLSIPLDEGEDEAQRKRG
 Mm_Dnchc1 2299 LVFDGVDPEWENLNSVLDNKLTLTPNGERLSLPPNVRIMEVQDLKYATLATVSRCGWVWFSDVLTDMIFNNFLARLSIPLDEGEDEAQRKRG
 Hs_DNCH1 2401 KEDEGEAAASPMLOIQORDAATTINQPYTTSNGLVTKALEHAFQLEHIMDLRLRCIGSLFSLHQAQNNVAQYANANHPDFPMQIEQLERYIQRYLVVYAILW
 Mm_Dnchc1 2399 KEDEGEAAASPMLOIQORDAATTINQPYTTSNGLVTKALEHAFQLEHIMDLRLRCIGSLFSLHQAQNNVAQYANANHPDFPMQIEQLERYIQRYLVVYAILW
 Hs_DNCH1 2501 SLSGDSRLKMAELGEYIRITTVPLPTAPNPIIIDYEVSI SGEMSPWQAKVPQIEVETHKVAAPDVVPTLDTVRHEALLYTWLAEHKPLVLCGPPGSG
 Mm_Dnchc1 2499 SLSGDSRLKMAELGEYIRITTVPLPTAPNPIIIDYEVSI SGEMSPWQAKVPQIEVETHKVAAPDVVPTLDTVRHEALLYTWLAEHKPLVLCGPPGSG
 Hs_DNCH1 2601 KTWTLFSALRALPDMEVVGINFSSATTPPELLKTFDHYCEYRRTPNGVVLAPVOLGKWLVLFCDEINLPMDKYGTVQVISEFIQMVHGEHGFYRTSDQW
 Mm_Dnchc1 2599 KTWTLFSALRALPDMEVVGINFSSATTPPELLKTFDHYCEYRRTPNGVVLAPVOLGKWLVLFCDEINLPMDKYGTVQVISEFIQMVHGEHGFYRTSDQW
 Hs_DNCH1 2701 VKLRIQEVGACNPPDPGRKPLSHRLRHPVNVVYDYPGPASLTQIYGTENRAMRLIPSLRTVAEPLVAAMVEFYTHSQBRFTQDTQPHYIYSPREMT
 Mm_Dnchc1 2699 VKLRIQEVGACNPPDPGRKPLSHRLRHPVNVVYDYPGPASLTQIYGTENRAMRLIPSLRTVAEPLVAAMVEFYTHSQBRFTQDTQPHYIYSPREMT
 Hs_DNCH1 2801 RWRGIFEARLPLETLPVEGLIRIWAHEALRLFDRLVDEDEERRWTDENIDVAKKHFPNIDKRAMSRPILYSNNLSKDYIPVDOEELRDYVKARLKV
 Mm_Dnchc1 2799 RWRGIFEARLPLETLPVEGLIRIWAHEALRLFDRLVDEDEERRWTDENIDVAKKHFPNIDKRAMSRPILYSNNLSKDYIPVDOEELRDYVKARLKV

(Figure 9 continued)

Hs_DNCH1	2901	YEEELDVLVLFNEVLDHVLRI
Mm_Dnchc1	2899	YEEELDVLVLFNEVLDHVLRI
Hs_DNCH1	3001	DSGELRMNTLLANGEVPG
Mm_Dnchc1	2999	DSGELRMNTLLANGEVPG
Hs_DNCH1	3101	ALXQVGKFTSKMDLEKPNY
Mm_Dnchc1	3099	ALXQVGKFTSKMDLEKPNY
Hs_DNCH1	3201	LNVGLRKIKETVDQVEELRRDLRI
Mm_Dnchc1	3199	LNVGLRKIKETVDQVEELRRDLRI
Hs_DNCH1	3301	KQHLVEVRSMANPPAAVKLALES
Mm_Dnchc1	3299	KQHLVEVRSMANPPAAVKLALES
Hs_DNCH1	3401	NYADMLKRVPELRNELQLEDDAK
Mm_Dnchc1	3399	NYADMLKRVPELRNELQLEDDAK
Hs_DNCH1	3501	STIAGDCLLSAAFIAYAGY
Mm_Dnchc1	3499	STIAGDCLLSAAFIAYAGY
Hs_DNCH1	3601	MMEYKDRKIKITRTSFDDA
Mm_Dnchc1	3599	MMEYKDRKIKITRTSFDDA
Hs_DNCH1	3701	FTVTRSLQSQCLNEVLKAE
Mm_Dnchc1	3699	FTVTRSLQSQCLNEVLKAE
Hs_DNCH1	3801	YLPSTACSSSYFTWESLQK
Mm_Dnchc1	3799	YLPSTACSSSYFTWESLQK
Hs_DNCH1	3901	YDAEFQHLRGNEIVLSAG
Mm_Dnchc1	3899	YDAEFQHLRGNEIVLSAG
Hs_DNCH1	4001	LLAMAHMEVSTNLGESFWS
Mm_Dnchc1	3999	LLAMAHMEVSTNLGESFWS
Hs_DNCH1	4101	LAPGWLQLEKKLHSLQPH
Mm_Dnchc1	4099	LAPGWLQLEKKLHSLQPH
Hs_DNCH1	4201	WSKKYFEGESDLRSACD
Mm_Dnchc1	4199	WSKKYFEGESDLRSACD
Hs_DNCH1	4301	RREEFQVQVVELLPDQ
Mm_Dnchc1	4299	RREEFQVQVVELLPDQ
Hs_DNCH1	4401	TVENIKDPLPRFFEREV
Mm_Dnchc1	4399	TVENIKDPLPRFFEREV

(Figure 9 continued)

Hs_DNCH1	4501	AKELKNIHVCLGGLFVPEAYITATROYVAQANSWSLEELCLEVNVTTSCGATLDACSFQVGTGLKIQGATCNKKLSLSNAISTALPLTQLRWVKQNTTEK
Mm_Dnchc1	4499	AKELKNIHVCLGGLFVPEAYITATROYVAQANSWSLEELCLEVNVTAQSGATLDACSFQVGTGLKIQGATCSNNKKLSLSNAISTVDFLTQLRWVKQTSAEK
Hs_DNCH1	4601	KASVVTLPVYVNFTRADLIFTVDFFEIATREDPRSFYERGVAVLCPE
Mm_Dnchc1	4599	KASVVTLPVYVNFTRADLIFTVDFFEIATREDPRSFYERGVAVICTE

Figure 10. Amino Acid Alignment of Human DNCH1, Mouse Dnchc1, and rat Dnchc1 Proteins –highly conserved amino acid residues.

Software used:

- Multalin via <http://prodes.toulouse.inra.fr/multalin/multalin.html> [Corpet. F. (1988), Multiple sequence alignment with hierarchical clustering, Nucl. Acids Res., 16 (22), 10881-10890]
- BOXSHADE 3.21 via http://www.ch.embnet.org/software/BOX_form.html

Hs: Homo sapiens; deduced by homology
Mm: Mus musculus; NP_084514
Rn: Rattus norvegicus; NP_062099

Mm	1	MSEPCGG...EDGSAGLEVS	AVQNVADVAVLQKHRLKLVPLLEDGGDA	PAALAEAEKKSALQMRKFLSDPQVHTV	VERSTLKEDVGDGEGEKEKFTS
Rn	1	MSEPCGG...EDGSAGLEVS	AVQNVADVSVLQKHRLKLVPLLEDGGDA	PAALAEAEKKSALQMRKFLSDPQVHTV	VERSTLKEDVGDGEGEKEKFTS
Hs	1	MSEPCGGGGE	EDGSAGLEVS	AVQNVADVSVLQKHRLKLVPLLEDGGDA	PAALAEAEKKSALQMRKFLSDPQVHTV
Consensus	1	MSEPCGGG...EDGSAGLEVS	AVQNVADVSVLQKHRLKLVPLLEDGGDA	PAALAEAEKKSALQMRKFLSDPQVHTV	VERSTLKEDVGDGEGEKEKFTS
Mm	99	YMINIDIHYGVKNSLA	FIKRAPVIDADKPVSQRLVLT	SEDSPYETLHSTFISNAVAPFEKSY	IRESGKADRDGDKMAPSVEKKTAELEMLLHQNI
Rn	99	YMINIDIHYGVKNSLA	FIKRAPVIDADKPVSQRLVLT	SEDSPYETLHSTFISNAVAPFEKSY	IRESGKADRDGDKMAPSVEKKTAELEMLLHQNI
Hs	101	YMINIDIHYGVKNSLA	FIKRAPVIDADKPVSQRLVLT	SEDSPYETLHSTFISNAVAPFEKSY	IRESGKADRDGDKMAPSVEKKTAELEMLLHQNI
Consensus	98	YMINIDIHYGVKNSLA	FIKRAPVIDADKPVSQRLVLT	SEDSPYETLHSTFISNAVAPFEKSY	IRESGKADRDGDKMAPSVEKKTAELEMLLHQNI
Mm	199	EIPETSLPHPIITN	VAKQCYERGEKPKVTDGDKVEDPT	FLNQLQSGVNRWIREIQVTKLDRDP	PASGTALQETSFNINLERALYRIQEKRESPEVLIT
Rn	199	EIPETSLPHPIITN	VAKQCYERGEKPKVTDGDKVEDPT	FLNQLQSGVNRWIREIQVTKLDRDP	PASGTALQETSFNINLERALYRIQEKRESPEVLIT
Hs	201	EIPETSLPHPIITN	VAKQCYERGEKPKVTDGDKVEDPT	FLNQLQSGVNRWIREIQVTKLDRDP	PASGTALQETSFNINLERALYRIQEKRESPEVLIT
Consensus	198	EIPETSLPHPIITN	VAKQCYERGEKPKVTDGDKVEDPT	FLNQLQSGVNRWIREIQVTKLDRDP	PASGTALQETSFNINLERALYRIQEKRESPEVLIT
Mm	299	LDILKHGRFHATVS	FDDTDTGLKQALETVNDY	NPLMKDPFNDLLSATELDKIRQALVAI	FTHLRKIRNTKYPIQRALRIVEAISRDLSOLLKVLGTRK
Rn	299	LDILKHGRFHATVS	FDDTDTGLKQALETVNDY	NPLMKDPFNDLLSATELDKIRQALVAI	FTHLRKIRNTKYPIQRALRIVEAISRDLSOLLKVLGTRK
Hs	301	LDILKHGRFHATVS	FDDTDTGLKQALETVNDY	NPLMKDPFNDLLSATELDKIRQALVAI	FTHLRKIRNTKYPIQRALRIVEAISRDLSOLLKVLGTRK
Consensus	298	LDILKHGRFHATVS	FDDTDTGLKQALETVNDY	NPLMKDPFNDLLSATELDKIRQALVAI	FTHLRKIRNTKYPIQRALRIVEAISRDLSOLLKVLGTRK
Mm	399	LMHVAEEFEKVMVAC	FEVFTQWDEYEKQLVLLRDI	VKKRENLKMWIRNP	PAHRKLQARLDQMRKFRQHEQLRAVIVRILRPQVTA
Rn	399	LMHVAEEFEKVMVAC	FEVFTQWDEYEKQLVLLRDI	VKKRENLKMWIRNP	PAHRKLQARLDQMRKFRQHEQLRAVIVRILRPQVTA
Hs	401	LMHVAEEFEKVMVAC	FEVFTQWDEYEKQLVLLRDI	VKKRENLKMWIRNP	PAHRKLQARLDQMRKFRQHEQLRAVIVRILRPQVTA
Consensus	398	LMHVAEEFEKVMVAC	FEVFTQWDEYEKQLVLLRDI	VKKRENLKMWIRNP	PAHRKLQARLDQMRKFRQHEQLRAVIVRILRPQVTA
Mm	499	EPQDKKVAEVLFD	AAADANATIEEVNLAYEN	VEKVDGLDVSKEGTAEWAA	AMKRYDERIDRVETRI
Rn	499	EPQDKKVAEVLFD	AAADANATIEEVNLAYEN	VEKVDGLDVSKEGTAEWAA	AMKRYDERIDRVETRI
Hs	501	EPQDKKVAEVLFD	AAADANATIEEVNLAYEN	VEKVDGLDVSKEGTAEWAA	AMKRYDERIDRVETRI
Consensus	498	EPQDKKVAEVLFD	AAADANATIEEVNLAYEN	VEKVDGLDVSKEGTAEWAA	AMKRYDERIDRVETRI

(Figure 10 continued)

Mm	599	I R E Y T Q L I Q R V K D D I E S L H D K F K V Q P Q S Q A C K M S H V R D L P P V S G S I I W A K Q I D R Q L T A Y A K R V E D V L G K G W H H V E G Q K L Q D G S F R M K L N T Q E I F D
Rn	599	I R E Y T Q L I Q R V K D D I E S L H D K F K V Q P Q S Q A C K M S H V R D L P P V S G S I I W A K Q I D R Q L T A Y A K R V E D V L G K G W H H V E G Q K L Q D G S F R M K L N T Q E I F D
Hs	601	I R E Y T Q L I Q R V K D D I E S L H D K F K V Q P Q S Q A C K M S H V R D L P P V S G S I I W A K Q I D R Q L T A Y A K R V E D V L G K G W H H V E G Q K L Q D G S F R M K L N T Q E I F D
Consensus	598	I R E Y T Q L I Q R V K D D I E S L H D K F K V Q P Q S Q A C K M S H V R D L P P V S G S I I W A K Q I D R Q L T A Y A K R V E D V L G K G W H H V E G Q K L Q D G S F R M K L N T Q E I F D
Mm	699	D W A R K V Q Q R N L G V S G R I F T I E S A R V R G T G V L K L K V N F L P E I I T L S K E V R N L K W L G F R V P L A I V N K A H Q A N Q L Y P P A I S L I E S V R T Y E R T C E K V E E R N T
Rn	699	D W A R K V Q Q R N L G V S G R I F T I E S A R V R G T G V L K L K V N F L P E I I T L S K E V R N L K W L G F R V P L A I V N K A H Q A N Q L Y P P A I S L I E S V R T Y E R T C E K V E E R N T
Hs	701	D W A R K V Q Q R N L G V S G R I F T I E S A R V R G T G V L K L K V N F L P E I I T L S K E V R N L K W L G F R V P L A I V N K A H Q A N Q L Y P P A I S L I E S V R T Y E R T C E K V E E R N T
Consensus	698	D W A R K V Q Q R N L G V S G R I F T I E S A R V R G T G V L K L K V N F L P E I I T L S K E V R N L K W L G F R V P L A I V N K A H Q A N Q L Y P P A I S L I E S V R T Y E R T C E K V E E R N T
Mm	799	I S L L V A G L K K E V Q A L I A E G I A L V W E S Y K L D P Y V Q R L A E T V F N F Q E K V D D L L I I E E K I D E V S L E T C M Y D H K T F S E I L N R V Q K A V D D L N L H S Y S N L P I W
Rn	799	I S L L V A G L K K E V Q A L I A E G I A L V W E S Y K L D P Y V Q R L A E T V F N F Q E K V D D L L I I E E K I D E V S L E T C M Y D H K T F S E I L N R V Q K A V D D L N L H S Y S N L P I W
Hs	801	I S L L V A G L K K E V Q A L I A E G I A L V W E S Y K L D P Y V Q R L A E T V F N F Q E K V D D L L I I E E K I D E V S L E T C M Y D H K T F S E I L N R V Q K A V D D L N L H S Y S N L P I W
Consensus	798	I S L L V A G L K K E V Q A L I A E G I A L V W E S Y K L D P Y V Q R L A E T V F N F Q E K V D D L L I I E E K I D E V S L E T C M Y D H K T F S E I L N R V Q K A V D D L N L H S Y S N L P I W
Mm	899	N K L D M E I E R I L G V R L Q A G L R A W T Q V L L G Q A E D K A E V D M D T D A P Q V S H K P G G E P K I K N V V H E L R I T T Q V I Y L N P P I E E C R Y K L Y Q E M F A M K W V L S L P R I Q
Rn	899	N K L D M E I E R I L G V R L Q A G L R A W T Q V L L G Q A E D K A E V D M D T D A P Q V S H K P G G E P K I K N V V H E L R I T T Q V I Y L N P P I E E C R Y K L Y Q E M F A M K W V L S L P R I Q
Hs	901	N K L D M E I E R I L G V R L Q A G L R A W T Q V L L G Q A E D K A E V D M D T D A P Q V S H K P G G E P K I K N V V H E L R I T T Q V I Y L N P P I E E C R Y K L Y Q E M F A M K W V L S L P R I Q
Consensus	898	N K L D M E I E R I L G V R L Q A G L R A W T Q V L L G Q A E D K A E V D M D T D A P Q V S H K P G G E P K I K N V V H E L R I T T Q V I Y L N P P I E E C R Y K L Y Q E M F A M K W V L S L P R I Q
Mm	999	S Q R Y Q V G V H Y E L T E E E K F Y R N A L T R M P D G P V A L E E S Y S A V M G I V T E V Q Y V K W L Q Y O C L M D M Q A E N I Y N R L G E D L N K W Q A L L V O I R K A R G T F D N A E T K K
Rn	999	S Q R Y Q V G V H Y E L T E E E K F Y R N A L T R M P D G P V A L E E S Y S A V M G I V T E V Q Y V K W L Q Y O C L M D M Q A E N I Y N R L G E D L N K W Q A L L V O I R K A R G T F D N A E T K K
Hs	1001	S Q R Y Q V G V H Y E L T E E E K F Y R N A L T R M P D G P V A L E E S Y S A V M G I V T E V Q Y V K W L Q Y O C L M D M Q A E N I Y N R L G E D L N K W Q A L L V O I R K A R G T F D N A E T K K
Consensus	997	S Q R Y Q V G V H Y E L T E E E K F Y R N A L T R M P D G P V A L E E S Y S A V M G I V T E V Q Y V K W L Q Y O C L M D M Q A E N I Y N R L G E D L N K W Q A L L V O I R K A R G T F D N A E T K K
Mm	1099	E F G P V I D Y G K V Q S K V N L K Y D S W H K E V L S K F G M L G S N N T E F H S Q I S K S R Q E L Q H S V D T A S T S D A V T F T Y V Q S L R K K I K O F E K Q V E L Y R N G O R L L E K Q
Rn	1099	E F G P V I D Y G K V Q S K V N L K Y D S W H K E V L S K F G M L G S N N T E F H S Q I S K S R Q E L Q H S V D T A S T S D A V T F T Y V Q S L R K K I K O F E K Q V E L Y R N G O R L L E K Q
Hs	1101	E F G P V I D Y G K V Q S K V N L K Y D S W H K E V L S K F G M L G S N N T E F H S Q I S K S R Q E L Q H S V D T A S T S D A V T F T Y V Q S L R K K I K O F E K Q V E L Y R N G O R L L E K Q
Consensus	1097	E F G P V I D Y G K V Q S K V N L K Y D S W H K E V L S K F G M L G S N N T E F H S Q I S K S R Q E L Q H S V D T A S T S D A V T F T Y V Q S L R K K I K O F E K Q V E L Y R N G O R L L E K Q
Mm	1199	R F Q F P P S W L Y I D N I E G W G A F N D I M R R K D S A I Q Q Q V A N L Q M K I V Q E D R A V E S R T T D L L T D W E K T K P V T G N L R P E A L Q A L T I Y E G K F G R L K D D R E K C A K A
Rn	1199	R F Q F P P S W L Y I D N I E G W G A F N D I M R R K D S A I Q Q Q V A N L Q M K I V Q E D R A V E S R T T D L L T D W E K T K P V T G N L R P E A L Q A L T I Y E G K F G R L K D D R E K C A K A
Hs	1201	R F Q F P P S W L Y I D N I E G W G A F N D I M R R K D S A I Q Q Q V A N L Q M K I V Q E D R A V E S R T T D L L T D W E K T K P V T G N L R P E A L Q A L T I Y E G K F G R L K D D R E K C A K A
Consensus	1197	R F Q F P P S W L Y I D N I E G W G A F N D I M R R K D S A I Q Q Q V A N L Q M K I V Q E D R A V E S R T T D L L T D W E K T K P V T G N L R P E A L Q A L T I Y E G K F G R L K D D R E K C A K A
Mm	1299	K E A L E L T D T G L I S G S E E R V Q V A L E E L Q D L K G W S E L S K W E Q I D Q M K E Q P W S V Q P R K L R Q N L D G L L N Q L K N F P A R L Q Y A S Y E F V Q R L L K G Y M K I N N L V
Rn	1299	K E A L E L T D T G L I S G S E E R V Q V A L E E L Q D L K G W S E L S K W E Q I D Q M K E Q P W S V Q P R K L R Q N L D G L L N Q L K N F P A R L Q Y A S Y E F V Q R L L K G Y M K I N N L V
Hs	1301	K E A L E L T D T G L I S G S E E R V Q V A L E E L Q D L K G W S E L S K W E Q I D Q M K E Q P W S V Q P R K L R Q N L D G L L N Q L K N F P A R L Q Y A S Y E F V Q R L L K G Y M K I N N L V
Consensus	1297	K E A L E L T D T G L I S G S E E R V Q V A L E E L Q D L K G W S E L S K W E Q I D Q M K E Q P W S V Q P R K L R Q N L D G L L N Q L K N F P A R L Q Y A S Y E F V Q R L L K G Y M K I N N L V
Mm	1399	I E L K S E A L K D R H W K Q L M K R L H V N V S E L T L G Q I W D V D L Q K N E A I V K D V L V A Q E M A L E E F L K Q R E V N T Y E L D V A V Y Q N K C R L I R G H D D L F N K V K E H
Rn	1399	I E L K S E A L K D R H W K Q L M K R L H V N V S E L T L G Q I W D V D L Q K N E A I V K D V L V A Q E M A L E E F L K Q R E V N T Y E L D V A V Y Q N K C R L I R G H D D L F N K V K E H
Hs	1401	I E L K S E A L K D R H W K Q L M K R L H V N V S E L T L G Q I W D V D L Q K N E A I V K D V L V A Q E M A L E E F L K Q R E V N T Y E L D V A V Y Q N K C R L I R G H D D L F N K V K E H
Consensus	1397	I E L K S E A L K D R H W K Q L M K R L H V N V S E L T L G Q I W D V D L Q K N E A I V K D V L V A Q E M A L E E F L K Q R E V N T Y E L D V A V Y Q N K C R L I R G H D D L F N K V K E H
Mm	1499	I N S V S A M K L S P Y K V F E E D A L S W E D K L N R I W A L F D W I D V Q R R W V L E G I T G S A D I K H L L P V E T Q F Q S I S T E L A L M K K V S K S P L V M D V L N I Q G V Q R S
Rn	1499	I N S V S A M K L S P Y K V F E E D A L S W E D K L N R I W A L F D W I D V Q R R W V L E G I T G S A D I K H L L P V E T Q F Q S I S T E L A L M K K V S K S P L V M D V L N I Q G V Q R S
Hs	1501	I N S V S A M K L S P Y K V F E E D A L S W E D K L N R I W A L F D W I D V Q R R W V L E G I T G S A D I K H L L P V E T Q F Q S I S T E L A L M K K V S K S P L V M D V L N I Q G V Q R S
Consensus	1496	I N S V S A M K L S P Y K V F E E D A L S W E D K L N R I W A L F D W I D V Q R R W V L E G I T G S A D I K H L L P V E T Q F Q S I S T E L A L M K K V S K S P L V M D V L N I Q G V Q R S

Vcral (YVC)

(Figure 10 continued)

Mm	1599	LERADLGGKIQKALGEYLERERSSFRPFYFVGDEDLLELIGNSKNVAKLQHKFKMFAGVSSIIINEDNSVLGSSREGGEVMFKTPVSIITEHPKINE
Rn	1599	LERADLGGKIQKALGEYLERERSSFRPFYFVGDEDLLELIGNSKNVAKLQHKFKMFAGVSSIIINEDNSVLGSSREGGEVMFKTPVSIITEHPKINE
Hs	1601	LERADLGGKIQKALGEYLERERSSFRPFYFVGDEDLLELIGNSKNVAKLQHKFKMFAGVSSIIINEDNSVLGSSREGGEVMFKTPVSIITEHPKINE
Consensus	1596	LERADLGGKIQKALGEYLERERSSFRPFYFVGDEDLLELIGNSKNVAKLQHKFKMFAGVSSIIINEDNSVLGSSREGGEVMFKTPVSIITEHPKINE
Mm	1699	WLTAVEKEMRVTLAKLLAESVTEVEIFGKATSIDNTYITWIDKYQQLVLSAQIAWSENVENALSNVGGGCVGPLOSLSNVENVTLNVLADSVLMEQ
Rn	1699	WLTAVEKEMRVTLAKLLAESVTEVEIFGKATSIDNTYITWIDKYQQLVLSAQIAWSENVENALSNVGGGCVGPLOSLSNVENVTLNVLADSVLMEQ
Hs	1701	WLTAVEKEMRVTLAKLLAESVTEVEIFGKATSIDNTYITWIDKYQQLVLSAQIAWSENVENALSNVGGGCVGPLOSLSNVENVTLNVLADSVLMEQ
Consensus	1696	WLTAVEKEMRVTLAKLLAESVTEVEIFGKATSIDNTYITWIDKYQQLVLSAQIAWSENVENALSNVGGGCVGPLOSLSNVENVTLNVLADSVLMEQ
Mm	1799	PPLRRRKLEHLITELVHQRDVTRSLIKSKIDNAKSEFELISQMRPFYFPKQTDVLQQLSIQMANAKFNFGFYLGVDKLVQVPLTDRCYLTWTQALEARL
Rn	1799	PPLRRRKLEHLITELVHQRDVTRSLIKSKIDNAKSEFELISQMRPFYFPKQTDVLQQLSIQMANAKFNFGFYLGVDKLVQVPLTDRCYLTWTQALEARL
Hs	1801	PPLRRRKLEHLITELVHQRDVTRSLIKSKIDNAKSEFELISQMRPFYFPKQTDVLQQLSIQMANAKFNFGFYLGVDKLVQVPLTDRCYLTWTQALEARL
Consensus	1796	PPLRRRKLEHLITELVHQRDVTRSLIKSKIDNAKSEFELISQMRPFYFPKQTDVLQQLSIQMANAKFNFGFYLGVDKLVQVPLTDRCYLTWTQALEARL
Mm	1899	GGSPFGPAGTGKTESKALGHQLGFRFVLVFNCDDETFDQAMGRI FVGLCOVGAMGCFDFENRLEERMLSAVSQVQCCIQAALREHSPNPNYDKTSAPITCE
Rn	1899	GGSPFGPAGTGKTESKALGHQLGFRFVLVFNCDDETFDQAMGRI FVGLCOVGAMGCFDFENRLEERMLSAVSQVQCCIQAALREHSPNPNYDKTSAPITCE
Hs	1901	GGSPFGPAGTGKTESKALGHQLGFRFVLVFNCDDETFDQAMGRI FVGLCOVGAMGCFDFENRLEERMLSAVSQVQCCIQAALREHSPNPNYDKTSAPITCE
Consensus	1896	GGSPFGPAGTGKTESKALGHQLGFRFVLVFNCDDETFDQAMGRI FVGLCOVGAMGCFDFENRLEERMLSAVSQVQCCIQAALREHSPNPNYDKTSAPITCE
Mm	1999	LLNKQVKVSPDWAIFITMNPGYAGRSNLPDLKKLFRSLAMTKPDROLIAQVMLYSQGFRTAEVLANKI VPFKKLDCDEQLSSQSHYDFGLRALKSVLVA
Rn	1999	LLNKQVKVSPDWAIFITMNPGYAGRSNLPDLKKLFRSLAMTKPDROLIAQVMLYSQGFRTAEVLANKI VPFKKLDCDEQLSSQSHYDFGLRALKSVLVA
Hs	2001	LLNKQVKVSPDWAIFITMNPGYAGRSNLPDLKKLFRSLAMTKPDROLIAQVMLYSQGFRTAEVLANKI VPFKKLDCDEQLSSQSHYDFGLRALKSVLVA
Consensus	1996	LLNKQVKVSPDWAIFITMNPGYAGRSNLPDLKKLFRSLAMTKPDROLIAQVMLYSQGFRTAEVLANKI VPFKKLDCDEQLSSQSHYDFGLRALKSVLVA
Mm	2099	GNVKRERIQTKRKEERGEAVDEGEFAEMPEQELILOSVCTMTWPKLVAEDIPLLSLSDVFPQVQVHRGEMTALREELKKVCQEMVLTGDEGEVNG
Rn	2099	GNVKRERIQTKRKEERGEAVDEGEFAEMPEQELILOSVCTMTWPKLVAEDIPLLSLSDVFPQVQVHRGEMTALREELKKVCQEMVLTGDEGEVNG
Hs	2101	GNVKRERIQTKRKEERGEAVDEGEFAEMPEQELILOSVCTMTWPKLVAEDIPLLSLSDVFPQVQVHRGEMTALREELKKVCQEMVLTGDEGEVNG
Consensus	2096	GNVKRERIQTKRKEERGEAVDEGEFAEMPEQELILOSVCTMTWPKLVAEDIPLLSLSDVFPQVQVHRGEMTALREELKKVCQEMVLTGDEGEVNG
Mm	2199	GMWVEKVLQLYQITQINHGIMMVGPSGSGKSNWVRVLLKALERLEGEVGAHIIIDPKAISKDHLXGTLDPNTRMTDGLFTHVLRLKIIDNVRGELQKRQW
Rn	2199	GMWVEKVLQLYQITQINHGIMMVGPSGSGKSNWVRVLLKALERLEGEVGAHIIIDPKAISKDHLXGTLDPNTRMTDGLFTHVLRLKIIDNVRGELQKRQW
Hs	2201	GMWVEKVLQLYQITQINHGIMMVGPSGSGKSNWVRVLLKALERLEGEVGAHIIIDPKAISKDHLXGTLDPNTRMTDGLFTHVLRLKIIDNVRGELQKRQW
Consensus	2196	GMWVEKVLQLYQITQINHGIMMVGPSGSGKSNWVRVLLKALERLEGEVGAHIIIDPKAISKDHLXGTLDPNTRMTDGLFTHVLRLKIIDNVRGELQKRQW
Mm	2299	IVFDGVDPEWVENLNSVLDDNKLITLPPNGERLSLPPNVRIMFEVQDLKYATLATVSRGGMWVFSDDLSTDMIFNNFLARLSIPLDEGEDEAQRNRKG
Rn	2299	IVFDGVDPEWVENLNSVLDDNKLITLPPNGERLSLPPNVRIMFEVQDLKYATLATVSRGGMWVFSDDLSTDMIFNNFLARLSIPLDEGEDEAQRNRKG
Hs	2301	IVFDGVDPEWVENLNSVLDDNKLITLPPNGERLSLPPNVRIMFEVQDLKYATLATVSRGGMWVFSDDLSTDMIFNNFLARLSIPLDEGEDEAQRNRKG
Consensus	2296	IVFDGVDPEWVENLNSVLDDNKLITLPPNGERLSLPPNVRIMFEVQDLKYATLATVSRGGMWVFSDDLSTDMIFNNFLARLSIPLDEGEDEAQRNRKG
Mm	2399	KEDEGEAASPMLOIQORDAATTMQPYTSSNGLVTKALEHAFKLEHMDLRLRCIGLSFMSLHQACRNVAQYANAHHPDFPMQIEQLEERYIQRYLVVAILW
Rn	2399	KEDEGEAASPMLOIQORDAATTMQPYTSSNGLVTKALEHAFKLEHMDLRLRCIGLSFMSLHQACRNVAQYANAHHPDFPMQIEQLEERYIQRYLVVAILW
Hs	2401	KEDEGEAASPMLOIQORDAATTMQPYTSSNGLVTKALEHAFKLEHMDLRLRCIGLSFMSLHQACRNVAQYANAHHPDFPMQIEQLEERYIQRYLVVAILW
Consensus	2396	KEDEGEAASPMLOIQORDAATTMQPYTSSNGLVTKALEHAFKLEHMDLRLRCIGLSFMSLHQACRNVAQYANAHHPDFPMQIEQLEERYIQRYLVVAILW
Mm	2499	SLSGDSRLKMRALGEYIRITTVPLTPAPNPIIIDYEVSI SGEMSPWQAKVPOLEVTHKVAAPDVVPTLDTVRHEALLYTWLAEHKPLVLCGPPGSG
Rn	2499	SLSGDSRLKMRALGEYIRITTVPLTPAPNPIIIDYEVSI SGEMSPWQAKVPOLEVTHKVAAPDVVPTLDTVRHEALLYTWLAEHKPLVLCGPPGSG
Hs	2501	SLSGDSRLKMRALGEYIRITTVPLTPAPNPIIIDYEVSI SGEMSPWQAKVPOLEVTHKVAAPDVVPTLDTVRHEALLYTWLAEHKPLVLCGPPGSG
Consensus	2496	SLSGDSRLKMRALGEYIRITTVPLTPAPNPIIIDYEVSI SGEMSPWQAKVPOLEVTHKVAAPDVVPTLDTVRHEALLYTWLAEHKPLVLCGPPGSG

(Figure 10 continued)

Mm	2599	KTWTLFSALRALPDMEVVGCLNFSSATTPPELLIKTFDHXYCEYRRTPHGVVLAPVOLGKWLVLFCDEINLPDMDKYGTQVVISFIQWVEHGGFYRTSDQTW
Rn	2599	KTWTLFSALRALPDMEVVGCLNFSSATTPPELLIKTFDHXYCEYRRTPHGVVLAPVOLGKWLVLFCDEINLPDMDKYGTQVVISFIQWVEHGGFYRTSDQTW
Hs	2601	KTWTLFSALRALPDMEVVGCLNFSSATTPPELLIKTFDHXYCEYRRTPHGVVLAPVOLGKWLVLFCDEINLPDMDKYGTQVVISFIQWVEHGGFYRTSDQTW
Consensus	2595	KTWTLFSALRALPDMEVVGCLNFSSATTPPELLIKTFDHXYCEYRRTPHGVVLAPVOLGKWLVLFCDEINLPDMDKYGTQVVISFIQWVEHGGFYRTSDQTW
Mm	2699	VKLERIQEVGACNPPTDGRKPLSHRELRAHVPVYVDYVPGPASTLQIYGFNFRAMLRLIPLSRTVAEPLTAAMVEFYTMSQERFTQDTQPHYIYSPREMT
Rn	2699	VKLERIQEVGACNPPTDGRKPLSHRELRAHVPVYVDYVPGPASTLQIYGFNFRAMLRLIPLSRTVAEPLTAAMVEFYTMSQERFTQDTQPHYIYSPREMT
Hs	2701	VKLERIQEVGACNPPTDGRKPLSHRELRAHVPVYVDYVPGPASTLQIYGFNFRAMLRLIPLSRTVAEPLTAAMVEFYTMSQERFTQDTQPHYIYSPREMT
Consensus	2695	VKLERIQEVGACNPPTDGRKPLSHRELRAHVPVYVDYVPGPASTLQIYGFNFRAMLRLIPLSRTVAEPLTAAMVEFYTMSQERFTQDTQPHYIYSPREMT
Mm	2799	RAWRGIFEALRPLETLPVEGLIRIMAHEALRFQDLRAVEDEERRWTDENIDWALVKHFPNIDKEKAMSRILYSNWLISKDYIPVQDEELRDYVKARLKVF
Rn	2799	RAWRGIFEALRPLETLPVEGLIRIMAHEALRFQDLRAVEDEERRWTDENIDWALVKHFPNIDKEKAMSRILYSNWLISKDYIPVQDEELRDYVKARLKVF
Hs	2801	RAWRGIFEALRPLETLPVEGLIRIMAHEALRFQDLRAVEDEERRWTDENIDWALVKHFPNIDKEKAMSRILYSNWLISKDYIPVQDEELRDYVKARLKVF
Consensus	2795	RAWRGIFEALRPLETLPVEGLIRIMAHEALRFQDLRAVEDEERRWTDENIDWALVKHFPNIDKEKAMSRILYSNWLISKDYIPVQDEELRDYVKARLKVF
Mm	2899	YEEELDVPLVLFNEVLDHVLRI DRI FRQPOGHLLILIGVSGAGKTTLSRFVAMNGLSVYQIKVHRKYTGEDFDEDLRTVLRSSGCKNEKIAFIIMDES NVL
Rn	2899	YEEELDVPLVLFNEVLDHVLRI DRI FRQPOGHLLILIGVSGAGKTTLSRFVAMNGLSVYQIKVHRKYTGEDFDEDLRTVLRSSGCKNEKIAFIIMDES NVL
Hs	2901	YEEELDVPLVLFNEVLDHVLRI DRI FRQPOGHLLILIGVSGAGKTTLSRFVAMNGLSVYQIKVHRKYTGEDFDEDLRTVLRSSGCKNEKIAFIIMDES NVL
Consensus	2895	YEEELDVPLVLFNEVLDHVLRI DRI FRQPOGHLLILIGVSGAGKTTLSRFVAMNGLSVYQIKVHRKYTGEDFDEDLRTVLRSSGCKNEKIAFIIMDES NVL
Mm	2999	DSGFLERMNTLLANGEVPLFGEGDEYATLMTQCKEQAQKEGIMLDSHEELYKWTFSOVI RNLHVVTWNPSSSGLKDRAAVSPALFNRCVLNWFQDWSTE
Rn	2999	DSGFLERMNTLLANGEVPLFGEGDEYATLMTQCKEQAQKEGIMLDSHEELYKWTFSOVI RNLHVVTWNPSSSGLKDRAAVSPALFNRCVLNWFQDWSTE
Hs	3001	DSGFLERMNTLLANGEVPLFGEGDEYATLMTQCKEQAQKEGIMLDSHEELYKWTFSOVI RNLHVVTWNPSSSGLKDRAAVSPALFNRCVLNWFQDWSTE
Consensus	2995	DSGFLERMNTLLANGEVPLFGEGDEYATLMTQCKEQAQKEGIMLDSHEELYKWTFSOVI RNLHVVTWNPSSSGLKDRAAVSPALFNRCVLNWFQDWSTE
Mm	3099	ALYQVKEFTSKMDLEKNYIYVPDYPVYVDKLPQPTTHREAI INSCVFVHQTLHQANARLAKRGRTWAIITPRHYLDFTINHYANL FHEKRSLELEQQMH
Rn	3099	ALYQVKEFTSKMDLEKNYIYVPDYPVYVDKLPQPTTHREAI INSCVFVHQTLHQANARLAKRGRTWAIITPRHYLDFTINHYANL FHEKRSLELEQQMH
Hs	3101	ALYQVKEFTSKMDLEKNYIYVPDYPVYVDKLPQPTTHREAI INSCVFVHQTLHQANARLAKRGRTWAIITPRHYLDFTINHYANL FHEKRSLELEQQMH
Consensus	3095	ALYQVKEFTSKMDLEKNYIYVPDYPVYVDKLPQPTTHREAI INSCVFVHQTLHQANARLAKRGRTWAIITPRHYLDFTINHYANL FHEKRSLELEQQMH
Mm	3199	LVNGLRKIKETVDQVEELRRDLRI KSOELEVNKNAANDKLKKWKDQQAENKKNVMSQEI QEQLHKQOEVIADKQMSVKEDLDKVEPAVIEAQNAAVKS IK
Rn	3199	LVNGLRKIKETVDQVEELRRDLRI KSOELEVNKNAANDKLKKWKDQQAENKKNVMSQEI QEQLHKQOEVIADKQMSVKEDLDKVEPAVIEAQNAAVKS IK
Hs	3201	LVNGLRKIKETVDQVEELRRDLRI KSOELEVNKNAANDKLKKWKDQQAENKKNVMSQEI QEQLHKQOEVIADKQMSVKEDLDKVEPAVIEAQNAAVKS IK
Consensus	3195	LVNGLRKIKETVDQVEELRRDLRI KSOELEVNKNAANDKLKKWKDQQAENKKNVMSQEI QEQLHKQOEVIADKQMSVKEDLDKVEPAVIEAQNAAVKS IK
Mm	3299	KOHLVEVRSMANPPAAVKLALESICILLGESTTDMKQIRSI IMRENFTPTI VNFSAEEI SDAI REKMKKNYMSNP SNYELVNRSALACGPNVKKWALIAQL
Rn	3299	KOHLVEVRSMANPPAAVKLALESICILLGESTTDMKQIRSI IMRENFTPTI VNFSAEEI SDAI REKMKKNYMSNP SNYELVNRSALACGPNVKKWALIAQL
Hs	3301	KOHLVEVRSMANPPAAVKLALESICILLGESTTDMKQIRSI IMRENFTPTI VNFSAEEI SDAI REKMKKNYMSNP SNYELVNRSALACGPNVKKWALIAQL
Consensus	3295	KOHLVEVRSMANPPAAVKLALESICILLGESTTDMKQIRSI IMRENFTPTI VNFSAEEI SDAI REKMKKNYMSNP SNYELVNRSALACGPNVKKWALIAQL
Mm	3399	NYADMLKRVPEPLRNELQKLEDDAKDNQKANEVEQMT RDLEASTARYKEEYAVLI SEAQA I KADIAA VEA KVNRSALLKLSLSAERERWEKTS ETKNQW
Rn	3399	NYADMLKRVPEPLRNELQKLEDDAKDNQKANEVEQMT RDLEASTARYKEEYAVLI SEAQA I KADIAA VEA KVNRSALLKLSLSAERERWEKTS ETKNQW
Hs	3401	NYADMLKRVPEPLRNELQKLEDDAKDNQKANEVEQMT RDLEASTARYKEEYAVLI SEAQA I KADIAA VEA KVNRSALLKLSLSAERERWEKTS ETKNQW
Consensus	3395	NYADMLKRVPEPLRNELQKLEDDAKDNQKANEVEQMT RDLEASTARYKEEYAVLI SEAQA I KADIAA VEA KVNRSALLKLSLSAERERWEKTS ETKNQW
Mm	3499	STIAGDCLLSAAFTAYAGYFQQMRQNLFTTWSHHLQOANI QFRDIA RTEYLSNADERLRWQASSLPADDICTENA IMLKRFNRYPLI IDPSGQATEFI
Rn	3499	STIAGDCLLSAAFTAYAGYFQQMRQNLFTTWSHHLQOANI QFRDIA RTEYLSNADERLRWQASSLPADDICTENA IMLKRFNRYPLI IDPSGQATEFI
Hs	3501	STIAGDCLLSAAFTAYAGYFQQMRQNLFTTWSHHLQOANI QFRDIA RTEYLSNADERLRWQASSLPADDICTENA IMLKRFNRYPLI IDPSGQATEFI
Consensus	3495	STIAGDCLLSAAFTAYAGYFQQMRQNLFTTWSHHLQOANI QFRDIA RTEYLSNADERLRWQASSLPADDICTENA IMLKRFNRYPLI IDPSGQATEFI

(Figure 10 continued)

Mm	3599	WNEYKDRKI	TRTSFLDDAFRNKLESALRFGNPLLVQVESYDPVLPVLPVLRVRRTRGRLVITLIGDQDIDLSPSFVIELSTRDPTVEFPDPLCSRVT	FN			
Rn	3599	WNEYKDRKI	TRTSFLDDAFRNKLESALRFGNPLLVQVESYDPVLPVLPVLRVRRTRGRLVITLIGDQDIDLSPSFVIELSTRDPTVEFPDPLCSRVT	FN			
Hs	3601	WNEYKDRKI	TRTSFLDDAFRNKLESALRFGNPLLVQVESYDPVLPVLPVLRVRRTRGRLVITLIGDQDIDLSPSFVIELSTRDPTVEFPDPLCSRVT	FN			
Consensus	3595	WNEYKDRKI	TRTSFLDDAFRNKLESALRFGNPLLVQVESYDPVLPVLPVLRVRRTRGRLVITLIGDQDIDLSPSFVIELSTRDPTVEFPDPLCSRVT	FN			
Mm	3699	FVTVRSLSQ	QCLNEVLKAERPDVDEKRSDDLKLQGFQRLRLQLEKSLQALNEVKGRILLVDDPTITITTEMUKREAAAEVTRKVEETDI	VMQEVETVSQ			
Rn	3699	FVTVRSLSQ	QCLNEVLKAERPDVDEKRSDDLKLQGFQRLRLQLEKSLQALNEVKGRILLVDDPTITITTEMUKREAAAEVTRKVEETDI	VMQEVETVSQ			
Hs	3701	FVTVRSLSQ	QCLNEVLKAERPDVDEKRSDDLKLQGFQRLRLQLEKSLQALNEVKGRILLVDDPTITITTEMUKREAAAEVTRKVEETDI	VMQEVETVSQ			
Consensus	3695	FVTVRSLSQ	QCLNEVLKAERPDVDEKRSDDLKLQGFQRLRLQLEKSLQALNEVKGRILLVDDPTITITTEMUKREAAAEVTRKVEETDI	VMQEVETVSQ			
Mm	3799	YIPLSTACSS	IYFTMESLKQVHFLQYQSYQFFLDIYHNVLKENPILKATDHTQRLSVITKDLFOVAFNRVARGMLHQDHITFAMLLARIKIKLGTGVEPT				
Rn	3799	YIPLSTACSS	IYFTMESLKQVHFLQYQSYQFFLDIYHNVLKENPILKATDHTQRLSVITKDLFOVAFNRVARGMLHQDHITFAMLLARIKIKLGTGVEPT				
Hs	3801	YIPLSTACSS	IYFTMESLKQVHFLQYQSYQFFLDIYHNVLKENPILKATDHTQRLSVITKDLFOVAFNRVARGMLHQDHITFAMLLARIKIKLGTGVEPT				
Consensus	3795	YIPLSTACSS	IYFTMESLKQVHFLQYQSYQFFLDIYHNVLKENPILKATDHTQRLSVITKDLFOVAFNRVARGMLHQDHITFAMLLARIKIKLGTGVEPT				
Mm	3899	YDAEFQHF	LRGKEIVLSAGSTPKIQGLTVEQAEAVRLSCLPAFKDLIAKVAQAEQFGIMLDSSPEQIVPVYLMSEETPTPIQQA	IHRLLLIQAERPDR			
Rn	3899	YDAEFQHF	LRGKEIVLSAGSTPKIQGLTVEQAEAVRLSCLPAFKDLIAKVAQAEQFGIMLDSSPEQIVPVYLMSEETPTPIQQA	IHRLLLIQAERPDR			
Hs	3901	YDAEFQHF	LRGKEIVLSAGSTPKIQGLTVEQAEAVRLSCLPAFKDLIAKVAQAEQFGIMLDSSPEQIVPVYLMSEETPTPIQQA	IHRLLLIQAERPDR			
Consensus	3893	YDAEFQHF	LRGKEIVLSAGSTPKIQGLTVEQAEAVRLSCLPAFKDLIAKVAQAEQFGIMLDSSPEQIVPVYLMSEETPTPIQQA	IHRLLLIQAERPDR			
Mm	3999	LIAMAHMF	VSTNIGESFMSIMEQPLDLTHIVGTEVRKNTPVLMCSVPGVDASHVEDLAARQNTQITSIAIGSAEGFNQADKAINAVKSGRVMMLKNVH				
Rn	3999	LIAMAHMF	VSTNIGESFMSIMEQPLDLTHIVGTEVRKNTPVLMCSVPGVDASHVEDLAARQNTQITSIAIGSAEGFNQADKAINAVKSGRVMMLKNVH				
Hs	4001	LIAMAHMF	VSTNIGESFMSIMEQPLDLTHIVGTEVRKNTPVLMCSVPGVDASHVEDLAARQNTQITSIAIGSAEGFNQADKAINAVKSGRVMMLKNVH				
Consensus	3991	LIAMAHMF	VSTNIGESFMSIMEQPLDLTHIVGTEVRKNTPVLMCSVPGVDASHVEDLAARQNTQITSIAIGSAEGFNQADKAINAVKSGRVMMLKNVH				
Mm	4099	LAPGMIMQ	LEKKLHSLQPHACFRLEITIMEINPKVPVNNLRAGRIEIVFEPPPGVKANMLRTFSSIPVSRICKSPNERARLYELLAWFHAI	IOERLRVAPLG			
Rn	4099	LAPGMIMQ	LEKKLHSLQPHACFRLEITIMEINPKVPVNNLRAGRIEIVFEPPPGVKANMLRTFSSIPVSRICKSPNERARLYELLAWFHAI	IOERLRVAPLG			
Hs	4101	LAPGMIMQ	LEKKLHSLQPHACFRLEITIMEINPKVPVNNLRAGRIEIVFEPPPGVKANMLRTFSSIPVSRICKSPNERARLYELLAWFHAI	IOERLRVAPLG			
Consensus	4091	LAPGMIMQ	LEKKLHSLQPHACFRLEITIMEINPKVPVNNLRAGRIEIVFEPPPGVKANMLRTFSSIPVSRICKSPNERARLYELLAWFHAI	IOERLRVAPLG			
Mm	4199	WSKKYFEG	SDLSACDVTVDLDDTAKGRQNI	SPDKIPWSALKT	LMQOSIYGGRV	DNEFDQRLNTEFLERLTT	RSFSEFKLACKVDGHKDIQHPDGI
Rn	4199	WSKKYFEG	SDLSACDVTVDLDDTAKGRQNI	SPDKIPWSALKT	LMQOSIYGGRV	DNEFDQRLNTEFLERLTT	RSFSEFKLACKVDGHKDIQHPDGI
Hs	4201	WSKKYFEG	SDLSACDVTVDLDDTAKGRQNI	SPDKIPWSALKT	LMQOSIYGGRV	DNEFDQRLNTEFLERLTT	RSFSEFKLACKVDGHKDIQHPDGI
Consensus	4190	WSKKYFEG	SDLSACDVTVDLDDTAKGRQNI	SPDKIPWSALKT	LMQOSIYGGRV	DNEFDQRLNTEFLERLTT	RSFSEFKLACKVDGHKDIQHPDGI
Mm	4299	RREEFQVW	VELLPDAQTPSWIGLPNNAERVLITQGVDMISKNLKNQMLEDEDDLA	YAETEKKRTDSTSDGR	PAMWRTLHTT	TASNWLHLIPQTLSP	PLKR
Rn	4299	RREEFQVW	VELLPDAQTPSWIGLPNNAERVLITQGVDMISKNLKNQMLEDEDDLA	YAETEKKRTDSTSDGR	PAMWRTLHTT	TASNWLHLIPQTLSP	PLKR
Hs	4301	RREEFQVW	VELLPDAQTPSWIGLPNNAERVLITQGVDMISKNLKNQMLEDEDDLA	YAETEKKRTDSTSDGR	PAMWRTLHTT	TASNWLHLIPQTLSP	PLKR
Consensus	4290	RREEFQVW	VELLPDAQTPSWIGLPNNAERVLITQGVDMISKNLKNQMLEDEDDLA	YAETEKKRTDSTSDGR	PAMWRTLHTT	TASNWLHLIPQTLSP	PLKR
Mm	4399	TVENIKDPL	FRFFEREVKNGAKLLQDVRODLADWQVCEGKKKQNTYLR	TLINELVKGLIPRSHSHY	TV	PAGMTVIQWVSD	FSRIKOLQNISQAAA
Rn	4399	TVENIKDPL	FRFFEREVKNGAKLLQDVRODLADWQVCEGKKKQNTYLR	TLINELVKGLIPRSHSHY	TV	PAGMTVIQWVSD	FSRIKOLQNISQAAA
Hs	4401	TVENIKDPL	FRFFEREVKNGAKLLQDVRODLADWQVCEGKKKQNTYLR	TLINELVKGLIPRSHSHY	TV	PAGMTVIQWVSD	FSRIKOLQNISQAAA
Consensus	4390	TVENIKDPL	FRFFEREVKNGAKLLQDVRODLADWQVCEGKKKQNTYLR	TLINELVKGLIPRSHSHY	TV	PAGMTVIQWVSD	FSRIKOLQNISQAAA

(Figure 10 continued)

Mm	4499	AKELKNIHVCLGGLFVPEAYITATRQYVAQANSWSLEELCLEVNVVTASQSAWLDACSFVGTGLKQGATCSNNKLSLSNAISTVLPITQLRRVKQTSAEK
Rn	4499	AKELKNIHVCLGGLFVPEAYITATRQYVAQANSWSLEELCLEVNVVTASQSAWLDACSFVGTGLKQGATCSNNKLSLSNAISTVLPITQLRRVKQTSAEK
Hs	4501	AKELKNIHVCLGGLFVPEAYITATRQYVAQANSWSLEELCLEVNVVTASQSAWLDACSFVGTGLKQGATCSNNKLSLSNAISTVLPITQLRRVKQTSAEK
Consensus	4490	AKELKNIHVCLGGLFVPEAYITATRQYVAQANSWSLEELCLEVNVVTASQSAWLDACSFVGTGLKQGATCSNNKLSLSNAISTVLPITQLRRVKQTSAEK
Mm	4599	KASVVTLPVYLNFTRADLIFTVDPEIATKEDPRSFYERGVAVLCTE
Rn	4599	KASVVTLPVYLNFTRADLIFTVDPEIATKEDPRSFYERGVAVLCTE
Hs	4601	KASVVTLPVYLNFTRADLIFTVDPEIATKEDPRSFYERGVAVLCTE
Consensus	4590	KASVVTLPVYLNFTRADLIFTVDPEIATKEDPRSFYERGVAVLCTE

Percentage of identical amino acid residues: 95%
Percentage of identical and similar amino acid residues: 96%

Figure 11. Amino Acid Alignment of Mouse, and Human Dynein Intermediate Chain 1 Proteins –Highly Conserved Amino Acid Residues.

Software used:

- MultAlin via <http://prodes.toulouse.inra.fr/multalin/multalin.html> [Corpet. F. (1988), Multiple sequence alignment with hierarchical clustering, Nucl. Acids Res., 16 (22), 10881-10890]
- BOXSHADE 3.21 via http://www.ch.embnet.org/software/BOX_form.html

NP_034193.1 (mouse)	1	MSDKSDLKAELEKQRLAQIREKKRKEERKKKEADMQQKKEPVQDDSDLDRKRRETE
NP_004402.1 (human)	1	MSDKSDLKAELEKQRLAQIREKKRKEERKKKEADMQQKKEPVQDDSDLDRKRRETE
Consensus	1	MSDKSDLKAELEKQRLAQIREKKRKEERKKKEADMQQKKEPVQDDSDLDRKRRETE
NP_034193.1 (mouse)	61	ALLQSIGISPEPLV.....PTPMSPSSKSVSTPS#AGSQDSGDLGPL
NP_004402.1 (human)	61	ALLQSIGISPEPLVQLPHFLTWDTCYFHYLVPTPMSPSSKSVSTPS#AGSQDSGDLGPL
Consensus	61	ALLQSIGISPEPLV.....PTPMSPSSKSVSTPS#AGSQDSGDLGPL
NP_034193.1 (mouse)	104	TRTLQWDTPSVLQLQSDSELGRRHLKLGVSQVTVQVDFLPREVVSYSKETQTPLATHQSE
NP_004402.1 (human)	121	TRTLQWDTPSVLQLQSDSELGRRHLKLGVSQVTVQVDFLPREVVSYSKETQTPLATHQSE
Consensus	103	TRTLQWDTPSVLQLQSDSELGRRHLKLGVSQVTVQVDFLPREVVSYSKETQTPLATHQSE
NP_034193.1 (mouse)	164	EDEEDEENVEPKKCHDSELENOKKQETKEAPPRELTEEEKQQILHSEEFLLFFDRTIRV
NP_004402.1 (human)	181	EDEEDEEMVSEKKGQDSELENOKKQEVKEAPPRELTEEEKQQILHSEEFLLFFDRTIRV
Consensus	163	EDEEDEEMVEPKKQDSELENOKKQETKEAPPRELTEEEKQQILHSEEFLLFFDRTIRV
NP_034193.1 (mouse)	224	IERALAEDSDIFFDYSGRELEEKDGDVQAGANLSFNRQFYDEHWSKHRVVTCDWLSLQYP
NP_004402.1 (human)	241	IERALAEDSDIFFDYSGRELEEKDGDVQAGANLSFNRQFYDEHWSKHRVVTCDWLSLQYP
Consensus	221	IERALAEDSDIFFDYSGRELEEKDGDVQAGANLSFNRQFYDEHWSKHRVVTCDWLSLQYP
NP_034193.1 (mouse)	284	ELMVASYSHNEDAPHEPDGVALVWNMKFKKTTPEYVFHCQSSVMSVCFARFHPNLVVGGT
NP_004402.1 (human)	301	ELMVASYSHNEDAPHEPDGVALVWNMKFKKTTPEYVFHCQSSVMSVCFARFHPNLVVGGT
Consensus	281	ELMVASYSHNEDAPHEPDGVALVWNMKFKKTTPEYVFHCQSSVMSVCFARFHPNLVVGGT
NP_034193.1 (mouse)	344	YSGQIVLWDNRSHRRTVPVQRTPLSAAATHPVYCVHVVGTHHARNLITVSTDGKMCWSL
NP_004402.1 (human)	361	YSGQIVLWDNRSHRRTVPVQRTPLSAAATHPVYCVHVVGTHHARNLITVSTDGKMCWSL
Consensus	341	YSGQIVLWDNRSHRRTVPVQRTPLSAAATHPVYCVHVVGTHHARNLITVSTDGKMCWSL
NP_034193.1 (mouse)	404	DMLSTPQESMELVYNKSKPVAVTGMAFPTGDVNNFVVGSEEGTVYTACRHGSKAGIGEVF
NP_004402.1 (human)	421	DMLSTPQESMELVYNKSKPVAVTGMAFPTGDVNNFVVGSEEGTVYTACRHGSKAGIGEVF
Consensus	401	DMLSTPQESMELVYNKSKPVAVTGMAFPTGDVNNFVVGSEEGTVYTACRHGSKAGIGEVF
NP_034193.1 (mouse)	464	EGHQGPVTGINCHMAVGPIDFSHLFTSSFDWTVKLWTTKHNKPLYSFEDNADYVDVMW
NP_004402.1 (human)	481	EGHQGPVTGINCHMAVGPIDFSHLFTSSFDWTVKLWTTKHNKPLYSFEDNADYVDVMW
Consensus	461	EGHQGPVTGINCHMAVGPIDFSHLFTSSFDWTVKLWTTKHNKPLYSFEDNADYVDVMW
NP_034193.1 (mouse)	524	SPVHPALFACVDGCMGRDLWNLNNDTEVPTASVAIEGASALNRVRWAQAGKEVAVGDSEG
NP_004402.1 (human)	541	SPVHPALFACVDGCMGRDLWNLNNDTEVPTASVAIEGASALNRVRWAQAGKEVAVGDSEG
Consensus	521	SPVHPALFACVDGCMGRDLWNLNNDTEVPTASVAIEGASALNRVRWAQAGKEVAVGDSEG
NP_034193.1 (mouse)	584	RIWYIDVGELAVPHNDEWTRFARTLVEIRANRADSEEEGAVELAA
NP_004402.1 (human)	601	RIWYIDVGELAVPHNDEWTRFARTLVEIRANRADSEEEGAVELAA
Consensus	581	RIWYIDVGELAVPHNDEWTRFARTLVEIRANRADSEEEGAVELAA

Amino acid identity: 88%

Amino acid similarity: 89%

Figure 12. Amino Acid Alignment of Mouse, Rattus Norvegicus, and Human Dynein Intermediate Chain1 Proteins –Highly Conserved Amino Acid Residues.

Software used:

MultAlin via <http://prodes.toulouse.inra.fr/multalin/multalin.html> [Corpet. F. (1988), Multiple sequence alignment with hierarchical clustering, Nucl. Acids Res., 16 (22), 10881-10890]

BOXSHADE 3.21 via http://www.ch.embnet.org/software/BOX_form.html

		1M
NP_034193.1 (mouse)	1	MSDKSDLKAELEKQRLAQIREKKRKEERKKKEADMQQKKEPVQDDSDLDKRRETE
NP_004402.1 (human)	1	MSDKSDLKAELEKQRLAQIREKKRKEERKKKEADMQQKKEPVQDDSDLDKRRETE
NP_062107.1 (rat)	1	MSDKSDLKAELEKQRLAQIREKKRKEERKKKEADMQQKKEPVQDDSDLDKRRETE
Consensus	1	MSDKSDLKAELEKQRLAQIREKKRKEERKKKEADMQQKKEPVQDDSDLDKRRETE
NP_034193.1 (mouse)	61	ALLQSIGISPEPPLV.....PTMSPSSKSVSTPS#AGSQDSGDLGPL
NP_004402.1 (human)	61	ALLQSIGISPEPPLVQPLHFLTWDTCYFHYLVPTMSPSSKSVSTPSEAGSQDSGDLGPL
NP_062107.1 (rat)	61	ALLQSIGISPEPPLVQPLHFLTWDTCYFHYLVPTMSPSSKSVSTPSEAGSQD..DLGPL
Consensus	61	ALLQSIGISPEPPLVQPLHFLTWDTCYFHYLVPTMSPSSKSVSTPS#AGSQDSGDLGPL
		140E 157F 164S 174A
NP_034193.1 (mouse)	104	TRTLQWDTPSVLQQLQSDSELGRRLHKLGVSKVTQVDFLPREVVSYSKETQTPLATHQSE
NP_004402.1 (human)	121	TRTLQWDTPSVLQQLQSDSELGRRLHKLGVSKVTQVDFLPREVVSYSKETQTPLATHQSE
NP_062107.1 (rat)	119	TRTLQWDTPSVLQQLQSDSELGRRLHKLGVSKVTQVDFLPREVVSYSKETQTPLATHQSE
Consensus	120	TRTLQWDTPSVLQQLQSDSELGRRLHKLGVSKVTQVDFLPREVVSYSKETQTPLATHQSE
NP_034193.1 (mouse)	164	EDEEDEEMVEPK#GHDSLENC#KKQETKEAPPRELTEEEKQQILHSEEFLLFFDRTIRV
NP_004402.1 (human)	181	EDEEDEEMVEPKVQ#QSELENQDKKQEV#KEAPPRELTEEEKQQILHSEEFLLFFDRTIRV
NP_062107.1 (rat)	179	EDEEDEEMVEPKVGHDSLENCQDKKQETKEAPPRELTEEEKQQILHSEEFLLFFDRTIRV
Consensus	180	EDEEDEEMVEPK#GHDSLENC#KKQETKEAPPRELTEEEKQQILHSEEFLLFFDRTIRV
		260L
NP_034193.1 (mouse)	224	IERALAEDSDIFFDYSGRELEEKDGDVQAGANLSFNRFYDEHWSKHRVVTCDWSLQYP
NP_004402.1 (human)	241	IERALAEDSDIFFDYSGRELEEKDGDVQAGANLSFNRFYDEHWSKHRVVTCDWSLQYP
NP_062107.1 (rat)	239	IERALAEDSDIFFDYSGRELEEKDGDVQAGANLSFNRFYDEHWSKHRVVTCDWSLQYP
Consensus	238	IERALAEDSDIFFDYSGRELEEKDGDVQAGANLSFNRFYDEHWSKHRVVTCDWSLQYP
		331T
NP_034193.1 (mouse)	284	ELMVASYSNNEDAPHEPDGVALVWNMKFKKTTP EYVFHCQSSVMSVCFARFHPNLVVG GT
NP_004402.1 (human)	301	ELMVASYSNNEDAPHEPDGVALVWNMKFKKTTP EYVFHCQSSVMSVCFARFHPNLVVG GT
NP_062107.1 (rat)	299	ELMVASYSNNEDAPHEPDGVALVWNMKFKKTTP EYVFHCQSSVMSVCFARFHPNLVVG GT
Consensus	298	ELMVASYSNNEDAPHEPDGVALVWNMKFKKTTP EYVFHCQSSVMSVCFARFHPNLVVG GT
NP_034193.1 (mouse)	344	YSGQIVLWDNRSRRRTPVQRTPLSAAAHHPVYCVNVVGTQNAHNLITVSTDGKMCSWSL
NP_004402.1 (human)	361	YSGQIVLWDNRSRRRTPVQRTPLSAAAHHPVYCVNVVGTQNAHNLITVSTDGKMCSWSL
NP_062107.1 (rat)	359	YSGQIVLWDNRSRRRTPVQRTPLSAAAHHPVYCVNVVGTQNAHNLITVSTDGKMCSWSL
Consensus	358	YSGQIVLWDNRSRRRTPVQRTPLSAAAHHPVYCVNVVGTQNAHNLITVSTDGKMCSWSL
NP_034193.1 (mouse)	404	DMLSTPQESMELVYNKSPVAVTGM AFTGDVNNFVVGSEEGTVYTACRHGSKAGIGEVF
NP_004402.1 (human)	421	DMLSTPQESMELVYNKSPVAVTGM AFTGDVNNFVVGSEEGTVYTACRHGSKAGIGEVF
NP_062107.1 (rat)	419	DMLSTPQESMELVYNKSPVAVTGM AFTGDVNNFVVGSEEGTVYTACRHGSKAGIGEVF
Consensus	418	DMLSTPQESMELVYNKSPVAVTGM AFTGDVNNFVVGSEEGTVYTACRHGSKAGIGEVF
NP_034193.1 (mouse)	464	EGHQGPVTGINCHMAVGPIDFSHLFVTSSFDWTVKLWTTKHNKPLYSFEDNADYVYDVMW
NP_004402.1 (human)	481	EGHQGPVTGINCHMAVGPIDFSHLFVTSSFDWTVKLWTTKHNKPLYSFEDNADYVYDVMW
NP_062107.1 (rat)	479	EGHQGPVTGINCHMAVGPIDFSHLFVTSSFDWTVKLWTTKHNKPLYSFEDNADYVYDVMW
Consensus	478	EGHQGPVTGINCHMAVGPIDFSHLFVTSSFDWTVKLWTTKHNKPLYSFEDNADYVYDVMW

(figure 12 continued)

NP_034193.1 (mouse)	524	SPVHPALFACVDGMGRDLWNLNSDTEVPTASVAIEGASALNRVRWAQGGKEVAVGDSEG
NP_004402.1 (human)	541	SPVHPALFACVDGMGRDLWNLNSDTEVPTASVAIEGASALNRVRWAQGGKEVAVGDSEG
NP_062107.1 (rat)	539	SPVHPALFACVDGMGRDLWNLNSDTEVPTASVAIEGASALNRVRWAQGGKEVAVGDSEG
Consensus	538	SPVHPALFACVDGMGRDLWNLNSDTEVPTASVAIEGASALNRVRWAQGGKEVAVGDSEG
NP_034193.1 (mouse)	584	RIWIYDVGELAVPHNDEWTRFARTLVEIRANRADSEEEGAVELAA
NP_004402.1 (human)	601	RIWIYDVGELAVPHNDEWTRFARTLVEIRANRADSEEEGAVELAA
NP_062107.1 (rat)	599	RIWIYDVGELAVPHNDEWTRFARTLVEIRANRADSEEEGAVELAA
Consensus	598	RIWIYDVGELAVPHNDEWTRFARTLVEIRANRADSEEEGAVELAA

Amino acid identity: 87%

Amino acid similarity: 88%

The following binding domains are indicated by their N-terminal and C-terminal amino acids (positions correspond to the human amino acid sequence):

p150d (DCTN1 (p150) binding domain)	1M – 140E
Tctex1d (Tctex1 binding domain)	157F-174A
10kDad (10kDa light chain binding domain)	164S-174A
2Bd (2B light chain binding domain)	260L-331T

Figure 13. Amino Acid Alignment of Mouse and Human Dynein Intermediate Chain 2 Proteins –Highly Conserved Amino Acid Residues.

Software used:

- MultAlin via <http://prodes.toulouse.inra.fr/multalin/multalin.html> [Corpet. F. (1988), Multiple sequence alignment with hierarchical clustering, Nucl. Acids Res., 16 (22), 10881-10890]
- BOXSHADE 3.21 via http://www.ch.embnet.org/software/BOX_form.html

NP_034194.1 (mouse)	1	MSDKS	LKAELERKKQRLAQIREKKRKEEERKKKETDQKKEA	VS	VQEE	SDLEKKRREA																																																			
NP_001369.1 (human)	1	MSDKS	LKAELERKKQRLAQIREKKRKEEERKKKETDQKKEA	V	APVQ	EE	SDLEKKRREA																																																		
Consensus	1	MSDKS	LKAELERKKQRLAQIREKKRKEEERKKKETDQKKEA	AA	PVQ	EE	SDLEKKRREA																																																		
NP_034194.1 (mouse)	61	EALLQSMGLT	P	SPIV	PPPMSPSSKS	SV	TP	SEAGS	QDS	GD	GAV	GSF																																											
NP_001369.1 (human)	61	EALLQSMGLT	P	SPIV	FSEYV	PPPMSPSSKS	SV	TP	SEAGS	QDS	GD	GAV	GSF	TLHWDTDP																																											
Consensus	60	EALLQSMGLT	P	SPIV	PPPMSPSSKS	SV	TP	SEAGS	QDS	GD	GAV	GSF																																											
NP_034194.1 (mouse)	107	RGPIKLGMAKITQVD	FPPREIV	TYTKETQ	TPV	LAQPK	ED	EE	EE	DD	VAT																																													
NP_001369.1 (human)	121	SVLQLHSDSDL	RGPIKLGMAKITQVD	FPPREIV	TYTKETQ	TPV	MAQPK	ED	EE	EE	DD	VAT																																													
Consensus	105	RGPIKLGMAKITQVD	FPPREIV	TYTKETQ	TPV	MAQPK	ED	EE	EE	DD	VAT																																													
NP_034194.1 (mouse)	155	PKPP	EE	EE	EK	TL	KK	DE	END	SK	AP	PH	EL	TE	EE	KQ	IL	H	SE	E	FL	S	FD	H	S	T	R	I	V	E	R	A	L	S	E	Q																					
NP_001369.1 (human)	181	PKPP	EE	EE	EK	TL	KK	DE	END	SK	AP	PH	EL	TE	EE	KQ	IL	H	SE	E	FL	S	FD	H	S	T	R	I	V	E	R	A	L	S	E	Q																					
Consensus	152	PKPP	EE	EE	EK	TL	KK	DE	END	SK	AP	PH	EL	TE	EE	KQ	IL	H	SE	E	FL	S	FD	H	S	T	R	I	V	E	R	A	L	S	E	Q																					
NP_034194.1 (mouse)	215	INIFFDYSGRDLED	KEGEI	QAGAK	LS	LN	RQ	FF	DER	WS	KH	RV	V	S	C	L	D	W	S	S	Q	P	E	L	L	V	A	S	Y	N																											
NP_001369.1 (human)	241	INIFFDYSGRDLED	KEGEI	QAGAK	LS	LN	RQ	FF	DER	WS	KH	RV	V	S	C	L	D	W	S	S	Q	P	E	L	L	V	A	S	Y	N																											
Consensus	211	INIFFDYSGRDLED	KEGEI	QAGAK	LS	LN	RQ	FF	DER	WS	KH	RV	V	S	C	L	D	W	S	S	Q	P	E	L	L	V	A	S	Y	N																											
NP_034194.1 (mouse)	275	NNE	EP	HE	PD	G	V	A	L	V	N	N	M	K	Y	K	K	T	P	E	Y	V	F	H	C	S	A	V	M	S	A	T	F	A	K	F	H	P	N	L	V	V	G	T	Y	S	G	I	V	L	W						
NP_001369.1 (human)	301	NNE	EP	HE	PD	G	V	A	L	V	N	N	M	K	Y	K	K	T	P	E	Y	V	F	H	C	S	A	V	M	S	A	T	F	A	K	F	H	P	N	L	V	V	G	T	Y	S	G	I	V	L	W						
Consensus	271	NNE	EP	HE	PD	G	V	A	L	V	N	N	M	K	Y	K	K	T	P	E	Y	V	F	H	C	S	A	V	M	S	A	T	F	A	K	F	H	P	N	L	V	V	G	T	Y	S	G	I	V	L	W						
NP_034194.1 (mouse)	335	DNRS	NK	R	T	P	V	Q	R	T	P	L	S	A	A	A	H	T	H	P	V	C	N	V	V	G	T	Q	N	A	H	N	L	I	S	I	S	T	D	G	K	I	C	S	W	S	L	D	M	L	S	H	P	Q			
NP_001369.1 (human)	361	DNRS	NK	R	T	P	V	Q	R	T	P	L	S	A	A	A	H	T	H	P	V	C	N	V	V	G	T	Q	N	A	H	N	L	I	S	I	S	T	D	G	K	I	C	S	W	S	L	D	M	L	S	H	P	Q			
Consensus	330	DNRS	NK	R	T	P	V	Q	R	T	P	L	S	A	A	A	H	T	H	P	V	C	N	V	V	G	T	Q	N	A	H	N	L	I	S	I	S	T	D	G	K	I	C	S	W	S	L	D	M	L	S	H	P	Q			
NP_034194.1 (mouse)	395	SMEL	V	H	K	Q	S	K	A	V	A	V	T	S	M	S	F	P	V	G	D	V	N	N	F	V	G	S	E	E	G	S	V	Y	T	A	C	R	H	G	S	K	A	G	I	S	E	M	F	E	G	H	Q	G	P	I	T
NP_001369.1 (human)	421	SMEL	V	H	K	Q	S	K	A	V	A	V	T	S	M	S	F	P	V	G	D	V	N	N	F	V	G	S	E	E	G	S	V	Y	T	A	C	R	H	G	S	K	A	G	I	S	E	M	F	E	G	H	Q	G	P	I	T
Consensus	390	SMEL	V	H	K	Q	S	K	A	V	A	V	T	S	M	S	F	P	V	G	D	V	N	N	F	V	G	S	E	E	G	S	V	Y	T	A	C	R	H	G	S	K	A	G	I	S	E	M	F	E	G	H	Q	G	P	I	T
NP_034194.1 (mouse)	455	GIH	C	H	A	A	V	G	A	V	D	F	S	H	L	F	V	T	S	S	F	D	T	V	K	L	W	T	T	K	N	N	K	P	L	Y	S	F	E	D	N	A	D	Y	V	D	V	M	W	S	P	T	H	P	A	L	F
NP_001369.1 (human)	481	GIH	C	H	A	A	V	G	A	V	D	F	S	H	L	F	V	T	S	S	F	D	T	V	K	L	W	T	T	K	N	N	K	P	L	Y	S	F	E	D	N	A	D	Y	V	D	V	M	W	S	P	T	H	P	A	L	F
Consensus	450	GIH	C	H	A	A	V	G	A	V	D	F	S	H	L	F	V	T	S	S	F	D	T	V	K	L	W	T	T	K	N	N	K	P	L	Y	S	F	E	D	N	A	D	Y	V	D	V	M	W	S	P	T	H	P	A	L	F
NP_034194.1 (mouse)	515	ACVD	G	M	G	R	L	D	L	W	N	L	N	D	T	E	V	P	T	A	S	I	S	V	E	G	N	P	A	L	N	R	V	R	W	T	H	S	G	R	E	I	A	V	G	D	S	E	G	I	V	I	Y	D	V	G	
NP_001369.1 (human)	541	ACVD	G	M	G	R	L	D	L	W	N	L	N	D	T	E	V	P	T	A	S	I	S	V	E	G	N	P	A	L	N	R	V	R	W	T	H	S	G	R	E	I	A	V	G	D	S	E	G	I	V	I	Y	D	V	G	
Consensus	510	ACVD	G	M	G	R	L	D	L	W	N	L	N	D	T	E	V	P	T	A	S	I	S	V	E	G	N	P	A	L	N	R	V	R	W	T	H	S	G	R	E	I	A	V	G	D	S	E	G	I	V	I	Y	D	V	G	
NP_034194.1 (mouse)	575	EQIA	V	P	R	N	D	E	W	A	R	F	G	R	T	L	A	E	I	N	A	N	R	A	D	A	E	E	E	A	T	R	I	P	A																						
NP_001369.1 (human)	601	EQIA	V	P	R	N	D	E	W	A	R	F	G	R	T	L	A	E	I	N	A	N	R	A	D	A	E	E	E	A	T	R	I	P	A																						
Consensus	570	EQIA	V	P	R	N	D	E	W	A	R	F	G	R	T	L	A	E	I	N	A	N	R	A	D	A	E	E	E	A	T	R	I	P	A																						

Amino acid identity: 94%
Amino acid similarity: 95%

Figure 14. Amino Acid Alignment of Mouse, Rattus Norvegicus, and Human Dynein Intermediate Chain 2 Proteins –Highly Conserved Amino Acid Residues.

Software used:

MultAlin via <http://prodes.toulouse.inra.fr/multalin/multalin.html> [Corpet. F. (1988), Multiple sequence alignment with hierarchical clustering, Nucl. Acids Res., 16 (22), 10881-10890]

BOXSHADE 3.21 via http://www.ch.embnet.org/software/BOX_form.html

		1M
NP_034194.1 (mouse)	1	MSDKS ¹ LKAELE ² RKKQ ³ RLAQI ⁴ REEKK ⁵ RKEE ⁶ ERKK ⁷ ETD ⁸ QKKEA ⁹ AVSVQ ¹⁰ EESD ¹¹ LEKK ¹² RREA
NP_001369.1 (human)	1	MSDKSELKAELE ² RKKQ ³ RLAQI ⁴ REEKK ⁵ RKEE ⁶ ERKK ⁷ ETD ⁸ QKKEA ⁹ VAP ¹⁰ VQ ¹¹ EESD ¹² LEKK ¹³ RREA
NP_446332.1 (rat)	1	MSDKSELKAELE ² RKKQ ³ RLAQI ⁴ REEKK ⁵ RKEE ⁶ ERKK ⁷ ETD ⁸ QKKEA ⁹ AVSVQ ¹⁰ EESD ¹¹ LEKK ¹² RREA
Consensus	1	MSDKS ¹ LKAELE ² RKKQ ³ RLAQI ⁴ REEKK ⁵ RKEE ⁶ ERKK ⁷ ETD ⁸ QKKEA ⁹ AVSVQ ¹⁰ EESD ¹¹ LEKK ¹² RREA
NP_034194.1 (mouse)	61	EALLQSMGLTTD ⁶² SP ⁶³ IV ⁶⁴ ⁶⁵ PPPMSPSSKSVSTP ⁶⁶ SEAGS ⁶⁷ QDSGD ⁶⁸ GAVGS ⁶⁹ F ⁷⁰
NP_001369.1 (human)	61	EALLQSMGLT ⁶² SP ⁶³ IVFSE ⁶⁴ YV ⁶⁵ PPPMSPSSKSVSTP ⁶⁶ SEAGS ⁶⁷ QDSGD ⁶⁸ GAVGS ⁶⁹ R ⁷⁰ TLHWD ⁷¹ TDF
NP_446332.1 (rat)	61	EALLQSMGLTTD ⁶² SP ⁶³ IVFSE ⁶⁴ HW ⁶⁵ PPPMSPSSKSVSTP ⁶⁶ SEAGS ⁶⁷ QDSGD ⁶⁸ GAVGS ⁶⁹ R ⁷⁰ TLHWD ⁷¹ TDF
Consensus	60	EALLQSMGLTT ⁶² SP ⁶³ IVFSE ⁶⁴ ⁶⁵ PPPMSPSSKSVSTP ⁶⁶ SEAGS ⁶⁷ QDSGD ⁶⁸ GAVGS ⁶⁹ R ⁷⁰ TLHWD ⁷¹ TDF
		148F
		149P 155T 165M
NP_034194.1 (mouse)	107 ¹⁰⁸ RGPIKLGMAKITQ ¹⁰⁹ VD ¹¹⁰ FP ¹¹¹ PREIV ¹¹² TYTKET ¹¹³ QTPV ¹¹⁴ TAQPKED ¹¹⁵ EEED ¹¹⁶ DDV ¹¹⁷ AT
NP_001369.1 (human)	121	SVLQLHSDSD ¹²² LG ¹²³ RGPIKLGMAKITQ ¹²⁴ VD ¹²⁵ FP ¹²⁶ PREIV ¹²⁷ TYTKET ¹²⁸ QTPV ¹²⁹ MAQPKED ¹³⁰ EEED ¹³¹ DDV ¹³² V ¹³³ A
NP_446332.1 (rat)	121	SALQLHSDSD ¹²² LG ¹²³ RGPIKLGMAKITQ ¹²⁴ VD ¹²⁵ FP ¹²⁶ PREIV ¹²⁷ TYTKET ¹²⁸ QTPV ¹²⁹ TAQPKED ¹³⁰ EEED ¹³¹ DDV ¹³² A ¹³³ A
Consensus	118	S.LQLHSDSD ¹²² LG ¹²³ RGPIKLGMAKITQ ¹²⁴ VD ¹²⁵ FP ¹²⁶ PREIV ¹²⁷ TYTKET ¹²⁸ QTPV ¹²⁹ TAQPKED ¹³⁰ EEED ¹³¹ DDV ¹³² A ¹³³ A
NP_034194.1 (mouse)	155	PKPPVEPEEEK ¹⁵⁶ TLKKDE ¹⁵⁷ ENDSKAP ¹⁵⁸ PH ¹⁵⁹ ELTEEEK ¹⁶⁰ Q ¹⁶¹ QILHSE ¹⁶² EFLS ¹⁶³ FFDH ¹⁶⁴ STRIVER ¹⁶⁵ ALSEC
NP_001369.1 (human)	181	PKPPVEPEEEK ¹⁸² TLKKDE ¹⁸³ ENDSKAP ¹⁸⁴ PH ¹⁸⁵ ELTEEEK ¹⁸⁶ Q ¹⁸⁷ QILHSE ¹⁸⁸ EFLS ¹⁸⁹ FFDH ¹⁹⁰ STRIVER ¹⁹¹ ALSEC
NP_446332.1 (rat)	181	PKPPVEPEEEK ¹⁸² TLKKDE ¹⁸³ ENDSKAP ¹⁸⁴ PH ¹⁸⁵ ELTEEEK ¹⁸⁶ Q ¹⁸⁷ QILHSE ¹⁸⁸ EFLS ¹⁸⁹ FFDH ¹⁹⁰ STRIVER ¹⁹¹ ALSEC
Consensus	176	PKPPVEPEEEK ¹⁸² TLKKDE ¹⁸³ ENDSKAP ¹⁸⁴ PH ¹⁸⁵ ELTEEEK ¹⁸⁶ Q ¹⁸⁷ QILHSE ¹⁸⁸ EFLS ¹⁸⁹ FFDH ¹⁹⁰ STRIVER ¹⁹¹ ALSEC
		252L
NP_034194.1 (mouse)	215	INIFFDYSGRD ²¹⁶ LEDKEGEI ²¹⁷ QAGAK ²¹⁸ LSLN ²¹⁹ RQFF ²²⁰ DERWSK ²²¹ HRV ²²² VSCL ²²³ DWSSQ ²²⁴ YPELLV ²²⁵ ASYN
NP_001369.1 (human)	241	INIFFDYSGRD ²⁴² LEDKEGEI ²⁴³ QAGAK ²⁴⁴ LSLN ²⁴⁵ RQFF ²⁴⁶ DERWSK ²⁴⁷ HRV ²⁴⁸ VSCL ²⁴⁹ DWSSQ ²⁵⁰ YPELLV ²⁵¹ ASYN
NP_446332.1 (rat)	241	INIFFDYSGRD ²⁴² LEDKEGEI ²⁴³ QAGAK ²⁴⁴ LSLN ²⁴⁵ RQFF ²⁴⁶ DERWSK ²⁴⁷ HRV ²⁴⁸ VSCL ²⁴⁹ DWSSQ ²⁵⁰ YPELLV ²⁵¹ ASYN
Consensus	235	INIFFDYSGRD ²⁴² LEDKEGEI ²⁴³ QAGAK ²⁴⁴ LSLN ²⁴⁵ RQFF ²⁴⁶ DERWSK ²⁴⁷ HRV ²⁴⁸ VSCL ²⁴⁹ DWSSQ ²⁵⁰ YPELLV ²⁵¹ ASYN
		323T
NP_034194.1 (mouse)	275	NNEEAPHEPDG ²⁷⁶ VALV ²⁷⁷ NMKY ²⁷⁸ KTTPEY ²⁷⁹ VFHC ²⁸⁰ QSAVMS ²⁸¹ ATFA ²⁸² KFHP ²⁸³ NLVV ²⁸⁴ GGTYS ²⁸⁵ SGQIV ²⁸⁶ LW
NP_001369.1 (human)	301	NNEEAPHEPDG ³⁰² VALV ³⁰³ NMKY ³⁰⁴ KTTPEY ³⁰⁵ VFHC ³⁰⁶ QSAVMS ³⁰⁷ ATFA ³⁰⁸ KFHP ³⁰⁹ NLVV ³¹⁰ GGTYS ³¹¹ SGQIV ³¹² LW
NP_446332.1 (rat)	301	NNEEAPHEPDG ³⁰² VALV ³⁰³ NMKY ³⁰⁴ KTTPEY ³⁰⁵ VFHC ³⁰⁶ QSAVMS ³⁰⁷ ATFA ³⁰⁸ KFHP ³⁰⁹ NLVV ³¹⁰ GGTYS ³¹¹ SGQIV ³¹² LW
Consensus	295	NNEEAPHEPDG ³⁰² VALV ³⁰³ NMKY ³⁰⁴ KTTPEY ³⁰⁵ VFHC ³⁰⁶ QSAVMS ³⁰⁷ ATFA ³⁰⁸ KFHP ³⁰⁹ NLVV ³¹⁰ GGTYS ³¹¹ SGQIV ³¹² LW
NP_034194.1 (mouse)	335	DNRSNKRT ³³⁶ FPVQ ³³⁷ RTPLS ³³⁸ AAATH ³³⁹ TPVY ³⁴⁰ CVNV ³⁴¹ VGTQ ³⁴² NAHNL ³⁴³ ISIST ³⁴⁴ DGKICS ³⁴⁵ WSLD ³⁴⁶ MLSH ³⁴⁷ PQD
NP_001369.1 (human)	361	DNRSNKRT ³⁶² FPVQ ³⁶³ RTPLS ³⁶⁴ AAATH ³⁶⁵ TPVY ³⁶⁶ CVNV ³⁶⁷ VGTQ ³⁶⁸ NAHNL ³⁶⁹ ISIST ³⁷⁰ DGKICS ³⁷¹ WSLD ³⁷² MLSH ³⁷³ PQD
NP_446332.1 (rat)	361	DNRSNKRT ³⁶² FPVQ ³⁶³ RTPLS ³⁶⁴ AAATH ³⁶⁵ TPVY ³⁶⁶ CVNV ³⁶⁷ VGTQ ³⁶⁸ NAHNL ³⁶⁹ ISIST ³⁷⁰ DGKICS ³⁷¹ WSLD ³⁷² MLSH ³⁷³ PQD
Consensus	354	DNRSNKRT ³⁶² FPVQ ³⁶³ RTPLS ³⁶⁴ AAATH ³⁶⁵ TPVY ³⁶⁶ CVNV ³⁶⁷ VGTQ ³⁶⁸ NAHNL ³⁶⁹ ISIST ³⁷⁰ DGKICS ³⁷¹ WSLD ³⁷² MLSH ³⁷³ PQD
NP_034194.1 (mouse)	395	SMELVHKQSKA ³⁹⁶ VA ³⁹⁷ VTSM ³⁹⁸ SPV ³⁹⁹ GDV ⁴⁰⁰ NNF ⁴⁰¹ VVG ⁴⁰² SEEG ⁴⁰³ SVYT ⁴⁰⁴ ACRH ⁴⁰⁵ GSKAGI ⁴⁰⁶ SEM ⁴⁰⁷ FE ⁴⁰⁸ GHQ ⁴⁰⁹ GPIT
NP_001369.1 (human)	421	SMELVHKQSKA ⁴²² VA ⁴²³ VTSM ⁴²⁴ SPV ⁴²⁵ GDV ⁴²⁶ NNF ⁴²⁷ VVG ⁴²⁸ SEEG ⁴²⁹ SVYT ⁴³⁰ ACRH ⁴³¹ GSKAGI ⁴³² SEM ⁴³³ FE ⁴³⁴ GHQ ⁴³⁵ GPIT
NP_446332.1 (rat)	421	SMELVHKQSKA ⁴²² VA ⁴²³ VTSM ⁴²⁴ SPV ⁴²⁵ GDV ⁴²⁶ NNF ⁴²⁷ VVG ⁴²⁸ SEEG ⁴²⁹ SVYT ⁴³⁰ ACRH ⁴³¹ GSKAGI ⁴³² SEM ⁴³³ FE ⁴³⁴ GHQ ⁴³⁵ GPIT
Consensus	414	SMELVHKQSKA ⁴²² VA ⁴²³ VTSM ⁴²⁴ SPV ⁴²⁵ GDV ⁴²⁶ NNF ⁴²⁷ VVG ⁴²⁸ SEEG ⁴²⁹ SVYT ⁴³⁰ ACRH ⁴³¹ GSKAGI ⁴³² SEM ⁴³³ FE ⁴³⁴ GHQ ⁴³⁵ GPIT
NP_034194.1 (mouse)	455	GIHCHAAVGA ⁴⁵⁶ VD ⁴⁵⁷ FSH ⁴⁵⁸ LFT ⁴⁵⁹ SSFD ⁴⁶⁰ WTV ⁴⁶¹ KLW ⁴⁶² TTK ⁴⁶³ NNK ⁴⁶⁴ PLY ⁴⁶⁵ SFED ⁴⁶⁶ NSDY ⁴⁶⁷ VYD ⁴⁶⁸ V ⁴⁶⁹ MWS ⁴⁷⁰ SP ⁴⁷¹ TH ⁴⁷² PALE
NP_001369.1 (human)	481	GIHCHAAVGA ⁴⁸² VD ⁴⁸³ FSH ⁴⁸⁴ LFT ⁴⁸⁵ SSFD ⁴⁸⁶ WTV ⁴⁸⁷ KLW ⁴⁸⁸ TTK ⁴⁸⁹ NNK ⁴⁹⁰ PLY ⁴⁹¹ SFED ⁴⁹² NSDY ⁴⁹³ VYD ⁴⁹⁴ V ⁴⁹⁵ MWS ⁴⁹⁶ SP ⁴⁹⁷ TH ⁴⁹⁸ PALE
NP_446332.1 (rat)	481	GIHCHAAVGA ⁴⁸² VD ⁴⁸³ FSH ⁴⁸⁴ LFT ⁴⁸⁵ SSFD ⁴⁸⁶ WTV ⁴⁸⁷ KLW ⁴⁸⁸ TTK ⁴⁸⁹ NNK ⁴⁹⁰ PLY ⁴⁹¹ SFED ⁴⁹² NSDY ⁴⁹³ VYD ⁴⁹⁴ V ⁴⁹⁵ MWS ⁴⁹⁶ SP ⁴⁹⁷ TH ⁴⁹⁸ PALE
Consensus	474	GIHCHAAVGA ⁴⁸² VD ⁴⁸³ FSH ⁴⁸⁴ LFT ⁴⁸⁵ SSFD ⁴⁸⁶ WTV ⁴⁸⁷ KLW ⁴⁸⁸ TTK ⁴⁸⁹ NNK ⁴⁹⁰ PLY ⁴⁹¹ SFED ⁴⁹² NSDY ⁴⁹³ VYD ⁴⁹⁴ V ⁴⁹⁵ MWS ⁴⁹⁶ SP ⁴⁹⁷ TH ⁴⁹⁸ PALE
NP_034194.1 (mouse)	515	ACVDGMGR ⁵¹⁶ LDL ⁵¹⁷ WNL ⁵¹⁸ ND ⁵¹⁹ TEV ⁵²⁰ PTAS ⁵²¹ ISVEG ⁵²² NPAL ⁵²³ NRV ⁵²⁴ RW ⁵²⁵ THSG ⁵²⁶ REI ⁵²⁷ AVG ⁵²⁸ DSEG ⁵²⁹ QIV ⁵³⁰ YD ⁵³¹ VG
NP_001369.1 (human)	541	ACVDGMGR ⁵⁴² LDL ⁵⁴³ WNL ⁵⁴⁴ ND ⁵⁴⁵ TEV ⁵⁴⁶ PTAS ⁵⁴⁷ ISVEG ⁵⁴⁸ NPAL ⁵⁴⁹ NRV ⁵⁵⁰ RW ⁵⁵¹ THSG ⁵⁵² REI ⁵⁵³ AVG ⁵⁵⁴ DSEG ⁵⁵⁵ QIV ⁵⁵⁶ YD ⁵⁵⁷ VG
NP_446332.1 (rat)	541	ACVDGMGR ⁵⁴² LDL ⁵⁴³ WNL ⁵⁴⁴ ND ⁵⁴⁵ TEV ⁵⁴⁶ PTAS ⁵⁴⁷ ISVEG ⁵⁴⁸ NPAL ⁵⁴⁹ NRV ⁵⁵⁰ RW ⁵⁵¹ THSG ⁵⁵² REI ⁵⁵³ AVG ⁵⁵⁴ DSEG ⁵⁵⁵ QIV ⁵⁵⁶ YD ⁵⁵⁷ VG
Consensus	534	ACVDGMGR ⁵⁴² LDL ⁵⁴³ WNL ⁵⁴⁴ ND ⁵⁴⁵ TEV ⁵⁴⁶ PTAS ⁵⁴⁷ ISVEG ⁵⁴⁸ NPAL ⁵⁴⁹ NRV ⁵⁵⁰ RW ⁵⁵¹ THSG ⁵⁵² REI ⁵⁵³ AVG ⁵⁵⁴ DSEG ⁵⁵⁵ QIV ⁵⁵⁶ YD ⁵⁵⁷ VG

(Figure 13 continued)

NP_034194.1(mouse)	575	EQIAVPRNDEWARFGRTLAEINANRADAEEEEATRIPA
NP_001369.1(human)	601	EQIAVPRNDEWARFGRTLAEINANRADAEEEEATRIPA
NP_446332.1(rat)	601	EQIAVPRNDEWARFGRTLAEINASRADAEEEEATRIPA
Consensus	594	EQIAVPRNDEWARFGRTLAEINANRADAEEEEATRIP

Amino acid identity: 93,5%

Amino acid similarity: 94,5%

The following binding domains are indicated (positions correspond to the human amino acid sequence):

P150d (DCTN1 (p150) binding domain)	1M-149P
Tctex1d (Tctex1 binding domain)	148F-165T
10kDa (10kda light chain binding domain)	155T-165T
2Bd (2B light chain binding domain)	252L-323T

Figure 15. Amino Acid Alignment of Mouse and Human DCTN1 (p150) Proteins – highly conserved Amino Acid Residues.

Software used:

- MultAlin via <http://prodes.toulouse.inra.fr/multalin/multalin.html> [Corpet. F. (1988), Multiple sequence alignment with hierarchical clustering, Nucl. Acids Res., 16 (22), 10881-10890]

- BOXSHADE 3.21 via http://www.ch.embnet.org/software/BOX_form.html

NP_031861.1 (mouse)	1	MAQSRRHMSRTPSGSRMS	TEASARPLRVGSRVEVIGKGRGTVAIVGATLFATGKWWGV
AAD55811.1 (human)	1	MAQSRRHMSRTPSGSPMSAEASARPLRVGSRVEVIGKGRGTVAIVGATLFATGKWWGV	
Consensus	1	MAQSRRHMSRTPSGSRMSAEASARPLRVGSRVEVIGKGRGTVAIVGATLFATGKWWGV	
NP_031861.1 (mouse)	61	ILDEAKGKNDGTVQGRKYFTCDEGHGIFVRQSQIQVFEDGADTTSPETPDSSASKVLKRE	
AAD55811.1 (human)	61	ILDEAKGKNDGTVQGRKYFTCDEGHGIFVRQSQIQVFEDGADTTSPETPDSSASKVLKRE	
Consensus	61	ILDEAKGKNDGTVQGRKYFTCDEGHGIFVRQSQIQVFEDGADTTSPETPDSSASKVLKRE	
NP_031861.1 (mouse)	121	GADAAAKTSKLRGLPKPKAPTARKTTTRRPKPTRPASTGVAG	PSSSLGPSGSASAGELSS
AAD55811.1 (human)	121	GADAAAKTSKLRGLPKPKAPTARKTTTRRPKPTRPASTGVAG	ASSSLGPSGSASAGELSS
Consensus	121	GADAAAKTSKLRGLPKPKAPTARKTTTRRPKPTRPASTGVAG	ASSSLGPSGSASAGELSS
NP_031861.1 (mouse)	181	SEPSTPAQTPLAAPIIPTPALTSFGAAPPPLPSPSKEEEGLRAQVRDLEEKLETLRRLKRAE	
AAD55811.1 (human)	181	SEPSTPAQTPLAAPIIPTPALTSFGAAPPPLPSPSKEEEGLRAQVRDLEEKLETLRRLKRAE	
Consensus	181	SEPSTPAQTPLAAPIIPTPALTSFGAAPPPLPSPSKEEEGLRAQVRDLEEKLETLRRLKRAE	
NP_031861.1 (mouse)	241	DKAKLKELEKHKIQLEQVQEWKSKMQEQQADLQRLKEARKEAKEALEAKERYMEEMADT	
AAD55811.1 (human)	241	DKAKLKELEKHKIQLEQVQEWKSKMQEQQADLQRLKEARKEAKEALEAKERYMEEMADT	
Consensus	241	DKAKLKELEKHKIQLEQVQEWKSKMQEQQADLQRLKEARKEAKEALEAKERYMEEMADT	
NP_031861.1 (mouse)	301	ADAIEMATLDKEMAEERAEESLQEQVEALKERVDELTTDLEILKAEIEEKSGDGAASSYQL	
AAD55811.1 (human)	301	ADAIEMATLDKEMAEERAEESLQEQVEALKERVDELTTDLEILKAEIEEKSGDGAASSYQL	
Consensus	301	ADAIEMATLDKEMAEERAEESLQEQVEALKERVDELTTDLEILKAEIEEKSGDGAASSYQL	
NP_031861.1 (mouse)	361	KQLEEQNARLKDALVPMRDLSSEKQEHVKLQKLMEKKNQLEVVRRQERLQEELSQAE	
AAD55811.1 (human)	361	KQLEEQNARLKDALVPMRDLSSEKQEHVKLQKLMEKKNQLEVVRRQERLQEELSQAE	
Consensus	361	KQLEEQNARLKDALVPMRDLSSEKQEHVKLQKLMEKKNQLEVVRRQERLQEELSQAE	
NP_031861.1 (mouse)	421	STIDELKEQVDAALGAENVEMLTDRNLNLEEKVRELRETVDLEAMNEMNDLQENARE	
AAD55811.1 (human)	421	STIDELKEQVDAALGAENVEMLTDRNLNLEEKVRELRETVDLEAMNEMNDLQENARE	
Consensus	421	STIDELKEQVDAALGAENVEMLTDRNLNLEEKVRELRETVDLEAMNEMNDLQENARE	
NP_031861.1 (mouse)	481	TELELREQLDMAGARVREAAQKRVEAAQETVADYQQTIKKYRQLTAHLQDVNRELTNQOE	
AAD55811.1 (human)	481	TELELREQLDMAGARVREAAQKRVEAAQETVADYQQTIKKYRQLTAHLQDVNRELTNQOE	
Consensus	481	TELELREQLDMAGARVREAAQKRVEAAQETVADYQQTIKKYRQLTAHLQDVNRELTNQOE	
NP_031861.1 (mouse)	541	SVERQQQPPPETFDFFIKFAETKAHAKAIEMELRQMEVAQANRHMSLLTAFMPDPSFLRPG	
AAD55811.1 (human)	541	SVERQQQPPPETFDFFIKFAETKAHAKAIEMELRQMEVAQANRHMSLLTAFMPDPSFLRPG	
Consensus	541	SVERQQQPPPETFDFFIKFAETKAHAKAIEMELRQMEVAQANRHMSLLTAFMPDPSFLRPG	
NP_031861.1 (mouse)	601	GDHDCVLVLLNMPRLICFAELIRKQAQAEKFLSENCSERPGLRGAAAGEQLSFAAGLVYSL	
AAD55811.1 (human)	601	GDHDCVLVLLNMPRLICFAELIRKQAQAEKFLSENCSERPGLRGAAAGEQLSFAAGLVYSL	
Consensus	601	GDHDCVLVLLNMPRLICFAELIRKQAQAEKFLSENCSERPGLRGAAAGEQLSFAAGLVYSL	
NP_031861.1 (mouse)	661	SLQATLHRYEHALSQCSVDVYKVGSLYPEMSAHERSLDFLIELLHKDQLDETNNVEPL	
AAD55811.1 (human)	661	SLQATLHRYEHALSQCSVDVYKVGSLYPEMSAHERSLDFLIELLHKDQLDETNNVEPL	
Consensus	660	SLQATLHRYEHALSQCSVDVYKVGSLYPEMSAHERSLDFLIELLHKDQLDETNNVEPL	
NP_031861.1 (mouse)	721	NKAIKYYQHLYRIHLAEQPEDCTMQLADHIKFTQSALDCMGVEVGRRLRAFLQGGQEATDI	
AAD55811.1 (human)	721	TRAIKYYQHLYSIHLAEQPEDCTMQLADHIKFTQSALDCMGVEVGRRLRAFLQGGQEATDI	
Consensus	720	NKAIKYYQHLYRIHLAEQPEDCTMQLADHIKFTQSALDCMGVEVGRRLRAFLQGGQEATDI	

(Figure 15 continued)

NP_031861.1 (mouse)	781	ALLLRDLETSCSDIRQFCKKIRRRMPGTDAPGIPAALAFGSQVSDTLLDCRKHHTWVVAV
AAD55811.1 (human)	781	ALLLRDLETSCSDIRQFCKKIRRRMPGTDAPGIPAALAFGQVSDTLLDCRKHHTWVVAV
Consensus	780	ALLLRDLETSCSDIRQFCKKIRRRMPGTDAPGIPAALAFGQVSDTLLDCRKHHTWVVAV
NP_031861.1 (mouse)	841	LQEVAAAAAQLIAPLAENEGLVAALEELAFKASEQIYGSPPSSSPYECLRQSCITILISTM
AAD55811.1 (human)	841	LQEVAAAAAQLIAPLAENEGLLVALEELAFKASEQIYGVPPSSSPYECLRQSCNIIISTM
Consensus	840	LQEVAAAAAQLIAPLAENEGLLVALEELAFKASEQIYGSPPSSSPYECLRQSCNIIISTM
NP_031861.1 (mouse)	901	NKLATAMQEGEYDAERPPSKPPVELRAAALRAEITDAEGLGLKLEDRETVIKELKKSLEK
AAD55811.1 (human)	901	NKLATAMQEGEYDAERPPSKPPVELRAAALRAEITDAEGLGLKLEDRETVIKELKKSLEK
Consensus	900	NKLATAMQEGEYDAERPPSKPPVELRAAALRAEITDAEGLGLKLEDRETVIKELKKSLEK
NP_031861.1 (mouse)	961	IKGEELSEANVVKSLLEKKLDSAADADERIEKVQTRLDETQTLRRKKEKFEETMDALQ
AAD55811.1 (human)	961	IKGEELSEANVRLSLEKKLDSAADADERIEKVQTRLDETQALLRKKEKFEETMDALQ
Consensus	960	IKGEELSEANVRLSLEKKLDSAADADERIEKVQTRLDETQALLRKKEKFEETMDALQ
NP_031861.1 (mouse)	1021	ADIDOLEAEKAEKQRLNSQSKRTIEGLRGPPPSGIATLVSGIAGEEPQRCHAPGQAPGA
AAD55811.1 (human)	1021	ADIDOLEAEKAEKQRLNSQSKRTIEGLRGPPPSGIATLVSGIAGEEQQRGAPGQAPGS
Consensus	1018	ADIDOLEAEKAEKQRLNSQSKRTIEGLRGPPPSGIATLVSGIAGEEQQRGAPGQAPGA
NP_031861.1 (mouse)	1081	LPGPGLVKDSPLLLQQISAMRLHISQLQHENSILRGAQMKASLAALPPLHVAKLSLPPEHE
AAD55811.1 (human)	1081	LPGPGLVKDSPLLLQQISAMRLHISQLQHENSILRGAQMKASLAALPPLHVAKLS...HE
Consensus	1078	LPGPGLVKDSPLLLQQISAMRLHISQLQHENSILRGAQMKASLAALPPLHVAKLS...HE
NP_031861.1 (mouse)	1141	GPGGNLVAGALYRKTSQLEKLNQLSTHVVVDITRSPAAKSPSAQLMEQVAQLKSLSD
AAD55811.1 (human)	1138	GPGSELVAGALYRKTSQLEKLNQLSTHVVVDITRSPAAKSPSAQLMEQVAQLKSLSD
Consensus	1135	GPGGNLVAGALYRKTSQLEKLNQLSTHVVVDITRSPAAKSPSAQLMEQVAQLKSLSD
NP_031861.1 (mouse)	1201	TTEKLDKDEVLKETVQRPGATVPTDFATFPSSAFLRAKEEQDDTVYMGKVTFSKAAGLG
AAD55811.1 (human)	1198	TTEKLDKDEVLKETVQRPGATVPTDFATFPSSAFLRAKEEQDDTVYMGKVTFSKAAGLG
Consensus	1194	TTEKLDKDEVLKETVQRPGATVPTDFATFPSSAFLRAKEEQDDTVYMGKVTFSKAAGLG
NP_031861.1 (mouse)	1261	QRHRLVLTQEQQLHQLHSRLIS
AAD55811.1 (human)	1258	QRHRLVLTQEQQLHQLHSRLIS
Consensus	1253	QRHRLVLTQEQQLHQLHSRLIS

Amino acid identity 97%
Amino acid similarity 98%

Figure 16. Amino Acid Alignment of Mouse, Rattus Norvegicus, and Human DCTN1 (p150) Proteins – highly conserved Amino Acid Residues.

Software used:

- MultAlin via <http://prodes.toulouse.inra.fr/multalin/multalin.html> [Corpet. F. (1988), Multiple sequence alignment with hierarchical clustering, Nucl. Acids Res., 16 (22), 10881-10890]

- BOXSHADE 3.21 via http://www.ch.embnet.org/software/BOX_form.html

		39G	
NP_031861.1 (mouse)	1	MAQSKRHMS	SRTPSGSRMSTEASARPLRVGSRVEVIGKGRGTVAIVGATLFATGKMWGV
NP_077044.1 (rat)	1	MAQSKRHMYN	NRTPSGSRMSTEASARPLRVGSRVEVIGKGRGTVAIVGATLFATGKMWGV
AAD55811.1 (human)	1	MAQSKRHMY	SRTPSGSRMSAEASARPLRVGSRVEVIGKGRGTVAIVGATLFATGKMWGV
Consensus	1	MAQSKRHMY	SRTPSGSRMSTEASARPLRVGSRVEVIGKGRGTVAIVGATLFATGKMWGV
		133G 150P	
NP_031861.1	61	ILDEAKGKNDGT	VQGRKRYFTCDEGHGIFVRQSQIQVFEDGADTTSPETPDSSASKVLKRE
NP_077044.1	61	ILDEAKGKNDGT	VQGRKRYFTCDEGHGIFVRQSQIQVFEDGADTTSPETPDSSASKVLKRE
AAD55811.1	61	ILDEAKGKNDGT	VQGRKRYFTCDEGHGIFVRQSQIQVFEDGADTTSPETPDSSASKVLKRE
Consensus	61	ILDEAKGKNDGT	VQGRKRYFTCDEGHGIFVRQSQIQVFEDGADTTSPETPDSSASKVLKRE
NP_031861.1	121	GADAAAKTSKLRGL	PEKAPTARKTTTRRPKPTRPASTGVAGPSSSLGPGSGSASAGELSS
NP_077044.1	121	GADAAAKTSKLRGL	PEKAPTARKTTTRRPKPTRPASTGVAGPSSSLGPGSGSASAGELSS
AAD55811.1	121	GADAAAKTSKLRGL	PEKAPTARKTTTRRPKPTRPASTGVAGPSSSLGPGSGSASAGELSS
Consensus	120	GADAAAKTSKLRGL	PEKAPTARKTTTRRPKPTRPASTGVAGPSSSLGPGSGSASAGELSS
NP_031861.1	181	SEPSTPAQTPLA	APIIPTPALTSPGAAPPLPSPSKEEEGLRAQVRDLEEKLETLRKRSE
NP_077044.1	181	SEPSTPAQTPLA	APIIPTPALTSPGAAPPLPSPSKEEEGLRAQVRDLEEKLETLRKRSE
AAD55811.1	181	SEPSTPAQTPLA	APIIPTPALTSPGAAPPLPSPSKEEEGLRAQVRDLEEKLETLRKRSE
Consensus	180	SEPSTPAQTPLA	APIIPTPALTSPGAAPPLPSPSKEEEGLRAQVRDLEEKLETLRKRSE
NP_031861.1	241	DKAKLKELEKHKI	QLEQVQEWKSKMQEQQADLQRLKEARKEAKEALEAKERYMEEMADT
NP_077044.1	241	DKAKLKELEKHKI	QLEQVQEWKSKMQEQQADLQRLKEARKEAKEALEAKERYMEEMADT
AAD55811.1	241	DKAKLKELEKHKI	QLEQVQEWKSKMQEQQADLQRLKEARKEAKEALEAKERYMEEMADT
Consensus	240	DKAKLKELEKHKI	QLEQVQEWKSKMQEQQADLQRLKEARKEAKEALEAKERYMEEMADT
NP_031861.1	301	ADAIEMATLDKEM	AEERAEESLQOEVEALKERVDELTTDLLEILKAEIEEKSGDGAASSYQL
NP_077044.1	300	ADAIEMATLDKEM	AEERAEESLQOEVEALKERVDELTTDLLEILKAEIEEKSGDGAASSYQL
AAD55811.1	301	ADAIEMATLDKEM	AEERAEESLQOEVEALKERVDELTTDLLEILKAEIEEKSGDGAASSYQL
Consensus	300	ADAIEMATLDKEM	AEERAEESLQOEVEALKERVDELTTDLLEILKAEIEEKSGDGAASSYQL
NP_031861.1	361	KQLEEQNARLKDAL	VPMRDLSSEKQEHVKLQKLMEKKNQEQLEVVRRQQRERLQEELSQAE
NP_077044.1	360	KQLEEQNARLKDAL	VPMRDLSSEKQEHVKLQKLMEKKNQEQLEVVRRQQRERLQEELSQAE
AAD55811.1	361	KQLEEQNARLKDAL	VPMRDLSSEKQEHVKLQKLMEKKNQEQLEVVRRQQRERLQEELSQAE
Consensus	360	KQLEEQNARLKDAL	VPMRDLSSEKQEHVKLQKLMEKKNQEQLEVVRRQQRERLQEELSQAE
NP_031861.1	421	STIDELKEQVDAAL	GAEENVEMLTDRNLNLEEKVRELRETVDLEAMNEMNDELQENARE
NP_077044.1	420	STIDELKEQVDAAL	GAEENVEMLTDRNLNLEEKVRELRETVDLEAMNEMNDELQENARE
AAD55811.1	421	STIDELKEQVDAAL	GAEENVEMLTDRNLNLEEKVRELRETVDLEAMNEMNDELQENARE
Consensus	420	STIDELKEQVDAAL	GAEENVEMLTDRNLNLEEKVRELRETVDLEAMNEMNDELQENARE
NP_031861.1	481	TELELREQLDMAG	ARVPEAQKRVEAAQETVADYQOTIKKYRQLTAHLQDVNRELNTQOEAA
NP_077044.1	480	TELELREQLDMAG	ARVPEAQKRVEAAQETVADYQOTIKKYRQLTAHLQDVNRELNTQOEAA
AAD55811.1	481	TELELREQLDMAG	ARVPEAQKRVEAAQETVADYQOTIKKYRQLTAHLQDVNRELNTQOEAA
Consensus	480	TELELREQLDMAG	ARVPEAQKRVEAAQETVADYQOTIKKYRQLTAHLQDVNRELNTQOEAA
NP_031861.1	541	SVERQQQPPPET	DFDKIKFAETKAHAKAIEMELRQMEVAQANRHMSLLTAFMPDSFLRPG
NP_077044.1	540	SVERQQQPPPET	DFDKIKFAETKAHAKAIEMELRQMEVAQANRHMSLLTAFMPDSFLRPG
AAD55811.1	541	SVERQQQPPPET	DFDKIKFAETKAHAKAIEMELRQMEVAQANRHMSLLTAFMPDSFLRPG
Consensus	540	SVERQQQPPPET	DFDKIKFAETKAHAKAIEMELRQMEVAQANRHMSLLTAFMPDSFLRPG
NP_031861.1	601	GDHDCVLVLLMP	RLICKAELIRKQAEKEFDLSENCSERPGLRGAGEQLSFAAGLVYSI
NP_077044.1	600	GDHDCVLVLLMP	RLICKAELIRKQAEKEFDLSENCSERPGLRGAGEQLSFAAGLVYSI
AAD55811.1	601	GDHDCVLVLLMP	RLICKAELIRKQAEKEFDLSENCSERPGLRGAGEQLSFAAGLVYSI
Consensus	600	GDHDCVLVLLMP	RLICKAELIRKQAEKEFDLSENCSERPGLRGAGEQLSFAAGLVYSI

(Figure 16 continued)

NP_031861.1	661	SLQATLHRYEHALSQCSVDVYKKVGSYPMSAHERSLDFLIELLHKDQLDETNNVEPL
NP_077044.1	660	SLQATLHRYEHALSQCSVDVYKKVGSYPMSAHERSLDFLIELLHKDQLDETNNVEPL
AAD55811.1	661	SLQATLHRYEHALSQCSVDVYKKVGSYPMSAHERSLDFLIELLHKDQLDETNNVEPL
Consensus	659	SLQATLHRYEHALSQCSVDVYKKVGSYPMSAHERSLDFLIELLHKDQLDETNNVEPL
NP_031861.1	721	NKGIKYYQHLVRIHLAEQPEDSTMQLADHIKFTQSALDCMGVEVGRRAFLQGGQEATDI
NP_077044.1	720	TKAIKYYQHLVSIHLAEQPE#STMQLADHIKFTQSALDCMSVEVGRRAFLQGGQEATDI
AAD55811.1 (human)	721	TKAIKYYQHLVSIHLAEQPEDCTMQLADHIKFTQSALDCMSVEVGRRAFLQGGQEATDI
Consensus	719	TKAIKYYQHLVSIHLAEQPE#STMQLADHIKFTQSALDCMSVEVGRRAFLQGGQEATDI
NP_031861.1	781	ALLLRDLETSCSDIRQFCKKIRRRMPGTDAPGIPAALAFGSQVSDTLDCRKHLTWVVAV
NP_077044.1	780	ALLLRDLETSCSDIRQFCKKIRRRMPGTDAPGIPAALAFGSQVSDTLDCRKHLTWVVAV
AAD55811.1 (human)	781	ALLLRDLETSCSDIRQFCKKIRRRMPGTDAPGIPAALAFGEQVSDTLDCRKHLTWVVAV
Consensus	778	ALLLRDLETSCSDIRQFCKKIRRRMPGTDAPGIPAALAFGSQVSDTLDCRKHLTWVVAV
NP_031861.1	841	LQEVAAAAAQLIAPLAENEGLPVAALEELAFKASEQIYGPSSSPYECRLQSC#ILISTM
NP_077044.1	840	LQEVAAAAAQLIAPLAENEGLPVAALEELAFKASEQIYGPSSSPYECRLQSC#ILISTM
AAD55811.1 (human)	841	LQEVAAAAAQLIAPLAENEGLPVAALEELAFKASEQIYGPSSSPYECRLQSC#ILISTM
Consensus	838	LQEVAAAAAQLIAPLAENEGLPVAALEELAFKASEQIYGPSSSPYECRLQSC#ILISTM
NP_031861.1	901	NKLATAMQEGEYDAERPPSKPPPVELRAAALRAEITDAEGLGLKLEDRETVIKELKKSLE
NP_077044.1	900	NKLATAMQEGEYDAERPPSKPPPVE#PWPRAALRAEITDAEGLGLKLEDRETVIKELKKSLE
AAD55811.1 (human)	901	NKLATAMQEGEYDAERPPSKPPPVELRAAALRAEITDAEGLGLKLEDRETVIKELKKSLE
Consensus	897	NKLATAMQEGEYDAERPPSKPPPVELRAAALRAEITDAEGLGLKLEDRETVIKELKKSLE
NP_031861.1	961	IKGEELSEANVRLS#LLEKKLDSAAKDADERIEKVQTRL#ETQTLRRKKE#FEETMDALQ
NP_077044.1	960	IKGEELSEANVRLS#LLEKKLDSAAKDADERIEKVQTRL#ETQTLRRKKE#FEETMDALQ
AAD55811.1 (human)	961	IKGEELSEANVRLS#LLEKKLDSAAKDADERIEKVQTRL#ETQTLRRKKE#FEETMDALQ
Consensus	957	IKGEELSEANVRLS#LLEKKLDSAAKDADERIEKVQTRL#ETQTLRRKKE#FEETMDALQ
NP_031861.1	1021	ADIDQLEAEKAEKQRLNSQSKRTIEGLRGPPPSGIATLVSGIAGEEQ#QRCGAPQAPGA
NP_077044.1	1020	ADIDQLEAEKAEKQRLNSQSKRTIEGLRGPPPSGIATLVSGIAGEEQ#QRCGAPQAPGA
AAD55811.1 (human)	1021	ADIDQLEAEKAEKQRLNSQSKRTIEGLRGPPPSGIATLVSGIAGEEQ#QRCGAPQAPGA
Consensus	1015	ADIDQLEAEKAEKQRLNSQSKRTIEGLRGPPPSGIATLVSGIAGEEQ#QRCGAPQAPGA
NP_031861.1	1081	LPGPGLVKDSPLLLQOISAMRLHISQLOHENSILRGAQMKASLAALPPLHVAKLSLPPHE
NP_077044.1	1080	LPGPGLVKDSPLLLQOISAMRLHISQLOHENSILRGAQMKASLAALPPLHVAKLSLPPHE
AAD55811.1 (human)	1081	LPGPGLVKDSPLLLQOISAMRLHISQLOHENSILRGAQMKASLAALPPLHVAKLSLPPHE
Consensus	1074	LPGPGLVKDSPLLLQOISAMRLHISQLOHENSILRGAQMKASLAALPPLHVAKLSLPPHE
NP_031861.1	1141	GPGGNL#AGALYRKTSQLEKLNQLSTH#VVDITRSPPAKSPSAQLMQVAQLKSLSD
NP_077044.1	1140	GPGGNL#AGALYRKTSQLEKLNQLSTH#VVDITRSPPAKSPSAQLMQVAQLKSLSD
AAD55811.1 (human)	1138	GPGSEL#AGALYRKTSQLEKLNQLSTH#VVDITRSPPAKSPSAQLMQVAQLKSLSD
Consensus	1134	GPGG#L#AGALYRKTSQLEKLNQLSTH#VVDITRSPPAKSPSAQLMQVAQLKSLSD
NP_031861.1	1201	TIEKLEKDEVLEKTVTORPGATVPTDFATFPSSAFLRAKEEQDDTVYMGKVTFSCAAGLG
NP_077044.1	1200	TIEKLEKDEVLEKTVTORPGATVPTDFATFPSSAFLRAKEEQDDTVYMGKVTFSCAAGLG
AAD55811.1 (human)	1198	TIEKLEKDEVLEKTVTORPGATVPTDFATFPSSAFLRAKEEQDDTVYMGKVTFSCAAGLG
Consensus	1192	TIEKLEKDEVLEKTVTORPGATVPTDFATFPSSAFLRAKEEQDDTVYMGKVTFSCAAGLG
NP_031861.1	1261	QRHRLVLTQEQQLHQLHSRLIS
NP_077044.1	1260	QRHRLVLTQEQQLHQLH#RLIS
AAD55811.1 (human)	1258	QRHRLVLTQEQQLHQLHSRLIS
Consensus	1251	QRHRLVLTQEQQLHQLHSRLIS

Amino acid identity: 95%

Amino acid similarity: 96%

The following binding domains are indicated by their N-terminal and C-terminal amino acid (positions correspond to the human amino acid sequence):

Microd (microtubules binding domain)

39G – 150P

Dcd (dynein intermediate chain1 binding domain)

133G-899T

ARP1d (ARP1 binding domain)

1006R-1021A

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record.**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☒ **FADED TEXT OR DRAWING**
- ☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.